WO2022093640A1 - Anti-nkg2c agents and compositions and methods for making and using the same - Google Patents
Anti-nkg2c agents and compositions and methods for making and using the same Download PDFInfo
- Publication number
- WO2022093640A1 WO2022093640A1 PCT/US2021/056211 US2021056211W WO2022093640A1 WO 2022093640 A1 WO2022093640 A1 WO 2022093640A1 US 2021056211 W US2021056211 W US 2021056211W WO 2022093640 A1 WO2022093640 A1 WO 2022093640A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- nkg2c
- amino acid
- sequence
- agent
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 72
- 239000000203 mixture Substances 0.000 title claims abstract description 39
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 577
- 230000027455 binding Effects 0.000 claims abstract description 177
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 57
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 56
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 56
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 claims abstract description 23
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 19
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 claims abstract description 15
- 150000001413 amino acids Chemical class 0.000 claims description 927
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 333
- 210000004027 cell Anatomy 0.000 claims description 189
- 239000012634 fragment Substances 0.000 claims description 135
- 239000000427 antigen Substances 0.000 claims description 104
- 108091007433 antigens Proteins 0.000 claims description 104
- 102000036639 antigens Human genes 0.000 claims description 104
- 229910052727 yttrium Inorganic materials 0.000 claims description 94
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims description 74
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims description 74
- 229910052717 sulfur Inorganic materials 0.000 claims description 71
- 102000000834 NK Cell Lectin-Like Receptor Subfamily C Human genes 0.000 claims description 70
- 108010001880 NK Cell Lectin-Like Receptor Subfamily C Proteins 0.000 claims description 70
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 64
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 64
- 229910052757 nitrogen Inorganic materials 0.000 claims description 62
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 59
- -1 X3 is I Inorganic materials 0.000 claims description 55
- 210000004698 lymphocyte Anatomy 0.000 claims description 44
- 229910052739 hydrogen Inorganic materials 0.000 claims description 43
- 201000010099 disease Diseases 0.000 claims description 35
- 239000002773 nucleotide Substances 0.000 claims description 30
- 125000003729 nucleotide group Chemical group 0.000 claims description 30
- 210000002865 immune cell Anatomy 0.000 claims description 28
- 206010028980 Neoplasm Diseases 0.000 claims description 25
- 238000001514 detection method Methods 0.000 claims description 24
- 208000035475 disorder Diseases 0.000 claims description 24
- 230000014509 gene expression Effects 0.000 claims description 23
- 210000000822 natural killer cell Anatomy 0.000 claims description 21
- 201000011510 cancer Diseases 0.000 claims description 20
- 229910052720 vanadium Inorganic materials 0.000 claims description 20
- 238000004519 manufacturing process Methods 0.000 claims description 19
- 229910052721 tungsten Inorganic materials 0.000 claims description 19
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 17
- 239000007787 solid Substances 0.000 claims description 17
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 15
- 230000000295 complement effect Effects 0.000 claims description 15
- 229910052731 fluorine Inorganic materials 0.000 claims description 15
- 102100028970 HLA class I histocompatibility antigen, alpha chain E Human genes 0.000 claims description 12
- 101000986085 Homo sapiens HLA class I histocompatibility antigen, alpha chain E Proteins 0.000 claims description 12
- 229910052698 phosphorus Inorganic materials 0.000 claims description 12
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 claims description 12
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 9
- 229910052722 tritium Inorganic materials 0.000 claims description 9
- 238000000338 in vitro Methods 0.000 claims description 8
- 239000003550 marker Substances 0.000 claims description 8
- 239000013604 expression vector Substances 0.000 claims description 7
- 229910052740 iodine Inorganic materials 0.000 claims description 7
- 210000001616 monocyte Anatomy 0.000 claims description 7
- 230000001472 cytotoxic effect Effects 0.000 claims description 6
- 238000001727 in vivo Methods 0.000 claims description 6
- 210000003734 kidney Anatomy 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 208000023275 Autoimmune disease Diseases 0.000 claims description 5
- 208000036142 Viral infection Diseases 0.000 claims description 5
- 208000027866 inflammatory disease Diseases 0.000 claims description 5
- 238000003259 recombinant expression Methods 0.000 claims description 5
- 230000009385 viral infection Effects 0.000 claims description 5
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 4
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 4
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 4
- 208000035143 Bacterial infection Diseases 0.000 claims description 4
- 208000017604 Hodgkin disease Diseases 0.000 claims description 4
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 4
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 4
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 4
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 4
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 4
- 210000001072 colon Anatomy 0.000 claims description 4
- 210000004443 dendritic cell Anatomy 0.000 claims description 4
- 210000003238 esophagus Anatomy 0.000 claims description 4
- 230000002496 gastric effect Effects 0.000 claims description 4
- 208000005017 glioblastoma Diseases 0.000 claims description 4
- 210000003128 head Anatomy 0.000 claims description 4
- 210000000265 leukocyte Anatomy 0.000 claims description 4
- 210000004185 liver Anatomy 0.000 claims description 4
- 210000004072 lung Anatomy 0.000 claims description 4
- 210000002540 macrophage Anatomy 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 210000003739 neck Anatomy 0.000 claims description 4
- 230000002611 ovarian Effects 0.000 claims description 4
- 210000000496 pancreas Anatomy 0.000 claims description 4
- 210000003651 basophil Anatomy 0.000 claims description 3
- 210000003979 eosinophil Anatomy 0.000 claims description 3
- 210000003630 histaminocyte Anatomy 0.000 claims description 3
- 210000004964 innate lymphoid cell Anatomy 0.000 claims description 3
- 210000000440 neutrophil Anatomy 0.000 claims description 3
- 230000009089 cytolysis Effects 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract description 45
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract description 45
- 235000001014 amino acid Nutrition 0.000 description 920
- 229940024606 amino acid Drugs 0.000 description 912
- 108090000765 processed proteins & peptides Proteins 0.000 description 89
- 241000282414 Homo sapiens Species 0.000 description 82
- 102000004196 processed proteins & peptides Human genes 0.000 description 82
- 229920001184 polypeptide Polymers 0.000 description 81
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 62
- 238000003556 assay Methods 0.000 description 41
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 40
- 108090000623 proteins and genes Proteins 0.000 description 33
- 230000002209 hydrophobic effect Effects 0.000 description 29
- 238000005516 engineering process Methods 0.000 description 26
- 235000018102 proteins Nutrition 0.000 description 25
- 102000004169 proteins and genes Human genes 0.000 description 25
- 238000006467 substitution reaction Methods 0.000 description 23
- 108060003951 Immunoglobulin Proteins 0.000 description 22
- 230000002378 acidificating effect Effects 0.000 description 22
- 125000000539 amino acid group Chemical group 0.000 description 22
- 102000018358 immunoglobulin Human genes 0.000 description 22
- 238000000684 flow cytometry Methods 0.000 description 20
- 241001465754 Metazoa Species 0.000 description 17
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 17
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 17
- 210000004408 hybridoma Anatomy 0.000 description 17
- 102000004190 Enzymes Human genes 0.000 description 16
- 108090000790 Enzymes Proteins 0.000 description 16
- 229940088598 enzyme Drugs 0.000 description 16
- 239000013598 vector Substances 0.000 description 16
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 15
- 108010076504 Protein Sorting Signals Proteins 0.000 description 15
- 230000004048 modification Effects 0.000 description 15
- 238000012986 modification Methods 0.000 description 15
- 238000011282 treatment Methods 0.000 description 15
- 230000000903 blocking effect Effects 0.000 description 14
- 239000000758 substrate Substances 0.000 description 14
- 239000000562 conjugate Substances 0.000 description 11
- 239000012636 effector Substances 0.000 description 11
- 238000003780 insertion Methods 0.000 description 11
- 230000037431 insertion Effects 0.000 description 11
- 229920000642 polymer Polymers 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 10
- 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 description 10
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 10
- 206010035226 Plasma cell myeloma Diseases 0.000 description 10
- 201000000050 myeloid neoplasm Diseases 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 101150074862 KLRC3 gene Proteins 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 102100022701 NKG2-E type II integral membrane protein Human genes 0.000 description 9
- 241000283973 Oryctolagus cuniculus Species 0.000 description 9
- 229940127089 cytotoxic agent Drugs 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000003446 ligand Substances 0.000 description 9
- 239000002245 particle Substances 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 8
- 230000004071 biological effect Effects 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 230000001086 cytosolic effect Effects 0.000 description 8
- 102000057658 human KLRC2 Human genes 0.000 description 8
- 229940127121 immunoconjugate Drugs 0.000 description 8
- 239000002502 liposome Substances 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 230000004962 physiological condition Effects 0.000 description 8
- 241000894007 species Species 0.000 description 8
- 238000010186 staining Methods 0.000 description 8
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 7
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 7
- 101001109508 Homo sapiens NKG2-A/NKG2-B type II integral membrane protein Proteins 0.000 description 7
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 description 7
- 102100023616 Neural cell adhesion molecule L1-like protein Human genes 0.000 description 7
- 230000004075 alteration Effects 0.000 description 7
- 239000002246 antineoplastic agent Substances 0.000 description 7
- 239000002254 cytotoxic agent Substances 0.000 description 7
- 238000012217 deletion Methods 0.000 description 7
- 230000037430 deletion Effects 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 239000000377 silicon dioxide Substances 0.000 description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 6
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 6
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 6
- 230000003213 activating effect Effects 0.000 description 6
- 239000012472 biological sample Substances 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 231100000599 cytotoxic agent Toxicity 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000013595 glycosylation Effects 0.000 description 6
- 238000006206 glycosylation reaction Methods 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 230000001900 immune effect Effects 0.000 description 6
- 230000002163 immunogen Effects 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 229940049595 antibody-drug conjugate Drugs 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 229960002685 biotin Drugs 0.000 description 5
- 235000020958 biotin Nutrition 0.000 description 5
- 239000011616 biotin Substances 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 230000016784 immunoglobulin production Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 238000002823 phage display Methods 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000003053 toxin Substances 0.000 description 5
- 231100000765 toxin Toxicity 0.000 description 5
- 108700012359 toxins Proteins 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 4
- 108091035707 Consensus sequence Proteins 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 4
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
- 102100029205 Low affinity immunoglobulin gamma Fc region receptor II-b Human genes 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 4
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 150000001720 carbohydrates Chemical group 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 239000000833 heterodimer Substances 0.000 description 4
- 229940072221 immunoglobulins Drugs 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 210000003292 kidney cell Anatomy 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Chemical class 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 239000003094 microcapsule Substances 0.000 description 4
- 238000002703 mutagenesis Methods 0.000 description 4
- 231100000350 mutagenesis Toxicity 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000003127 radioimmunoassay Methods 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 108090001008 Avidin Proteins 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 102100022436 CMRF35-like molecule 8 Human genes 0.000 description 3
- 102000000844 Cell Surface Receptors Human genes 0.000 description 3
- 108010001857 Cell Surface Receptors Proteins 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 3
- 102000002090 Fibronectin type III Human genes 0.000 description 3
- 108050009401 Fibronectin type III Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 101000990055 Homo sapiens CMRF35-like molecule 1 Proteins 0.000 description 3
- 101000901669 Homo sapiens CMRF35-like molecule 8 Proteins 0.000 description 3
- 101000935587 Homo sapiens Flavin reductase (NADPH) Proteins 0.000 description 3
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 3
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 3
- 101150069255 KLRC1 gene Proteins 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 description 3
- 101100404845 Macaca mulatta NKG2A gene Proteins 0.000 description 3
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- 230000001594 aberrant effect Effects 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 238000012867 alanine scanning Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 3
- 230000001588 bifunctional effect Effects 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000003915 cell function Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 229940044683 chemotherapy drug Drugs 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 239000003593 chromogenic compound Substances 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 239000005289 controlled pore glass Substances 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 239000003431 cross linking reagent Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 238000012083 mass cytometry Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 102000013415 peroxidase activity proteins Human genes 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 230000005180 public health Effects 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 238000010188 recombinant method Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000009261 transgenic effect Effects 0.000 description 3
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 2
- GANZODCWZFAEGN-UHFFFAOYSA-N 5-mercapto-2-nitro-benzoic acid Chemical compound OC(=O)C1=CC(S)=CC=C1[N+]([O-])=O GANZODCWZFAEGN-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 108091023037 Aptamer Proteins 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000194108 Bacillus licheniformis Species 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 241000255789 Bombyx mori Species 0.000 description 2
- 108090000342 C-Type Lectins Proteins 0.000 description 2
- 102000003930 C-Type Lectins Human genes 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 238000009007 Diagnostic Kit Methods 0.000 description 2
- 241000255925 Diptera Species 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108010021468 Fc gamma receptor IIA Proteins 0.000 description 2
- 108010021472 Fc gamma receptor IIB Proteins 0.000 description 2
- 108010087819 Fc receptors Proteins 0.000 description 2
- 102000009109 Fc receptors Human genes 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101100334515 Homo sapiens FCGR3A gene Proteins 0.000 description 2
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 2
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 244000285963 Kluyveromyces fragilis Species 0.000 description 2
- 241001138401 Kluyveromyces lactis Species 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 108050003738 Neural cell adhesion molecule 1 Proteins 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 230000004989 O-glycosylation Effects 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 108010004729 Phycoerythrin Proteins 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 241000607720 Serratia Species 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000256251 Spodoptera frugiperda Species 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000003926 acrylamides Chemical class 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 239000000611 antibody drug conjugate Substances 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000002981 blocking agent Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 229960005156 digoxin Drugs 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 150000004662 dithiols Chemical class 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000005038 ethylene vinyl acetate Substances 0.000 description 2
- 239000012997 ficoll-paque Substances 0.000 description 2
- 238000002825 functional assay Methods 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 2
- 238000012872 hydroxylapatite chromatography Methods 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000009851 immunogenic response Effects 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 108091008042 inhibitory receptors Proteins 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 235000013980 iron oxide Nutrition 0.000 description 2
- 238000001155 isoelectric focusing Methods 0.000 description 2
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 210000000581 natural killer T-cell Anatomy 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 239000000123 paper Substances 0.000 description 2
- 230000005298 paramagnetic effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- AQIXEPGDORPWBJ-UHFFFAOYSA-N pentan-3-ol Chemical compound CCC(O)CC AQIXEPGDORPWBJ-UHFFFAOYSA-N 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 210000001322 periplasm Anatomy 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 238000013391 scatchard analysis Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- XMQUEQJCYRFIQS-YFKPBYRVSA-N (2s)-2-amino-5-ethoxy-5-oxopentanoic acid Chemical compound CCOC(=O)CC[C@H](N)C(O)=O XMQUEQJCYRFIQS-YFKPBYRVSA-N 0.000 description 1
- KYBXNPIASYUWLN-WUCPZUCCSA-N (2s)-5-hydroxypyrrolidine-2-carboxylic acid Chemical compound OC1CC[C@@H](C(O)=O)N1 KYBXNPIASYUWLN-WUCPZUCCSA-N 0.000 description 1
- IEUUDEWWMRQUDS-UHFFFAOYSA-N (6-azaniumylidene-1,6-dimethoxyhexylidene)azanium;dichloride Chemical compound Cl.Cl.COC(=N)CCCCC(=N)OC IEUUDEWWMRQUDS-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- VILFTWLXLYIEMV-UHFFFAOYSA-N 1,5-difluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC([N+]([O-])=O)=C(F)C=C1F VILFTWLXLYIEMV-UHFFFAOYSA-N 0.000 description 1
- YBBNVCVOACOHIG-UHFFFAOYSA-N 2,2-diamino-1,4-bis(4-azidophenyl)-3-butylbutane-1,4-dione Chemical compound C=1C=C(N=[N+]=[N-])C=CC=1C(=O)C(N)(N)C(CCCC)C(=O)C1=CC=C(N=[N+]=[N-])C=C1 YBBNVCVOACOHIG-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- KGLPWQKSKUVKMJ-UHFFFAOYSA-N 2,3-dihydrophthalazine-1,4-dione Chemical class C1=CC=C2C(=O)NNC(=O)C2=C1 KGLPWQKSKUVKMJ-UHFFFAOYSA-N 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 125000000979 2-amino-2-oxoethyl group Chemical group [H]C([*])([H])C(=O)N([H])[H] 0.000 description 1
- XBBVURRQGJPTHH-UHFFFAOYSA-N 2-hydroxyacetic acid;2-hydroxypropanoic acid Chemical compound OCC(O)=O.CC(O)C(O)=O XBBVURRQGJPTHH-UHFFFAOYSA-N 0.000 description 1
- OBWSOTREAMFOCQ-UHFFFAOYSA-N 4-(4-amino-3,5-dimethylphenyl)-2,6-dimethylaniline;hydrochloride Chemical compound Cl.CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 OBWSOTREAMFOCQ-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- 229940117976 5-hydroxylysine Drugs 0.000 description 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 206010073363 Acinar cell carcinoma of pancreas Diseases 0.000 description 1
- 241000256118 Aedes aegypti Species 0.000 description 1
- 241000256173 Aedes albopictus Species 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 101100107610 Arabidopsis thaliana ABCF4 gene Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000351920 Aspergillus nidulans Species 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 241001203868 Autographa californica Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 108090000363 Bacterial Luciferases Proteins 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 241000409811 Bombyx mori nucleopolyhedrovirus Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 101100120609 Caenorhabditis elegans frh-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102100032231 Caveolae-associated protein 2 Human genes 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 102100037579 D-3-phosphoglycerate dehydrogenase Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000255601 Drosophila melanogaster Species 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 101710181478 Envelope glycoprotein GP350 Proteins 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588698 Erwinia Species 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241001522878 Escherichia coli B Species 0.000 description 1
- 241001302584 Escherichia coli str. K-12 substr. W3110 Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 229910052693 Europium Inorganic materials 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 208000033371 Extranodal NK/T-cell lymphoma, nasal type Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000724791 Filamentous phage Species 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 108010015133 Galactose oxidase Proteins 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
- 102100022624 Glucoamylase Human genes 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 102100035172 Glucose-6-phosphate 1-dehydrogenase Human genes 0.000 description 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000219146 Gossypium Species 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000869050 Homo sapiens Caveolae-associated protein 2 Proteins 0.000 description 1
- 101100127356 Homo sapiens KLRD1 gene Proteins 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- 101000971513 Homo sapiens Natural killer cells antigen CD94 Proteins 0.000 description 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
- 101000809875 Homo sapiens TYRO protein tyrosine kinase-binding protein Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical class C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 238000012695 Interfacial polymerization Methods 0.000 description 1
- 101150018199 KLRC4 gene Proteins 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 241000235649 Kluyveromyces Species 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 238000012773 Laboratory assay Methods 0.000 description 1
- 241000481961 Lachancea thermotolerans Species 0.000 description 1
- 241000235651 Lachancea waltii Species 0.000 description 1
- 102100038609 Lactoperoxidase Human genes 0.000 description 1
- 108010023244 Lactoperoxidase Proteins 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
- 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 239000004907 Macro-emulsion Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 108010026217 Malate Dehydrogenase Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 102100022700 NKG2-F type II integral membrane protein Human genes 0.000 description 1
- 102100021462 Natural killer cells antigen CD94 Human genes 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 241000221960 Neurospora Species 0.000 description 1
- 241000221961 Neurospora crassa Species 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 206010061332 Paraganglion neoplasm Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- 240000007377 Petunia x hybrida Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920000805 Polyaspartic acid Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 102220492414 Ribulose-phosphate 3-epimerase_H35A_mutation Human genes 0.000 description 1
- 229910006124 SOCl2 Inorganic materials 0.000 description 1
- 101100068078 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) GCN4 gene Proteins 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- 241000311088 Schwanniomyces Species 0.000 description 1
- 241001123650 Schwanniomyces occidentalis Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 102100038717 TYRO protein tyrosine kinase-binding protein Human genes 0.000 description 1
- 241000255588 Tephritidae Species 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 241001149964 Tolypocladium Species 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 241000223259 Trichoderma Species 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108091005956 Type II transmembrane proteins Proteins 0.000 description 1
- 108010092464 Urate Oxidase Proteins 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 244000000188 Vaccinium ovalifolium Species 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 241000235013 Yarrowia Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 229920006397 acrylic thermoplastic Polymers 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000009824 affinity maturation Effects 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 238000005460 biophysical method Methods 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- HUTDDBSSHVOYJR-UHFFFAOYSA-H bis[(2-oxo-1,3,2$l^{5},4$l^{2}-dioxaphosphaplumbetan-2-yl)oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O HUTDDBSSHVOYJR-UHFFFAOYSA-H 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N butyl alcohol Substances CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000012219 cassette mutagenesis Methods 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000011098 chromatofocusing Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000013377 clone selection method Methods 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 239000002322 conducting polymer Substances 0.000 description 1
- 229920001940 conductive polymer Polymers 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 210000005220 cytoplasmic tail Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- 125000005442 diisocyanate group Chemical group 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- ZWIBGKZDAWNIFC-UHFFFAOYSA-N disuccinimidyl suberate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)CCC1=O ZWIBGKZDAWNIFC-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 150000002222 fluorine compounds Chemical class 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 238000003500 gene array Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 150000002463 imidates Chemical class 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 210000004020 intracellular membrane Anatomy 0.000 description 1
- 210000005061 intracellular organelle Anatomy 0.000 description 1
- 238000010212 intracellular staining Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229940057428 lactoperoxidase Drugs 0.000 description 1
- 230000000503 lectinlike effect Effects 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000000207 lymphocyte subset Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 230000005291 magnetic effect Effects 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 229960003151 mercaptamine Drugs 0.000 description 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical group 0.000 description 1
- 229910052752 metalloid Inorganic materials 0.000 description 1
- 150000002738 metalloids Chemical class 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 108010029942 microperoxidase Proteins 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 1
- 239000002102 nanobead Substances 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002071 nanotube Substances 0.000 description 1
- 239000002070 nanowire Substances 0.000 description 1
- 230000031942 natural killer cell mediated cytotoxicity Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 201000011519 neuroendocrine tumor Diseases 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000014511 neuron projection development Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000001293 nucleolytic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 201000010287 pancreatic acinar cell adenocarcinoma Diseases 0.000 description 1
- 208000030352 pancreatic acinar cell carcinoma Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 208000007312 paraganglioma Diseases 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 108010054442 polyalanine Proteins 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 108010064470 polyaspartate Proteins 0.000 description 1
- 229920001748 polybutylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 229910052761 rare earth metal Inorganic materials 0.000 description 1
- 150000002910 rare earth metals Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000000717 sertoli cell Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 150000003376 silicon Chemical class 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- PTLRDCMBXHILCL-UHFFFAOYSA-M sodium arsenite Chemical compound [Na+].[O-][As]=O PTLRDCMBXHILCL-UHFFFAOYSA-M 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- CNHYKKNIIGEXAY-UHFFFAOYSA-N thiolan-2-imine Chemical compound N=C1CCCS1 CNHYKKNIIGEXAY-UHFFFAOYSA-N 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000012876 topography Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Definitions
- NK inhibitory receptor CD94/NK group 2-member C bind the NK inhibitory receptor CD94/NK group 2-member C (NKG2C), particularly monoclonal antibodies, antibody fragments, and antibody derivatives specifically reactive to NKG2C under physiological and/or in vitro conditions.
- Such agents can be useful for laboratory/research purposes (e.g., flow cytometry), and may be used in the treatment and/or prevention of various diseases or disorders through the delivery of pharmaceutical or other compositions that contain such agents.
- Background includes information that may be useful in understanding the present technology.
- Natural Killer (NK) cells play an important role in host immune regulation to a variety of pathological challenges, from viral infections to cancer. Natural Killer cells show a broad array of tissue distribution and phenotypic variability, and therefore express several activating and inhibitory receptors in order to control their function. Natural-killer group 2, member A (NKG2C) is a C-type lectin family activating receptor that forms a heterodimer with CD94, and specifically recognizes the ubiquitously expressed non- classical MHC molecule HLA-E.
- NKG2C Alterations in the expression of NKG2C have been observed in numerous diseases, including human cytomegalovirus (HCMV) and chronic or early HIV-infections.
- HCMV human cytomegalovirus
- anti-NKG2C agents that bind NKG2C, including anti-NKG2C antibodies, NKG2C-binding antibody fragments, derivatives, and variants of such antibodies and antibody fragments or antigen-binding fragments thereof (including immunoconjugates, labeled antibodies and antigen-binding antibody fragments, and the like), diagnostic reagents that comprise such agents, containers and kits that include an anti-NKG2C agent provided herein, and methods of making and using the same.
- an anti-NKG2C agent that binds NKG2C under laboratory or physiological conditions, where the agent comprises at least one immunoglobulin heavy chain variable domain and at least one immunoglobulin light chain variable domain, where a) each immunoglobulin heavy chain variable domain of the anti-NKG2C agent comprises first, second, and third heavy chain complementarity determining regions (CDRs), where the first heavy chain CDR (CDRH1) comprises an amino acid sequence that is at least 80% identical to the amino acid sequence X 1 X 2 X 3 X 4 X 5 (SEQ ID NO: 50), where X 1 is N, S, or D, X 2 is F, T, or Y, X 3 is G, Y, or W X 4 is M or I, and X 5 is H or N; the second heavy chain CDR (CDRH2) comprises an amino acid sequence that is at least 80% identical to the amino acid sequence X 1 IX 3 X 4 X 5 X 6 X 7 X 8
- first anti-NKG2C agent that binds NKG2C under laboratory or physiological conditions, where the first agent competitively binds with a second anti-NKG2C agent, which the second agent comprises at least one immunoglobulin heavy chain variable domain and at least one immunoglobulin light chain variable domain, where a) each immunoglobulin heavy chain variable domain of the anti-NKG2C agent comprises first, second, and third heavy chain complementarity determining regions (CDRs), where the first heavy chain CDR (CDRH1) comprises an amino acid sequence that is at least 80% identical to the amino acid sequence X 1 X 2 X 3 X 4 X 5 (SEQ ID NO: 50), where X 1 is N, S, or D, X 2 is F, T, or Y, X 3 is G, Y, or W X 4 is M or I, and X 5 is H or N; the second heavy chain CDR (CDRH2) comprises an amino acid sequence that is at least 80% identical to the amino acid sequence
- first anti-NKG2C agent that binds NKG2C under laboratory or physiological conditions, where the first agent binds to the same epitope as a second anti-NKG2C agent, which the second agent comprises at least one immunoglobulin heavy chain variable domain and at least one immunoglobulin light chain variable domain, where a) each immunoglobulin heavy chain variable domain of the anti-NKG2C agent comprises first, second, and third heavy chain complementarity determining regions (CDRs), where the first heavy chain CDR (CDRH1) comprises an amino acid sequence that is at least 80% identical to the amino acid sequence X 1 X 2 X 3 X 4 X 5 (SEQ ID NO: 50), where X 1 is N, S, or D, X 2 is F, T, or Y, X 3 is G, Y, or M, X 4 is M or I, and X 5 is H or N; the second heavy chain CDR (CDRH2) comprises an amino acid sequence that is at least 80% identical to
- anti-NKG2C agents for detecting NKG2C in a heterogeneous population of immune cells, where NKG2C is detected at a significant level in NK cells and NK T- lymphocytes in the population, and NKG2C is not significantly detected in other immune cells in the population.
- methods of detecting NKG2C is a heterogeneous population of immune cells, comprising contacting the population with an anti-NKG2C agent provided herein, wherein NKG2C is not significantly detected in other immune cells in the population.
- isolated, non-naturally occurring anti-NKG2C agents particularly antibodies, or antigen-binding fragments or derivatives thereof, that bind NKG2C under physiological conditions.
- such molecules generally comprise two immunoglobulin heavy chain variable domains and two immunoglobulin light chain variable domains.
- each of the immunoglobulin heavy and light chain variable domains comprise first, second, and third complementarity determining regions (CDRs) arrayed as follows: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4.
- the first heavy chain CDR (CDRH1) comprises an amino acid sequence that has a sequence identity of at least 65%, optionally a sequence identity of at least 80%, at least 90%, at least 95%, and 100% identity with the amino acid sequence DYYMH, SFGMH, NFGMH, DTYIH, NYWMN, and DTYMH (SEQ ID NOS: 17, 23, 29, 33, 39, 45, respectively)
- the second heavy chain CDR (CDRH2) comprises an amino acid sequence that has a sequence identity of at least 65%, optionally a sequence of at least 80%, at least 90%, at least 95%, and 100% identity with the amino acid sequence Y RIDPANGYTKYDPKFQG (SEQ ID NOS: 18, 24, 30, 34, 40, 46, 49, respectively)
- the third heavy chain CDR (CDRH3) comprises an amino acid sequence that has a sequence identity of at least 65%, optionally a sequence identity of at least 80%, at least 90%, at least 95%, and 100% identity with the amino acid sequence DY
- the first light chain CDR (CDRL1) comprises an amino acid sequence that has a sequence identity of at least 65%, optionally a sequence identity of at least 80%, at least 90%, at least 95%, and 100% identity with the amino acid sequence SASSSVSYMY, KASQSVDYDGDSYMN, KSSQSVLYSSNQKNYLA, and KASQSVSNDVG (SEQ ID NOS: 20, 26, 36, 42, respectively)
- the second light chain CDR (CDRL2) comprises an amino acid sequence that has a sequence identity of at least 65%, optionally a sequence of at least 80%, at least 90%, at least 95%, and 100% identity with the amino acid sequence RTSNLAS, AASNLES, GASNLES, WASTRES, and YASNRYT (SEQ ID NOS: 21, 27, 32, 37, 43, respectively)
- the third light chain CDR (CDRL3) comprises an amino acid sequence that has a sequence identity of at least 65%, optionally a sequence identity of at least 80%, at least
- the isolated, non-naturally occurring anti-NKG2C antibodies, or NKG2C-binding fragments thereof including a first heavy chain CDR having the amino acid sequence NFGMH (SEQ ID NO: 29), the second heavy chain CDR has the amino acid sequence YISSGSSSIYYADTMKG (SEQ ID NO: 34), the third heavy chain CDR has the amino acid sequence SVIYYDYDRYLMDY (SEQ ID NO: 25), the first light chain CDR has the amino acid sequence KASQSVDYDGDSYMN (SEQ ID NO: 26) the second light chain CDR has the amino acid sequence GASNLES (SEQ ID NO: 32), and the third light chain CDR has the amino acid sequence QQSNEVPLT (SEQ ID NO: 38).
- the isolated anti-NKG2C agent comprises a non-naturally occurring anti-NKG2C antibody (mAb) comprising two immunoglobulin heavy chain variable domains comprising first, second, and third heavy chain complementarity determining regions (CDRH1-3, respectively) and two immunoglobulin light chain variable domains comprising first, second, and third light chain complementarity determining regions (CDRL1-3, respectively).
- mAb non-naturally occurring anti-NKG2C antibody
- CDRL1-3 two immunoglobulin heavy chain variable domains comprising first, second, and third heavy chain complementarity determining regions
- CDRL1-3 light chain complementarity determining regions
- the isolated anti-NKG2C agent comprises a non-naturally occurring anti-NKG2C antibody (mAb) comprising two immunoglobulin heavy chain variable domains and two immunoglobulin light chain variable domains, where the immunoglobulin heavy chain variable domains have an amino acid sequence selected from amongst SEQ ID NOs: 1-3 and 5-8 or an amino acid sequence having at least 65%-95% or more sequence identity with any such heavy chain variable domain sequence and the immunoglobulin light chain variable domains are selected from amongst SEQ ID NOS: 9-11 and 13-16 or an amino acid sequence having at least 65%-95% or more sequence identity with any such immunoglobulin light chain variable domain sequence.
- mAb non-naturally occurring anti-NKG2C antibody
- the antibodies (or fragments thereof) are monoclonal antibodies, and may be camel, human, humanized, mouse, rabbit, or other mammalian antibodies or antigen-binding antibody fragments.
- the antibody (antigen-binding antibody fragment) is an IgG.
- the IgG is an IgG1, IgG2a or IgG2b, or IgG3, or IgG4.
- anti-NKG2C antibodies and antigen-binding antibody fragments that are other than fully human antibodies (i.e., antibodies produced or derived from a mammal capable of producing all or a portion of the human antibody repertoire)
- the molecules are chimeric or humanized anti-NKG2C antibodies and antigen-binding antibody fragments.
- the anti-NKG2C antibody, antigen-binding antibody fragment, or derivative or variant thereof includes a detectable label.
- the anti-NKG2C agent for example, an anti-NKG2C antibody, antigen-binding antibody fragment, or derivative or variant thereof, is part of immunoconjugate that further includes a cytotoxic agent, for example, a nucleic acid, a peptide, a polypeptide, a small molecule, or an aptamer.
- a cytotoxic agent for example, a nucleic acid, a peptide, a polypeptide, a small molecule, or an aptamer.
- compositions may be packaged in containers, which in some embodiments, are further packaged into kits that also include instructions for use.
- kit instructions are a package insert containing not only instructions or use but also information about the pharmaceutically active ingredient (e.g., the anti- NKG2C antibody, antigen-binding antibody fragment, or derivative or variant thereof).
- Another related aspect concerns diagnostics configured to detect NKG2C in a biological sample, often a biological sample taken from a subject.
- kits include a diagnostic reagent that includes an anti- NKG2C agent described herein, for example, an anti-NKG2C antibody, antigen-binding antibody fragment, or derivative or variant thereof conjugated with detectable reagents such as fluorophores or enzyme substrates and/or immobilized on a solid support.
- detectable reagents such as fluorophores or enzyme substrates and/or immobilized on a solid support.
- Still other aspects of the technology provided herein concern the manufacture of an anti-NKG2C agent described herein.
- anti-NKG2C antibodies or antigen-binding antibody fragments or derivatives or variants thereof
- one such aspect concerns isolated nucleic acid molecules that encode polypeptides provided herein.
- such nucleic acid molecules encode an immunoglobulin heavy chain variable domain having a first heavy chain CDR (CDRH1) that includes an amino acid sequence that has a sequence identity of at least 65%, optionally a sequence identity of at least 80%, at least 90%, at least 95%, and 100% identity with the amino acid sequence 65%, optionally a sequence identity of at least 80%, at least 90%, at least 95%, and 100% identity with the amino acid sequence DYYMH, SFGMH, NFGMH, DTYIH, NYWMN, and DTYMH (SEQ ID NOS: 17, 23, 29, 33, 39, 45, respectively),
- the second heavy chain CDR (CDRH2) comprises an amino acid sequence that has a sequence identity of at least 65%, optionally a sequence of at least 80%, at least 90%, at least 95%, and 100% identity with the amino acid sequence WIDPENDDTEYAPKFQG, YISSGSSTIYYRDTLKG, YISSGSSTIYYADTVKG, YISSGSSSIYYAD
- Such nucleic acids may also encode an immunoglobulin light chain variable domain where a first light chain CDR (CDRL1) that includes an amino acid sequence that has a sequence identity of at last 65%, optionally a sequence identity of at least 80%, at least 90%, at least 95%, and 100% identity with the amino acid sequence SASSSVSYMY, KASQSVDYDGDSYMN, KSSQSVLYSSNQKNYLA, and KASQSVSNDVG (SEQ ID NOS: 20, 26, 36, 42, respectively), a second light chain CDR (CDRL2) that includes an amino acid sequence that has a sequence identity of at least 65%, optionally a sequence of at least 80%, at least 90%, at least 95%, and 100% identity with the amino acid sequence RTSNLAS, AASNLES, GASNLES, WASTRES, and YASNRYT (SEQ ID NOS: 21, 27, 32, 37, 43, respectively), and the third light chain CDR (CDRL3) comprises an amino acid sequence that has a sequence identity of at least 65%
- nucleic acid molecules provided herein encode an immunoglobulin heavy chain variable domain having an amino acid sequence selected from among SEQ ID NOS: 1-3 and 5-8 or an amino acid sequence having at least 65%-95% or more sequence identity with any such heavy chain variable domain sequence and an immunoglobulin light chain variable domain having an amino acid sequence selected from among SEQ ID NOS: 9-11 and 13-16 or an amino acid sequence having at least 65%-95% or more sequence identity with any such light chain variable domain sequence.
- Related aspects concern plasmids, and expression cassettes and vectors, that carry nucleic acids provided herein, as well as recombinant host cells transfected with such nucleic acid molecules.
- Still other aspects of the technology provided herein concern methods of treating or preventing a disease or disorder associated with aberrant levels of NKG2C.
- Such methods include administering to a subject in need of such treatment an anti-NKG2C agent provided herein (e.g., an anti-NKG2C antibody or antigen-binding fragment, derivative, or variant thereof) in an amount sufficient to effect treatment, thereby treating or preventing the disease or disorder.
- an anti-NKG2C agent provided herein e.g., an anti-NKG2C antibody or antigen-binding fragment, derivative, or variant thereof
- an adjuvant e.g., for vaccines.
- FIG.1 shows the amino acid sequence of a representative full-length human NKG2C protein (SEQ ID NO: 56).
- amino acid residues 1-70 comprise the cytoplasmic domain
- amino acid residues 71-93 comprise the transmembrane domain
- amino acid residues 94-231 comprise the extracellular domain.
- Figs.2A-2B shows the amino acid sequences of the variable domains of the immunoglobulin heavy (SEQ ID NOS: 1-3 and 5-8) and light (SEQ ID NOS: 9-11 and 13-16) chains of the eight different anti-NKG2C antibodies (AB1-8) provided herein.
- the CDR regions of each of the heavy and light chains are shown in bold and underline.
- FIG.3 lists the source, isotype and format for the anti-NKG2C agents described herein.
- Figs.4A-4D depict the gating strategy used for the detection of cells expressing NKG2C, as assessed by flow cytometry.
- FIG.4A shows the identification of singlets based on side scatter.
- FIG.4B shows the forward and side scatter of singlets from FIG.4A.
- FIG.4C shows lymphocytes co-stained with CD3 and CD19.
- FIG.4D shows CD3+CD19- lymphocytes co-stained with CD4 and CD8.
- FIG.5A and 5B depict results for surface expression of NKG2C on lymphocytes co-stained with CD56 and AB5.
- FIG.5A depicts a dot plot showing lymphocytes co-stained with AB5 and CD56.
- FIG.5B shows a histogram of lymphocytes stained with AB5.
- Figs.6A-6D depict dot plots of total lymphocytes (FIG.6A and FIG.6B) and CD3-CD19- lymphocytes (FIG.6C and FIG.6D) co-stained with CD56 and AB5 (FIG.6A A and FIG.6C) and CD56 and ABI (FIG.6B and FIG.6D).
- Figs.7A-7F depict histograms showing the staining of subsets of CD3+CD19- lymphocytes with AB5 (FIGs.7A-7C) and Commercial ABI (FIGs.7D-7F).
- Figs.8A-8P depict dot plots of total lymphocytes (FIGs.8A-8H) co-stained with CD94 and AB1 (FIG.
- Figs.9A-9D depict histograms of mouse splenocytes stained with AB3 (FIG.9A), AB4 (Fig.9B), AB5 (Fig.9C), and AB6 (Fig.9D).
- Figs.10A and 10B depict results of the ability of the anti-NKG2C antibodies described herein to mediate cell toxicity.
- Fig.10A depicts the percent of DAPI positive cells in a population of purified primary NK and K562 cells at different effector to target ratios (E:T), with no effector used as control.
- Fig.10B depicts the percent of DAPI positive cells after treatment with AB1-AB8 antibodies or no-antibody at 10 ⁇ g/well at an E:T of 2:1, or T only as control.
- agents that bind NKG2C are antibodies or fragments thereof or antigen binding fragments thereof, that bind to NKG2C.
- particular monoclonal antibodies to NKG2C that provide superior target specificity, signal-to-noise ratios, and the like, as compared to other reported anti-NKG2C antibodies, as well as antigen-binding fragments of such antibodies that bind NKG2C, are provided herein.
- NKG2 Killer Cell Lectin-Like Receptor
- CD159 Cluster of Differentiation 159
- the human NKG2 family comprises seven members referred to as NKG2A, NKG2B, NKG2C, NKG2D, NKG2E, NKG2F, and NKG2H. With the exception of NKG2D, all other NKG2 members share substantial sequence homology.
- NKG2A, NKG2B, NKG2C, NKG2E and NKG2H have been shown to form disulfide-linked heterodimers with the invariant Cluster of Differentiation 94 (CD94) protein, to form functionally distinct heterodimeric receptors.
- the CD94 associated NKG2 family members (CD94/NKG2) are comprised of C-type lectin receptors that are predominantly expressed on the surface of NK cells, as well as a subset of CD8 + T-lymphocytes.
- HLA Human Leukocyte Antigen
- NKG2A and NKG2B receptors contain immunoreceptor tyrosine-based inhibition motifs (ITAM) and transmit inhibitory signals
- the NKG2C, NKG2D, NKG2E, and NKG2H receptors are characterized by the presence of a charged amino acid residue in the transmembrane domain mediating interaction with DAP- 12, an adapter molecule containing an immunoreceptor tyrosine-based activation motif (ITAM), that transmit activating signals.
- ITAM immunoreceptor tyrosine-based activation motif
- the murine CD94-NKG2 receptors recognize the class Ib molecule Qa-1b.
- the CD94/NKG2C heterodimer is found on the surface of Natural Killer (NK) cells, a subset of T cells, including ⁇ T cells and memory T cells.
- NK Natural Killer
- binding to the HLA-E receptor delivers activating signals through immunoreceptor tyrosine-based activation motifs at the cytoplasmic tails of DAP12 transmembrane proteins (Call et al. Nat. Immunol 2010, 11:1023-9).
- Anti-NKG2C Agents The anti-NKG2C agents (e.g., anti-NKG2C antibodies) provided herein may have a strong binding affinity and/or specificity for NKG2C. In some embodiments, the anti-NKG2C agents provided herein bind all or a portion of the NKG2C receptor, or a fragment thereof. In some embodiments, the antibody or antigen-binding fragment thereof provided herein bind the NKG2C receptor or a fragment thereof.
- the anti-NKG2C agents provided herein bind a portion of the NKG2C receptor that is 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:56.
- the antibody or antigen-binding fragment thereof provided herein bind the NKG2C receptor or a fragment thereof that is 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:56.
- the anti-NKG2C agents provided herein bind all or a portion of the NKG2C receptor described in SEQ ID NO:56.
- the antibody or antigen-binding fragment thereof provided herein bind the NKG2C receptor or a fragment thereof comprising the sequence of amino acids described in SEQ ID NO:56.
- Precursor human NKG2C protein sequence (UniProtKB - P26717 (NKG2C_HUMAN)/ NCBI Reference Sequence: NP_002251.2) (SEQ ID NO: 56) MDNQGVIYSD LNLPPNPKRQ QRKPKGNKNS ILATEQEITYAELNLQKASQDFQG NDKTYHCKDLPSAPEK LIVGILGIIC LILMASVVTI VVIPSTLIQR HNNSSLNTRT QKARHCGHCPEEWITYSNSC YYIGKERRTW EESLLACTSK NSSLLSIDNE EEMKFLSIIS PSSWIGVFRNSSHHPWVTMN GLAFKHEIKD SDNAELNCAV LQVNRLKSAQ CGSSIIYHCK HKL
- the human NKG2C protein sequence comprises a cytoplasmic domain corresponding to amino acid residues 1-70 of SEQ ID NO:56. In some embodiments, the cytoplasmic domain corresponds to the sequence of amino acids of SEQ ID NO:96. In some embodiments, the human NKG2C protein sequence comprises a transmembrane domain corresponding to amino acid residues 71- 93 of SEQ ID NO:56. In some embodiments, the transmembrane domain corresponds to the sequence of amino acids of SEQ ID NO:97. In some embodiments, the human NKG2C protein sequence comprises an extracellular domain corresponding to amino acid residues 94-231 of SEQ ID NO:56.
- the extracellular domain corresponds to the sequence of amino acids of SEQ ID NO:98.
- the anti-NKG2C agents provided herein bind all or a portion of the NKG2C receptor extracellular domain. In some embodiments, the anti-NKG2C agents provided herein bind all or a portion of the NKG2C receptor extracellular domain corresponding to amino acid residues 94-231 of SEQ ID NO:56. In some embodiments, the anti-NKG2C agents provided herein bind all or a portion of the NKG2C receptor extracellular domain described in SEQ ID NO:98.
- the anti-NKG2C agents provided herein bind all or a portion of the NKG2C receptor extracellular domain that is 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid residues 94-231 of SEQ ID NO:56. In some embodiments, the anti-NKG2C agents provided herein bind all or a portion of the NKG2C receptor extracellular domain that is 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:98.
- the agent, antibody or antigen-binding fragment thereof provided herein bind the NKG2C receptor extracellular domain described in SEQ ID NO:98.
- anti-NKG2C agents may be chimeric antibodies.
- anti- NKG2C agents may be humanized antibodies.
- anti-NKG2C agents may be variant antibodies.
- Antibodies, for example, may have beneficial properties from a therapeutic perspective.
- Assays for determining the activity of anti-NKG2C antibodies provided herein include, for example, cell-based ELISA (e.g., to measure relative avidity of the antibody for the target on cells), flow cytometry (e.g., to measure cell specificity of the antibody), and cytotoxicity (e.g., to measure potential to mediate direct or indirect killing of NKG2C-expressing target cells).
- a humanized or variant antibody fails to elicit an immunogenic response upon administration of a therapeutically effective amount of the antibody to a human patient.
- the response may be such that the antibody still provides a therapeutic benefit to the patient treated therewith.
- the anti-NKG2C agents bind the same epitope.
- a cross-blocking assay such as that described in Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory, Ed Harlow and David Lane (1988), can be performed.
- epitope mapping e.g. as described in Champe et al., J. Biol.
- the anti-NKG2C agents provided herein may include anti- NKG2C antibodies, anti-NKG2C antibody fragments (e.g.,anti-NKG2C antigen binding fragments), and anti-NKG2C antibody derivatives.
- the agent is isolated (e.g., separated from a component of its natural environment (e.g. an animal, a biological sample)).
- the agent is non- naturally occurring (e.g., produced by human intervention).
- the agent is a humanized antibody, or an antigen binding fragment thereof.
- the agent is a derivative of a humanized antibody that binds NKG2C.
- the agent binds NKG2C under laboratory conditions (e.g., binds NKG2C in vitro, binds NKG2C in a flow cytometry assay, binds NKG2C in an ELISA).
- the agent binds NKG2C under physiological conditions (e.g., binds NKG2C in a cell in a subject).
- Antibodies such as those described herein may have an immunoglobulin heavy chain variable domain comprising an amino acid sequence represented by the formula: FRH1-CDRH1-FRH2-CDRH2-FRH3- CDRH3-FRH4, where “FRH1-4” represent the four heavy chain framework regions and “CDRH1-3” represent the three hypervariable regions of an anti-NKG2C antibody variable heavy domain.
- FRH1-4 may be derived from a consensus sequence (for example the most common amino acids of a class, subclass or subgroup of heavy or light chains of human immunoglobulins) or may be derived from an individual human antibody framework region or from a combination of different framework region sequences. Many human antibody framework region sequences are compiled in Kabat et al.
- variable heavy FR is provided by a consensus sequence of a human immunoglobulin subgroup as compiled by Kabat et al., supra.
- the human variable heavy FR sequence may have substitutions therein, e.g. where the human FR residue is replaced by a corresponding nonhuman residue (by “corresponding nonhuman residue” is meant the nonhuman residue with the same Kabat positional numbering as the human residue of interest when the human and nonhuman sequences are aligned), but replacement with the nonhuman residue is not necessary.
- a replacement FR residue other than the corresponding nonhuman residue may be selected by phage display.
- Antibodies such as those described herein, may have an immunoglobulin light chain variable domain comprising an amino acid sequence represented by the formula: FRL1-CDRL1-FRL2-CDRL2-FRL3- CDRL3-FRL4, where “FRL1-4” represents the four framework regions and “CDRL1-3” represents the three hypervariable regions of an anti-NKG2C antibody variable light domain.
- FRL1-4 may be derived from a consensus sequence (for example the most common amino acids of a class, subclass or subgroup of heavy or light chains of human immunoglobulins) or may be derived from an individual human antibody framework region or from a combination of different framework region sequences.
- the immunoglobulin variable light FR is provided by a consensus sequence of a human immunoglobulin subgroup as compiled by Kabat et al., supra.
- the human immunoglobulin variable light FR sequence may have substitutions therein, e.g. where the human FR residue is replaced by a corresponding mouse residue, but replacement with the nonhuman residue is not necessary. For example, a replacement residue other than the corresponding nonhuman residue may be selected by phage display.
- Methods for generating humanized anti-NKG2C antibodies of interest herein are elaborated in more detail below.
- the anti-NKG2C agent provided herein comprises at least one immunoglobulin heavy chain variable domain and at least one immunoglobulin light chain variable domain.
- an anti-NKG2C agent herein comprises two immunoglobulin heavy chain variable domains and two immunoglobulin light chain variable domains.
- each immunoglobulin heavy chain variable domain of the anti-NKG2C agent comprises first, second, and third heavy chain complementarity determining regions (CDRs; CDRH1, CDRH2, CDRH3)
- each immunoglobulin light chain variable domain of the anti-NKG2C agent comprises first, second, and third light chain CDRs (DCRL1, CDRL2, CDRL3).
- the first heavy chain CDR (CDRH1) of an anti-NKG2C agent provided herein comprises an amino acid sequence that is at least 80% identical to the amino acid sequence X 1 X 2 X 3 X 4 X 5 (SEQ ID NO: 50), X 1 is N, S, or D, X 2 is F, T, or Y, X 3 is G, Y, or W X 4 is M or I, and X 5 is H or N.
- the CDRH1 comprises and amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 50.
- the CDRH1 comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 50.
- the CDRH1 comprises an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 50. In some embodiments, the CDRH1 comprises the sequence of amino acids set forth in SEQ ID NO:50.
- the amino acid X 1 of SEQ ID NO: 50 may be substituted with any amino acid. In some embodiments, the amino acid X 1 of SEQ ID NO: 50 is substituted with a conservative amino acid (e.g., conservative to N, S, and/or D). In some embodiments, the amino acid X 1 of SEQ ID NO: 50 is substituted with a neutral amino acid. In some embodiments, the amino acid X 1 of SEQ ID NO: 50 is substituted with a hydrophilic amino acid.
- the amino acid X 1 of SEQ ID NO: 50 is substituted with an acidic amino acid.
- the amino acid X 2 of SEQ ID NO: 50 may be substituted with any amino acid.
- the amino acid X 2 of SEQ ID NO: 50 is substituted with a conservative amino acid (e.g., conservative to F, T, and/or Y).
- the amino acid X 2 of SEQ ID NO: 50 is substituted with an aromatic amino acid.
- the amino acid X 2 of SEQ ID NO: 50 is substituted with a hydrophilic amino acid.
- the amino acid X 3 of SEQ ID NO: 50 may be substituted with any amino acid.
- the amino acid X 3 of SEQ ID NO: 50 is substituted with a conservative amino acid (e.g., conservative to G, Y, and/or W). In some embodiments, the amino acid X 3 of SEQ ID NO: 50 is substituted with an amino acid that influences chain orientation. In some embodiments, the amino acid X 3 of SEQ ID NO: 50 is substituted with an aromatic amino acid. In some embodiments, the amino acid X3 of SEQ ID NO: 50 is substituted with a hydrophobic amino acid. The amino acid X 4 of SEQ ID NO: 50 may be substituted with any amino acid.
- the amino acid X 4 of SEQ ID NO: 50 is substituted with a conservative amino acid (e.g., conservative to M and/or I). In some embodiments, the amino acid X 4 of SEQ ID NO: 50 is substituted with a hydrophobic amino acid.
- the amino acid X 5 of SEQ ID NO: 50 may be substituted with any amino acid. In some embodiments, the amino acid X 5 of SEQ ID NO: 50 is substituted with a conservative amino acid (e.g., conservative to H and/or N). In some embodiments, the amino acid X 5 of SEQ ID NO: 50 is substituted with a basic amino acid.
- the amino acid X 5 of SEQ ID NO: 50 is substituted with a neutral hydrophilic amino acid.
- the CDRH1 of any of the anti-NKG2C agent provided herein comprises an amino acid sequence chosen from DYYMH (SEQ ID NO: 17), SFGMH (SEQ ID NO: 23), NFGMH (SEQ ID NO: 29), DTYIH (SEQ ID NO: 33), NYWMN (SEQ ID NO: 39), and DTYMH (SEQ ID NO: 45).
- the CDRH1 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids DYYMH (SEQ ID NO: 17), or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:17.
- the CDRH1 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids DYYMH (SEQ ID NO: 17).
- the CDRH1 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids SFGMH (SEQ ID NO: 23), or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:23.
- the CDRH1 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids SFGMH (SEQ ID NO: 23).
- the CDRH1 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids NFGMH (SEQ ID NO: 29), or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:29.
- the CDRH1 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids NFGMH (SEQ ID NO: 29).
- the CDRH1 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids DTYIH (SEQ ID NO: 33), or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:33.
- the CDRH1 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids DTYIH (SEQ ID NO: 33).
- the CDRH1 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids NYWMN (SEQ ID NO: 39), or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:39.
- the CDRH1 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids NYWMN (SEQ ID NO: 39).
- the CDRH1 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids DTYMH (SEQ ID NO: 45), or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:45.
- the CDRH1 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids DTYMH (SEQ ID NO: 45).
- the second heavy chain CDR (CDRH2) of an anti-NKG2C agent provided herein comprises an amino acid sequence that is at least 80% identical to the amino acid sequence X 1 IX 3 X 4 X 5 X 6 X 7 X 8 X 9 X 10 X 11 X 12 X 13 X 14 X 15 X 16 X 17 (SEQ ID NO: 51), where X 1 is Y, R, W, or M; X 3 is S, D, or H; X 4 is S or P; X 5 is G, E, A, or S; X 6 is S, N, or D; X 7 is S, G, or D; X 8 is T, S, N, Y, D, or E; X 9 is I or T; X 10 is Y, K, E, or R; X 11 is Y or L; X 12 is A, R, D, or N; X 13 is D, P, or Q; X 14 is T or K;
- the CDRH2 comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 51. In some embodiments, the CDRH2 comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 51. In some embodiments, the CDRH2 comprises an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 51. In some embodiments, the CDRH2 comprises the sequence of amino acids set forth in SEQ ID NO: 51. The amino acid X 1 of SEQ ID NO: 51 may be substituted with any amino acid.
- the amino acid X 1 of SEQ ID NO: 51 is substituted with a conservative amino acid (e.g., Y, R, W, and/or M). In some embodiments, the amino acid X 1 of SEQ ID NO: 51 is substituted with an aromatic amino acid. In some embodiments, the amino acid X 1 of SEQ ID NO: 51 is substituted with a basic amino acid. In some embodiments, the amino acid X 1 of SEQ ID NO: 51 is substituted with a hydrophobic amino acid. The amino acid X 3 of SEQ ID NO: 51 may be substituted with any amino acid.
- a conservative amino acid e.g., Y, R, W, and/or M
- the amino acid X 1 of SEQ ID NO: 51 is substituted with an aromatic amino acid.
- the amino acid X 1 of SEQ ID NO: 51 is substituted with a basic amino acid.
- the amino acid X 1 of SEQ ID NO: 51 is substituted with a hydrophobic amino acid.
- the amino acid X 3 of SEQ ID NO: 51 is substituted with a conservative amino acid (e.g., S, D, and/or H). In some embodiments, the amino acid X 3 of SEQ ID NO: 51 is substituted with a hydrophilic amino acid. In some embodiments, the amino acid X 3 of SEQ ID NO: 51 is substituted with an acidic amino acid. In some embodiments, the amino acid X 3 of SEQ ID NO: 51 is substituted with a basic amino acid. The amino acid X 4 of SEQ ID NO: 51 may be substituted with any amino acid. In some embodiments, the amino acid X 4 of SEQ ID NO: 51 is substituted with a conservative amino acid (e.g., S and/or P).
- a conservative amino acid e.g., S, D, and/or H
- the amino acid X 3 of SEQ ID NO: 51 is substituted with a hydrophilic amino acid. In some embodiments, the amino acid X 3 of SEQ ID NO: 51 is substituted with
- the amino acid X 4 of SEQ ID NO: 51 is a hydrophilic amino acid. In some embodiments, the amino acid X 4 of SEQ ID NO: 51 is an amino acid that influences chain orientation.
- the amino acid X 5 of SEQ ID NO: 51 may be substituted with any amino acid. In some embodiments, the amino acid X 5 of SEQ ID NO: 51 is substituted with a conservative amino acid (e.g., G, E, A, and/or S). In some embodiments, the amino acid X 5 of SEQ ID NO: 51 is an amino acid that influences chain orientation. In some embodiments, the amino acid X 5 of SEQ ID NO: 51 is an acidic amino acid.
- the amino acid X 5 of SEQ ID NO: 51 is a hydrophobic amino acid. In some embodiments, the amino acid X 5 of SEQ ID NO: 51 is a hydrophilic amino acid.
- the amino acid X 6 of SEQ ID NO: 51 may be substituted with any amino acid. In some embodiments, the amino acid X 6 of SEQ ID NO: 51 is substituted with a conservative amino acid (e.g., S, N, and/or D).
- the amino acid X 6 of SEQ ID NO: 51 is a hydrophilic amino acid. In some embodiments, the amino acid X 6 of SEQ ID NO: 51 is an acidic amino acid.
- the amino acid X 7 of SEQ ID NO: 51 may be substituted with any amino acid.
- the amino acid X 7 of SEQ ID NO: 51 is substituted with a conservative amino acid (e.g., S, G, and/or D).
- the amino acid X 7 of SEQ ID NO: 51 is a hydrophilic amino acid.
- the amino acid X 7 of SEQ ID NO: 51 is an amino acid that influences chain orientation.
- the amino acid X 7 of SEQ ID NO: 51 is an acidic amino acid.
- the amino acid X 8 of SEQ ID NO: 51 may be substituted with any amino acid.
- the amino acid X 8 of SEQ ID NO: 51 is substituted with a conservative amino acid (e.g., T, S, N, Y, D, and/or E).
- the amino acid X 8 of SEQ ID NO: 51 is a hydrophilic amino acid. In some embodiments, the amino acid X 8 of SEQ ID NO: 51 is an aromatic amino acid. In some embodiments, the amino acid X 8 of SEQ ID NO: 51 is an acidic amino acid.
- the amino acid X 9 of SEQ ID NO: 51 may be substituted with any amino acid. In some embodiments, the amino acid X 9 of SEQ ID NO: 51 is substituted with a conservative amino acid (e.g., I and/or T). In some embodiments, the amino acid X 9 of SEQ ID NO: 51 is a hydrophobic amino acid. In some embodiments, the amino acid X 9 of SEQ ID NO: 51 is a hydrophilic amino acid.
- the amino acid X 10 of SEQ ID NO: 51 may be substituted with any amino acid.
- the amino acid X 10 of SEQ ID NO: 51 is substituted with a conservative amino acid (e.g. Y, K, E, and/or R).
- the amino acid X 10 of SEQ ID NO: 51 is an aromatic amino acid.
- the amino acid X 10 of SEQ ID NO: 51 is a basic amino acid.
- the amino acid X 10 of SEQ ID NO: 51 is an acidic amino acid.
- the amino acid X 11 of SEQ ID NO: 51 may be substituted with any amino acid.
- the amino acid X 11 of SEQ ID NO: 51 is substituted with a conservative amino acid (e.g., Y and/or L). In some embodiments, the amino acid X 11 of SEQ ID NO: 51 is substituted with an aromatic amino acid. In some embodiments, the amino acid X 11 of SEQ ID NO: 51 is substituted with a hydrophobic amino acid.
- the amino acid X 12 of SEQ ID NO: 51 may be substituted with any amino acid. In some embodiments, the amino acid X 12 of SEQ ID NO: 51 is substituted with a conservative amino acid (e.g., A, R, D, and/or N). In some embodiments, the amino acid X 12 of SEQ ID NO: 51 is a hydrophobic amino acid.
- the amino acid X 12 of SEQ ID NO: 51 is a basic amino acid. In some embodiments, the amino acid X 12 of SEQ ID NO: 51 is an acid amino acid. In some embodiments, the amino acid X 12 of SEQ ID NO: 51 is a hydrophilic amino acid. The amino acid X 13 of SEQ ID NO: 51 may be substituted with any amino acid. In some embodiments, the amino acid X 13 of SEQ ID NO: 51 is substituted with a conservative amino acid (e.g., D, P, and/or Q). In some embodiments, the amino acid X 13 of SEQ ID NO: 51 is an acidic amino acid. In some embodiments, the amino acid X 13 of SEQ ID NO: 51 is an amino acid that influences chain orientation.
- a conservative amino acid e.g., D, P, and/or Q
- the amino acid X 13 of SEQ ID NO: 51 is a hydrophilic amino acid.
- the amino acid X 14 of SEQ ID NO: 51 may be substituted with any amino acid.
- the amino acid X 14 of SEQ ID NO: 51 is substituted with a conservative amino acid (e.g., T and/or K).
- the amino acid X 14 of SEQ ID NO: 51 is a hydrophilic amino acid.
- the amino acid X 14 of SEQ ID NO: 51 is a basic amino acid.
- the amino acid X 15 of SEQ ID NO: 51 may be substituted with any amino acid.
- the amino acid X 15 of SEQ ID NO: 51 is substituted with a conservative amino acid (e.g., V, L, M, and/or F).
- the amino acid X 15 of SEQ ID NO: 51 is a hydrophobic amino acid.
- the amino acid X 15 of SEQ ID NO: 51 is an aromatic amino acid.
- the amino acid X 16 of SEQ ID NO: 51 may be substituted with any amino acid.
- the amino acid X 16 of SEQ ID NO: 51 is substituted with a conservative amino acid (e.g., K and/or Q).
- the amino acid X 16 of SEQ ID NO: 51 is a basic amino acid.
- the amino acid X 16 of SEQ ID NO: 51 is a hydrophilic amino acid.
- the amino acid X 17 of SEQ ID NO: 51 may be substituted with any amino acid.
- the amino acid X 17 of SEQ ID NO: 51 is substituted with a conservative amino acid (e.g., G and/or D).
- the amino acid X 17 of SEQ ID NO: 51 is an amino acid that influences chain orientation.
- the amino acid X 17 of SEQ ID NO: 51 is an acidic amino acid.
- the CDRH2 of any of the anti-NKG2C agents provided herein comprises an amino acid sequence chosen from WIDPENDDTEYAPKFQG (SEQ ID NO: 18), YISSGSSTIYYRDTLKG (SEQ ID NO: 24), YISSGSSTIYYADTVKG (SEQ ID NO: 30), YISSGSSSIYYADTMKG (SEG ID NO: 34), RIDPENGNTKYDPKFQG (SEQ ID NO: 40), MIHPSDSETRLNQKFKD (SEQ ID NO: 46), and RIDPANGYTKYDPKFQG (SEQ ID NO: 49).
- the CDRH2 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids WIDPENDDTEYAPKFQG (SEQ ID NO: 18), or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 18.
- the CDRH2 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids WIDPENDDTEYAPKFQG (SEQ ID NO: 18).
- the CDRH2 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids YISSGSSTIYYRDTLKG (SEQ ID NO: 24), or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 24.
- the CDRH2 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids YISSGSSTIYYRDTLKG (SEQ ID NO: 24).
- the CDRH2 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids YISSGSSTIYYADTVKG (SEQ ID NO: 30), or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 30.
- the CDRH2 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids YISSGSSTIYYADTVKG (SEQ ID NO: 30).
- the CDRH2 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids YISSGSSSIYYADTMKG (SEG ID NO: 34), or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 34.
- the CDRH2 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids YISSGSSSIYYADTMKG (SEG ID NO: 34).
- the CDRH2 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids RIDPENGNTKYDPKFQG (SEQ ID NO: 40), or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 40.
- the CDRH2 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids RIDPENGNTKYDPKFQG (SEQ ID NO: 40).
- the CDRH2 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids MIHPSDSETRLNQKFKD (SEQ ID NO: 46), or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 46.
- the CDRH2 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids MIHPSDSETRLNQKFKD (SEQ ID NO: 46).
- the CDRH2 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids RIDPANGYTKYDPKFQG (SEQ ID NO: 49), or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 49.
- the CDRH2 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids RIDPANGYTKYDPKFQG (SEQ ID NO: 49).
- the third heavy chain CDR (CDRH3) of an anti-NKG2C agent provided herein comprises an amino acid sequence that is at least 80% identical to the amino acid sequence X 1 X 2 X 3 X 4 X 5 X 6 X 7 X 8 X 9 X 10 X 11 X 12 X 13 X 14 (SEQ ID NO: 52), where X 1 is S, T, V or H, X 2 is V, A, I, or H or Y, X 3 is I, T, H, or G, X 4 is Y, V, T, or S, X 5 is Y, F, H, or N, X 6 is A, D, W, or Y, X 7 is Y, G, or no amino acid, X 8 is D or no amino acid, X 9 is R or no amino acid, X 10 is Y or no amino acid, X 11 is L, Y, N, or W or no amino acid, X 12 is M, F, or
- the third heavy chain CDR (CDRH3) of an anti-NKG2C agent provided herein comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 52. In some embodiments, the CDRH3 comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 52. In some embodiments, the CDRH3 comprises an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 52. In some embodiments, the CDRH3 comprises the sequence of amino acids set forth in SEQ ID NO: 52. The amino acid X 1 of SEQ ID NO: 52 may be substituted with any amino acid.
- the amino acid X 1 of SEQ ID NO: 52 is substituted with a conservative amino acid (e.g., S, T, V and/or H). In some embodiments, the amino acid X 1 of SEQ ID NO: 52 is substituted with a hydrophilic amino acid. In some embodiments, the amino acid X 1 of SEQ ID NO: 52 is substituted with a hydrophobic amino acid.
- the amino acid X 2 of SEQ ID NO: 52 may be substituted with any amino acid. In some embodiments, the amino acid X 2 of SEQ ID NO: 52 is substituted with a conservative amino acid (e.g., V, A, I, H and/or Y).
- the amino acid X 2 of SEQ ID NO: 52 is substituted with a hydrophobic amino acid.
- the amino acid X 2 of SEQ ID NO: 52 is a basic amino acid.
- the amino acid X 3 of SEQ ID NO: 52 may be substituted with any amino acid.
- the amino acid X 3 of SEQ ID NO: 52 is substituted with a conservative amino acid (e.g., I, T, H, and/or G).
- the amino acid X 3 of SEQ ID NO: 52 is substituted with a hydrophobic amino acid.
- the amino acid X 3 of SEQ ID NO: 52 is substituted with a basic amino acid.
- the amino acid X 3 of SEQ ID NO: 52 is substituted with an amino acid that influences chain orientation.
- the amino acid X 4 of SEQ ID NO: 52 may be substituted with any amino acid.
- the amino acid X 4 of SEQ ID NO: 52 is substituted with a conservative amino acid (e.g., Y, V, T, and/or S).
- the amino acid X 4 of SEQ ID NO: 52 is substituted with an aromatic amino acid.
- the amino acid X 4 of SEQ ID NO: 52 is substituted with a hydrophobic amino acid.
- the amino acid X 4 of SEQ ID NO: 52 is substituted with a hydrophilic amino acid.
- the amino acid X 5 of SEQ ID NO: 52 may be substituted with any amino acid.
- the amino acid X 5 of SEQ ID NO: 52 is substituted with a conservative amino acid (e.g., Y, F, H, and/or N).
- the amino acid X 5 of SEQ ID NO: 52 is substituted with an aromatic amino acid.
- the amino acid X 5 of SEQ ID NO: 52 is substituted with a basic amino acid.
- the amino acid X 5 of SEQ ID NO: 52 is substituted with a hydrophilic amino acid.
- the amino acid X 6 of SEQ ID NO: 52 may be substituted with any amino acid.
- the amino acid X 6 of SEQ ID NO: 52 is substituted with a conservative amino acid (e.g., A, D, W, and/or Y). In some embodiments, the amino acid X 6 of SEQ ID NO: 52 is substituted with a hydrophobic amino acid. In some embodiments, the amino acid X 6 of SEQ ID NO: 52 is substituted with an acidic amino acid. In some embodiments, the amino acid X 6 of SEQ ID NO: 52 is substituted with an aromatic amino acid. The amino acid X 7 of SEQ ID NO: 52 may be substituted with any amino acid.
- a conservative amino acid e.g., A, D, W, and/or Y
- the amino acid X 6 of SEQ ID NO: 52 is substituted with a hydrophobic amino acid.
- the amino acid X 6 of SEQ ID NO: 52 is substituted with an acidic amino acid.
- the amino acid X 6 of SEQ ID NO: 52 is substituted with an aromatic amino acid.
- the amino acid X 7 of SEQ ID NO: 52 is substituted with a conservative amino acid (e.g., Y, G, and/or no amino acid). In some embodiments, the amino acid X 7 of SEQ ID NO: 52 is substituted with an aromatic amino acid. In some embodiments, the amino acid X 7 of SEQ ID NO: 52 is substituted with an amino acid that influences chain orientation. In some embodiments, the amino acid X 7 of SEQ ID NO: 52 is substituted with no amino acid. The amino acid X 8 of SEQ ID NO: 52 may be substituted with any amino acid. In some embodiments, the amino acid X 8 of SEQ ID NO: 52 is substituted with a conservative amino acid (e.g., D and/or no amino acid).
- a conservative amino acid e.g., Y, G, and/or no amino acid.
- the amino acid X 8 of SEQ ID NO: 52 is substituted with an acidic amino acid. In some embodiments, the amino acid X 8 of SEQ ID NO: 52 is substituted with no amino acid.
- the amino acid X 9 of SEQ ID NO: 52 may be substituted with any amino acid. In some embodiments, the amino acid X 9 of SEQ ID NO: 52 is substituted with a conservative amino acid (e.g., R and/or no amino acid). In some embodiments, the amino acid X 9 of SEQ ID NO: 52 is substituted with a basic amino acid. In some embodiments, the amino acid X 9 of SEQ ID NO: 52 is substituted with no amino acid.
- the amino acid X 10 of SEQ ID NO: 52 may be substituted with any amino acid. In some embodiments, the amino acid X 10 of SEQ ID NO: 52 is substituted with a conservative amino acid (e.g. Y and/or no amino acid). In some embodiments, the amino acid X 10 of SEQ ID NO: 52 is substituted with an aromatic amino acid. In some embodiments, the amino acid X 10 of SEQ ID NO: 52 is substituted with no amino acid. The amino acid X 11 of SEQ ID NO: 52 may be substituted with any amino acid. In some embodiments, the amino acid X 11 of SEQ ID NO: 52 is substituted with a conservative amino acid (e.g., L, Y, N, W and/or no amino acid).
- a conservative amino acid e.g., L, Y, N, W and/or no amino acid.
- the amino acid X 11 of SEQ ID NO: 52 is substituted with a hydrophobic amino acid. In some embodiments, the amino acid X 11 of SEQ ID NO: 52 is substituted with an aromatic amino acid. In some embodiments, the amino acid X 11 of SEQ ID NO: 52 is substituted with a hydrophilic amino acid.
- the amino acid X 12 of SEQ ID NO: 52 may be substituted with any amino acid. In some embodiments, the amino acid X 12 of SEQ ID NO: 52 is substituted with a conservative amino acid (e.g., M, F, D and/or no amino acid). In some embodiments, the amino X 12 of SEQ ID NO: 52 is substituted with a hydrophobic amino acid.
- the amino acid X 12 of SEQ ID NO: 52 is substituted with an aromatic amino acid. In some embodiments, the amino acid X 12 of SEQ ID NO: 52 is substituted with an acidic amino acid.
- the amino acid X 13 of SEQ ID NO: 52 may be substituted with any amino acid. In some embodiments, the amino acid X 13 of SEQ ID NO: 52 is substituted with a conservative amino acid (e.g., D, P, and/or A). In some embodiments, the amino acid X 13 of SEQ ID NO: 52 is substituted with an acidic amino acid. In some embodiments, the amino acid X 13 of SEQ ID NO: 52 is substituted with an amino acid that influences chain orientation.
- the amino acid X 13 of SEQ ID NO: 52 is substituted with a hydrophobic amino acid.
- the amino acid X 14 of SEQ ID NO: 52 may be substituted with any amino acid.
- the amino acid X 14 of SEQ ID NO: 52 is substituted with a conservative amino acid (e.g., F, Y, and/or V).
- the amino acid X 14 of SEQ ID NO: 52 is substituted with an aromatic amino acid.
- the amino acid X 14 of SEQ ID NO: 52 is substituted with a hydrophobic amino acid.
- the CDRH3 of anti-NKG2C agents provided herein comprises an amino acid sequence chosen from HYHYNDPY (SEQ ID NO: 19), SVIYYDYDRYLMDY (SEQ ID NO: 25), SVIYYAYDRYLMDF (SEQ ID NO: 31), TATVFWYFDV (SEQ ID NO: 35), SHGSNYGWFAY (SEQ ID NO: 41), and VITTHWYFDV (SEQ ID NO: 47).
- the CDRH3 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids HYHYNDPY (SEQ ID NO: 19), or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 19.
- the CDRH3 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids HYHYNDPY (SEQ ID NO: 19).
- the CDRH3 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids SVIYYDYDRYLMDY (SEQ ID NO: 25), or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 25.
- the CDRH3 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids SVIYYDYDRYLMDY (SEQ ID NO: 25).
- the CDRH3 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids SVIYYAYDRYLMDF (SEQ ID NO: 31), or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 31.
- the CDRH3 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids SVIYYAYDRYLMDF (SEQ ID NO: 31).
- the CDRH3 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids TATVFWYFDV (SEQ ID NO: 35), or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 35.
- the CDRH3 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids TATVFWYFDV (SEQ ID NO: 35).
- the CDRH3 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids SHGSNYGWFAY (SEQ ID NO: 41), or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 41.
- the CDRH3 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids SHGSNYGWFAY (SEQ ID NO: 41).
- the CDRH3 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids VITTHWYFDV (SEQ ID NO: 47), or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 47.
- the CDRH3 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids VITTHWYFDV (SEQ ID NO: 47).
- the first light chain CDR (CDRL1) of an anti-NKG2C agent provided herein comprises an amino acid sequence that is at least 80% identical to the amino acid sequence KX 2 SX 4 SVX 7 X 8 X 9 X 10 X 11 X 12 X 13 X 14 X 15 X 16 X 17 (SEQ ID NO: 53), where X 1 is S or K , X 2 is A or S, X 4 is Q or S, X 7 is D, L, S, or no amino acid, X 8 is Y or no amino acid, X 9 is D, S, or no amino acid, X 10 is G, S, or no amino acid, X 11 is D, N, or no amino acid, X 12 is Q or no amino acid, X 13 is K or no amino acid, X 14 is S or N, X 15 is Y or D, X 16 is M, L, or V; and X 17 is Y, N, A or G.
- the CDRL1 comprises an amino acid sequence that is 90% identical to the amino acid sequence of SEQ ID NO: 53. In some embodiments, the CDRL1 comprises and amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 53. In some embodiments, the CDRL1 comprises an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 53. In some embodiments, the CDRL1 comprises the sequence of amino acids set forth in SEQ ID NO: 53.
- the amino acid X 1 of SEQ ID NO: 53 may be substituted with any amino acid. In some embodiments, the amino acid X1 of SEQ ID NO: 53 is substituted with a conservative amino acid (e.g., S and/or K , ).
- the amino acid X 1 of SEQ ID NO: 53 is substituted with a hydrophobic amino acid. In some embodiments, the amino acid X 1 of SEQ ID NO: 53 is substituted with a hydrophilic amino acid.
- the amino acid X 2 of SEQ ID NO: 53 may be substituted with any amino acid. In some embodiments, the amino acid X2 of SEQ ID NO: 53 is substituted with a conservative amino acid (e.g., A and/or S). In some embodiments, the amino acid X 2 of SEQ ID NO: 53 is substituted with a hydrophobic amino acid. In some embodiments, the amino acid X 2 of SEQ ID NO: 53 is substituted with a hydrophilic amino acid.
- the amino acid X 4 of SEQ ID NO: 53 may be substituted with any amino acid. In some embodiments, the amino acid X 4 of SEQ ID NO: 53 is substituted with a conservative amino acid (e.g., Q and/or S). In some embodiments, the amino acid X 4 of SEQ ID NO: 53 is substituted with a hydrophilic amino acid.
- the amino acid X 7 of SEQ ID NO: 53 may be substituted with any amino acid. In some embodiments, the amino acid X 7 of SEQ ID NO: 53 is substituted with a conservative amino acid (e.g., D, L, S, and/or no amino acid). In some embodiments, the amino acid X 7 of SEQ ID NO: 53 is substituted with an acidic amino acid.
- the amino acid X 7 of SEQ ID NO: 53 is substituted with a hydrophobic amino acid. In some embodiments, the amino acid X 7 of SEQ ID NO: 53 is substituted with a hydrophilic amino acid. In some embodiments, the amino acid X 7 of SEQ ID NO: 53 is substituted with no amino acid.
- the amino acid X 8 of SEQ ID NO: 53 may be substituted with any amino acid. In some embodiments, the amino acid X 8 of SEQ ID NO: 53 is substituted with a conservative amino acid (e.g., Y and/or no amino acid). In some embodiments, the amino acid X 8 of SEQ ID NO: 53 is substituted with an aromatic amino acid.
- the amino acid X 8 of SEQ ID NO: 53 is substituted with no amino acid.
- the amino acid X 9 of SEQ ID NO: 53 may be substituted with any amino acid.
- the amino acid X 9 of SEQ ID NO: 53 is substituted with a conservative amino acid (e.g., D, S, and/or no amino acid).
- the amino acid X 9 of SEQ ID NO: 53 is substituted with an acidic amino acid.
- the amino acid X 9 of SEQ ID NO: 53 is substituted with a hydrophilic amino acid.
- the amino acid X 9 of SEQ ID NO: 53 is substituted with no amino acid.
- the amino acid X 10 of SEQ ID NO: 53 may be substituted with any amino acid.
- the amino acid X 10 of SEQ ID NO: 53 is substituted with a conservative amino acid (e.g., G, S, and/or no amino acid).
- the amino acid X 10 of SEQ ID NO: 53 is substituted with an amino acid that influences chain orientation.
- the amino acid X 10 of SEQ ID NO: 53 the amino acid is substituted with a hydrophilic amino acid.
- the amino acid X 10 of SEQ ID NO: 53 is substituted with no amino acid.
- the amino acid X 11 of SEQ ID NO: 53 may be substituted with any amino acid.
- the amino acid X 11 of SEQ ID NO: 53 is substituted with a conservative amino acid (e.g., D, N, and/or no amino acid). In some embodiments, the amino acid X 11 of SEQ ID NO: 53 is substituted with an acidic amino acid. In some embodiments, the amino acid X 11 of SEQ ID NO: 53 is substituted with a hydrophilic amino acid. In some embodiments, the amino acid X 11 of SEQ ID NO: 53 is substituted with no amino acid.
- the amino acid X 12 of SEQ ID NO: 53 may be substituted with any amino acid. In some embodiments, the amino acid X 12 of SEQ ID NO: 53 is substituted with a conservative amino acid (e.g., Q and/or no amino acid).
- the amino acid X 12 of SEQ ID NO: 53 is substituted with a hydrophilic amino acid. In some embodiments, the amino acid X 12 of SEQ ID NO: 53 is substituted with no amino acid.
- the amino acid X 13 of SEQ ID NO: 53 may be substituted with any amino acid. In some embodiments, the amino acid X 13 is substituted with a conservative amino acid (e.g., K and/or no amino acid). In some embodiments, the amino acid X 13 of SEQ ID NO: 53 is substituted with a basic amino acid. In some embodiments, the amino acid X 13 of SEQ ID NO: 53 is substituted with no amino acid.
- the amino acid X 14 of SEQ ID NO: 53 may be substituted with any amino acid.
- the amino acid X 14 of SEQ ID NO: 53 is substituted with a conservative amino acid (e.g., S and/or N). In some embodiments, the amino acid X 14 of SEQ ID NO: 53 is substituted with a hydrophilic amino acid. The amino acid X 15 of SEQ ID NO: 53 may be substituted with any amino acid. In some embodiments, the amino acid X 15 of SEQ ID NO: 53 is substituted with a conservative amino acid (e.g., Y and/or D). In some embodiments, the amino acid X 15 of SEQ ID NO: 53 is substituted with an aromatic amino acid. In some embodiments, the amino acid X 15 of SEQ ID NO: 53 is substituted with an acidic amino acid.
- a conservative amino acid e.g., S and/or N
- the amino acid X 14 of SEQ ID NO: 53 is substituted with a hydrophilic amino acid.
- the amino acid X 15 of SEQ ID NO: 53 may be substituted with any amino acid.
- the amino acid X 16 of SEQ ID NO: 53 may be substituted with any amino acid. In some embodiments, the amino acid X 16 of SEQ ID NO: 53 is substituted with a conservative amino acid (e.g., M, L, and/or V). In some embodiments, the amino acid X 16 of SEQ ID NO: 53 is substituted with a hydrophobic amino acid.
- the amino acid X 17 of SEQ ID NO: 53 may be substituted with any amino acid. In some embodiments, the amino acid X17 of SEQ ID NO: 53 is substituted with a conservative amino acid (e.g., Y, N, A and/or G , ).
- the amino acid X 17 of SEQ ID NO: 53 is substituted with a hydrophobic amino acid. In some embodiments, the amino acid X 17 of SEQ ID NO: 53 is substituted with a hydrophilic amino acid.
- the CDRL1 of any of the anti-NKG2C agents provided herein comprises an amino acid sequence chosen from SASSSVSYMY (SEQ ID NO: 20), KASQSVDYDGDSYMN (SEQ ID NO: 26), KSSQSVLYSSNQKNYLA (SEQ ID NO: 36), and KASQSVSNDVG (SEQ ID NO: 42).
- the CDRL1 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids SASSSVSYMY (SEQ ID NO: 20), or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:20.
- the CDRL1 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids SASSSVSYMY (SEQ ID NO: 20).
- the CDRL1 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids KASQSVDYDGDSYMN (SEQ ID NO: 26), or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:26.
- the CDRL1 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids KASQSVDYDGDSYMN (SEQ ID NO: 26).
- the CDRL1 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids KSSQSVLYSSNQKNYLA (SEQ ID NO: 36), or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:36.
- the CDRL1 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids KSSQSVLYSSNQKNYLA (SEQ ID NO: 36).
- the CDRL1 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids KASQSVSNDVG (SEQ ID NO: 42), or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:42.
- the CDRL1 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids KASQSVSNDVG (SEQ ID NO: 42).
- the second light chain CDR (CDRL2) of an anti-NKG2C agent provided herein comprises an amino acid sequence that is at least 80% identical to the amino acid sequence X 1 X 2 SX 4 X 5 X 6 X 7 (SEQ ID NO: 54), where X 1 is G, A, R, W, or Y, X 2 is A or T, X 4 is N or T, X 5 is L or R, X 6 is E or Y or A, and X 7 is S or T.
- the CDRL2 comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 54.
- the CDRL2 comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 54. In some embodiments, the CDRL2 comprises an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 54. n some embodiments, the CDRL2 comprises the sequence of amino acids set forth in SEQ ID NO: 54.
- the amino acid X 1 of SEQ ID NO: 54 may be substituted with any amino acid. In some embodiments, the amino acid X 1 of SEQ ID NO: 54 is substituted with a conservative amino acid (e.g., G, A, R, W, and/or Y). In some embodiments, the amino acid X 1 of SEQ ID NO 54 is substituted with an amino acid that influences chain orientation.
- the amino acid X 1 of SEQ ID NO: 54 is substituted with a hydrophobic amino acid. In some embodiments, the amino acid X 1 of SEQ ID NO: 54 is substituted with a basic amino acid. In some embodiments, the amino acid X 1 of SEQ ID NO: 54 is substituted with an aromatic amino acid.
- the amino acid X 2 of SEQ ID NO: 54 may be substituted with any amino acid. In some embodiments, the amino acid X 2 of SEQ ID NO: 54 is substituted with a conservative amino acid (e.g., A and/or T). In some embodiments, the amino acid X 2 of SEQ ID NO: 54 is substituted with a hydrophobic amino acid.
- the amino acid X 2 of SEQ ID NO: 54 is substituted with a hydrophilic amino acid.
- the amino acid X 4 of SEQ ID NO: 54 may be substituted with any amino acid.
- the amino acid X 4 of SEQ ID NO: 54 is substituted with a conservative amino acid (e.g., N and/or T).
- the amino acid X 4 of SEQ ID NO: 54 is substituted with a hydrophilic amino acid.
- the amino acid X 5 of SEQ ID NO: 54 may be substituted with any amino acid.
- the amino acid X 5 of SEQ ID NO: 54 is substituted with a conservative amino acid (e.g. L and/or R).
- the amino acid X 5 of SEQ ID NO: 54 is substituted with a hydrophobic amino acid. In some embodiments, the amino acid X 5 of SEQ ID NO: 54 is substituted with a basic amino acid. The amino acid X 6 of SEQ ID NO: 54 may be substituted with any amino acid. In some embodiments, the amino acid X 6 of SEQ ID NO: 54 is substituted with a conservative amino acid (e.g., E, Y or A). In some embodiments, the amino acid X 6 of SEQ ID NO: 54 is substituted with an acidic amino acid. In some embodiments, the amino acid X 6 of SEQ ID NO: 54 is substituted with an aromatic amino acid.
- a conservative amino acid e.g., E, Y or A
- the amino acid X 7 of SEQ ID NO: 54 may be substituted with any amino acid.
- the amino acid X 7 of SEQ ID NO: 54 is substituted with a conservative amino acid (e.g., S and/or T).
- the amino acid X 7 of SEQ ID NO: 54 is a hydrophilic amino acid.
- the CDRL2 of any of the anti-NKG2C agents provided herein comprises an amino acid sequence chosen from RTSNLAS (SEQ ID NO: 21), AASNLES (SEQ ID NO: 27), GASNLES (SEQ ID NO: 32), WASTRES (SEQ ID NO: 37), and YASNRYT (SEQ ID NO: 43).
- the CDRL2 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids RTSNLAS (SEQ ID NO: 21), or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 21.
- the CDRL2 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids RTSNLAS (SEQ ID NO: 21).
- the CDRL2 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids AASNLES (SEQ ID NO: 27), or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 27.
- the CDRL2 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids AASNLES (SEQ ID NO: 27).
- the CDRL2 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids GASNLES (SEQ ID NO: 32), or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 32.
- the CDRL2 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids GASNLES (SEQ ID NO: 32).
- the CDRL2 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids WASTRES (SEQ ID NO: 37), or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 37.
- the CDRL2 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids WASTRES (SEQ ID NO: 37).
- the CDRL2 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids YASNRYT (SEQ ID NO: 43), or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 43.
- the CDRL2 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids YASNRYT (SEQ ID NO: 43).
- the third light chain CDR (CDRL3) of an anti-NKG2C agent provided herein comprises an amino acid sequence that is at least 80% identical to the amino acid sequence X 1 X 2 X 3 X 4 X 5 X 6 X 7 X 8 T (SEQ ID NO: 55), where X 1 is Q or H; X 2 is Q or H; X 3 is S, Y, D, or no amino acid; X 4 is N, H, or Y; X 5 is E, S, or L; X 6 is D, V, Y, or S; X 7 is P or S; and X 8 is L, Y, or H.
- the CDRL3 comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 55. In some embodiments, the CDRL3 comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 55. In some embodiments, the CDRL3 comprises an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 55. In some embodiments, the CDRL3 comprises the sequence of amino acids set forth in SEQ ID NO: 55. The amino acid X 1 of SEQ ID NO: 55 may be substituted with any amino acid. In some embodiments, the amino acid X 1 of SEQ ID NO: 55 is substituted with a conservative amino acid (e.g., Q and/or H).
- a conservative amino acid e.g., Q and/or H
- the amino acid X 1 of SEQ ID NO: 55 is substituted with a hydrophilic amino acid. In some embodiments, the amino acid X 1 of SEQ ID NO: 55 is substituted with a basic amino acid.
- the amino acid X 2 of SEQ ID NO: 55 may be substituted with any amino acid. In some embodiments, the amino acid X 2 of SEQ ID NO: 55 is substituted with a conservative amino acid (e.g., Q and/or H). In some embodiments, the amino acid X 2 of SEQ ID NO: 55 is substituted with a hydrophilic amino acid. In some embodiments, the amino acid X 2 of SEQ ID NO: 55 is substituted with a basic amino acid.
- the amino acid X 3 of SEQ ID NO: 55 may be substituted with any amino acid.
- the amino acid X 3 of SEQ ID NO: 55 is substituted with a conservative amino acid (e.g., S, Y, D, and/or no amino acid).
- the amino acid X 3 of SEQ ID NO: 55 is substituted with a hydrophilic amino acid.
- the amino acid X 3 of SEQ ID NO: 55 is substituted with an aromatic amino acid.
- the amino acid X 3 of SEQ ID NO: 55 is substituted with an acidic amino acid.
- the amino acid X 3 of SEQ ID NO: 55 is substituted with no amino acid.
- the amino acid X 4 of SEQ ID NO: 55 may be substituted with any amino acid.
- the amino acid X 4 of SEQ ID NO: 55 is substituted with a conservative amino acid (e.g., N, H, and/or Y).
- the amino acid X 4 of SEQ ID NO: 55 is substituted with a hydrophilic amino acid.
- the amino acid X 4 of SEQ ID NO: 55 is substituted with a basic amino acid.
- the amino acid X 4 of SEQ ID NO: 55 is substituted with an aromatic amino acid.
- the amino acid X 5 of SEQ ID NO: 55 may be substituted with any amino acid.
- the amino acid X 5 of SEQ ID NO: 55 is substituted with a conservative amino acid (e.g., E, S, and/or L).
- the amino acid X 5 of SEQ ID NO: 55 is an acidic amino acid.
- the amino acid X 5 of SEQ ID NO: 55 is a hydrophilic amino acid.
- the amino acid X 5 of SEQ ID NO: 55 is a hydrophobic amino acid.
- the amino acid X 6 of SEQ ID NO: 55 may be substituted with any amino acid.
- the amino acid X6 of SEQ ID NO: 55 is substituted with a conservative amino acid (e.g., D, V, Y, and/or S).
- the amino acid X 6 of SEQ ID NO: 55 is substituted with an acidic amino acid. In some embodiments, the amino acid X 6 of SEQ ID NO: 55 is substituted with a hydrophobic amino acid. In some embodiments, the amino acid X 6 of SEQ ID NO: 55 is substituted with an aromatic amino acid. In some embodiments, the amino acid X 6 of SEQ ID NO: 55 is substituted with a hydrophilic amino acid.
- the amino acid X 7 of SEQ ID NO: 55 may be substituted with any amino acid. In some embodiments, the amino acid X 7 of SEQ ID NO: 55 is substituted with a conservative amino acid (e.g., P and/or S).
- the amino acid X 7 of SEQ ID NO: 55 is substituted with an amino acid that influences chain orientation. In some embodiments, the amino acid X 7 of SEQ ID NO: 55 is substituted with a hydrophilic amino acid.
- the amino acid X 8 of SEQ ID NO: 55 may be substituted with any amino acid. In some embodiments, the amino acid X 8 of SEQ ID NO: 55 is substituted with a conservative amino acid (e.g., L, Y, and/or H). In some embodiments, the amino acid X 8 of SEQ ID NO: 55 is substituted with a hydrophobic amino acid. In some embodiments, the amino acid X 8 of SEQ ID NO: 55 is substituted with an aromatic amino acid.
- the amino acid X 8 of SEQ ID NO: 55 is substituted with a basic amino acid.
- the CDRL3 of an anti-NKG2C agent provided herein comprises an amino acid sequence chosen from QHYHSYPYT (SEQ ID NO: 22), QQSNEDPLT (SEQ ID NO: 28), QQSNEVPLT (SEQ ID NO: 38), HQYLSSHT (SEQ ID NO: 44), and QQDYSSPLT (SEQ ID NO: 48).
- the CDRL3 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids QHYHSYPYT (SEQ ID NO: 22), or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 22.
- the CDRL3 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids QHYHSYPYT (SEQ ID NO: 22).
- the CDRL3 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids QQSNEDPLT (SEQ ID NO: 28), or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 28.
- the CDRL3 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids QQSNEDPLT (SEQ ID NO: 28), In some embodiments, the CDRL3 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids QQSNEVPLT (SEQ ID NO: 38), or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 38.
- the CDRL3 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids QQSNEVPLT (SEQ ID NO: 38). In some embodiments, the CDRL3 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids HQYLSSHT (SEQ ID NO: 44), or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 44.
- the CDRL3 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids HQYLSSHT (SEQ ID NO: 44). In some embodiments, the CDRL3 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids QQDYSSPLT (SEQ ID NO: 48), or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 48.
- the CDRL3 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids QQDYSSPLT (SEQ ID NO: 48).
- CDR sets any of the anti-NKG2C agents described herein comprises an immunoglobulin heavy chain variable domain comprising a set of CDRs (i.e., CDRH1, CDRH2, CDRH3); and an immunoglobulin light chain variable domain comprising a set of CDRs (i.e., CDRL1, CDRL2, CDRL3).
- any of the antibodies or antigen-binding fragments thereof that bind the NKG2C receptor or fragment thereof described herein comprises an immunoglobulin heavy chain variable domain comprising a set of CDRs (i.e., CDRH1, CDRH2, CDRH3); and an immunoglobulin light chain variable domain comprising a set of CDRs (i.e., CDRL1, CDRL2, CDRL3).
- any of the anti-NKG2C agents provided herein comprises two immunoglobulin heavy chain variable domains each comprising a set of CDRs (i.e., CDRH1, CDRH2, CDRH3); and two immunoglobulin light chain variable domains each comprising a set of CDRs (i.e., CDRL1, CDRL2, CDRL3).
- any of the antibodies or antigen-binding fragments thereof that bind the NKG2C receptor or fragment thereof described herein comprise one or more immunoglobulin heavy chain variable domains each comprising a set of CDRs (i.e., CDRH1, CDRH2, CDRH3); and one or more immunoglobulin light chain variable domains each comprising a set of CDRs (i.e., CDRL1, CDRL2, CDRL3).
- any of the antibodies or antigen-binding fragments thereof that bind the NKG2C receptor or fragment thereof described herein comprise two immunoglobulin heavy chain variable domains each comprising a set of CDRs (i.e., CDRH1, CDRH2, CDRH3); and two immunoglobulin light chain variable domains each comprising a set of CDRs (i.e., CDRL1, CDRL2, CDRL3).
- Sets of CDRs may comprise any combination of CDR amino acid sequences (i.e., CDRH1, CDRH2, CDRH3; and CDRL1, CDRL2, CDRL3) provided herein.
- an immunoglobulin heavy chain variable domain comprises a set of CDRH1, CDRH2 and CDRH3 amino acid sequences
- an immunoglobulin light chain variable domain comprises a set of CDRL1, CDRL2 and CDRL3 amino acid sequences chosen from sets 1-6 provided in the table below.
- each immunoglobulin heavy chain variable domain may comprise a set of CDRH1, CDRH2 and CDRH3 amino acid sequences
- each immunoglobulin light chain variable domain may comprise a set of CDRL1, CDRL2 and CDRL3 amino acid sequences chosen from sets 1-6 provided in Table 2.
- the anti-NKG2C agent contains CDRs corresponding to the same set.
- each immunoglobulin heavy chain variable domain may comprise a set of CDRH1, CDRH2 and CDRH3 amino acid sequences from set 1
- each immunoglobulin light chain variable domain may comprise a set of CDRL1, CDRL2 and CDRL3 amino acid sequences from set 1.
- the anti-NKG2C agent contains CDRs corresponding to the different sets.
- each immunoglobulin heavy chain variable domain may comprise a set of CDRH1, CDRH2 and CDRH3 amino acid sequences from set 1
- each immunoglobulin light chain variable domain may comprise a set of CDRL1, CDRL2 and CDRL3 amino acid sequences from set 2.
- one immunoglobulin heavy chain variable domain may comprise a set of CDRH1, CDRH2 and CDRH3 amino acid sequences from set 1 and the other immunoglobulin heavy chain variable domain may comprise a set of CDRH1, CDRH2 and CDRH3 amino acid sequences from set 2; and one immunoglobulin light chain variable domain may comprise a set of CDRL1, CDRL2 and CDRL3 amino acid sequences from set 1 and the other immunoglobulin light chain variable domain may comprise a set of CDRL1, CDRL2 and CDRL3 amino acid sequences from set 2.
- the agent that binds the NKG2C receptor or a fragment thereof comprises one or more of: a) an immunoglobulin heavy chain variable domain comprising: (i) a heavy chain complementary determining region 1 (CDRH1) comprising the sequence X 1 X 2 X 3 X 4 X 5 (SEQ ID NO: 50), wherein X 1 is N, S, or D, X 2 is F, T, or Y, X 3 is G, Y, or W, X 4 is M or I, and X 5 is H or N; (ii) a heavy chain complementary determining region 2 (CDRH2) comprising the sequence X 1 IX 3 X 4 X 5 X 6 X 7 X 8 X 9 X 10 X 11 X 12 X 13 X 14 X 15 X 16 X 17 (SEQ ID NO: 51), wherein X 1 is Y, R, W, or M, X 3 is S, D, or H, X 4 is S or P,
- the agent that binds the NKG2C receptor or a fragment thereof comprises an immunoglobulin heavy chain variable domain comprising: a CDRH1 comprising the sequence of amino acids set forth in SEQ ID NO: 17, SEQ ID NO: 23, SEQ ID NO: 29, SEQ ID NO: 33, SEQ ID NO: 39 or SEQ ID NO:45, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 17, SEQ ID NO: 23, SEQ ID NO: 29, SEQ ID NO: 33, SEQ ID NO: 39 or SEQ ID NO:45; a CDRH2 comprising the sequence of amino acids set forth in SEQ ID NO: 18, SEQ ID NO: 24, SEQ ID NO:30, SEQ ID NO:34, SEQ ID NO:40, S
- the agent that binds the NKG2C receptor or a fragment thereof comprises an immunoglobulin heavy chain variable domain that comprises a CDRH1 comprising the sequence of amino acids set forth in SEQ ID NO: 17, SEQ ID NO: 23, SEQ ID NO: 29, SEQ ID NO: 33, SEQ ID NO: 39 or SEQ ID NO:45; a CDRH2 comprising the sequence of amino acids set forth in SEQ ID NO: 18, SEQ ID NO: 24, SEQ ID NO:30, SEQ ID NO:34, SEQ ID NO:40, SEQ ID NO:46, SEQ ID NO:49; and a CDRH3 comprising the sequence of amino acids set forth in SEQ ID NO: 19, SEQ ID NO: 25, SEQ ID NO: 31, SEQ ID NO: 35, SEQ ID NO: 41, SEQ ID NO: 47.
- a CDRH1 comprising the sequence of amino acids set forth in SEQ ID NO: 17, SEQ ID NO: 23, SEQ ID NO: 29, SEQ ID NO: 33, SEQ ID NO: 39 or S
- the agent that binds the NKG2C receptor or a fragment thereof comprises an immunoglobulin light chain variable domain comprising a CDRL1 comprising the sequence of amino acids set forth in SEQ ID NO: 20; SEQ ID NO: 26, SEQ ID NO: 36 or SEQ ID NO: 42 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 20; SEQ ID NO: 26, SEQ ID NO: 36 or SEQ ID NO: 42; a CDRL2 comprising the sequence of amino acids set forth in SEQ ID NO: 21, SEQ ID NO: 27, SEQ ID NO: 32, SEQ ID NO: 37, SEQ ID NO: 43, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%
- the agent that binds the NKG2C receptor or a fragment thereof comprises a CDRH1 comprising the sequence set forth in SEQ ID NO: 17, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 17, a CDRH2 comprising the sequence set forth in SEQ ID NO: 18, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 18; and a CDRH3 comprising the sequence set forth in SEQ ID NO: 19, or a sequence of amino acids that exhibits
- the agent that binds the NKG2C receptor or a fragment thereof comprises a CDRH1 comprising the sequence set forth in SEQ ID NO: 17, the CDRH2 comprises the sequence set forth in SEQ ID NO: 18; and the CDRH3 comprises the sequence set forth in SEQ ID NO: 19.
- the agent that binds the NKG2C receptor or a fragment thereof comprises a CDRH1 comprising the sequence set forth in SEQ ID NO: 23, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 23, a CDRH2 comprising the sequence set forth in SEQ ID NO: 24,or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 24; and a CDRH3 comprising the sequence set forth in SEQ ID NO: 25, or a sequence of amino acids that exhibits
- the agent that binds the NKG2C receptor or a fragment thereof comprises a CDRH1 comprising the sequence set forth in SEQ ID NO: 23, the CDRH2 comprises the sequence set forth in SEQ ID NO: 24; and the CDRH3 comprises the sequence set forth in SEQ ID NO: 25.
- the agent that binds the NKG2C receptor or a fragment thereof comprises a CDRH1 comprising the sequence set forth in SEQ ID NO: 29, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:29, a CDRH2 comprising the sequence set forth in SEQ ID NO: 30,or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 30; and a CDRH3 comprising the sequence set forth in SEQ ID NO: 31, or a sequence of amino acids that exhibit
- the agent that binds the NKG2C receptor or a fragment thereof comprises a CDRH1 comprising the sequence set forth in SEQ ID NO: 29, the CDRH2 comprises the sequence set forth in SEQ ID NO: 30; and the CDRH3 comprises the sequence set forth in SEQ ID NO: 31.
- the agent that binds the NKG2C receptor or a fragment thereof comprises a CDRH1 comprising the sequence set forth in SEQ ID NO: 29, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:29, a CDRH2 comprising the sequence set forth in SEQ ID NO: 34, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:34; and a CDRH3 comprising the sequence set forth in SEQ ID NO: 25, or a sequence of amino acids that
- the agent that binds the NKG2C receptor or a fragment thereof comprises a CDRH1 comprising the sequence set forth in SEQ ID NO: 29, the CDRH2 comprises the sequence set forth in SEQ ID NO: 34; and the CDRH3 comprises the sequence set forth in SEQ ID NO: 25.
- the agent that binds the NKG2C receptor or a fragment thereof comprises a CDRH1 comprising the sequence set forth in SEQ ID NO: 33, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 33, a CDRH2 comprising the sequence set forth in SEQ ID NO: 40, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:40; and a CDRH3 comprising the sequence set forth in SEQ ID NO: 35, or a sequence of amino acids that exhibits at
- the agent that binds the NKG2C receptor or a fragment thereof comprises a CDRH1 comprising the sequence set forth in SEQ ID NO:33 , the CDRH2 comprises the sequence set forth in SEQ ID NO: 40; and the CDRH3 comprises the sequence set forth in SEQ ID NO: 35.
- the agent that binds the NKG2C receptor or a fragment thereof comprises a CDRH1 comprising the sequence set forth in SEQ ID NO: 39, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 39, a CDRH2 comprising the sequence set forth in SEQ ID NO: 46, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 46; and a CDRH3 comprising the sequence set forth in SEQ ID NO: 41, or a sequence of amino acids that exhibits at
- the agent that binds the NKG2C receptor or a fragment thereof comprises a CDRH1 comprising the sequence set forth in SEQ ID NO: 39, the CDRH2 comprises the sequence set forth in SEQ ID NO: 46; and the CDRH3 comprises the sequence set forth in SEQ ID NO: 41.
- the agent that binds the NKG2C receptor or a fragment thereof comprises a CDRH1 comprising the sequence set forth in SEQ ID NO: 45, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 45, a CDRH2 comprising the sequence set forth in SEQ ID NO: 49, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 49; and a CDRH3 comprising the sequence set forth in SEQ ID NO: 47, or a sequence of amino acids that exhibits at
- the agent that binds the NKG2C receptor or a fragment thereof comprises a CDRH1 comprising the sequence set forth in SEQ ID NO: 45, the CDRH2 comprises the sequence set forth in SEQ ID NO: 49; and the CDRH3 comprises the sequence set forth in SEQ ID NO: 47.
- the agent that binds the NKG2C receptor or a fragment thereof comprises a CDRL1 comprising the sequence set forth in SEQ ID NO: 20, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 20; a CDRL2 comprising the sequence set forth in SEQ ID NO: 21, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:21; and a CDRL3 comprising the sequence set forth in SEQ ID NO: 22, or a sequence of amino acids that exhibits at least
- the agent that binds the NKG2C receptor or a fragment thereof comprises a CDRL1 comprising the sequence set forth in SEQ ID NO: 20, a CDRL2 comprising the sequence set forth in SEQ ID NO: 21; and a CDRL3 comprising the sequence set forth in SEQ ID NO: 22.
- the agent that binds the NKG2C receptor or a fragment thereof comprises a CDRL1 comprising the sequence set forth in SEQ ID NO: 26, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:26; a CDRL2 comprising the sequence set forth in SEQ ID NO: 27 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:27; and a CDRL3 comprising the sequence set forth in SEQ ID NO:28 or a sequence of amino acids that exhibits at least
- the agent that binds the NKG2C receptor or a fragment thereof comprises a CDRL1 comprising the sequence set forth in SEQ ID NO: 26, a CDRL2 comprising the sequence set forth in SEQ ID NO: 27; and a CDRL3 comprising the sequence set forth in SEQ ID NO: 28.
- the agent that binds the NKG2C receptor or a fragment thereof comprises a CDRL1 comprising the sequence set forth in SEQ ID NO: 26, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:26; a CDRL2 comprising the sequence set forth in SEQ ID NO: 32 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:32; and a CDRL3 comprising the sequence set forth in SEQ ID NO: 28 or a sequence of amino acids that exhibits at least
- the agent that binds the NKG2C receptor or a fragment thereof comprises a CDRL1 comprising the sequence set forth in SEQ ID NO: 26, a CDRL2 comprising the sequence set forth in SEQ ID NO: 32; and a CDRL3 comprising the sequence set forth in SEQ ID NO: 28.
- the agent that binds the NKG2C receptor or a fragment thereof comprises a CDRL1 comprising the sequence set forth in SEQ ID NO: 26, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:26; a CDRL2 comprising the sequence set forth in SEQ ID NO: 32 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:32; and a CDRL3 comprising the sequence set forth in SEQ ID NO: 38 or a sequence of amino acids that exhibits at least
- the agent that binds the NKG2C receptor or a fragment thereof comprises a CDRL1 comprising the sequence set forth in SEQ ID NO: 26, a CDRL2 comprising the sequence set forth in SEQ ID NO: 32; and a CDRL3 comprising the sequence set forth in SEQ ID NO: 38.
- the agent that binds the NKG2C receptor or a fragment thereof comprises a CDRL1 comprising the sequence set forth in SEQ ID NO: 36, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:36; a CDRL2 comprising the sequence set forth in SEQ ID NO:37 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:37; and a CDRL3 comprising the sequence set forth in SEQ ID NO:44 or a sequence of amino acids that exhibits at least 80%, 8
- the agent that binds the NKG2C receptor or a fragment thereof comprises a CDRL1 comprising the sequence set forth in SEQ ID NO: 36, a CDRL2 comprising the sequence set forth in SEQ ID NO: 37; and a CDRL3 comprising the sequence set forth in SEQ ID NO: 44.
- the agent that binds the NKG2C receptor or a fragment thereof comprises a CDRL1 comprising the sequence set forth in SEQ ID NO: 42, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:42; a CDRL2 comprising the sequence set forth in SEQ ID NO: 43 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:43; and a CDRL3 comprising the sequence set forth in SEQ ID NO:48 or a sequence of amino acids that exhibits at least 80%, 8
- the agent that binds the NKG2C receptor or a fragment thereof comprises a CDRL1 comprising the sequence set forth in SEQ ID NO:42 , a CDRL2 comprising the sequence set forth in SEQ ID NO: 43; and a CDRL3 comprising the sequence set forth in SEQ ID NO: 48.
- the agent that binds the NKG2C receptor or a fragment thereof comprises a CDRL1 comprising the sequence set forth in SEQ ID NO: 48, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:48; a CDRL2 comprising the sequence set forth in SEQ ID NO: 37 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:37; and a CDRL3 comprising the sequence set forth in SEQ ID NO: 44 or a sequence of amino acids that exhibits at least 80%, 8
- the agent that binds the NKG2C receptor or a fragment thereof comprises a CDRL1 comprising the sequence set forth in SEQ ID NO: 48, a CDRL2 comprising the sequence set forth in SEQ ID NO: 37; and a CDRL3 comprising the sequence set forth in SEQ ID NO: 44.
- the agent binds the NKG2C receptor or a fragment thereof, comprises a CDRH1 comprising the sequence of amino acids set forth in SEQ ID NO: 17, 23, 29, 33, 39 or 45, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 17, 23, 29, 33, 39 or 45, a CDRH2 comprising a sequence of amino acids set forth in SEQ ID NO: 18, 24, 30, 34, 40, 46 or 49, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:
- the agent binds the NKG2C receptor or a fragment thereof, comprises a CDRH1 comprising the sequence of amino acids set forth in SEQ ID NO: 17, 23, 29, 33, 39 or 45; a CDRH2 comprising a sequence of amino acids set forth in SEQ ID NO: 18, 24, 30, 34, 40, 46 or 49; a CDRH3 comprising a sequence of amino acids set forth in SEQ ID NO: 19, 25, 31, 35, 41 or 47; a CDRL1 comprising a sequence of amino acids set forth in SEQ ID NO: 20, 26, 36 or 42; a CDRL2 comprising a sequence of amino acids set forth in SEQ ID NO: 21, 27, 32, 37 or 43; and a CDRL3 comprising a sequence of amino acids set forth in SEQ ID NO: 22, 28, 38, 44 or 48.
- a CDRH1 comprising the sequence of amino acids set forth in SEQ ID NO: 17, 23, 29, 33, 39 or 45
- a CDRH2 comprising a sequence of amino acids set forth in SEQ ID NO: 18,
- the agent that binds the NKG2C receptor or a fragment thereof comprises a CDRH1 comprising the sequence set forth in SEQ ID NO: 17 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:17, a CDRH2 comprising the sequence set forth in SEQ ID NO:18 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:18; a CDRH3 comprising the sequence set forth in SEQ ID NO:19 or a sequence of amino acids that exhibits
- the agent that binds the NKG2C receptor or a fragment thereof comprises a CDRH1 comprising the sequence set forth in SEQ ID NO: 17, a CDRH2 comprising the sequence set forth in SEQ ID NO: 18; a CDRH3 comprising the sequence set forth in SEQ ID NO: 19; a CDRL1 comprising the sequence set forth in SEQ ID NO: 20, a CDRL2 comprising the sequence set forth in SEQ ID NO: 21; and a CDRL3 comprising the sequence set forth in SEQ ID NO: 22.
- the agent that binds the NKG2C receptor or a fragment thereof comprises a CDRH1 comprising the sequence set forth in SEQ ID NO:23 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:23, a CDRH2 comprising the sequence set forth in SEQ ID NO:24 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:24; a CDRH3 comprising the sequence set forth in SEQ ID NO:25 or a sequence of amino acids that exhibits
- the agent that binds the NKG2C receptor or a fragment thereof comprises a CDRH1 comprising the sequence set forth in SEQ ID NO:23, a CDRH2 comprising the sequence set forth in SEQ ID NO: 24; a CDRH3 comprising the sequence set forth in SEQ ID NO: 25; a CDRL1 comprising the sequence set forth in SEQ ID NO: 26, a CDRL2 comprising the sequence set forth in SEQ ID NO: 27; and a CDRL3 comprising the sequence set forth in SEQ ID NO: 28.
- the agent that binds the NKG2C receptor or a fragment thereof comprises a CDRH1 comprising the sequence set forth in SEQ ID NO:29 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:29, a CDRH2 comprising the sequence set forth in SEQ ID NO:30 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:30; a CDRH3 comprising the sequence set forth in SEQ ID NO:31, or a sequence of amino acids that exhibit
- the agent that binds the NKG2C receptor or a fragment thereof comprises a CDRH1 comprising the sequence set forth in SEQ ID NO: 29, a CDRH2 comprising the sequence set forth in SEQ ID NO: 30; a CDRH3 comprising the sequence set forth in SEQ ID NO: 31; a CDRL1 comprising the sequence set forth in SEQ ID NO: 26, a CDRL2 comprising the sequence set forth in SEQ ID NO: 32; and a CDRL3 comprising the sequence set forth in SEQ ID NO: 28.
- the agent that binds the NKG2C receptor or a fragment thereof comprises a CDRH1 comprising the sequence set forth in SEQ ID NO:29 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:29, a CDRH2 comprising the sequence set forth in SEQ ID NO:34 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:34; a CDRH3 comprising the sequence set forth in SEQ ID NO:25, or a sequence of amino acids that exhibit
- the agent that binds the NKG2C receptor or a fragment thereof comprises a CDRH1 comprising the sequence set forth in SEQ ID NO: 29, a CDRH2 comprising the sequence set forth in SEQ ID NO: 34; a CDRH3 comprising the sequence set forth in SEQ ID NO: 25; a CDRL1 comprising the sequence set forth in SEQ ID NO: 26, a CDRL2 comprising the sequence set forth in SEQ ID NO: 32; and a CDRL3 comprising the sequence set forth in SEQ ID NO: 38.
- the agent that binds the NKG2C receptor or a fragment thereof comprises a CDRH1 comprising the sequence set forth in SEQ ID NO:33, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:33, a CDRH2 comprising the sequence set forth in SEQ ID NO:40, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:40; a CDRH3 comprising the sequence set forth in SEQ ID NO:35, or a sequence of amino acids
- the agent that binds the NKG2C receptor or a fragment thereof comprises a CDRH1 comprising the sequence set forth in SEQ ID NO:33, a CDRH2 comprising the sequence set forth in SEQ ID NO:40; a CDRH3 comprising the sequence set forth in SEQ ID NO: 35; a CDRL1 comprising the sequence set forth in SEQ ID NO: 36, a CDRL2 comprising the sequence set forth in SEQ ID NO: 37; and a CDRL3 comprising the sequence set forth in SEQ ID NO: 44.
- the agent that binds the NKG2C receptor or a fragment thereof comprises a CDRH1 comprising the sequence set forth in SEQ ID NO:39, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:39, a CDRH2 comprising the sequence set forth in SEQ ID NO:46, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:46; a CDRH3 comprising the sequence set forth in SEQ ID NO:41, or a sequence of amino acids
- the agent that binds the NKG2C receptor or a fragment thereof comprises a CDRH1 comprising the sequence set forth in SEQ ID NO:39, a CDRH2 comprising the sequence set forth in SEQ ID NO: 46; a CDRH3 comprising the sequence set forth in SEQ ID NO: 41; a CDRL1 comprising the sequence set forth in SEQ ID NO: 42, a CDRL2 comprising the sequence set forth in SEQ ID NO: 43; and a CDRL3 comprising the sequence set forth in SEQ ID NO: 48.
- the agent that binds the NKG2C receptor or a fragment thereof comprises a CDRH1 comprising the sequence set forth in SEQ ID NO:45, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:45, a CDRH2 comprising the sequence set forth in SEQ ID NO:49, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:49; a CDRH3 comprising the sequence set forth in SEQ ID NO:47 or a sequence of amino acids that
- the agent that binds the NKG2C receptor or a fragment thereof comprises a CDRH1 comprising the sequence set forth in SEQ ID NO:45, a CDRH2 comprising the sequence set forth in SEQ ID NO:49; a CDRH3 comprising the sequence set forth in SEQ ID NO:47; a CDRL1 comprising the sequence set forth in SEQ ID NO:48, a CDRL2 comprising the sequence set forth in SEQ ID NO:37; and a CDRL3 comprising the sequence set forth in SEQ ID NO:44.
- VH immunoglobulin heavy chain variable domain
- an immunoglobulin heavy chain variable domain (VH) of an anti-NKG2C agent provided herein comprises a polypeptide that is at least 80% identical to the amino acid sequence NO: 1), e.g., 80% or more, 81% or more, 82% or more, 83% or more, 84% or more, 85% or more, 86% or more, 87% or more, 88% or more, 89% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more, identical to the amino acid sequence of SEQ ID NO: 1.
- the VH comprises a polypeptide that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1. In some embodiments, the VH comprises a polypeptide that is at least 95% identical to the amino acid sequence of SEQ ID NO: 1. In some embodiments, the VH comprises a polypeptide that is 100% identical to the amino acid sequence of SEQ ID NO: 1. In some embodiments, the VH comprises the sequence of amino acids set forth in SEQ ID NO: 1. In some embodiments, the anti-NKG2C agent provided herein may comprise a heavy chain variable domain (VH).
- VH heavy chain variable domain
- a heavy chain variable domain (VH) of an anti-NKG2C agent comprises a polypeptide that is at least 80% identical to the amino acid sequence (SEQ ID NO: 2), e.g., 80% or more, 81% or more, 82% or more, 83% or more, 84% or more, 85% or more, 86% or more, 87% or more, 88% or more, 89% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more, identical to the amino acid sequence of SEQ ID NO: 2.
- the VH comprises a polypeptide that is at least 90 % identical to the amino acid sequence of SEQ ID NO: 2. In some embodiments, the VH comprises a polypeptide that is at least 95 % identical to the amino acid sequence of SEQ ID NO: 2. In some embodiments, the VH comprises a polypeptide that is 100 % identical to the amino acid sequence of SEQ ID NO: 2. In some embodiments, the VH comprises the sequence of amino acids set forth in SEQ ID NO:2 In some embodiments, the anti-NKG2C agent provided herein may comprise a heavy chain variable domain (VH).
- VH heavy chain variable domain
- a heavy chain variable domain (VH) of an anti-NKG2C agent provided herein comprises a polypeptide that is at least 80% identical to the amino acid sequence D A (SEQ ID NO: 3), e.g., 80% or more, 81% or more, 82% or more, 83% or more, 84% or more, 85% or more, 86% or more, 87% or more, 88% or more, 89% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more, identical to the amino acid sequence of SEQ ID NO: 3.
- a VH comprises a polypeptide that is at least 90 % identical to the amino acid sequence of SEQ ID NO: 3. In some embodiments, a VH comprises a polypeptide that is at least 95 % identical to the amino acid sequence of SEQ ID NO: 3. In some embodiments, a VH comprises a polypeptide that is 100 % identical to the amino acid sequence of SEQ ID NO: 3. In some embodiments, the VH comprises the sequence of amino acids set forth in SEQ ID NO:3. In some embodiments, the anti-NKG2C agent provided herein may comprise a heavy chain variable domain (VH).
- VH heavy chain variable domain
- a heavy chain variable domain (VH) of an anti-NKG2C agent comprises a polypeptide that is at least 80% identical to the amino acid sequence Q Q (SEQ ID NO: 5), e.g., 80% or more, 81% or more, 82% or more, 83% or more, 84% or more, 85% or more, 86% or more, 87% or more, 88% or more, 89% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more, identical to the amino acid sequence of SEQ ID NO: 5.
- a VH comprises a polypeptide that is at least 90% identical to the amino acid sequence of SEQ ID NO: 5. In some embodiments, a VH comprises a polypeptide that is at least 95% identical to the amino acid sequence of SEQ ID NO: 5. In some embodiments, a VH comprises a polypeptide that is 100% identical to the amino acid sequence of SEQ ID NO: 5. In some embodiments, the VH comprises the sequence of amino acids set forth in SEQ ID NO:5. In some embodiments, the anti-NKG2C agent provided herein may comprise a heavy chain variable domain (VH).
- VH heavy chain variable domain
- a heavy chain variable domain (VH) of an anti-NKG2C agent comprises a polypeptide that is at least 80% identical to the amino acid sequence E Q QQ Q Q D ID NO: 6), e.g., 80% or more, 81% or more, 82% or more, 83% or more, 84% or more, 85% or more, 86% or more, 87% or more, 88% or more, 89% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more, identical to the amino acid sequence of SEQ ID NO: 6.
- a VH comprises a polypeptide that is at least 90% identical to the amino acid sequence of SEQ ID NO: 6. In some embodiments, a VH comprises a polypeptide that is at least 95 % identical to the amino acid sequence of SEQ ID NO: 6. In some embodiments, a VH comprises a polypeptide that is 100% identical to the amino acid sequence of SEQ ID NO: 6. In some embodiments, the VH comprises the sequence of amino acids set forth in SEQ ID NO:6. In some embodiments, the anti-NKG2C agent provided herein may comprise a heavy chain variable domain (VH).
- VH heavy chain variable domain
- a heavy chain variable domain (VH) of an anti-NKG2C agent provided herein comprises a polypeptide that is at least 80% identical to the amino acid sequence Q N (SEQ ID NO: 7), e.g., 80% or more, 81% or more, 82% or more, 83% or more, 84% or more, 85% or more, 86% or more, 87% or more, 88% or more, 89% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more, identical to the amino acid sequence of SEQ ID NO: 7.
- a VH comprises a polypeptide that is at least 90% identical to the amino acid sequence of SEQ ID NO: 7. In some embodiments, a VH comprises a polypeptide that is at least 95% identical to the amino acid sequence of SEQ ID NO: 7. In some embodiments, a VH comprises a polypeptide that is 100% identical to the amino acid sequence of SEQ ID NO: 7. In some embodiments, the VH comprises the sequence of amino acids set forth in SEQ ID NO:7. In some embodiments, the anti-NKG2C agent provided herein may comprise a heavy chain variable domain (VH).
- VH heavy chain variable domain
- a heavy chain variable domain (VH) of an anti-NKG2C agent provided herein comprises a polypeptide that is at least 80% identical to the amino acid sequence NO: 8), e.g., 80% or more, 81% or more, 82% or more, 83% or more, 84% or more, 85% or more, 86% or more, 87% or more, 88% or more, 89% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more, identical to the amino acid sequence of SEQ ID NO: 8.
- a VH comprises a polypeptide that is at least 90% identical to the amino acid sequence of SEQ ID NO: 8. In some embodiments, a VH comprises a polypeptide that is at least 95% identical to the amino acid sequence of SEQ ID NO: 8. In some embodiments, a VH comprises a polypeptide that is 100 % identical to the amino acid sequence of SEQ ID NO: 8. In some embodiments, the VH comprises the sequence of amino acids set forth in SEQ ID NO:8.
- a VH of an anti-NKG2C agent provided herein comprises a polypeptide chosen from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO: 8.
- the VH of any of the anti-NKG2C agents provided herein further comprises a signal sequence.
- VH signal sequence of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids set forth in SEQ ID NO: 90, 92 or 94.
- VH signal sequence of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids set forth in SEQ ID NO:90.
- VH signal sequence of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids set forth in SEQ ID NO:92. In some embodiments, VH signal sequence of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids set forth in SEQ ID NO:94. VL In some embodiments, the anti-NKG2C agent provided herein may comprise an immunoglobulin light chain variable domain (VL).
- a immunoglobulin light chain variable domain (VL) of an anti-NKG2C agent comprises a polypeptide that is at least 80% identical to the amino acid sequence Q Q QQ A Q ( Q NO: 9), e.g., 80% or more, 81% or more, 82% or more, 83% or more, 84% or more, 85% or more, 86% or more, 87% or more, 88% or more, 89% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more, identical to the amino acid sequence of SEQ ID NO: 9.
- a VL comprises a polypeptide that is at least 90% identical to the amino acid sequence of SEQ ID NO: 9. In some embodiments, a VL comprises a polypeptide that is at least 95% identical to the amino acid sequence of SEQ ID NO: 9. In some embodiments, a VL comprises a polypeptide that is 100% identical to the amino acid sequence of SEQ ID NO: 9. In some embodiments, the VL comprises the sequence of amino acids set forth in SEQ ID NO: 9. In some embodiments, the anti-NKG2C agent provided herein may comprise an immunoglobulin light chain variable domain (VL).
- VL immunoglobulin light chain variable domain
- an immunoglobulin light chain variable domain (VL) of an anti-NKG2C agent provided herein comprises a polypeptide that is at least 80% identical to the amino acid sequence D E : 10), e.g., 80% or more, 81% or more, 82% or more, 83% or more, 84% or more, 85% or more, 86% or more, 87% or more, 88% or more, 89% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more, identical to the amino acid sequence of SEQ ID NO: 10.
- a VL comprises a polypeptide that is at least 90% identical to the amino acid sequence of SEQ ID NO: 10. In some embodiments, a VL comprises a polypeptide that is at least 95% identical to the amino acid sequence of SEQ ID NO: 10. In some embodiments, a VL comprises a polypeptide that is 100% identical to the amino acid sequence of SEQ ID NO: 10. In some embodiments, the VL comprises the sequence of amino acids set forth in SEQ ID NO: 10. In some embodiments, any of the anti-NKG2C agents provided herein may comprise an immunoglobulin light chain variable domain (VL).
- VL immunoglobulin light chain variable domain
- a light chain variable domain (VL) of an anti- NKG2C agent comprises a polypeptide that is at least 80% identical to the amino acid sequence D ESGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPLTFGAGTKLELK (SEQ ID NO: 11), e.g., 80% or more, 81% or more, 82% or more, 83% or more, 84% or more, 85% or more, 86% or more, 87% or more, 88% or more, 89% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more, identical to the amino acid sequence of SEQ ID NO: 11.
- a VL comprises a polypeptide that is at least 90 % identical to the amino acid sequence of SEQ ID NO: 11. In some embodiments, a VL comprises a polypeptide that is at least 95% identical to the amino acid sequence of SEQ ID NO: 11. In some embodiments, a VL comprises a polypeptide that is 100% identical to the amino acid sequence of SEQ ID NO: 11. In some embodiments, the VL comprises the sequence of amino acids set forth in SEQ ID NO: 11. In some embodiments, the anti-NKG2C agent provided herein may comprise an immunoglobulin light chain variable domain (VL).
- VL immunoglobulin light chain variable domain
- an immunoglobulin light chain variable domain (VL) of an anti-NKG2C agent provided herein comprises a polypeptide that is at least 80% identical to the amino acid sequence D E e.g., 80% or more, 81% or more, 82% or more, 83% or more, 84% or more, 85% or more, 86% or more, 87% or more, 88% or more, 89% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more, identical to the amino acid sequence of SEQ ID NO: 13.
- a VL comprises a polypeptide that is at least 90 % identical to the amino acid sequence of SEQ ID NO: 13. In some embodiments, a VL comprises a polypeptide that is at least 95% identical to the amino acid sequence of SEQ ID NO: 13. In some embodiments, a VL comprises a polypeptide that is 100% identical to the amino acid sequence of SEQ ID NO: 13. In some embodiments, the VL comprises the sequence of amino acids set forth in SEQ ID NO: 13. In some embodiments, the anti-NKG2C agent provided herein may comprise an immunoglobulin light chain variable domain (VL).
- VL immunoglobulin light chain variable domain
- an immunoglobulin light chain variable domain (VL) of an anti-NKG2C agent provided herein comprises a polypeptide that is at least 80% identical to the amino acid sequence e.g., 80% or more, 81% or more, 82% or more, 83% or more, 84% or more, 85% or more, 86% or more, 87% or more, 88% or more, 89% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more, identical to the amino acid sequence of SEQ ID NO: 14.
- a VL comprises a polypeptide that is at least 90% identical to the amino acid sequence of SEQ ID NO: 14. In some embodiments, a VL comprises a polypeptide that is at least 95% identical to the amino acid sequence of SEQ ID NO: 14. In some embodiments, a VL comprises a polypeptide that is 100% identical to the amino acid sequence of SEQ ID NO: 14. In some embodiments, the VL comprises the sequence of amino acids set forth in SEQ ID NO: 14. In some embodiments, the anti-NKG2C agent provided herein may comprise an immunoglobulin light chain variable domain (VL).
- VL immunoglobulin light chain variable domain
- an immunoglobulin light chain variable domain (VL) of an anti-NKG2C agent provided herein comprises a polypeptide that is at least 80% identical to the amino acid sequence S (SEQ ID NO: 15), e.g., 80% or more, 81% or more, 82% or more, 83% or more, 84% or more, 85% or more, 86% or more, 87% or more, 88% or more, 89% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more, identical to the amino acid sequence of SEQ ID NO: 15.
- a VL comprises a polypeptide that is at least 90 % identical to the amino acid sequence of SEQ ID NO: 15. In some embodiments, a VL comprises a polypeptide that is at least 95% identical to the amino acid sequence of SEQ ID NO: 15. In some embodiments, a VL comprises a polypeptide that is 100% identical to the amino acid sequence of SEQ ID NO: 15. In some embodiments, the VL comprises the sequence of amino acids set forth in SEQ ID NO: 15. In some embodiments, the anti-NKG2C agent provided herein may comprise an immunoglobulin light chain variable domain (VL).
- VL immunoglobulin light chain variable domain
- an immunoglobulin light chain variable domain (VL) of an anti-NKG2C agent provided herein comprises a polypeptide that is at least 80% identical to the amino acid sequence N E e.g., 80% or more, 81% or more, 82% or more, 83% or more, 84% or more, 85% or more, 86% or more, 87% or more, 88% or more, 89% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more, identical to the amino acid sequence of SEQ ID NO: 16.
- a VL comprises a polypeptide that is at least 90% identical to the amino acid sequence of SEQ ID NO: 16. In some embodiments, a VL comprises a polypeptide that is at least 95% identical to the amino acid sequence of SEQ ID NO: 16. In some embodiments, a VL comprises a polypeptide that is 100% identical to the amino acid sequence of SEQ ID NO: 16. In some embodiments, the VL comprises the sequence of amino acids set forth in SEQ ID NO: 16.
- a VL of an anti-NKG2C agent provided herein comprises a polypeptide chosen from SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, and SEQ ID NO: 16.
- the VL of any of the anti-NKG2C agents provided herein further comprises a signal sequence.
- VL signal sequence of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids set forth in SEQ ID NO: 91, 93 or 95.
- VL signal sequence of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids set forth in SEQ ID NO:91.
- VL signal sequence of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids set forth in SEQ ID NO:93. In some embodiments, VL signal sequence of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids set forth in SEQ ID NO:95.
- Fc any of the anti-NKG2C agents provided herein may comprise a fragment crystallizable region (Fc region). An Fc region typically forms the tail of an antibody and can interact with certain cell surface receptors and certain components of the complement system. An Fc region may include, for example, two polypeptides, each derived from the second (CH2) and third (CH3) constant domains of an antibody heavy chain.
- an Fc region includes one or more modifications (e.g., one or more amino acid substitutions, insertions, or deletions relative to a comparable wild-type Fc region).
- Agents comprising modified Fc regions typically have altered phenotypes relative to agents comprising wild- type Fc regions.
- a variant agent phenotype may be expressed as altered serum half-life, altered stability, altered susceptibility to cellular enzymes, or altered effector function (e.g., as assayed in an NK dependent or macrophage dependent assay).
- Fc region modifications that alter effector function may include modifications that increase binding to activating receptors (e.g., Fc ⁇ RIIA (CD16A) and reduce binding to inhibitory receptors (e.g., Fc ⁇ RIIB (CD32B) (see, e.g., Stavenhagen, J.B. et al. (2007) Cancer Res.57(18):8882-8890)).
- variants of human IgG1 Fc regions with reduced binding to CD32B and/or increased binding to CD16A contain F243L, R292P, Y300L, V305I and/or P396L substitutions. Amino acid positions correspond to the amino acid numbering of the CH2-CH3 domain provided above.
- an Fc region includes one or more modifications that reduce or abrogate binding of the Fc to Fc receptors. Such modifications may include amino acid substitutions at positions 234, 235, 265 and 297 (see e.g., U.S. Patent No 5,624,821, which is incorporated by reference herein).
- Example substitutions include one or more of L234A, L235A, D265A and N297Q.
- an Fc region includes one or more modifications that alter (relative to a wild-type Fc region) the Ratio of Affinities of the modified Fc region to an activating Fc ⁇ R (such as Fc ⁇ RIIA or Fc ⁇ RIIIA) relative to an inhibiting Fc ⁇ R (such as Fc ⁇ RIIB):
- an anti-NKG2C agent herein may have particular use in providing a therapeutic or prophylactic treatment of a disease, disorder, or infection, or the amelioration of a symptom thereof, where an enhanced efficacy of effector cell function (e.g., ADCC) mediated by Fc ⁇ R is desired, e.g., cancer or infectious disease.
- an anti-NKG2C agent herein may have particular use in providing a therapeutic or prophylactic treatment of a disease or disorder, or the amelioration of a symptom thereof, where a decreased efficacy of effector cell function mediated by Fc ⁇ R is desired, e.g., autoimmune or inflammatory disorders.
- Table 3 lists example single, double, triple, quadruple and quintuple amino acid substitutions having a Ratio of Affinities greater than 1 or less than 1 (see e.g., PCT Publication Nos.
- anti-NKG2C agents that competitively bind, or are capable of competitively binding, with one or more anti-NKG2C agents described herein.
- anti-NKG2C agents that compete, or are capable of competing, with one or more anti-NKG2C agents described herein for binding to NKG2C.
- Such agents that compete, or are capable of competing, with anti-NKG2C agents described herein may be referred to as competitor agents.
- an agent i.e., competitor agent
- an agent may be considered to compete for binding to NKG2C when the competitor binds to the same general region of NKG2C as an anti-NKG2C agent described herein (i.e., extracellular region or leucine- rich binding domain).
- an agent i.e., competitor agent
- an agent i.e., competitor agent
- an agent may be considered capable of competing for binding to NKG2C when the competitor binds to the same general region of NKG2C as an anti-NKG2C agent described herein (i.e., extracellular region or leucine-rich binding domain) under suitable assay conditions.
- an agent i.e., competitor agent
- an agent may be considered capable of competing for binding to NKG2C when the competitor binds to the exact same region of NKG2C as an anti-NKG2C agent described herein (e.g., exact same peptide (linear epitope) or exact same surface amino acids (conformational epitope)) under suitable assay conditions.
- an agent i.e., competitor agent
- an agent may be considered to compete for binding to NKG2C when the competitor blocks the binding of one or more anti-NKG2C agents described herein to NKG2C.
- an agent i.e., competitor agent
- an agent may be considered capable of competing for binding to NKG2C when the competitor blocks the binding of one or more anti-NKG2C agents described herein to NKG2C under suitable assay conditions.
- Whether a competitor blocks the binding of one or more anti-NKG2C agents described herein to NKG2C may be determined using a suitable competition assay or blocking assay, such as, for example, a blocking assay as described in Example x herein.
- a competitor agent may block binding of one or more anti-NKG2C agents described herein to NKG2C in a competition or blocking assay by 50% or more, and conversely, one or more anti-NKG2C agents described herein may block binding of the competitor agent to NKG2C in a competition or blocking assay by about 50% or more.
- an agent i.e., competitor agent
- one or more anti- NKG2C agents described herein may block binding of the competitor agent to NKG2C in a competition or blocking assay by about 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%.
- an agent i.e., competitor agent
- an agent may be considered to compete for binding to NKG2C when the competitor binds to NKG2C with a similar affinity as one or more anti-NKG2C agents described herein.
- an agent i.e., competitor agent
- an agent may be considered capable of competing for binding to NKG2C when the competitor binds to NKG2C with a similar affinity as one or more anti-NKG2C agents described herein under suitable assay conditions.
- an agent i.e., competitor agent
- an agent i.e., competitor agent
- a competitor agent may comprise any feature described herein for anti-NKG2C agents.
- anti-NKG2C agents that bind to, or are capable of binding to, the same epitope as one or more anti-NKG2C agents described herein.
- anti-NKG2C agents that compete with one or more anti-NKG2C agents described herein for binding to the same epitope on NKG2C.
- Such agents that bind the same epitope may be referred to as epitope competitors.
- an epitope competitor may bind to the exact same region of NKG2C as an anti-NKG2C agent described herein (e.g., exact same peptide (linear epitope) or exact same surface amino acids (conformational epitope)).
- epitope competitor blocks the binding of one or more anti-NKG2C agents described herein to NKG2C.
- An epitope competitor may block binding of one or more anti-NKG2C agents described herein to NKG2C in a competition assay by about 50% or more, and conversely, one or more anti-NKG2C agents described herein may block binding of the epitope competitor to NKG2C in a competition assay by 50% or more.
- an epitope competitor binds to NKG2C with a similar affinity as one or more anti-NKG2C agents described herein.
- an epitope competitor binds to NKG2C with an affinity that is at least about 50% of the affinity of one or more anti-NKG2C agents described herein.
- an epitope competitor may bind to NKG2C with an affinity that is at least about 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% of the affinity of one or more anti-NKG2C agents described herein.
- An epitope competitor may comprise any feature described herein for anti-NKG2C agents.
- Antibody Preparation In some embodiments, an anti-NKG2C agent is an antibody. In some embodiments, any of the anti- NKG2C agents provided herein is an antibody or antigen-binding fragment thereof. Methods for generating anti-NKG2C antibodies, antigen-binding fragments thereof and variants of anti-NKG2C antibodies are described in the Examples below.
- an anti-NKG2C agent is a humanized antibody, or an antigen binding fragment thereof.
- an anti-NKG2C agent is a humanized antibody, or a derivative thereof that binds NKG2C.
- Humanized anti-NKG2C antibodies may be prepared based on a nonhuman anti-NKG2C antibody. Fully human antibodies may also be prepared, e.g., in a genetically engineered (i.e., transgenic) mouse (e.g., from Medarex) that, when presented with an immunogen, can produce a human antibody that does not necessarily require CDR grafting.
- Antibodies are fully human (100% human protein sequences) from animals such as mice in which the non-human antibody genes are suppressed and replaced with human antibody gene expression.
- Antibodies may be generated against NKG2C when presented to these genetically engineered mice or other animals that can to produce human frameworks for the relevant CDRs. Where a variant is generated, the parent antibody is prepared. Example techniques for generating such nonhuman antibody and parent antibodies are described in the following sections.
- Antigen Preparation The antigen for production of antibodies may be, e.g., intact NKG2C, particularly expressed in cells, or a portion of NKG2C (e.g.
- Polyclonal Antibodies may be raised in animals (vertebrate or invertebrates, including mammals, birds and fish, including cartilaginous fish) by multiple subcutaneous (sc) or intraperitoneal (ip) injections of a relevant antigen and an adjuvant.
- a protein or other carrier that is immunogenic in the species to be immunized e.g., keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, or soybean trypsin inhibitor
- Non-protein carriers also may be used for antibody production.
- animals are immunized against the antigen, immunogenic conjugates, or derivatives by combining, e.g., 100 ⁇ g or 5 ⁇ g of the protein or conjugate (for rabbits or mice, respectively) with three volumes of Freund's complete adjuvant and injecting the solution intradermally at multiple sites.
- the animals are boosted with one-fifth to one-tenth of the original amount of peptide or conjugate in Freund's complete adjuvant by subcutaneous injection at multiple sites.
- Seven to 14 days later the animals are bled and the serum is assayed for antibody titer. Animals are boosted until the titer plateaus.
- the animal is boosted with the conjugate of the same antigen, but conjugated to a different protein and/or through a different cross-linking reagent.
- Conjugates also can be made in recombinant cell culture as protein fusions.
- aggregating agents such as alum are suitably used to enhance the immune response.
- Monoclonal Antibodies Monoclonal antibodies may be made using the hybridoma method first described by Kohler et al., Nature, 256:495 (1975), or may be made by other methods such as recombinant DNA methods (U.S. Pat. No. 4,816,567).
- a mouse or other appropriate host animal such as a hamster or macaque monkey
- lymphocytes that produce or are capable of producing antibodies that will specifically bind to the protein used for immunization.
- lymphocytes may be immunized in vitro. Lymphocytes then are fused with myeloma cells using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding, Monoclonal Antibodies: Principles and Practice, pp.59-103 (Academic Press, 1986)).
- hybridoma cells are seeded and grown in a suitable culture medium that may contain one or more substances that inhibit the growth or survival of the unfused, parental myeloma cells.
- a suitable culture medium that may contain one or more substances that inhibit the growth or survival of the unfused, parental myeloma cells.
- the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine (HAT medium), which substances prevent the growth of HGPRT-deficient cells.
- HAT medium hypoxanthine, aminopterin, and thymidine
- Preferred myeloma cells are those that fuse efficiently, support stable high-level production of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium.
- preferred myeloma cell lines are murine myeloma lines, such as SP-2 or X63-Ag8-653 cells available from the American Type Culture Collection, Rockville, Md. USA.
- Human myeloma and mouse- human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies (Kozbor, J. Immunol., 133:3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications, pp.51-63 (Marcel Dekker, Inc., New York, 1987)).
- Culture medium in which hybridoma cells are growing is assayed for production of monoclonal antibodies directed against the antigen.
- the binding specificity of monoclonal antibodies produced by hybridoma cells may be determined by immunoprecipitation, by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbant assay (ELISA), or by flow cytometric analysis of cells expressing the membrane antigen.
- the binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson et al., Anal. Biochem., 107:220 (1980).
- the clones may be subcloned by limiting dilution procedures and grown by standard methods (Goding, Monoclonal Antibodies: Principles and Practice, pp.59-103 (Academic Press, 1986)). Suitable culture media for this purpose include, for example, D-MEM or RPMI-1640 medium.
- the hybridoma cells may be grown in vivo as ascites tumors in an animal.
- the monoclonal antibodies secreted by the subclones are suitably separated from the culture medium, ascites fluid, or serum by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.
- DNA encoding the monoclonal antibodies is readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the monoclonal antibodies).
- cDNA may be prepared from mRNA and the cDNA then subjected to DNA sequencing.
- the hybridoma cells serve as a preferred source of such genomic DNA or RNA for cDNA preparation.
- the DNA may be placed into expression vectors, which are well known in the art, and which are then transfected into host cells such as E coli cells, simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. Recombinant production of antibodies will be described in more detail below. Humanization and Amino Acid Sequence Variants General methods for humanization of antibodies are described, for example, in U.S.
- Amino acid sequence variants of the anti-NKG2C antibody are prepared by introducing appropriate nucleotide changes into the anti-NKG2C antibody DNA, or by peptide synthesis.
- Such variants include, for example, deletions from, and/or insertions into and/or substitutions of, residues within the amino acid sequences of the anti-NKG2C antibodies of the examples herein. Any combination of deletion, insertion, and substitution is made to arrive at the final construct, provided that the final construct possesses the desired characteristics.
- the amino acid changes also may alter post-translational processes of the humanized or variant anti-NKG2C antibody, such as changing the number or position of glycosylation sites.
- alanine scanning mutagenesis One method for identification of certain residues or regions of the anti-NKG2C antibody that are preferred locations for mutagenesis is called “alanine scanning mutagenesis,” as described by Cunningham and Wells Science, 244:1081-1085 (1989).
- a residue or group of target residues are identified (e.g., charged residues such as arg, asp, his, lys, and glu) and replaced by a neutral or negatively charged amino acid (most preferably alanine or polyalanine) to affect the interaction of the amino acids with NKG2C antigen.
- Those amino acid locations demonstrating functional sensitivity to the substitutions then are refined by introducing further or other variants at, or for, the sites of substitution.
- Amino acid sequence insertions include amino- and/or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as intra-sequence insertions of single or multiple amino acid residues.
- terminal insertions include an N-terminal methionyl residue or the antibody fused to an epitope tag.
- insertional variants include the fusion of an enzyme or a polypeptide that increases the serum half-life of the antibody to the N- or C-terminus of the antibody.
- Another type of variant is an amino acid substitution variant. These variants have at least one amino acid residue removed from the antibody molecule and a different residue inserted in its place.
- the sites of greatest interest for substitutional mutagenesis include the hypervariable regions, but FR alterations are also contemplated. Conservative substitutions are preferred, but more substantial changes may be introduced and the products may be screened.
- substitutions are listed below: Example Amino Acid Residue Substitutions Substantial modifications in the biological properties of an antibody are accomplished by selecting substitutions that differ significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain.
- Naturally occurring residues are divided into groups based on common side-chain properties: (1) hydrophobic: norleucine, met, ala, val, leu, ile; (2) neutral hydrophilic: cys, ser, thr; (3) acidic: asp, glu; (4) basic: asn, gln, his, lys, arg; (5) residues that influence chain orientation: gly, pro; and (6) aromatic: trp, tyr, phe.
- Non-conservative substitutions will entail exchanging a member of one of these classes for another class. Any cysteine residue not involved in maintaining the proper conformation of the antibody also may be substituted, to improve the oxidative stability of the molecule and prevent aberrant crosslinking.
- cysteine bond(s) may be added to the antibody to improve its stability (particularly where the antibody is an antibody fragment such as an Fv fragment).
- substitutional variant involves substituting one or more hypervariable region residues of a parent antibody (e.g. a humanized or human antibody). Generally, the resulting variant(s) selected for further development will have improved biological properties relative to the parent antibody from which they are generated.
- affinity maturation using phage display Briefly, several hypervariable region sites (e.g.6-7 sites) are mutated to generate all possible amino substitutions at each site.
- the antibody variants thus generated are displayed in a monovalent fashion from filamentous phage particles as fusions to the gene III product of M13 packaged within each particle.
- the phage-displayed variants are then screened for their biological activity (e.g. binding affinity) as herein disclosed.
- alanine-scanning mutagenesis can be performed to identify hypervariable region residues contributing significantly to antigen binding.
- the panel of variants is subjected to screening as described herein and antibodies with superior properties in one or more relevant assays may be selected for further development.
- Another type of amino acid variant of the antibody alters the original glycosylation pattern of the antibody. By altering is meant deleting one or more carbohydrate moieties found in the antibody, and/or adding one or more glycosylation sites that are not present in the antibody.
- Glycosylation of antibodies is typically either N-linked and/or or O-linked. N-linked refers to the attachment of the carbohydrate moiety to the side chain of an asparagine residue.
- the tripeptide sequences asparagine-X-serine and asparagine- X-threonine, where X is any amino acid except proline, are the most common recognition sequences for enzymatic attachment of the carbohydrate moiety to the asparagine side chain.
- O-linked glycosylation refers to the attachment of one of the sugars N-acetylgalactosamine, galactose, or xylose to a hydroxyamino acid, most commonly serine or threonine, although 5-hydroxyproline or 5-hydroxylysine may also be used.
- glycosylation sites to the antibody is conveniently accomplished by altering the amino acid sequence such that it contains one or more of the above-described tripeptide sequences (for N-linked glycosylation sites). The alteration may also be made by the addition of, or substitution by, one or more serine or threonine residues to the sequence of the original antibody (for O-linked glycosylation sites).
- Nucleic acid molecules encoding amino acid sequence variants of anti-NKG2C antibodies herein are prepared by a variety of methods known in the art.
- human antibodies can be generated.
- transgenic animals e.g., mice
- transgenic animals may be generated that are capable, upon immunization, of producing a full repertoire of human antibodies in the absence of endogenous immunoglobulin production.
- J H antibody heavy-chain joining region
- a homozygous deletion of the antibody heavy-chain joining region (J H ) gene in chimeric and germ-line mutant mice results in complete inhibition of endogenous antibody production.
- Transfer of the human germ-line immunoglobulin gene array into such germ-line mutant mice can result in the production of human antibodies upon antigen challenge (see, e.g., Jakobovits et al., Proc. Natl. Acad. Sci. USA, 90:2551 (1993); Jakobovits et al., Nature, 362:255-258(1993); Bruggermann et al., Year in Immuno., 7:33 (1993); and U.S. Pat.
- an anti-NKG2C agent is an antibody fragment that retains at least one desired activity, including antigen binding.
- antibody fragments are derived via proteolytic digestion of intact antibodies (see, e.g., Morimoto et al., Journal of Biochemical and Biophysical Methods 24:107-117(1992) and Brennan et al., Science 229:81 (1985)). In some instances, these fragments are produced directly by recombinant host cells. For example, Fab'-SH fragments can be directly recovered from E. coli and chemically coupled to form F(ab') 2 fragments (Carter et al., Bio/Technology 10:163-167 (1992)).
- an anti-NKG2C agent comprises a first binding moiety and a second binding moiety, where the first binding moiety is specifically reactive with a first molecule that is NKG2C and the second binding moiety is specifically reactive with a second molecule that is a molecular species different from the first molecule.
- Such agents may comprise a plurality of first binding moieties, a plurality of second binding moieties, or a plurality of first binding moieties and a plurality of second binding moieties.
- the ratio of first binding moieties to second binding moieties is about 1:1, although it may range from about 1000:1 to about 1:1000, where the ratio may be measured in terms of valency.
- the first moiety is an antibody
- the second binding moiety may also be an antibody.
- the first and second moieties are linked via a linker moiety, which may have two to many 100’s or even thousands of valencies for attachment of first and second binding moieties by one or different chemistries.
- bispecific antibodies include those that are reactive against two different epitopes; in some instances, one epitope is a NKG2C epitope and the second epitope is on an unrelated soluble molecule. In some embodiments, the bispecific antibody is reactive against an epitope on NKG2C and against an epitope on a different molecule found on the surface of the same cell. In some embodiments, the bispecific antibody is reactive against an epitope on NKG2C and against an epitope on a different molecule found on the surface of a different cell.
- Compositions herein may also comprise a first agent and a second agent, where the first agent comprises a first binding moiety specifically reactive with a first molecule (e.g., NKG2C) and the second agent comprises a second binding moiety specifically reactive with a second molecule that is a molecular species different than the first molecule.
- the first and/or second agent may be an antibody.
- the ratio of first agent to second agent may range from about 1,000:1 to 1: 1,000, although the preferred ratio is about 1:1.
- Bispecific antibodies can be prepared as full-length antibodies or antibody fragments (e.g., F(ab') 2 bispecific antibodies).
- the interface between a pair of antibody molecules can be engineered to maximize the percentage of heterodimers that are recovered from recombinant cell culture.
- the preferred interface comprises at least a part of the C H 3 domain of an antibody constant domain.
- one or more small amino acid side chains from the interface of the first antibody molecule are replaced with larger side chains (e.g., tyrosine or tryptophan).
- Bispecific antibodies include cross-linked or “heteroconjugate” antibodies.
- one of the antibodies in the heteroconjugate can be coupled to avidin, the other to biotin.
- Heteroconjugate antibodies may be made using any convenient cross-linking methods.
- Suitable cross-linking agents are well known in the art, and are disclosed in U.S. Pat. No.4,676,980, along with a number of cross-linking techniques. Any suitable technique may be used for generating bispecific antibodies from antibody fragments.
- bispecific antibodies can be prepared using chemical linkage.
- intact antibodies are proteolytically cleaved to generate F(ab') 2 fragments (see e.g., Brennan et al., Science 229:81 (1985), which is incorporated by reference herein). These fragments are reduced in the presence of the dithiol complexing agent sodium arsenite to stabilize vicinal dithiols and prevent intermolecular disulfide formation.
- Fab' fragments generated are then converted to thionitrobenzoate (TNB) derivatives.
- TAB thionitrobenzoate
- One of the Fab'-TNB derivatives is then reconverted to the Fab'-thiol by reduction with mercaptoethylamine and is mixed with an equimolar amount of the other Fab'-TNB derivative to form the bispecific antibody.
- Fab'-SH fragments directly recovered from E. coli can be chemically coupled in vitro to form bispecific antibodies (see e.g., Shalaby et al., J. Exp. Med. 175:217-225 (1992), which is incorporated by reference herein).
- bispecific antibodies have been produced using leucine zippers (see e.g., Kostelny et al., J. Immunol.148(5):1547-1553 (1992), which is incorporated by reference herein).
- the leucine zipper peptides from the Fos and Jun proteins were linked to the Fab' portions of two different antibodies by gene fusion.
- the antibody homodimers were reduced at the hinge region to form monomers and then re-oxidized to form the antibody heterodimers. This method can also be utilized for the production of antibody homodimers.
- the fragments comprise a heavy-chain variable domain (V H ) connected to a light- chain variable domain (V L ) by a linker that is too short to allow pairing between the two domains on the same chain. Accordingly, the V H and V L domains of one fragment are forced to pair with the complementary V L and V H domains of another fragment, thereby forming two antigen-binding sites.
- V H and V L domains of one fragment are forced to pair with the complementary V L and V H domains of another fragment, thereby forming two antigen-binding sites.
- scFv single-chain Fv
- a bispecific antibody may be a “linear antibody” produced as described in Zapata et al. Protein Eng.8(10):1057-1062 (1995), which is incorporated by reference herein. Antibodies with two valencies or more are contemplated herein.
- An antibody (or polymer or polypeptide) herein comprising one or more binding sites per arm or fragment thereof will be referred to herein as “multivalent” antibody.
- a “bivalent” antibody herein comprises two binding sites per Fab or fragment thereof whereas a “trivalent” polypeptide herein comprises three binding sites per Fab or fragment thereof.
- the two or more binding sites per Fab may be binding to the same or different antigens.
- the two or more binding sites in a multivalent polypeptide herein may be directed against the same antigen, for example against the same parts or epitopes of said antigen or against two or more same or different parts or epitopes of said antigen; and/or may be directed against different antigens; or a combination thereof.
- a bivalent polypeptide herein may comprise two identical binding sites, may comprise a first binding sites directed against a first part or epitope of an antigen and a second binding site directed against the same part or epitope of said antigen or against another part or epitope of said antigen; or may comprise a first binding sites directed against a first part or epitope of an antigen and a second binding site directed against a different antigen.
- a multivalent polypeptide herein may comprise any number of binding sites directed against the same or different antigens.
- the multivalent polypeptide comprises at least two ligand binding elements, one of which contains one or more CDR peptide sequences shown herein.
- the multivalent polypeptide comprises three ligand binding sites, each independently selected from the CDR sequences disclosed herein.
- at least one of the ligand binding elements binds NKG2C.
- at least one of the ligand binding elements binds another target.
- a multivalent binding molecule there are up to 10,000 binding elements in a multivalent binding molecule, and the ligand binding elements may be linked to a scaffold.
- a “bispecific” polymer comprises at least one site directed against a first antigen and at least one second site directed against a second antigen
- a “trispecific” is a polymer that comprises at least one binding site directed against a first antigen, at least one further binding site directed against a second antigen, and at least one further binding site directed against a third antigen; and the like.
- a bispecific polypeptide herein is a bivalent polypeptide (per Fab) of the technology provided herein.
- the technology herein is not limited thereto, in the sense that a multispecific polypeptide herein may comprise any number of binding sites directed against two or more different antigens.
- Other Modifications Other modifications of an anti-NKG2C agent are contemplated.
- technology herein also pertains to immunoconjugates comprising an antibody described herein (e.g., an anti-NKG2C antibody) conjugated to a cytotoxic agent such as a toxin (e.g., an enzymatically active toxin of bacterial, fungal, plant or animal origin, or fragments thereof), or a radioactive isotope (for example, a radioconjugate), or a cytotoxic drug.
- a cytotoxic agent such as a toxin (e.g., an enzymatically active toxin of bacterial, fungal, plant or animal origin, or fragments thereof), or a radioactive isotope (for example, a radioconjugate), or a cytotoxic drug.
- ADC agent-drug conjugates
- Conjugates are made using a variety of bifunctional protein coupling agents such as N-succinimidyl-3-(2- pyridyldithiol) propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis (p-azidobenzoyl)hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as tolyene 2,6- diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene).
- SPDP N-succinimidyl-3-(2- pyridyldithi
- Anti-NKG2C agents e.g., anti-NKG2C antibodies
- Liposomes containing an antibody are prepared by methods known in the art, such as described in Epstein et al., Proc. Natl. Acad. Sci. USA 82:3688 (1985); Hwang et al., Proc. Natl Acad. Sci. USA 77:4030 (1980); and U.S. Pat. Nos.4,485,045 and 4,544,545. Liposomes with enhanced circulation time are disclosed in U.S. Pat. No.5,013,556.
- liposomes can be generated by the reverse phase evaporation method with a lipid composition comprising phosphatidyl choline, cholesterol and PEG-derivatized phosphatidylethanolamine (PEG-PE). Liposomes are extruded through filters of defined pore size to yield liposomes with the desired diameter.
- Fab' fragments of an antibody provided herein can be conjugated to the liposomes as described in Martin et al., J. Biol. Chem.257:286-288 (1982) via a disulfide interchange reaction. Another active ingredient is optionally contained within the liposome.
- Enzymes or other polypeptides can be covalently bound to an anti-NKG2C agent (e.g., anti-NKG2C antibody) by techniques well known in the art such as the use of the heterobifunctional cross-linking reagents discussed above.
- fusion proteins comprising at least the antigen binding region of an antibody provided herein linked to at least a functionally active portion of an enzyme can be constructed using recombinant DNA techniques well known in the art (see, e.g., Neuberger et al., Nature 312:604-608 (1984)).
- the antibody fragment in order to increase its serum half-life.
- This may be achieved, for example, by incorporation of a salvage receptor binding epitope into the antibody fragment (e.g., by mutation of the appropriate region in the antibody fragment or by incorporating the epitope into a peptide tag that is then fused to the antibody fragment at either end or in the middle, e.g., by DNA or peptide synthesis; see, e.g., WO96/32478 published Oct.17, 1996).
- Covalent modifications of an anti-NKG2C agent e.g., anti-NKG2C antibody
- anti-NKG2C antibody are also included within the scope of this technology.
- modifications may be made by chemical synthesis or by enzymatic or chemical cleavage of an anti-NKG2C antibody.
- Other types of covalent modifications of an antibody are introduced into the molecule by reacting targeted amino acid residues of the antibody with an organic derivatizing agent that is capable of reacting with selected side chains or the N- or C-terminal residues.
- Example covalent modifications of polypeptides are described in U.S. Pat. No.5,534,615, specifically incorporated herein by reference.
- a preferred type of covalent modification of the antibody comprises linking the antibody to one of a variety of non-proteinaceous polymers, e.g., polyethylene glycol, polypropylene glycol, or polyoxyalkylenes, in the manner set forth in U.S. Pat.
- nucleic acids, vectors, host cells, and recombinant methods Provided herein are isolated nucleic acids encoding any of the anti-NKG2C agents (e.g., anti-NKG2C antibody) described herein, and vectors and host cells comprising any of the nucleic acids provided herein, and recombinant techniques for the production of the agent or antibody.
- a nucleic acid herein may include one or more subsequences, each referred to as a polynucleotide.
- nucleic acids e.g., isolated nucleic acids
- a nucleic acid encodes an immunoglobulin heavy chain variable domain of an anti-NKG2C agent provided herein.
- the immunoglobulin heavy chain variable domain is encoded by the sequence of nucleotides set forth in any of SEQ ID NOs: 74, 76, 78, 80, 82, 84, 86 and 88, or sequence of nucleotides having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to any of SEQ ID NOs: 74, 76, 78, 80, 82, 84, 86 and 88.
- the immunoglobulin heavy chain variable domain is encoded by the sequence of nucleotides set forth in any of SEQ ID NOs: 74, 76, 78, 80, 82, 84, 86 and 88. In some embodiments, the immunoglobulin heavy chain variable domain is encoded by the sequence of nucleotides set forth in any of SEQ ID NOs: 58, 60, 62, 64, 66, 68, 70 and 72, or sequence of nucleotides having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to any of SEQ ID NOs: 58, 60, 62, 64, 66, 68, 70 and 72.
- the immunoglobulin heavy chain variable domain contains a signal sequence and is encoded by the sequence of nucleotides set forth in any of SEQ ID NOs:58, 60, 62, 64, 66, 68, 70 and 72.
- a nucleic acid encodes an immunoglobulin light chain variable domain of an anti- NKG2C agent provided herein.
- the immunoglobulin light chain variable domain does not contain a signal sequence, and is encoded by the sequence of nucleotides set forth in any of SEQ ID NOs:75, 77, 79, 81, 83, 85, 87, and 89 or sequence of nucleotides having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to any of SEQ ID NOs: 75, 77, 79, 81, 83, 85, 87, and 89.
- the immunoglobulin light chain variable domain does not contain a signal sequence, and is encoded by the sequence of nucleotides set forth in any of SEQ ID NOs: 59, 61, 63, 65, 67, 69, 71, and 73. or sequence of nucleotides having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to any of SEQ ID NOs: 59, 61, 63, 65, 67, 69, 71, and 73.
- the immunoglobulin light chain variable domain does contain a signal sequence, and is encoded by the sequence of nucleotides set forth in any of SEQ ID NOs:59, 61, 63, 65, 67, 69, 71, and 73.
- a nucleic acid encodes an immunoglobulin heavy chain variable domain and an immunoglobulin light chain variable domain of an anti-NKG2C agent provided herein.
- a nucleic acid comprises a nucleotide sequence that encodes an amino acid sequence of any one of SEQ ID NOS:1-8 and 9-16.
- a nucleic acid may comprise a nucleotide sequence that encodes a CDR amino acid sequence of any one of SEQ ID NOS: 17-49.
- a nucleic acid may comprise a nucleotide sequence that encodes an immunoglobulin heavy chain variable domain amino acid sequence of any one of SEQ ID NOS: 1-3 and 5-8.
- a nucleic acid may comprise a nucleotide sequence that encodes an immunoglobulin light chain variable domain amino acid sequence of any one of SEQ ID NOS: 9-11 and 13-16.
- a nucleic acid encoding the anti- NKG2C agent or antibody may be isolated and inserted into a replicable vector for further cloning (amplification of the DNA) or for expression.
- an anti-NKG2C agent or antibody may be produced by homologous recombination, e.g. as described in U.S. Pat. No.5,204,244, specifically incorporated herein by reference.
- DNA encoding an anti-NKG2C agent or antibody can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the antibody). Many vectors are available.
- the vector components generally include, but are not limited to, one or more of the following: a signal sequence, an origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence, e.g., as described in U.S. Pat. No.5,534,615 issued Jul.9, 1996 and specifically incorporated herein by reference.
- Suitable host cells for cloning or expressing DNA in vectors herein are prokaryote, yeast, or higher eukaryote cells.
- Suitable prokaryotes for this purpose include eubacteria, such as Gram-negative or Gram-positive organisms, for example, Enterobacteriaceae such as Escherichia, e.g., E.
- E. coli Enterobacter, Erwinia, Klebsiella, Proteus, Salmonella, e.g., Salmonella typhimurium, Serratia, e.g., Serratia marcescans, and Shigella, as well as Bacilli such as B. subtilis and B. licheniformis (e.g., B. licheniformis 41P disclosed in DD 266,710 published 12 Apr.1989), Pseudomonas such as P. aeruginosa, and Streptomyces.
- One preferred E. coli cloning host is E. coli 294 (ATCC 31,446), although other strains such as E. coli B, E.
- coli X1776 ATCC 31,537)
- E. coli W3110 ATCC 27,325
- eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for anti-NKG2C agent/antibody-encoding vectors.
- Saccharomyces cerevisiae, or common baker's yeast is the most commonly used among lower eukaryotic host microorganisms.
- a number of other genera, species, and strains are commonly available and useful herein, such as Schizosaccharomyces pombe; Kluyveromyces hosts such as, e.g., K. lactis, K.
- Suitable host cells for the expression of anti-NKG2C agents/antibodies are derived from multicellular organisms. Examples of invertebrate cells include plant and insect cells. Numerous baculoviral strains and variants and corresponding permissive insect host cells from hosts such as Spodoptera frugiperda (caterpillar), Aedes aegypti (mosquito), Aedes albopictus (mosquito), Drosophila melanogaster (fruitfly), and Bombyx mori (silk moth) have been identified.
- a variety of viral strains for transfection are publicly available, e.g., the L-1 variant of Autographa californica NPV and the Bm-5 strain of Bombyx mori NPV, and such viruses may be used as the virus herein according to the present technology, particularly for transfection of Spodoptera frugiperda cells.
- Plant cell cultures of cotton, corn, potato, soybean, petunia, tomato, and tobacco can also be utilized as hosts.
- Suitable host cells for the expression of anti-NKG2C agents/antibodies also may include vertebrate cells (e.g., mammalian cells). Vertebrate cells may be propagated in culture (tissue culture).
- Examples of useful mammalian host cell lines include monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture, Graham et al., J. Gen Virol.36:59 (1977)); baby hamster kidney cells (BHK, ATCC CCL 10); Chinese hamster ovary cells/-DHFR (CHO, Urlaub et al., Proc. Natl. Acad. Sci. USA 77:4216 (1980)); mouse Sertoli cells (TM4, Mather, Biol.
- COS-7 monkey kidney CV1 line transformed by SV40
- human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture, Graham et al., J. Gen Virol.36:59 (1977)
- baby hamster kidney cells BHK, ATCC CCL 10
- Chinese hamster ovary cells/-DHFR CHO, Urlaub et al., Proc. Natl. Ac
- monkey kidney cells (CV1 ATCC CCL 70); African green monkey kidney cells (VERO-76, ATCC CRL-1587); human cervical carcinoma cells (HELA, ATCC CCL 2); canine kidney cells (MDCK, ATCC CCL 34); buffalo rat liver cells (BRL 3A, ATCC CRL 1442); human lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065); mouse mammary tumor (MMT 060562, ATCC CCL51); TRI cells (Mather et al., Annals N.Y. Acad. Sci.
- Host cells may be transformed with the above-described expression or cloning vectors for antibody production and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences.
- Host cells used to produce an agent/antibody herein may be cultured in a variety of media.
- Commercially available media such as Ham's F10 (Sigma), Minimal Essential Medium ((MEM), (Sigma), RPMI-1640 (Sigma), and Dulbecco's Modified Eagle's Medium ((DMEM), Sigma) are suitable for culturing the host cells.
- any of the media described in Ham et al., Meth. Enz.58:44 (1979), Barnes et al., Anal. Biochem.102:255 (1980), U.S. Pat. Nos.4,767,704; 4,657,866; 4,927,762; 4,560,655; or 5,122,469; WO 90/03430; WO 87/00195; or U.S. Pat. Re.30,985 may be used as culture media for the host cells.
- any of these media may be supplemented as necessary with hormones and/or other growth factors (such as insulin, transferrin, or epidermal growth factor), salts (such as sodium chloride, calcium, magnesium, and phosphate), buffers (such as HEPES), nucleotides (such as adenosine and thymidine), antibiotics (such as GENTAMYCINTM), trace elements (defined as inorganic compounds usually present at final concentrations in the micromolar range), and glucose or an equivalent energy source. Any other necessary supplements may also be included at appropriate concentrations that would be known to those skilled in the art.
- the culture conditions such as temperature, pH, and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.
- an agent/antibody can be produced intracellularly, in the periplasmic space, or directly secreted into the medium. If the antibody is produced intracellularly, as a first step, the particulate debris, either host cells or lysed fragments, is removed, for example, by centrifugation or ultrafiltration. Carter et al., Bio/Technology 10:163-167 (1992) describe a procedure for isolating antibodies that are secreted to the periplasmic space of E. coli. Briefly, cell paste is thawed in the presence of sodium acetate (pH 3.5), EDTA, and phenylmethylsulfonylfluoride (PMSF) over about 30 minutes.
- sodium acetate pH 3.5
- EDTA EDTA
- PMSF phenylmethylsulfonylfluoride
- Cell debris can be removed by centrifugation.
- supernatants from such expression systems are generally first concentrated using a commercially available protein concentration filter, for example, an Amicon or Millipore Pellicon ultrafiltration unit.
- a protease inhibitor such as PMSF may be included in any of the foregoing steps to inhibit proteolysis and antibiotics may be included to prevent the growth of adventitious contaminants.
- the agent/antibody composition prepared from the cells can be purified using, for example, hydroxylapatite chromatography, gel electrophoresis, dialysis, and affinity chromatography, with affinity chromatography being the preferred purification technique.
- protein A as an affinity ligand depends on the species and isotype of any immunoglobulin Fc domain that is present in the antibody.
- Protein A can be used to purify antibodies that are based on human heavy chains (Lindmark et al., J. Immunol. Meth.62:1-13 (1983)).
- Protein G is recommended for all mouse isotypes and for human ⁇ 3 (Guss et al., EMBO J.5:15671575 (1986)).
- the matrix to which the affinity ligand is attached is most often agarose, but other matrices are available. Mechanically stable matrices such as controlled pore glass or poly(styrenedivinyl)benzene allow for faster flow rates and shorter processing times than can be
- the mixture comprising the agent or antibody of interest and contaminants may be subjected to low pH hydrophobic interaction chromatography using an elution buffer at a pH between about 2.5-4.5, and may be performed at low salt concentrations (e.g., from about 0-0.25M salt).
- elution buffer at a pH between about 2.5-4.5
- salt concentrations e.g., from about 0-0.25M salt.
- Pharmaceutical formulations, dosing, and routes of administration The present technology provides anti-NKG2C agents and antibodies, fragments or antigen-binding fragments thereof and related compositions, which may be useful for elimination of NKG2C expressing cells from the body, for example, and for identification and quantification of the number of NKG2C expressing cells in tissue samples, for example.
- NKG2C-based Therapeutic methods and compositions of the present technology may be referred to as “NKG2C-based” in order to indicate that these therapies can change the relative or absolute numbers of undesirable or toxic NKG2C expressing cells such as lymphomas or autoimmune B lymphocytes.
- one way to control the amount of undesirable NKG2C expressing cells in a patient is by providing a composition that comprises one or more anti-NKG2C antibodies fragments or antigen- binding fragments thereof to cause cytotoxic activity towards the NKG2C-expressing cells, for example.
- any of the anti-NKG2C agents or anti-NKG2C antibodies described herein are capable of binding a cell.
- the cell is a natural killer (NK) cell.
- the cell is a lymphocyte. In some embodiments, the lymphocyte is a CD8+ lymphocyte. In some embodiments, the cell selected from B cells, plasmacytoid dendritic cells (pDCs), lymphocytes, leukocytes, T cells, monocytes, macrophages, neutrophils, myeloid dendritic cells (mDCs), innate lymphoid cells, mast cells, eosinophils, basophils, natural killer cells, and the like. In some embodiments, the cell is selected from a heterogeneous population of immune cells including peripheral blood 81 mononuclear cells (PBMCs) which may include, for example, T cells, B cells, natural killer cells, and monocytes.
- PBMCs peripheral blood 81 mononuclear cells
- the cell bound by any of the anti-NKG2C agents or anti-NKG2C antibodies interacts with a target cell that expresses HLA-E.
- the target cell is a cancer cell.
- the target cell is a cancer cell that expresses HLA-E.
- the target cell is a cancer cell that over-expresses HLA-E.
- the HLA-E is expressed on the surface of the target or cancer cell.
- any of the anti-NKG2C agents or anti-NKG2C antibodies described herein specifically bind NKG2C on a cell.
- any of the anti-NKG2C agents or anti-NKG2C antibodies described herein specifically bind NKG2C and do not specifically bind NKG2C or NKG2E. In some embodiments, any of the anti-NKG2C agents or anti-NKG2C antibodies described herein block the binding of HLA-E to NKG2C.
- the cell is a cell with a disease or disorder. In some embodiments, the disease or disorder is a cancer, a viral infection, an autoimmune disease, an inflammatory disease or a bacterial infection.
- the disease or disorder is a cancer including but not limited to acute myeloid leukemia, acute lymphoblastic leukemia, colorectal, ovarian, gynecologic, liver, glioblastoma, Hodgkin lymphoma, chronic lymphocytic leukemia, esophagus, gastric, pancreas, colon, kidney, head and neck, lung and melanoma.
- any of the ani-NKG2C agents provided herein can be used to treat a disease or disorder by blocking the NKG2C receptor on NKG2C expressing cells in a subject.
- any of the anti-NKG2C agents provided herein are provided as a composition.
- the composition increases the cytotoxic activity of NKG2C-expressing cells. In some embodiments, the composition restores the cytotoxic activity of NKG2C-expressing cells. In some embodiments, the composition causes cytotoxic activity towards cells targeted by NKG2C-expressing cells. In some embodiments, one way to control the amount of undesirable NKG2C expressing cells in a patient is by providing a composition that comprises one or more anti-NKG2C agents, antibodies, fragments or antigen-binding fragments thereof to cause cytotoxic activity towards cells targeted by NKG2C-expressing cells. In some embodiments, the disease or disorder is associates with aberrant levels of HLA-E. In some embodiments, the disease or disorder is a cancer.
- the disease or disorder is a cancer that expresses HLA-E.
- the disease or disorder is a cancer, a viral infection, an autoimmune disease, an inflammatory disease or a bacterial infection.
- the disease or disorder is a cancer including but not limited to acute myeloid leukemia, acute lymphoblastic leukemia, colorectal, ovarian, gynecologic, liver, glioblastoma, Hodgkin lymphoma, chronic lymphocytic leukemia, esophagus, gastric, pancreas, colon, kidney, head and neck, lung and melanoma.
- the disease or disorder is a condition characterized by NK cell hyperactivity or NK cell hyperproliferation.
- the binding of NKG2C to HLA-E to on a target cell is blocked.
- the binding of any of the anti-NKG2C agents or anti-NKG2C antibodies described herein to NKG2C on a cell blocks to ability of the NKG2C on the cell from interacting with HLA-E to on a target cell.
- Anti-NKG2C agents/antibodies may be formulated in a pharmaceutical composition that is useful for a variety of purposes, including the treatment of diseases, disorders or physical trauma.
- Pharmaceutical compositions comprising one or more anti-NKG2C agents/antibodies herein may be incorporated into kits and medical devices for such treatment. Medical devices may be used to administer pharmaceutical compositions herein to a patient in need thereof, and according to one embodiment of the technology, kits are provided that include such devices. Such devices and kits may be designed for routine administration, including self-administration, of the pharmaceutical compositions herein.
- Therapeutic formulations of an agent or antibody may be prepared for storage by mixing the agent/antibody having the desired degree of purity with optional physiologically acceptable carriers, excipients or stabilizers (Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980)), in the form of lyophilized formulations or aqueous solutions.
- Acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine,
- Formulations herein may also contain more than one active compound as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. Such molecules are suitably present in combination in amounts that are effective for the purpose intended. Active ingredients may also be entrapped in microcapsule prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsule and poly-(methylmethacylate) microcapsule, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules) or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980).
- Formulations for in vivo administration generally are sterile. This may be accomplished for instance by filtration through sterile filtration membranes, for example.
- Sustained-release preparations may be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the agent/antibody, which matrices are in the form of shaped articles, e.g., films, or microcapsule. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly(vinyl alcohol)), polylactides (U.S. Pat. No.3,773,919), copolymers of L-glutamic acid and .gamma.
- ethyl-L- glutamate non-degradable ethylene-vinyl acetate
- degradable lactic acid-glycolic acid copolymers such as the Lupron Depot.TM. (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid. While polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods.
- encapsulated agents/antibodies When encapsulated agents/antibodies remain in the body for a long time, they may denature or aggregate as a result of exposure to moisture at 37° C, resulting in a loss of biological activity and possible changes in immunogenicity. Rational strategies can be devised for stabilization depending on the mechanism involved. For example, if the aggregation mechanism is discovered to be intermolecular S-- bond formation through thio-disulfide interchange, stabilization may be achieved by modifying sulfhydryl residues, lyophilizing from acidic solutions, controlling moisture content, using appropriate additives, and developing specific polymer matrix compositions.
- anti-NKG2C agents e.g., antibodies, provided herein are administered to a mammal, e.g., a human, in a pharmaceutically acceptable dosage form such as those discussed above, including those that may be administered to a human intravenously as a bolus or by continuous infusion over a period of time, or by intramuscular, intraperitoneal, intra-cerebrospinal, subcutaneous, intra- articular, intrasynovial, intrathecal, oral, topical, or inhalation routes.
- a mammal e.g., a human
- a pharmaceutically acceptable dosage form such as those discussed above, including those that may be administered to a human intravenously as a bolus or by continuous infusion over a period of time, or by intramuscular, intraperitoneal, intra-cerebrospinal, subcutaneous, intra- articular, intrasynovial, intrathecal, oral, topical, or inhalation routes.
- the appropriate dosage of agent/antibody will depend on the type of disease to be treated, as defined above, the severity and course of the disease, whether the antibody is administered for preventive or therapeutic purposes, previous therapy, the patient's clinical history and response to the antibody, and the discretion of the attending physician.
- the antibody is suitably administered to the patient at one time or over a series of treatments.
- about 1 ⁇ g/kg to about 50 mg/kg (e.g., 0.1-20 mg/kg) of antibody may be an initial candidate dosage for administration to the patient, whether, for example, by one or more separate administrations, or by continuous infusion.
- a typical daily or weekly dosage might range from about 1 ⁇ g/kg to about 20 mg/kg or more, depending on the factors mentioned above. For repeated administrations over several days or longer, depending on the condition, the treatment is repeated until a desired suppression of disease symptoms occurs. However, other dosage regimens may be useful. The progress of this therapy is easily monitored by conventional techniques and assays, including, for example, radiographic imaging. Detection methods using the antibody to determine NKG2C levels in bodily fluids or tissues may be used in order to optimize patient exposure to the therapeutic antibody.
- a composition comprising an anti-NKG2C agent herein is administered as a monotherapy, and in some embodiments, the composition comprising the anti-NKG2C agent is administered as part of a combination therapy.
- the effectiveness of the agent/antibody in preventing or treating disease may be improved by administering the agent/antibody serially or in combination with another agent that is effective for those purposes, such as a chemotherapeutic drug for treatment of cancer or a microbial infection.
- the anti-NKG2C agent may serve to enhance or sensitize cells to chemotherapeutic treatment, thus permitting efficacy at lower doses and with lower toxicity.
- Certain combination therapies include, in addition to administration of the composition comprising an agent that reduces the number of NKG2C expressing cells, delivering a second therapeutic regimen selected from the group consisting of administration of a chemotherapeutic agent, radiation therapy, surgery, and a combination of any of the foregoing.
- a second therapeutic regimen selected from the group consisting of administration of a chemotherapeutic agent, radiation therapy, surgery, and a combination of any of the foregoing.
- Such other agents may be present in the composition being administered or may be administered separately.
- the anti-NKG2C agent may be suitably administered serially or in combination with the other agent or modality, e.g., chemotherapeutic drug or radiation for treatment of cancer, infection, and the like, or an immunosuppressive drug.
- compositions comprising any of the anti-NKG2C agents described herein.
- the composition comprising any of the anti-NKG2C agents described herein includes a pharmaceutically acceptable excipient.
- Research and diagnostic, including clinical diagnostic, uses for anti-NKG2C agents herein Provided herein are diagnostic reagents comprising an anti-NKG2C agent described herein.
- anti-NKG2C agents e.g., antibodies
- diagnostic reagents comprising an anti-NKG2C agent described herein.
- anti-NKG2C agents e.g., antibodies
- methods for detecting NKG2C may be used to detect and/or purify NKG2C, e.g., from bodily fluid(s) or expressed on cells in bodily fluids or tissues.
- methods for detecting NKG2C are also provided herein are methods for detecting NKG2C.
- a method may comprise contacting a sample (e.g., a biological sample known or suspected of to contain NKG2C) with an anti-NKG2C agent provided herein, and, if the sample contains NKG2C, detecting NKG2C:anti-NKG2C complexes.
- reagents comprising an anti-NKG2C agent described herein and methods for detecting NKG2C for research purposes.
- Anti-NKG2C antibodies may be useful in diagnostic assays for NKG2C, e.g., detecting its presence in specific cells, tissues, or bodily fluids. Such diagnostic methods may be useful in diagnosis, e.g., of a hyperproliferative disease or disorder.
- the disease or disorder is a cancer, a viral infection, an autoimmune disease, an inflammatory disease or a bacterial infection.
- the disease or disorder is a cancer including but not limited to acute myeloid leukemia, acute lymphoblastic leukemia, colorectal, ovarian, gynecologic, liver, glioblastoma, Hodgkin lymphoma, chronic lymphocytic leukemia, esophagus, gastric, pancreas, colon, kidney, head and neck, lung and melanoma.
- any of the anti-NKG2C agents or anti-NKG2C antibodies described herein are capable of binding a cell.
- the cell is a natural killer (NK) cell.
- the cell is a lymphocyte.
- the lymphocyte is a CD8+ lymphocyte.
- any of the anti-NKG2C agents or anti-NKG2C antibodies described herein specifically bind NKG2C on a cell.
- any of the anti-NKG2C agents or anti-NKG2C antibodies described herein specifically bind NKG2C and do not specifically bind NKG2A or NKG2E.
- an anti-NKG2C agent/antibody comprises a detectable marker or label.
- an anti-NKG2C agent/antibody is conjugated to a detectable marker or label.
- an anti-NKG2C agent/antibody may be labeled with a detectable moiety.
- Numerous labels are available which are generally grouped into the following categories: (a) Radioisotopes, such as 35 S, 14 C, 125 I, 3 H, and 131 I.
- the antibody can be labeled with the radioisotope using the techniques described in Current Protocols in Immunology, Volumes 1 and 2, Coligen et al., Ed. Wiley-Interscience, New York, N.Y., Pubs. (1991), for example, and radioactivity can be measured using scintillation counting.
- Fluorescent labels such as rare earth chelates (europium chelates) or fluorescein and its derivatives, rhodamine and its derivatives, dansyl, Lissamine, phycoerythrin, Texas Red and Brilliant Violet TM are available.
- the fluorescent labels can be conjugated to the antibody using the techniques disclosed in Current Protocols in Immunology, supra, for example. Fluorescence can be quantified using a flow cytometer, imaging microscope or fluorimeter.
- Various enzyme-substrate labels are available and U.S. Pat. No.4,275,149 provides a review of some of these. The enzyme generally catalyzes a chemical alteration of the chromogenic substrate that can be measured using various techniques.
- the enzyme may catalyze a color change in a substrate, which can be measured spectrophotometrically.
- the enzyme may alter the fluorescence or chemiluminescence of the substrate.
- Techniques for quantifying a change in fluorescence are described above.
- the chemiluminescent substrate becomes electronically excited by a chemical reaction and may then emit light that can be measured (using a chemilluminometer, for example) or donates energy to a fluorescent acceptor.
- enzymatic labels include luciferases (e.g., firefly luciferase and bacterial luciferase; U.S. Pat.
- luciferin 2,3-dihydrophthalazinediones, malate dehydrogenase, urease, peroxidase such as horseradish peroxidase (HRPO), alkaline phosphatase, beta-galactosidase, glucoamylase, lysozyme, saccharide oxidases (e.g., glucose oxidase, galactose oxidase, and glucose-6-phosphate dehydrogenase), heterocyclicoxidases (such as uricase and xanthine oxidase), lactoperoxidase, microperoxidase, and the like.
- HRPO horseradish peroxidase
- alkaline phosphatase beta-galactosidase
- glucoamylase lysozyme
- saccharide oxidases e.g., glucose oxidase, galactose oxidase, and glucose-6-
- enzyme-substrate combinations include, for example: (i) Horseradish peroxidase (HRP) with hydrogen peroxidase as a substrate, where the hydrogen peroxidase oxidizes a dye precursor (e.g., orthophenylene diamine (OPD) or 3,3',5,5'-tetramethyl benzidine hydrochloride (TMB)); (ii) alkaline phosphatase (AP) with para-Nitrophenyl phosphate as chromogenic substrate; and (iii) .beta.-D-galactosidase (.beta.-D-Gal) with a chromogenic substrate (e.g., p-nitrophenyl- ⁇ -D- galactosidase) or fluorogenic substrate 4-methylumbelliferyl-.beta.-D-galactosidase.
- HRP Horseradish peroxidase
- OPD orthophenylene diamine
- TMB 3,3
- the label is indirectly conjugated with the agent/antibody.
- an antibody can be conjugated with biotin and any of the three broad categories of labels mentioned above can be conjugated with avidin, or vice versa. Biotin binds selectively to avidin and thus, the label can be conjugated with the antibody in this indirect manner.
- the antibody is conjugated with a small hapten (e.g., digoxin) and one of the different types of labels mentioned above is conjugated with an anti-hapten antibody (e.g., anti-digoxin antibody).
- an anti-NKG2C agent/antibody need not be labeled, and the presence thereof can be detected, e.g., using a labeled antibody which binds to an anti-NKG2C antibody.
- an anti-NKG2C agent/antibody herein is immobilized on a solid support or substrate.
- an anti-NKG2C agent/antibody herein is non-diffusively immobilized on a solid support (e.g., the anti-NKG2C agent/antibody does not detach from the solid support).
- a solid support or substrate can be any physically separable solid to which an anti-NKG2C agent/antibody can be directly or indirectly attached including, but not limited to, surfaces provided by microarrays and wells, and particles such as beads (e.g., paramagnetic beads, magnetic beads, microbeads, nanobeads), microparticles, and nanoparticles.
- Solid supports also can include, for example, chips, columns, optical fibers, wipes, filters (e.g., flat surface filters), one or more capillaries, glass and modified or functionalized glass (e.g., controlled-pore glass (CPG)), quartz, mica, diazotized membranes (paper or nylon), polyformaldehyde, cellulose, cellulose acetate, paper, ceramics, metals, metalloids, semiconductive materials, quantum dots, coated beads or particles, other chromatographic materials, magnetic particles; plastics (including acrylics, polystyrene, copolymers of styrene or other materials, polybutylene, polyurethanes, TEFLONTM, polyethylene, polypropylene, polyamide, polyester, polyvinylidenedifluoride (PVDF), and the like), polysaccharides, nylon or nitrocellulose, resins, silica or silica-based materials including silicon, silica gel, and modified silicon, Sephadex®, Sepharose®, carbon, metals (
- the solid support or substrate may be coated using passive or chemically-derivatized coatings with any number of materials, including polymers, such as dextrans, acrylamides, gelatins or agarose. Beads and/or particles may be free or in connection with one another (e.g., sintered).
- a solid support or substrate can be a collection of particles.
- the particles can comprise silica, and the silica may comprise silica dioxide.
- the silica can be porous, and in certain embodiments the silica can be non-porous.
- the particles further comprise an agent that confers a paramagnetic property to the particles.
- the agent comprises a metal
- the agent is a metal oxide, (e.g., iron or iron oxides, where the iron oxide contains a mixture of Fe2+ and Fe3+).
- An anti- NKG2C agent/antibody may be linked to a solid support by covalent bonds or by non-covalent interactions and may be linked to a solid support directly or indirectly (e.g., via an intermediary agent such as a spacer molecule or biotin).
- Agents and antibodies provided herein may be employed in any known assay method, such as flow cytometry, immunohistochemistry, immunofluorescence, mass cytometry (e.g., Cytof instrument), competitive binding assays, direct and indirect sandwich assays, and immunoprecipitation assays.
- assay method such as flow cytometry, immunohistochemistry, immunofluorescence, mass cytometry (e.g., Cytof instrument), competitive binding assays, direct and indirect sandwich assays, and immunoprecipitation assays.
- Zola Monoclonal Antibodies: A Manual of Techniques, pp.147-158 (CRC Press, Inc.1987).
- the method comprises the use of a single primary antibody to specifically identify the presence of the target molecule expressed on the surface of a dispersed suspension of individual cells.
- Flow cytometry and mass cytometry assays generally involve the use of a single primary antibody to specifically identify the presence of the target molecule expressed on the surface of a dispersed suspension of individual cells.
- the dispersed cells are typically obtained from a biological fluid sample, e.g., blood, but may also be obtained from a dispersion of single cells prepared from a solid tissue sample such as spleen or tumor biopsy.
- the primary antibody may be directly conjugated with a detectable moiety, e.g., a fluorophore such as phycoerythrin for flow cytometry or a heavy metal chelate for mass cytometry.
- the primary antibody may be unlabeled or labeled with an undetectable tag such as biotin, and the primary antibody is then detected by a detectably labeled secondary antibody that specifically recognizes the primary antibody itself or the tag on the primary antibody.
- the labeled cells are then analyzed in an instrument capable of single cell detection, e.g., flow cytometer, mass cytometer, fluorescence microscope or brightfield light microscope, to identify those individual cells in the dispersed population or tissue sample that express the target recognized by the primary antibody.
- flow cytometer e.g., flow cytometer, mass cytometer, fluorescence microscope or brightfield light microscope
- the method comprises the use of two antibodies, each capable of binding to a different immunogenic portion, or epitope.
- Sandwich assays involve the use of two antibodies, each capable of binding to a different immunogenic portion, or epitope, of the protein that is detected.
- the test sample analyte is bound by a first antibody that is immobilized on a solid support, and thereafter a second antibody binds to the analyte, thus forming an insoluble three-part complex. See, e.g., U.S. Pat. No.4,376,110.
- the second antibody may itself be labeled with a detectable moiety (direct sandwich assays) or may be measured using an anti-immunoglobulin antibody that is labeled with a detectable moiety (indirect sandwich assay).
- sandwich assay is an ELISA assay, in which case the detectable moiety is an enzyme.
- the target cell population may be attached to the solid support using antibodies first attached to the support and that recognize different cell surface proteins. These first antibodies capture the cells to the support. NKG2C on the surface of the cells can then be detected by adding anti-NKG2C antibody to the captured cells and detecting the amount of NKG2C antibody attached to the cells.
- the blood or tissue sample may be fresh or frozen or may be embedded in paraffin and fixed with a preservative such as formalin, for example.
- the agents/antibodies herein also may be used for in vivo diagnostic assays.
- the antibody is labeled with a radionuclide (such as 111 In, 99 Tc, 14 C, 131 I, 125 I, 3 H, 32 P, or 35 S) so that the bound target molecule can be localized using immunoscintillography.
- a radionuclide such as 111 In, 99 Tc, 14 C, 131 I, 125 I, 3 H, 32 P, or 35 S
- Detection of NKG2C in immune cells may refer to detection on the surface of immune cells (e.g., by surface staining) and/or inside immune cells (e.g., by intracellular staining). In some embodiments, any of the agents provided herein may be used for detection of NKG2C on the surface of immune cells. In some embodiments, any of the agents provided herein may be used for detection of intracellular NKG2C in immune cells.
- the immune cell is selected from B cells, plasmacytoid dendritic cells (pDCs), lymphocytes, leukocytes, T cells, monocytes, macrophages, neutrophils, myeloid dendritic cells (mDCs), innate lymphoid cells, mast cells, eosinophils, basophils, natural killer cells, and the like.
- a heterogeneous population of immune cells comprises peripheral blood mononuclear cells (PBMCs) which may include, for example, T cells, B cells, natural killer cells, and monocytes.
- PBMCs peripheral blood mononuclear cells
- agents and methods are provided for detecting NKG2C in a heterogeneous population of immune cells.
- a heterogeneous population of immune cells may comprise two or more types of immune cells.
- a heterogeneous population of immune cells may comprise two or more of lymphocytes, T cells, natural killer cells, and the like.
- a heterogeneous population of immune cells comprises peripheral blood mononuclear cells (PBMCs) which may include, for example, T cells, B cells, natural killer cells, and monocytes.
- PBMCs peripheral blood mononuclear cells
- cells are contacted with an anti-NKG2C agent described herein (e.g., in a flow cytometry assay as described in Example x; or any suitable protein or cell detection assay).
- NKG2C is detected at a significant level in certain immune cells by an anti-NKG2C agent described herein.
- NKG2C may be detected at a significant level by an anti-NKG2C agent described herein in certain immune cells and not significantly detected in other immune cells.
- the level of NKG2C detection in certain immune cells may vary according to certain factors such as, for example, type of detection assay, type of detection reagent (e.g., type of dye), antibody concentration, donor cell variability, and the like.
- Detection of NKG2C at a significant level may refer to a particular signal to noise (S:N) ratio (e.g., threshold or range) measured in a flow cytometry assay.
- S:N signal to noise
- NKG2C is detected at a significant level in NK cells, as well as a subset of CD8+ T-lymphocytes.
- NKG2C is detected at a significant level in CD56+ NK cells.
- CD56 also referred to as neural cell adhesion molecule (NCAM), NCAM1, MSK39, neural cell adhesion molecule 1
- NCAM neural cell adhesion molecule
- MSK39 neural cell adhesion molecule 1
- CD56 is a hemophilic binding glycoprotein expressed on the surface of neurons, glia, skeletal muscle, and also in the hematopoietic system.
- CD56 is most associated with natural killer cells, but is also detected on ⁇ T cells, activated CD8+ T cells, and dendritic cells.
- NCAM is a glycoprotein of the Immunoglobulin (Ig) superfamily, with 27 isoforms produced by alternative mRNA splicing.
- NCAM-120 kDa GPI anchored
- NCAM-140 kDa short cytoplasmic domain
- NCAM-180 kDa long cytoplasmic domain
- the extracellular domain of NCAM consists of five immunoglobulin-like (Ig) domains followed by two fibronectin type III (FNIII) domains.
- Ig domains of NCAM are involved in hemophilic binding to NCAM, while the FNIII domains are involved in signaling that leads to neurite outgrowth.
- NKG2C is not significantly detected in certain immune cells by an anti-NKG2C agent described herein.
- NKG2C may not be significantly detected in certain lymphocytes (e.g., plasmacytoid dendritic cells (pDCs) and/or B cells).
- NKG2C in certain lymphocytes e.g., CD304+ plasmacytoid dendritic cells and/or CD19 + CD3- B cells.
- No significant detection of NKG2C in certain lymphocytes may refer to a particular signal to noise (S:N) ratio (e.g., threshold or range) measured in a flow cytometry assay.
- S:N signal to noise
- no significant detection of noise (N) in certain lymphocytes refers to a signal to noise (S:N) ratio of about 1.5 or less.
- kits incorporating anti-NKG2C agents herein An anti-NKG2C agent (e.g., an anti-NKG2C antibody) herein may be provided in a kit, for example, a packaged combination of reagents in predetermined amounts with instructions for use (e.g., instructions for performing a diagnostic assay; instructions for performing a laboratory assay).
- the kit is a diagnostic kit configured to detect NKG2C in a sample (e.g., a biological sample).
- the kit may include an identical isotype negative control irrelevant antibody to control for non-specific binding of the anti-NKG2C agent.
- the kit may include substrates and cofactors required by the enzyme (e.g., a substrate precursor which provides the detectable chromophore or fluorophore). Additional additives may be included such as stabilizers, buffers (e.g., a block buffer or lysis buffer), and the like. The relative amounts of the various reagents may be varied widely to provide for concentrations in solution of the reagents that substantially optimize the sensitivity of the assay.
- reagents may be provided as dry powders (e.g., lyophilized powder), including excipients that on dissolution will provide a reagent solution having the appropriate concentration.
- An article of manufacture containing materials useful for the treatment, or diagnosis, of the disorders described above is provided.
- An article of manufacture may comprise a container and a label. Suitable containers include, for example, bottles, vials, syringes, and test tubes. Containers may be formed from a variety of materials such as glass or plastic.
- a container may hold a composition that is effective for treating a condition and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle).
- An active anti-NKG2C agent in the composition may be an anti-NKG2C antibody.
- a label on, or associated with, the container indicates that the composition is used for treating, or diagnosing, a condition of choice.
- the article of manufacture may further comprise a second container comprising a pharmaceutically acceptable buffer, such as phosphate-buffered saline, Ringer’s solution and dextrose solution; and may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, syringes, and package inserts with instructions for use.
- a pharmaceutically acceptable buffer such as phosphate-buffered saline, Ringer’s solution and dextrose solution
- Other materials desirable from a commercial and user standpoint including other buffers, diluents, filters, needles, syringes, and package inserts with instructions for use.
- An “agent” generally refers to an antibody, antibody fragment, antigen binding fragment thereof, derivative, variants of such antibodies and antibody fragments or antigen-binding fragments thereof (including immunoconjugates, labeled antibodies and antigen-binding antibody fragments, and the like).
- acceptor human framework generally refers to a framework comprising the amino acid sequence of an immunoglobulin heavy chain variable domain (VH) framework or an immunoglobulin light chain variable domain (VL) framework derived from a human immunoglobulin framework or a human consensus framework, as defined herein.
- An acceptor human framework “derived from” a human immunoglobulin framework or a human consensus framework may comprise the same amino acid sequence thereof, or it may contain amino acid sequence changes. In some embodiments, the number of framework amino acid changes are 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, or 2 or less.
- the VH and/or VL acceptor human framework(s) is(are) identical in sequence to the VH and/or VL human immunoglobulin framework amino acid sequence or human consensus framework amino acid sequence.
- “Framework” or “FR” generally refers to variable domain residues other than hypervariable region (HVR) residues.
- the FR of a variable domain generally consists of four FR domains: FR1; FR2; FR3; and FR4. Accordingly, the HVR and FR sequences generally appear in the following sequence in VH (or VL): FR1-H1(L1)-FR2-H2(L2)-FR3-H3(L3)-FR4.
- a “human consensus framework” generally refers to a framework that represents the most commonly occurring amino acid residues in a selection of human immunoglobulin VL or VH framework sequences.
- the selection of human immunoglobulin VL or VH sequences is from a subgroup of variable domain sequences.
- the subgroup of sequences is a subgroup as in Kabat et al., Sequences of Proteins of Immunological Interest, Fifth Edition, NIH Publication 91-3242, Bethesda Md. (1991), vols. 1-3.
- the subgroup is subgroup kappa I as in Kabat et al., supra.
- the subgroup is subgroup III as in Kabat et al., supra.
- the term “hypervariable region” or “HVR” generally refers to each of the regions of an antibody variable domain that are hypervariable in sequence and/or form structurally defined loops (“hypervariable loops”).
- native four-chain antibodies comprise six HVRs; three in the VH (H1, H2, H3), and three in the VL (L1, L2, L3).
- HVRs generally comprise amino acid residues from the hypervariable loops and/or from the “complementarity determining regions” (CDRs), the latter being of highest sequence variability and/or involved in antigen recognition.
- CDRs complementarity determining regions
- the Kabat scheme is based on structural alignments
- the Chothia scheme is based on structural information. Numbering for both the Kabat and Chothia schemes is based upon the most common antibody region sequence lengths, with insertions accommodated by insertion letters for example, “30aa” and deletions appearing in some antibodies. The two schemes place certain insertions and deletions (“indels”) at different positions, resulting in differential numbering.
- the Contact scheme is based on analysis of complex crystal structures and is similar in many respects to the Chothia numbering scheme. Table 1, below, lists exemplary position boundaries of CDRH1, CDRH2, CDRH3, and CDRL1, CDRL2, and CDRL3 as identified by Kabat, Chothia, and Contact schemes, respectively.
- CDRH1 residue numbering is listed using both the Kabat and Chothia numbering schemes. FRs are located between CDRs, for example, with FRH1 located between CDRH1 and CDRH2, and so forth. It is noted that because the shown Kabat numbering scheme places insertions at H35A and H35B, the end of the Chothia CDRH1 loop when numbered using the shown Kabat numbering convention varies between H32 and H34, depending on the length of the loop. 1 - Kabat et al. (1991), “Sequences of Proteins of Immunological Interest,” 5 th Ed.
- variable domain generally refers to the domain of an antibody heavy or light chain that is involved in binding the antibody to antigen.
- variable domains of the heavy chain and light chain (VH and VL, respectively) of a native antibody generally have similar structures, with each domain comprising four conserved framework regions (FRs) and three hypervariable regions (HVRs). See, e.g., Kindt et al. Kuby Immunology, 6th ed., W.H. Freeman and Co., page 91 (2007).
- a single VH or VL domain may be sufficient to confer antigen-binding specificity.
- antibodies that bind a particular antigen may be isolated using a VH or VL domain from an antibody that binds the antigen to screen a library of complementary VL or VH domains, respectively. See, e.g., Portolano et al., J.
- Bind generally refers to the strength of the sum total of non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen).
- binding affinity refers to intrinsic binding affinity, which reflects a 1:1 interaction between members of a binding pair (e.g., antibody and antigen).
- the affinity of a molecule X for its partner Y can generally be represented by a dissociation constant (Kd). Affinity can be measured by common methods known in the art, including those described herein.
- antibodies herein bind to a target (e.g., NKG2C) with a high affinity, e.g., a K d value of no more than about 1 x 10 -7 M; preferably no more than about 1 x 10 -8 M; and preferably no more than about 5 x 10 -9 M.
- a target e.g., NKG2C
- An “affinity matured” antibody generally refers to an antibody with one or more alterations in one or more hypervariable regions (HVRs), compared to a parent antibody that does not possess such alterations. Preferably, such alterations result in improved affinity of the antibody for its target antigen.
- anti-NKG2C agent generally refers to a molecule that is, or comprises, one or more anti- NKG2C antibodies, NKG2C-binding antibody fragments, or NKG2C-binding antibody derivatives.
- anti-NKG2C antibody and “an antibody that binds to NKG2C” generally refer to an antibody that is capable of binding NKG2C with sufficient affinity and/or specificity such that the antibody is useful as a research tool, diagnostic agent and/or therapeutic agent in targeting NKG2C.
- the extent of binding of an anti-NKG2C antibody (or antigen-binding fragment thereof) to an unrelated, non-NKG2C protein is less than about 10% of the binding of the antibody to NKG2C as measured, e.g., by a radioimmunoassay (RIA) or by Scatchard analysis or by surface plasmon resonance, such as, for example, Biacore.
- RIA radioimmunoassay
- Scatchard analysis or by surface plasmon resonance, such as, for example, Biacore.
- an antibody that binds to NKG2C has a dissociation constant (Kd) of 0.1 ⁇ M, 100 nM, 10 nM, 1 nM, 0.1 nM, 0.01 nM, or 0.001 nM (e.g., 10 -7 M or less, e.g., from 10 -7 M to 10 -13 M).
- Kd dissociation constant
- an anti-NKG2C antibody binds to an epitope of NKG2C that is conserved among NKG2C from different species.
- antibody herein is used in the broadest sense and includes polyclonal and monoclonal antibodies, including intact antibodies and functional (antigen-binding) antibody fragments, including fragment antigen binding (Fab) fragments, F(ab') 2 fragments, Fab’ fragments, Fv fragments, recombinant IgG (rIgG) fragments, variable heavy chain (V H ) regions capable of specifically binding the antigen, single chain antibody fragments, including single chain variable fragments (scFv), and single domain antibodies (e.g., sdAb, sdFv, nanobody) fragments.
- Fab fragment antigen binding
- rIgG recombinant IgG
- V H variable heavy chain
- the term encompasses genetically engineered and/or otherwise modified forms of immunoglobulins, such as intrabodies, peptibodies, chimeric antibodies, fully human antibodies, humanized antibodies, and heteroconjugate antibodies, multispecific, e.g., bispecific, antibodies, diabodies, triabodies, and tetrabodies, tandem di-scFv, tandem tri-scFv.
- antibody should be understood to encompass functional antibody fragments thereof.
- the term also encompasses intact or full-length antibodies, including antibodies of any class or sub-class, including IgG and sub-classes thereof, IgM, IgE, IgA, and IgD.
- an “antibody derivative” generally refers to a molecule other than an intact antibody that comprises a portion derived from an intact antibody (or antigen-binding fragment thereof) and that binds the antigen to which the intact antibody (or antigen-binding fragment thereof) binds.
- antibody derivatives include but are not limited to single chain variable fragments (scFv), diabodies, triabodies, and the like, aptamers comprising multiple antigen-binding antibody fragments, single chain variable fragments, diabodies, triabodies, and the like.
- An “antibody fragment” or “antigen-binding antibody fragment” generally refers to a molecule other than an intact antibody that comprises a portion of an intact antibody that binds the antigen to which the intact antibody binds.
- antibody fragments include but are not limited to Fv, Fab, Fab', Fab'-SH, F(ab')2 and multispecific antibodies formed from antibody fragments.
- full length antibody “intact antibody,” and “whole antibody” are used herein interchangeably to refer to an antibody having a structure substantially similar to a native antibody structure or having heavy chains that contain an Fc region as defined herein.
- Fc region generally refers to a C-terminal region of an immunoglobulin heavy chain that contains at least a portion of the constant region. The term includes native sequence Fc regions and variant Fc regions.
- a human IgG heavy chain Fc region extends from Cys226, or from Pro230, to the carboxyl-terminus of the heavy chain.
- the C-terminal lysine (Lys447) of the Fc region may or may not be present.
- numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system, also called the EU index, as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md., 1991.
- an “antibody that binds to the same epitope” as a reference antibody generally refers to an antibody that blocks binding of the reference antibody to its antigen in a competition assay by 50% or more, and conversely, the reference antibody blocks binding of the antibody to its antigen in a competition assay by 50% or more.
- the term “chimeric” antibody generally refers to an antibody in which a portion of the heavy and/or light chain is derived from a particular source or species, while the remainder of the heavy and/or light chain is derived from a different source or species.
- a “human antibody” generally refers to an antibody that possesses an amino acid sequence corresponding to that of an antibody produced by a human or a human cell or derived from a non-human source that utilizes human antibody repertoires or other human antibody-encoding sequences. This definition of a human antibody specifically excludes a “humanized” antibody comprising non-human antigen-binding residues.
- a “humanized” antibody generally refers to a chimeric antibody comprising amino acid residues from non-human HVRs and amino acid residues from human FRs.
- a humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the HVRs (e.g., CDRs) correspond to those of a non-human antibody, and all or substantially all of the FRs correspond to those of a human antibody.
- a humanized antibody optionally may comprise at least a portion of an antibody constant region derived from a human antibody.
- a humanized antibody (or antigen-binding fragment or derivative thereof), when aligned with the antibody from which the acceptor framework regions were derived, includes one or more amino acid substitutions (or deletions or insertions) at desired locations.
- the amino acid residue(s) substituted (or inserted or deleted) at a particular position in the human (or other) or other FR corresponds to the amino acid residue(s) at the corresponding location(s) in the parent antibody (i.e., the non-human antibody from which the CDRs or HVRs were derived).
- a “humanized form” of an antibody e.g., a non-human antibody, refers to an antibody that has undergone humanization.
- ADC antibody drug conjugate
- immunoconjugate generally refers to a particular class of agent-drug conjugates.
- agent-drug conjugate is an anti-NKG2C agent (e.g., an anti-NKG2C antibody or NKG2C-binding fragment or derivative thereof) conjugated to one or more heterologous molecule(s), including, but not limited to, a cytotoxic agent.
- cytotoxic agent generally refers to a substance that inhibits or prevents a cellular function and/or causes cell death or destruction.
- Cytotoxic agents include, but are not limited to, radioactive isotopes (e.g., At 211 , I 131 , I 125 , Y 90 , Re 186 , Re 188 , Sm 153 , Bi 212 , P 32 , Pb 212 , and radioactive isotopes of Lu); chemotherapeutic agents or drugs (e.g., methotrexate, adriamycin, vinca alkaloids (vincristine, vinblastine, etoposide), doxorubicin, melphalan, mitomycin C, chlorambucil, daunorubicin or other intercalating agents); growth inhibitory agents; enzymes and fragments thereof such as nucleolytic enzymes; antibiotics; toxins such as small molecule toxins or enzymatically active toxins of bacterial, fungal, plant or animal origin, including fragments and/or variants thereof; and the various antitumor or anticancer agents disclosed below.
- a “diagnostic reagent” generally refers to a compound, e.g., a target-specific antibody (or antigen- binding thereof) used to perform a diagnostic assay.
- “Effector functions” generally refer to those biological activities attributable to the Fc region of an antibody, which vary with the antibody isotype. Examples of antibody effector functions include: C1q binding and complement dependent cytotoxicity (CDC); Fc receptor binding; antibody-dependent cell- mediated cytotoxicity (ADCC); phagocytosis; down regulation of cell surface receptors (e.g. B cell receptor); and B cell activation.
- an “effective amount” of an agent generally refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic or prophylactic result.
- the term “epitope” generally refers to the particular site on an antigen molecule to which an antibody binds.
- the terms “host cell”, “host cell line”, and “host cell culture” are used interchangeably and generally refer to cells into which exogenous nucleic acid has been introduced, including the progeny of such cells.
- Host cells include “transformants” and “transformed cells,” which include the primary transformed cell and progeny derived therefrom without regard to the number of passages. Progeny may not be completely identical in nucleic acid content to a parent cell, but may contain mutations.
- a “rabbit antibody” generally refers to an antibody that possesses an amino acid sequence that corresponds to that of an antibody produced by a rabbit or a rabbit cell or derived from a non-rabbit source that utilizes rabbit antibody repertoires or other rabbit antibody-encoding sequences.
- An “immunoconjugate” generally refers to an antibody (or antigen-binding fragment or derivative thereof) conjugated to one or more heterologous molecule(s), including, but not limited to, a cytotoxic agent.
- An immunoconjugate is equivalent to the term “antibody drug conjugate” (ADC).
- mammals include, but are not limited to, domesticated animals (e.g., cows, sheep, cats, dogs, and horses), primates (e.g., humans and non- human primates such as monkeys), rabbits, and rodents (e.g., mice and rats).
- domesticated animals e.g., cows, sheep, cats, dogs, and horses
- primates e.g., humans and non- human primates such as monkeys
- rabbits e.g., mice and rats
- rodents e.g., mice and rats.
- the individual or subject is a human.
- an “isolated” molecule generally refers to a molecule that has been separated from a component of its original environment (e.g., the natural environment if it is naturally occurring, or a host cell if expressed exogenously), and thus is altered by human intervention (e.g., "by the hand of man") from its original environment.
- an antibody is purified to greater than 95% or 99% purity as determined by, for example, electrophoretic (e.g., SDS- PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatographic (e.g., ion exchange or reverse phase HPLC).
- An isolated nucleic acid may refer to a nucleic acid molecule contained in cells that ordinarily contain the nucleic acid molecule, but the nucleic acid molecule is present extra- chromosomally or at a chromosomal location that is different from its natural chromosomal location.
- an isolated nucleic acid can be provided with fewer non-nucleic acid components (e.g., protein, lipid) than the amount of components present in a source sample.
- a composition comprising isolated nucleic acid can be about 50% to greater than 99% free of non-nucleic acid components.
- a composition comprising isolated nucleic acid can be about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or greater than 99% free of non-nucleic acid components.
- isolated nucleic acid encoding an anti-NKG2C antibody or “isolated polynucleotide encoding an anti- NKG2C antibody” generally refers one or more nucleic acid molecules encoding antibody heavy and light chains (or fragments thereof), including such nucleic acid molecule(s) in a single vector or separate vectors, and such nucleic acid molecule(s) present at one or more locations in a recombinant host cell.
- NKG2C generally refers to any native, mature NKG2C that results from processing of a NKG2C precursor protein in a cell.
- the term includes NKG2C from any vertebrate source, including mammals such as primates (e.g. humans and cynomolgus or rhesus monkeys) and rodents (e.g., mice and rats), unless otherwise indicated.
- the term also includes naturally occurring variants of NKG2C, e.g., splice variants or allelic variants.
- the amino acid sequence of an example full-length human NKG2C protein is shown in Fig.1 (SEQ ID NO: 56).
- NKG2C-positive cell generally refers to any cell that expresses NKG2C on its surface or on an intracellular membrane or organelle (e.g., endosome, ER, Golgi apparatus, lysosome, and the like). Some cells, including those infected by a microbe or associated with some cancer types and tumors, exhibit up-regulation of NKG2C expression.
- an intracellular membrane or organelle e.g., endosome, ER, Golgi apparatus, lysosome, and the like.
- the term “monoclonal antibody” generally refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical (as assessed at the level of Ig heavy and/or light chain amino acid sequence) and/or bind the same epitope, except for possible variant antibodies, e.g., containing naturally occurring mutations or arising during production of a monoclonal antibody preparation, such variants generally being present in minor amounts.
- polyclonal antibody preparations which typically include different antibodies directed against different determinants (epitopes)
- each monoclonal antibody of a monoclonal antibody preparation is directed against a single determinant on an antigen.
- the modifier “monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous
- the monoclonal antibodies to be used in accordance with the present technology may be made by a variety of techniques, including, but not limited to, the hybridoma method, recombinant DNA methods, phage-display methods, and methods utilizing transgenic animals containing all or part of the human immunoglobulin loci, such methods and other example methods for making monoclonal antibodies being described herein.
- the term “package insert” generally refers to instructions customarily included in commercial packages of therapeutic products, that contain information about the indications, usage, dosage, administration, combination therapy, contraindications and/or warnings concerning the use of such therapeutic products.
- Percent (%) amino acid sequence identity with respect to a reference polypeptide sequence generally refers to the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the reference polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining % amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared.
- composition generally refers to a preparation that is in such form as to permit the biological activity of an active ingredient contained therein to be effective, and which contains no additional components which are unacceptably toxic to a subject to which the formulation would be administered.
- pharmaceutically acceptable carrier generally refers to an ingredient in a pharmaceutical formulation, other than an active ingredient, which is nontoxic to a subject.
- a pharmaceutically acceptable carrier includes, but is not limited to, a buffer, excipient, stabilizer, or preservative.
- treatment generally refers to clinical intervention in an attempt to alter the natural course of the individual being treated, and can be performed either for prophylaxis or during the course of clinical pathology.
- Desirable effects of 102 treatment include, but are not limited to, preventing occurrence or recurrence of disease, alleviation of symptoms, diminishment of any direct or indirect pathological consequences of the disease, preventing metastasis, decreasing the rate of disease progression, amelioration or palliation of the disease state, and remission or improved prognosis.
- antibodies herein are used to delay development of a disease or to slow the progression of a disease.
- vector generally refers to a nucleic acid molecule capable of propagating another nucleic acid to which it is linked.
- the term includes the vector as a self-replicating nucleic acid structure as well as the vector incorporated into the genome of a host cell into which it has been introduced.
- Certain vectors are capable of directing the expression of nucleic acids to which they are operatively linked. Such vectors are referred to herein as “expression vectors.” Examples The examples set forth below illustrate certain embodiments and do not limit the technology.
- Example 1 Creation and Characterization of anti-NKG2C Hybridomas This Example describes the preparation of hybridomas that secrete monoclonal antibodies that react with NKG2C, as expressed in vivo.
- the resulting anti-NKG2C antibodies are suitable for a variety of purposes, including in diagnostic assays, examples of which are provided in the examples below.
- hybridomas were formed using standard protocols to fuse myeloma cells with spleen, and draining lymph node cells harvested from the animals. Following selection, fusions were cloned in HAT medium and plated to approximately one cell/well in microtiter plates.
- Culture supernatants were subsequently tested against NKG2C-expressing cell transfectants, e.g., HEK 293 or RBL, by flow cytometry. Wells with successful staining profiles were then sub-cultured into larger vessels until sufficient cells were present to allow subcloning. Further characterization of the hybridoma subclone candidates was performed by flow cytometry using NKG2C- transfected cells. Selected candidate clones were further screened by flow cytometry against human blood cells divided into distinct subsets (e.g., lymphocytes), as well as against one or more cell lines generated from diseased and/or infected human cells. As compared to an isotype control, the percentage of positive cells in each blood cell subset was quantified.
- NKG2C-expressing cell transfectants e.g., HEK 293 or RBL
- Basis for clone selection included strong reactivity against immune cells that express NKG2C (e.g., natural killer cells, natural killer T cells, and activated CD8+ T cells) but no appreciable reactivity against other blood cell populations (e.g., certain lymphocytes, B cells); ability to detect NKG2C on the cell surface; ability to detect NKG2C on the cell surface of natural killer (NK) cells and natural killer T cells (NK T cells; ability to detect NKG2C on the cell surface of CD8+ T cells; ability to detect intracellular NKG2C in NK cells; ability to detect intracellular NKG2C in NK T cells; and/or ability to detect intracellular NKG2C in CD8+ T cells.
- NKG2C e.g., natural killer cells, natural killer T cells, and activated CD8+ T cells
- Example 2 Sequencing of the Anti- NKG2C Antibody Variable Regions
- Cells from the anti-NKG2C hybridoma cell lines described in Example 1, above were grown in standard mammalian tissue culture media.
- Total RNA was isolated from hybridoma cells from various clones expressing anti-NKG2C monoclonal antibodies using a procedure based on the RNeasy Mini kit (Qiagen). Briefly, the RNA was used to generate first strand cDNA, both light chain and heavy chain variable domain cDNAs were amplified by a 5’-RACE technique, and positive clones were prepared by PCR and then subjected to DNA sequencing of multiple clones.
- CDRs and Framework regions Amino acid sequences of the individual variable domains (CDRs and Framework regions), including the CDR1, CDR2, and CDR3 regions, for both the heavy and light chains for four different antibodies (clones), designated AB 1-8 (also referred to herein as antibodies 1-8, and clones 1-8), are shown in Fig. 2.
- the various heavy and light chain CDR sequences are shown in Table 1, below.
- Example 3 Detection of Cells Expressing NKG2C This example describes flow cytometry-based detection of human peripheral blood mononuclear cells (PBMCs) using certain anti-NKG2C monoclonal antibodies provided herein.
- PBMCs peripheral blood mononuclear cells
- PBMC Isolation Human peripheral blood mononuclear cells (PBMCs) were isolated under aseptic conditions through a gradient of Ficoll-Paque PLUS (GE Healthcare) according manufacturer instructions. Surface Staining PBMCs were counted and adjusted in Cell Staining Buffer (BioLegend, cat. #420201) to a cell density of 0.7-1x10 7 cells/mL. A 100 ⁇ L cell suspension (0.7-1x10 6 total cells) was stained with various cell surface markers (e.g., CD3, CD4, CD8, CD19, NCAM-1/CD56, and CD94, and/or NKG2C/CD159c for 15 minutes in the dark. All reagents used are from BioLegend unless otherwise indicated.
- Cell Staining Buffer BioLegend, cat. #420201
- Flow Cytometry/Gating Hierarchy Single cells were identified through flow cytometry by SSC-H and SSC-A (Fig.4A), and lymphocytes, monocytes, and granulocytes were identified based on their forward (FSC-A) and side scatter (SSC-A) profiles (Fig.4B). Subsets of lymphocytes (including CD3-CD19+ B lymphocytes, CD3+CD19- T lymphocytes, CD3-CD19- lymphocytes, were identified as shown in Fig.4C.
- CD4-CD8+ lymphocytes were identified as represented in the dot plots of Fig.4D.
- AB5 showed a similar staining pattern as commercially available anti-NKG2C antibody, ABI, in both total lymphocytes (Fig.6A and Fig.6B) as well as CD3-CD19- lymphocytes (Fig.6C and Fig.6D). Additionally, AB5 (Figs.7A-7C) specifically stained CD3+CD19- lymphocyte subsets (CD4+CD8-, CD4-CD8-, and CD4-CD8+) at a similar level of that of the commercially available anti-NKG2C antibody, ABI (Figs.7D-7F).
- AB1, AB2, AB3, AB4, AB5, AB6, AB7, and AB8 for NKG2C was supported by co-staining total lymphocytes with CD94/KLRD1, which is reported to form a heterodimer with NKG2 (Figs.8A-8H).
- NK cells were specifically identified within CD3- CD19- lymphocytes by co-staining with CD56 and each of AB1, AB2, AB3, AB4, AB5, AB6, AB7, and AB8 (Figs.8I-8P, panels I-P).
- Example 4 Functional Assay This example describes a functional assay based on NKG2C detection in cells that highly express the target.
- K562 cells (target) were labeled with CFSE (BioLegend Cat. #423801).
- PBMCs were isolated and purified primary NK (effector) cells were purified by MojoSort Isolation kit (BioLegend Cat. #480054).
- E:T effector:target ration
- E:T ratio was set to 2:1.
- Antibodies were mixed with target cells and effector cells at 440 nM (10 ⁇ g/well). Cells were then incubated at 37 0 C for 4 hours. After 4-hour incubation, cells were washed once and DAPI (BioLegend Cat. #422801) was added to the cells to label dead cells and samples were collected for flow cytometry analysis. As shown in Fig.10B, all exemplary anti-NKG2C antibodies were capable of inhibiting the cytotoxicity of NK cells, as compared to no antibody control.
- Example 6 Blocking assay This example describes the ability of the exemplary anti-NKG2C antibodies described herein to block the binding of a ligand to the cell surface receptor.
- PBMC isolation Human peripheral blood mononuclear cells (PBMCs) were isolated through a gradient of Ficoll-Paque PLUS (GE Healthcare) according to manufacturer instructions, and as described above. Blocking Assay PBMCs were incubated with 5 ⁇ g purified AB1, AB2, AB3, AB4, AB5, AB6, AB7, AB8, ABII antibodies, or 1.5 ⁇ g of NKG2E recombinant protein, for 15 minutes in the dark.
- PBMC isolation Human peripheral blood mononuclear cells (PBMCs) were isolated through a gradient of Ficoll-Paque PLUS (GE Healthcare) according to manufacturer instructions, and as described above. Blocking Assay PBMCs were incubated with 5 ⁇ g purified AB1, AB2, AB3, AB4, AB5, AB6, AB7,
- AB1, AB2, AB3, AB4, AB5, AB6, AB7, AB8, ABII antibodies, and NKG2E recombinant protein were used as blocking agents. In certain instances, no blocking agents were used.
- Cells were then incubated with PE conjugated antibody or isotype control for 15 minutes. Cells were washed, acquired on a BD Canto II and analyzed using FlowJo software. Calculations for % Blocking Percentage original MFI was calculated by dividing the MFI of samples blocked with AB1, AB2, AB3, AB4, AB5, AB6, AB7, AB8 ABII antibodies, and NKG2E recombinant protein by the MFI of samples blocked with isotype MOPC-21.
- Precursor human NKG2C protein sequence (UniProtKB - P26717 (NKG2C_HUMAN)/ NCBI Reference Sequence: NP_002251.2) (SEQ ID NO: 56) 1 mnkqrgtfse vslaqdpkrq qrkpkgnkss isgteqeifq velnlqnpsl nhqgidkiyd 61 cqgllpppek ltaevlgiic ivlmatvlkt ivlipfleqn nfspntrtqk arhcghcpee 121 witysnscyy igkerrtwee sllactskns sllsidneee mkflasilps swigvfrnss 181 hhpwvtingl afkhkikdsd naelncavlq v
- each immunoglobulin heavy chain variable domain of the anti-NKG2C agent comprises first, second, and third heavy chain complementarity determining regions (CDRs), wherein the first heavy chain CDR (CDRH1) comprises an amino acid sequence that is at least 80 percent identical to the amino acid sequence X 1 X 2 X 3 X 4 X 5 (SEQ ID NO: 50), wherein the second heavy chain CDR (CDRH2) comprises an amino acid sequence that is at least 80 percent identical to the amino acid sequence X NO: 51), wherein E, the third heavy chain CDR (CDRH3) comprises an amino acid sequence that is at least 80 percent identical to the amino acid sequence X 4 (SEQ ID NO: 52), wherein b) each immunoglobulin heavy chain variable domain of the anti-NKG2C agent comprises first, second, and third heavy chain complementarity determining regions (CDRs), wherein the first heavy chain CDR (CDRH1) comprises an amino acid sequence that is at least 80 percent identical to the amino acid sequence X 1 X 2 X 3 X
- the anti-NKG2C agent of embodiment A1, wherein the CDRH1 comprises and amino acid sequence that is at least 85 percent identical to the amino acid sequence of SEQ ID NO: 50.
- the anti-NKG2C agent of embodiment A1, wherein the CDRH1 comprises an amino acid sequence that is at least 90 percent identical to the amino acid sequence of SEQ ID NO: 50.
- the anti-NKG2C agent of embodiment A1, wherein the CDRH1 comprises an amino acid sequence that is at least 95 percent identical to the amino acid sequence of SEQ ID NO: 50.
- the anti-NKG2C agent of embodiment A1, wherein the CDRH1 comprises an amino acid sequence that is 100 percent identical to the amino acid sequence of SEQ ID NO: 50.
- A6 The anti-NKG2C agent of embodiment A1, wherein the CDRH1 comprises an amino acid sequence that is 100 percent identical to the amino acid sequence of SEQ ID NO: 50.
- the anti-NKG2C agent of any one of embodiments A1 to A5, wherein the CDRH2 comprises an amino acid sequence that is at least 95 percent identical to the amino acid sequence of SEQ ID NO: 51. A9.
- the anti-NKG2C agent of any one of embodiments A1 to A9, wherein the CDRH3 comprises an amino acid sequence that is at least 90 percent identical to the amino acid sequence of SEQ ID NO: 52. A12.
- the anti-NKG2C agent of any one of embodiments A1 to A13, wherein the CDRL1 comprises an amino acid sequence that is at least 85 percent identical to the amino acid sequence of SEQ ID NO: 53. A15.
- the anti-NKG2C agent of any one of embodiments A1 to A13, wherein the CDRL1 comprises an amino acid sequence that is at least 90 percent identical to the amino acid sequence of SEQ ID NO: 53. A16.
- the anti-NKG2C agent of any one of embodiments A1 to A13, wherein the CDRL1 comprises an amino acid sequence that is at least 95 percent identical to the amino acid sequence of SEQ ID NO: 53.
- the anti-NKG2C agent of any one of embodiments A1 to A13, wherein the CDRL1 comprises an amino acid sequence that is 100 percent identical to the amino acid sequence of SEQ ID NO: 53. A18.
- the anti-NKG2C agent of any one of embodiments A1 to A17, wherein the CDRL2 comprises an amino acid sequence that is at least 85 percent identical to the amino acid sequence of SEQ ID NO: 54. A19.
- the anti-NKG2C agent of any one of embodiments A1 to A17, wherein the CDRL2 comprises an amino acid sequence that is at least 90 percent identical to the amino acid sequence of SEQ ID NO: 54.
- the anti-NKG2C agent of any one of embodiments A1 to A17, wherein the CDRL2 comprises an amino acid sequence that is at least 95 percent identical to the amino acid sequence of SEQ ID NO: 54. A21.
- the anti-NKG2C agent of any one of embodiments A1 to A21, wherein the CDRL3 comprises an amino acid sequence that is at least 90 percent identical to the amino acid sequence of SEQ ID NO: 55. A24.
- the anti-NKG2C agent of any one of embodiments A1 to A21, wherein the CDRL3 comprises an amino acid sequence that is at least 95 percent identical to the amino acid sequence of SEQ ID NO: 55. A25.
- the anti-NKG2C agent of any one of embodiments A1 to A21, wherein the CDRL3 comprises an amino acid sequence that is 100 percent identical to the amino acid sequence of SEQ ID NO: 55. A26.
- the CDRH1 comprises an amino acid sequence chosen from DYYMH (SEQ ID NO: 17), SFGMH (SEQ ID NO: 23), NFGMH (SEQ ID NO: 29), DTYIH (SEQ ID NO: 33), NYWMN (SEQ ID NO: 39), and DTYMH (SEQ ID NO: 45).
- WIDPENDDTEYAPKFQG SEQ ID NO: 18
- YISSGSSTIYYRDTLKG SEQ ID NO: 24
- YISSGSSTIYYADTVKG SEQ ID NO: 30
- YISSGSSSIYYADTMKG SEQ ID NO: 34
- RIDPENGNTKYDPKFQG SEQ ID
- HYHYNDPY SEQ ID NO: 19
- SVIYYDYDRYLMDY SEQ ID NO: 25
- SVIYYAYDRYLMDF SEQ ID NO: 31
- TATVFWYFDV SEQ ID NO: 35
- SHGSNYGWFAY SEQ ID NO: 41
- VITTHWYFDV SEQ ID NO: 47
- CDRL1 comprises an amino acid sequence chosen from SASSSVSYMY (SEQ ID NO: 20), KASQSVDYDGDSYMN (SEQ ID NO: 26), KSSQSVLYSSNQKNYLA (SEQ ID NO: 36), KASQSVSNDVG (SEQ ID NO: 42), and KSSQSVLYSSNQKNYLA (SEQ ID NO: 48). A30.
- CDRL2 comprises an amino acid sequence chosen from RTSNLAS (SEQ ID NO: 21), AASNLES (SEQ ID NO: 27), GASNLES (SEQ ID NO: 32), WASTRES (SEQ ID NO: 37), and YASNRYT (SEQ ID NO: 43).
- RTSNLAS SEQ ID NO: 21
- AASNLES SEQ ID NO: 27
- GASNLES SEQ ID NO: 32
- WASTRES SEQ ID NO: 37
- YASNRYT SEQ ID NO: 43
- the anti-NKG2C agent of any one of embodiments A1 to A30 wherein CDRL3 comprises an amino acid sequence chosen from QHYHSYPYT (SEQ ID NO: 22), QQSNEDPLT (SEQ ID NO: 28), QQSNEVPLT (SEQ ID NO: 38), HQ-YLSSHT (SEQ ID NO: 44), and QQDYSSPLT (SEQ ID NO: 48).
- CDRL3 comprises an amino acid sequence chosen from QHYHSYPYT (SEQ ID NO: 22), QQSNEDPLT (SEQ ID NO: 28), QQSNEVPLT (SEQ ID NO: 38), HQ-YLSSHT (SEQ ID NO: 44), and QQDYSSPLT (SEQ ID NO: 48).
- A32 The anti-NKG2C agent of any one of embodiments A1 to A31, which comprises two immunoglobulin heavy chain variable domains and two immunoglobulin light chain variable domains.
- the anti-NKG2C agent of embodiment A32 wherein the two immunoglobulin heavy chain variable domains each comprise a set of CDRH1, CDRH2, and CDRH3 amino acid sequences.
- each immunoglobulin heavy chain variable domain comprises a set of CDRH1, CDRH2, CDRH3 amino acid sequences and each immunoglobulin light chain variable domain comprises a set of CDRL1, CDRL2, and CDRL3 amino acid sequences chosen from sets 1-8: A36.
- the anti-NKG2C agent of embodiment A35 wherein all CDR sequences are from the same set.
- A37. The anti-NKG2C agent of any one of embodiments A1 to A36, wherein the agent is isolated.
- A38. The anti-NKG2C agent of any one of embodiments A1 to A37 wherein the agent is non-naturally occurring.
- A44. The anti-NKG2C agent of any one of embodiments A1 to A43, wherein the agent is conjugated to a detectable marker or label.
- A45. The anti-NKG2C agent of any one of embodiments A1 to A44, wherein the agent is non-diffusively immobilized on a solid support.
- A46. A diagnostic reagent comprising the anti-NKG2C agent of any one of embodiments A1 to A45.
- A47. A kit comprising the anti-NKG2C agent of any one of embodiments A1 to A45 or the diagnostic reagent of embodiment A46.
- a diagnostic kit configured to detect NK inhibitory receptor CD94/NK group 2 member C (NKG2C) in a biological sample, wherein the kit comprises the anti-NKG2C agent of any one of embodiments A1 to A45 or the diagnostic reagent of embodiment A46.
- A49. An isolated nucleic acid molecule comprising a nucleotide sequence that encodes an immunoglobulin heavy chain variable domain of the anti-NKG2C agent of any one of embodiments A1 to A45.
- A50 An isolated nucleic acid molecule comprising a nucleotide sequence that encodes an immunoglobulin light chain variable domain of the anti-NKG2C agent of any one of embodiments A1 to A45.
- a recombinant expression vector comprising a first expression cassette and a second expression cassette, wherein the first expression cassette comprises a promoter and a nucleic acid molecule comprising a nucleotide sequence that encodes an immunoglobulin heavy chain variable domain of the anti-NKG2C agent of any one of embodiments A1 to A45, and the second expression cassette comprises a promoter and a nucleic acid molecule comprising a nucleotide sequence that encodes an immunoglobulin light chain variable domain of the anti-NKG2C agent of any one of embodiments A1 to A45.
- A52. A recombinant host cell transfected with the recombinant expression vector of embodiment A51.
- a method of detecting NKG2C comprising contacting a sample known or suspected to contain NKG2C with the anti-NKG2C agent of any one of embodiments A1 to A45, and, if the sample contains NKG2C, detecting NKG2C:anti-NKG2C complexes.
- B1. A first anti-NKG2C agent that binds NKG2C under laboratory or physiological conditions, wherein the first agent competitively binds, or is capable of competitively binding, with a second anti-NKG2C agent, which second agent is the anti-NKG2C agent of any one of embodiments A1 to A36.
- B6 The first anti-NKG2C agent of any one of embodiments B1 to B4, wherein the first agent and/or second agent is an antibody, or derivative thereof.
- B7 The first anti-NKG2C agent of any one of embodiments B1 to B6, wherein the first agent and/or second agent is a humanized antibody, or an antigen binding fragment thereof.
- B8. The first anti-NKG2C agent of any one of embodiments B1 to B6, wherein the first agent and/or second agent is a derivative of a humanized antibody that binds NKG2C.
- B9 The first anti-NKG2C agent of any one of embodiments B1 to B8, comprising a detectable marker or label.
- B11 The first anti-NKG2C agent of any one of embodiments B1 to B10, wherein the first agent is non- diffusively immobilized on a solid support.
- B12. A diagnostic reagent comprising the first anti-NKG2C agent of any one of embodiments B1 to B11.
- B13. A kit comprising the first anti-NKG2C agent of any one of embodiments B1 to B11 or the diagnostic reagent of embodiment B12. B14.
- a diagnostic kit configured to detect NK inhibitory receptor CD94/NK group 2 member A (NKG2C) in a biological sample, wherein the kit comprises the first anti-NKG2C agent of any one of embodiments B1 to B11 or the diagnostic reagent of embodiment B12.
- B15 An isolated nucleic acid molecule comprising a nucleotide sequence that encodes an immunoglobulin heavy chain variable domain of the first anti-NKG2C agent of any one of embodiments B1 to B11.
- B16 An isolated nucleic acid molecule comprising a nucleotide sequence that encodes an immunoglobulin light chain variable domain of the first anti-NKG2C agent of any one of embodiments B1 to B11.
- a recombinant expression vector comprising a first expression cassette and a second expression cassette, wherein the first expression cassette comprises a promoter and a nucleic acid molecule comprising a nucleotide sequence that encodes an immunoglobulin heavy chain variable domain of the first anti-NKG2C agent of any one of embodiments B1 to B11, and the second expression cassette comprises a promoter and a nucleic acid molecule comprising a nucleotide sequence that encodes an immunoglobulin light chain variable domain of the first anti-NKG2C agent of any one of embodiments B1 to B11.
- B18. A recombinant host cell transfected with the recombinant expression vector of embodiment B17. B19.
- a method of detecting NKG2C comprising contacting a sample known or suspected to contain NKG2C with the first anti-NKG2C agent of any one of embodiments B1 to B11, and, if the sample contains NKG2C, detecting NKG2C:anti-NKG2C complexes.
- An anti-NKG2C agent for detecting NKG2C in a heterogeneous population of immune cells wherein NKG2C is detected at a significant level in natural killer (NK) cells and/or CD8 + T lymphocytes in the population, and NKG2C is not significantly detected in other immune cells in the population.
- NK natural killer
- each immunoglobulin heavy chain variable domain of the anti-NKG2C agent comprises first, second, and third heavy chain complementarity determining regions (CDRs); and ii) each immunoglobulin light chain variable domain of the anti-NKG2C agent comprises first, second, and third light chain CDRs.
- CDRs heavy chain complementarity determining regions
- the anti-NKG2C agent of embodiment C2 wherein the first heavy chain CDR (CDRH1) comprises an amino acid sequence that is at least 80 percent identical to the amino acid sequence X 1 X 2 X 3 X 4 X 5 (SEQ ID NO: 50), wherein X 5 is H or N.
- C4 The anti-NKG2C agent of embodiment C2 or C3, wherein the second heavy chain CDR (CDRH2) comprises an amino acid sequence that is at least 80 percent identical to the amino acid sequence 1 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 (SEQ ID NO: 51), wherein C5.
- the anti-NKG2C agent of any one of embodiments C2 to C8, wherein the CDRH1 comprises an amino acid sequence that is at least 95 percent identical to the amino acid sequence of SEQ ID NO: 50. C12.
- the anti-NKG2C agent of any one of embodiments C2 to C12, wherein the CDRH2 comprises an amino acid sequence that is at least 90 percent identical to the amino acid sequence of SEQ ID NO: 51. C15.
- the anti-NKG2C agent of any one of embodiments C2 to C16, wherein the CDRH3 comprises an amino acid sequence that is at least 85 percent identical to the amino acid sequence SEQ ID NO: 52. C18.
- the anti-NKG2C agent of any one of embodiments C2 to C16, wherein the CDRH3 comprises an amino acid sequence that is 100 percent identical to the amino acid sequence of SEQ ID NO: 52. C21.
- the anti-NKG2C agent of any one of embodiments C2 to C20, wherein the CDRL1 comprises an amino acid sequence that is at least 85 percent identical to the amino acid sequence of SEQ ID NO: 53. C22.
- the anti-NKG2C agent of any one of embodiments C2 to C20, wherein the CDRL1 comprises an amino acid sequence that is at least 90 percent identical to the amino acid sequence of SEQ ID NO: 53. C23.
- the anti-NKG2C agent of any one of embodiments C2 to C20, wherein the CDRL1 comprises an amino acid sequence that is at least 95 percent identical to the amino acid sequence of SEQ ID NO: 53. C24.
- the anti-NKG2C agent of any one of embodiments C2 to C24, wherein the CDRL2 comprises an amino acid sequence that is at least 90 percent identical to the amino acid sequence of SEQ ID NO: 54. C27.
- the anti-NKG2C agent of any one of embodiments C2 to C28, wherein the CDRL3 comprises an amino acid sequence that is at least 85 percent identical to the amino acid sequence of SEQ ID NO: 55. C30.
- the anti-NKG2C agent of any one of embodiments C2 to C28, wherein the CDRL3 comprises an amino acid sequence that is at least 90 percent identical to the amino acid sequence of SEQ ID NO: 55. C31.
- the anti-NKG2C agent of any one of embodiments C2 to C28, wherein the CDRL3 comprises an amino acid sequence that is at least 95 percent identical to the amino acid sequence of SEQ ID NO: 55. C32.
- the anti-NKG2C agent of any one of embodiments C2 to C28, wherein the CDRL3 comprises an amino acid sequence that is 100 percent identical to the amino acid sequence of SEQ ID NO: 55. C33.
- C34 comprises an amino acid sequence chosen from DYYMH (SEQ ID NO: 17), SFGMH (SEQ ID NO: 23), NFGMH (SEQ ID NO: 29), DTYIH (SEQ ID NO: 33), NYWMN (SEQ ID NO: 39), and DTYMH (SEQ ID NO: 45).
- WIDPENDDTEYAPKFQG SEQ ID NO: 18
- Y SEQ ID NO: 24
- Y SEQ ID NO: 30
- Y 34 RIDPENGNTKYDPKFQG
- MIHPSDSETRLNQKFKD SEQ ID NO: 46
- RIDPANGYTKYDPKFQG SEQ ID NO: 49
- HYHYNDPY SEQ ID NO: 19
- SVIYYDYDRYLMDY SEQ ID NO: 25
- SVIYYAYDRYLMDF SEQ ID NO: 31
- TATVFWYFDV SEQ ID NO: 35
- SHGSNYGWFAY SEQ ID NO: 41
- VITTHWYFDV SEQ ID NO: 47
- RTSNLAS SEQ ID NO: 21
- AASNLES SEQ ID NO: 27
- GASNLES SEQ ID NO: 32
- WASTRES SEQ ID NO: 37
- YASNRYT SEQ ID NO: 43
- the CDRL3 comprises an amino acid sequence chosen from QHYHSYPYT (SEQ ID NO: 22), QQSNEDPLT (SEQ ID NO: 28), QQSNEVPLT (SEQ ID NO: 38), HQ-YLSSHT (SEQ ID NO: 44), and QQDYSSPLT (SEQ ID NO: 48).
- C39 The anti-NKG2C agent of any one of embodiments C1 to C38, which comprises two immunoglobulin heavy chain variable domains and two immunoglobulin light chain variable domains.
- the anti-NKG2C agent of embodiment C39 wherein the two immunoglobulin heavy chain variable domains each comprise a set of CDRH1, CDRH2, and CDRH3 amino acid sequences.
- each immunoglobulin heavy chain variable domain comprises a set of CDRH1, CDRH2, and CDRH3 amino acid sequences and each immunoglobulin light chain variable domain comprises a set of CDRL1, CDRL2, and CDRL3 amino acid sequences chosen from sets 1-8: C43.
- the anti-NKG2C agent of embodiment C42 wherein all CDR sequences are from the same set.
- C44 The anti-NKG2C agent of any one of embodiments C1 to C43, wherein NKG2C is detected at a significant level in NK cells.
- the anti-NKG2C agent o any one of embodiments C1 to C47, wherein NKG2C is not significantly detected in other immune cells in the population, wherein the other immune cells comprise one or more of plasmacytoid dendritic cells, B cells, and monocytes.
- C50 The anti-NKG2C agent of any one of embodiments C1 to C49, wherein the agent is non-naturally occurring.
- C51 The anti-NKG2C agent of any one of embodiments C1 to C50, wherein the agent is an antibody, or antigen-binding fragment thereof.
- C52 The anti-NKG2C agent of any one of embodiments C1 to C50, wherein the agent is an antibody, or derivative thereof.
- C54 The anti-NKG2C agent of any one of embodiments C1 to C52, wherein the agent is a humanized antibody, or an antigen binding fragment thereof.
- C55 The anti-NKG2C agent of any one of embodiments C1 to C54, wherein the agent comprises a detectable marker or label.
- C56 The anti-NKG2C agent of any one of embodiments C1 to C55, wherein the agent is conjugated to a detectable marker or label.
- C57 The anti-NKG2C agent of any one of embodiments C1 to C56, wherein the agent is non-diffusively immobilized on a solid support.
- C58 A diagnostic reagent comprising the anti-NKG2C agent of any one of embodiments C1 to C57.
- kits comprising the anti-NKG2C agent of any one of embodiments C1 to C57 or the diagnostic reagent of embodiment C58.
- C60 A diagnostic kit configured to detect NKG2C in a biological sample, wherein the kit comprises the anti-NKG2C agent of any one of embodiments C1 to C57 or the diagnostic reagent of embodiment C58.
- C61. An isolated nucleic acid molecule comprising a nucleotide sequence that encodes an immunoglobulin heavy chain variable domain of the anti-NKG2C agent of any one of embodiments C1 to C57.
- C62 An isolated nucleic acid molecule comprising a nucleotide sequence that encodes an immunoglobulin heavy chain variable domain of the anti-NKG2C agent of any one of embodiments C1 to C57.
- An isolated nucleic acid molecule comprising a nucleotide sequence that encodes an immunoglobulin light chain variable domain of the anti-NKG2C agent of any one of embodiments C1 to C57.
- a recombinant expression vector comprising a first expression cassette and a second expression cassette, wherein the first expression cassette comprises a promoter and a nucleic acid molecule comprising a nucleotide sequence that encodes an immunoglobulin heavy chain variable domain of the anti-NKG2C agent of any one of embodiments C1 to C57, and the second expression cassette comprises a promoter and a nucleic acid molecule comprising a nucleotide sequence that encodes an immunoglobulin light chain variable domain of the anti-NKG2C agent of any one of embodiments C1 to C57.
- C64 A recombinant host cell transfected with the recombinant expression vector of embodiment C63.
- C65. A method of detecting NKG2C, comprising contacting a sample known or suspected to contain NKG2C with the anti-NKG2C agent of any one of embodiments C1 to C57, and, if the sample contains NKG2C, detecting NKG2C:anti-NKG2C complexes.
- C66. A method of detecting NKG2C in a heterogeneous population of immune cells, comprising contacting the population with an anti-NKG2C agent of any one of embodiments C1 to C57, and, if the population contains cells expressing NKG2C, detecting NKG2C:anti-NKG2C complexes. D1.
- An anti-NKG2C agent that binds the NKG2C receptor or a fragment thereof, comprising one or more of: a) an immunoglobulin heavy chain variable domain comprising: (i) a heavy chain complementary determining region 1 (CDRH1) comprising the sequence X 1 X 2 X 3 X 4 X 5 (SEQ ID NO: 50), wherein X 1 is N, S, or D, X 2 is F, T, or Y, X 3 is G, Y, or W, X 4 is M or I, and X 5 is H or N; (ii) a heavy chain complementary determining region 2 (CDRH2) comprising the sequence X 1 IX 3 X 4 X 5 X 6 X 7 X 8 X 9 X 10 X 11 X 12 X 13 X 14 X 15 X 16 X 17 (SEQ ID NO: 51), wherein X 1 is Y, R, W, or M, X 3 is S, D, or H, X 4 is S
- the anti-NKG2C agent of embodiment D1, wherein the immunoglobulin heavy chain variable domain comprises a CDRH1 comprising the sequence of amino acids set forth in SEQ ID NO: 17, SEQ ID NO: 23, SEQ ID NO: 29, SEQ ID NO: 33, SEQ ID NO: 39 or SEQ ID NO:45, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 17, SEQ ID NO: 23, SEQ ID NO: 29, SEQ ID NO: 33, SEQ ID NO: 39 or SEQ ID NO:45; a CDRH2 comprising the sequence of amino acids set forth in SEQ ID NO: 18, SEQ ID NO: 24, SEQ ID NO:30, SEQ ID NO:34, SEQ ID NO:40, SEQ ID NO:46, SEQ ID NO:
- the anti-NKG2C agent of embodiment D1 or embodiment D2, wherein the immunoglobulin heavy chain variable domain comprises a CDRH1 comprising the sequence of amino acids set forth in SEQ ID NO: 17, SEQ ID NO: 23, SEQ ID NO: 29, SEQ ID NO: 33, SEQ ID NO: 39 or SEQ ID NO:45; a CDRH2 comprising the sequence of amino acids set forth in SEQ ID NO: 18, SEQ ID NO: 24, SEQ ID NO:30, SEQ ID NO:34, SEQ ID NO:40, SEQ ID NO:46, SEQ ID NO:49; and a CDRH3 comprising the sequence of amino acids set forth in SEQ ID NO: 19, SEQ ID NO: 25, SEQ ID NO: 31, SEQ ID NO: 35, SEQ ID NO: 41, SEQ ID NO: 47.
- the anti-NKG2C agent of any of embodiments D1-D3, wherein the immunoglobulin light chain variable domain comprises a CDRL1 comprising the sequence of amino acids set forth in SEQ ID NO: 20; SEQ ID NO: 26, SEQ ID NO: 36 or SEQ ID NO: 42 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 20; SEQ ID NO: 26, SEQ ID NO: 36 or SEQ ID NO: 42; a CDRL2 comprising the sequence of amino acids set forth in SEQ ID NO: 21, SEQ ID NO: 27, SEQ ID NO: 32, SEQ ID NO: 37, SEQ ID NO: 43, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%
- the immunoglobulin light chain variable domain comprises a CDRL1 comprising a sequence of amino acids set forth in SEQ ID NO: 20; SEQ ID NO: 26, SEQ ID NO: 36 or SEQ ID NO: 42; a CDRL2 comprising a sequence of amino acids set forth in SEQ ID NO: 21, SEQ ID NO: 27, SEQ ID NO: 32, SEQ ID NO: 37, SEQ ID NO: 43; and a CDRL3 comprising a sequence of amino acids set forth in SEQ ID NO: 22, SEQ ID NO: 28, SEQ ID NO: 38, SEQ ID NO: 44, SEQ ID NO: 48. D6.
- the CDRH1 comprises the sequence set forth in SEQ ID NO: 17, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 17,
- the CDRH2 comprises the sequence set forth in SEQ ID NO: 18, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 18;
- the CDRH3 comprises the sequence set forth in SEQ ID NO: 19, or a sequence of amino acids that exhibits at least 80%, 81%, 82%
- D7 The anti-NKG2C agent of any of embodiments D1-D6, wherein the CDRH1 comprises the sequence set forth in SEQ ID NO: 17, the CDRH2 comprises the sequence set forth in SEQ ID NO: 18; and the CDRH3 comprises the sequence set forth in SEQ ID NO: 19. D8.
- the CDRH1 comprises the sequence set forth in SEQ ID NO: 23, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 23,
- the CDRH2 comprises the sequence set forth in SEQ ID NO: 24,or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 24; and
- the CDRH3 comprises the sequence set forth in SEQ ID NO: 25, or a sequence of amino acids that exhibits at least 80%, 81%, 82%
- D11 The anti-NKG2C agent of any of embodiments D1-D5 and D10, wherein the CDRH1 comprises the sequence set forth in SEQ ID NO: 16, the CDRH2 comprises the sequence set forth in SEQ ID NO: 17; and the CDRH3 comprises the sequence set forth in SEQ ID NO: 18. D12.
- the CDRH1 comprises the sequence set forth in SEQ ID NO: 23, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 23,
- the CDRH2 comprises the sequence set forth in SEQ ID NO: 24,or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 24; and
- the CDRH3 comprises the sequence set forth in SEQ ID NO: 25, or a sequence of amino acids that exhibits at least 80%, 81%, 82%
- the CDRH1 comprises the sequence set forth in SEQ ID NO: 29, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:29
- the CDRH2 comprises the sequence set forth in SEQ ID NO: 30,or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 30
- the CDRH3 comprises the sequence set forth in SEQ ID NO: 31, or a sequence of amino acids that exhibits at least 80%, 81%, 8
- D15 The anti-NKG2C agent of any of embodiments D1-D5 and D14, wherein the CDRH1 comprises the sequence set forth in SEQ ID NO: 29, the CDRH2 comprises the sequence set forth in SEQ ID NO: 30; and the CDRH3 comprises the sequence set forth in SEQ ID NO: 31.
- the CDRH1 comprises the sequence set forth in SEQ ID NO: 29, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:29
- the CDRH2 comprises the sequence set forth in SEQ ID NO: 34, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:34
- the CDRH3 comprises the sequence set forth in SEQ ID NO: 25, or a sequence of amino acids that exhibits at least 80%,
- D17 The anti-NKG2C agent of any of embodiments D1-D5 and D16, wherein the CDRH1 comprises the sequence set forth in SEQ ID NO: 29, the CDRH2 comprises the sequence set forth in SEQ ID NO: 34; and the CDRH3 comprises the sequence set forth in SEQ ID NO: 25. D18.
- the CDRH1 comprises the sequence set forth in SEQ ID NO: 33, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 33
- the CDRH2 comprises the sequence set forth in SEQ ID NO: 40, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:40
- the CDRH3 comprises the sequence set forth in SEQ ID NO: 35, or a sequence of amino acids that exhibits at least 80%, 8
- the CDRH1 comprises the sequence set forth in SEQ ID NO: 39, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 39
- the CDRH2 comprises the sequence set forth in SEQ ID NO: 46, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 46
- the CDRH3 comprises the sequence set forth in SEQ ID NO: 41, or a sequence of amino acids that exhibits at least 80%, 8
- the CDRH1 comprises the sequence set forth in SEQ ID NO: 45, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 45
- the CDRH2 comprises the sequence set forth in SEQ ID NO: 49, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 49
- the CDRH3 comprises the sequence set forth in SEQ ID NO: 47, or a sequence of amino acids that exhibits at least 80%, 8
- the CDRL1 comprises the sequence set forth in SEQ ID NO: 20, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 20;
- the CDRL2 comprises the sequence set forth in SEQ ID NO: 21, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:21;
- the CDRL3 comprises the sequence set forth in SEQ ID NO: 22, or a sequence of amino acids that exhibits at least 80%, 81%, 82%,
- the CDRL1 comprises the sequence set forth in SEQ ID NO: 26, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:26;
- the CDRL2 comprises the sequence set forth in SEQ ID NO: 27 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:27;
- the CDRL3 comprises the sequence set forth in SEQ ID NO:28 or a sequence of amino acids that exhibits at least 80%, 81%, 82%,
- the CDRL1 comprises the sequence set forth in SEQ ID NO: 26, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:26;
- the CDRL2 comprises the sequence set forth in SEQ ID NO: 32 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:32;
- the CDRL3 comprises the sequence set forth in SEQ ID NO: 28 or a sequence of amino acids that exhibits at least 80%, 81%, 82%,
- the CDRL1 comprises the sequence set forth in SEQ ID NO: 26, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:26;
- the CDRL2 comprises the sequence set forth in SEQ ID NO: 32 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:32;
- the CDRL3 comprises the sequence set forth in SEQ ID NO: 38 or a sequence of amino acids that exhibits at least 80%, 81%, 82%,
- the CDRL1 comprises the sequence set forth in SEQ ID NO: 36, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:36;
- the CDRL2 comprises the sequence set forth in SEQ ID NO:37 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:37;
- the CDRL3 comprises the sequence set forth in SEQ ID NO:44 or a sequence of amino acids that exhibits at least 80%, 81%, 82%
- D33 The anti-NKG2C agent of any of embodiments D1-D23 and D32, wherein the CDRL1 comprises the sequence set forth in SEQ ID NO: 36, the CDRL2 comprises the sequence set forth in SEQ ID NO: 37; and the CDRL3 comprises the sequence set forth in SEQ ID NO: 44. D34.
- the CDRL1 comprises the sequence set forth in SEQ ID NO: 42, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:42;
- the CDRL2 comprises the sequence set forth in SEQ ID NO: 43 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:43;
- the CDRL3 comprises the sequence set forth in SEQ ID NO:48 or a sequence of amino acids that exhibits at least 80%, 81%, 82%
- D35 The anti-NKG2C agent of any of embodiments D1-D23 and D34, wherein the CDRL1 comprises the sequence set forth in SEQ ID NO:42, the CDRL2 comprises the sequence set forth in SEQ ID NO: 43; and the CDRL3 comprises the sequence set forth in SEQ ID NO: 48. D36.
- the CDRL1 comprises the sequence set forth in SEQ ID NO: 48, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:48;
- the CDRL2 comprises the sequence set forth in SEQ ID NO: 37 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:37;
- the CDRL3 comprises the sequence set forth in SEQ ID NO: 44 or a sequence of amino acids that exhibits at least 80%, 81%, 82%
- the CDRH1 comprises the sequence of amino acids set forth in SEQ ID NO: 17, 23, 29, 33, 39 or 45, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 17, 23, 29, 33, 39 or 45
- the CDRH2 comprises a sequence of amino acids set forth in SEQ ID NO: 18, 24, 30, 34, 40, 46 or 49, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 18, 24, 30, 34, 40
- the anti-NKG2C agent of any of embodiments D1-D38 wherein the CDRH1 comprises the sequence of amino acids set forth in SEQ ID NO: 17, 23, 29, 33, 39 or 45; the CDRH2 comprises a sequence of amino acids set forth in SEQ ID NO: 18, 24, 30, 34, 40, 46 or 49; the CDRH3 comprises a sequence of amino acids set forth in SEQ ID NO: 19, 25, 31, 35, 41 or 47; the CDRL1 comprises a sequence of amino acids set forth in SEQ ID NO: 20, 26, 36 or 42; the CDRL2 comprises a sequence of amino acids set forth in SEQ ID NO: 21, 27, 32, 37 or 43; and the CDRL3 comprises a sequence of amino acids set forth in SEQ ID NO: 22, 28, 38, 44 or 48.
- the CDRH1 comprises the sequence set forth in SEQ ID NO: 17 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:17
- the CDRH2 comprises the sequence set forth in SEQ ID NO:18 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:18
- the CDRH3 comprises the sequence set forth in SEQ ID NO:19 or a sequence of amino acids that exhibits at least 80%, 8
- D41 The anti-NKG2C agent of any of embodiments D1-D40, wherein the CDRH1 comprises the sequence set forth in SEQ ID NO: 17, a CDRH2 comprising the sequence set forth in SEQ ID NO: 18; a CDRH3 comprising the sequence set forth in SEQ ID NO: 19; a CDRL1 comprising the sequence set forth in SEQ ID NO: 20, a CDRL2 comprising the sequence set forth in SEQ ID NO: 21; and a CDRL3 comprising the sequence set forth in SEQ ID NO: 22. D42.
- the CDRH1 comprises the sequence set forth in SEQ ID NO:23, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:23
- the CDRH2 comprises the sequence set forth in SEQ ID NO:24 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:24
- the CDRH3 comprises the sequence set forth in SEQ ID NO:25 or a sequence of amino acids that exhibits at least 80%, 81%,
- D43 The anti-NKG2C agent of any of embodiments D1-D44, wherein the CDRH1 comprises the sequence set forth in SEQ ID NO:23, the CDRH2 comprises the sequence set forth in SEQ ID NO: 24; the CDRH3 comprises the sequence set forth in SEQ ID NO: 25; the CDRL1 comprises the sequence set forth in SEQ ID NO: 26, the CDRL2 comprises the sequence set forth in SEQ ID NO: 27; and the CDRL3 comprises the sequence set forth in SEQ ID NO: 28. D44.
- the CDRH1 comprises the sequence set forth in SEQ ID NO:29 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:29
- the CDRH2 comprises the sequence set forth in SEQ ID NO:30 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:30
- the CDRH3 comprises the sequence set forth in SEQ ID NO:31, or a sequence of amino acids that exhibits at least 80%, 81%,
- D45 The anti-NKG2C agent of any of embodiments D1-D44, wherein the CDRH1 comprises the sequence set forth in SEQ ID NO: 29, the CDRH2 comprises the sequence set forth in SEQ ID NO: 30; the CDRH3 comprises the sequence set forth in SEQ ID NO: 31; the CDRL1 comprises the sequence set forth in SEQ ID NO: 26, the CDRL2 comprises the sequence set forth in SEQ ID NO: 32; and the CDRL3 comprises the sequence set forth in SEQ ID NO: 28. D46.
- the CDRH1 comprises the sequence set forth in SEQ ID NO:29, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:29
- the CDRH2 comprises the sequence set forth in SEQ ID NO:34 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:34
- the CDRH3 comprises the sequence set forth in SEQ ID NO:25, or a sequence of amino acids that exhibits at least 80%, 81%
- the CDRL2 comprises the sequence set forth in SEQ ID NO:32, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:26
- the CDRL2 comprises the sequence set forth in SEQ ID NO:32, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:32
- the CDRL3 comprises the sequence set forth in SEQ ID NO:38 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%
- D47 The anti-NKG2C agent of any of embodiments D1-D46, wherein the CDRH1 comprises the sequence set forth in SEQ ID NO: 29, the CDRH2 comprises the sequence set forth in SEQ ID NO: 34; the CDRH3 comprises the sequence set forth in SEQ ID NO: 25; a CDRL1 comprising the sequence set forth in SEQ ID NO: 26, the CDRL2 comprises the sequence set forth in SEQ ID NO: 32; and the CDRL3 comprises the sequence set forth in SEQ ID NO: 38. D48.
- the CDRH1 comprises the sequence set forth in SEQ ID NO:33, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:33
- the CDRH2 comprises the sequence set forth in SEQ ID NO:40, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:40
- the CDRH3 comprises the sequence set forth in SEQ ID NO:35, or a sequence of amino acids that exhibits at least 80%, 8
- the anti-NKG2C agent of any of embodiments D1-D48 wherein the CDRH1 comprises the sequence set forth in SEQ ID NO:33, the CDRH2 comprises the sequence set forth in SEQ ID NO:40; the CDRH3 comprises the sequence set forth in SEQ ID NO: 35; the CDRL1 comprises the sequence set forth in SEQ ID NO: 36, the CDRL2 comprises the sequence set forth in SEQ ID NO: 37; and the CDRL3 comprises the sequence set forth in SEQ ID NO: 44. 141 D50.
- the CDRH1 comprises the sequence set forth in SEQ ID NO:39, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:39
- the CDRH2 comprises the sequence set forth in SEQ ID NO:46, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:46
- the CDRH3 comprises the sequence set forth in SEQ ID NO:41, or a sequence of amino acids that exhibits at least 80%, 8
- D51 The anti-NKG2C agent of any of embodiments D1-D50, wherein the CDRH1 comprises the sequence set forth in SEQ ID NO:39, the CDRH2 comprises the sequence set forth in SEQ ID NO: 46; the CDRH3 comprises the sequence set forth in SEQ ID NO: 41; the CDRL1 comprises the sequence set forth in SEQ ID NO: 42, the CDRL2 comprises the sequence set forth in SEQ ID NO: 43; and the CDRL3 comprises the sequence set forth in SEQ ID NO: 48. D52.
- the CDRH1 comprises the sequence set forth in SEQ ID NO:45, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:45
- the CDRH2 comprises the sequence set forth in SEQ ID NO:49, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:49
- the CDRH3 comprises the sequence set forth in SEQ ID NO:47 or a sequence of amino acids that exhibits at least 80%, 81%
- the CDRL3 comprises the sequence set forth in SEQ ID NO:44, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:37; and the CDRL3 comprises the sequence set forth in SEQ ID NO:44, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:44. D53.
- the anti-NKG2C agent of any of embodiments D1-D52 wherein the CDRH1 comprises the sequence set forth in SEQ ID NO:45, the CDRH2 comprises the sequence set forth in SEQ ID NO:49; the CDRH3 comprises the sequence set forth in SEQ ID NO:47; the CDRL1 comprises the sequence set forth in SEQ ID NO:48, the CDRL2 comprises the sequence set forth in SEQ ID NO:37; and the CDRL3 comprises the sequence set forth in SEQ ID NO:44. D54.
- the anti-NKG2C agent of any of embodiments D1-D53 wherein the immunoglobulin heavy chain variable domain comprises the amino acid sequence set forth in any of SEQ ID NOS: 1, 2, 3, 5, 6, 7, and 8, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to any of SEQ ID NOS: 1, 2, 3, 5, 6, 7, and 8. D55.
- D57. The anti-NKG2C agent of any of embodiments D1-D56, wherein the immunoglobulin heavy chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 2 or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO:2. D58.
- D63. The anti-NKG2C agent of any of embodiments D1-D62, wherein the immunoglobulin heavy chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 6, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO:6.
- D75 The anti-NKG2C agent of any of embodiments D1-D74, wherein the immunoglobulin light chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 13, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 13. D76.
- the anti-NKG2C agent of any of embodiments D1-D81, wherein the immunoglobulin light chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 16.
- the anti-NKG2C agent of any of embodiments D1-D82, wherein the immunoglobulin heavy chain variable domain comprises the amino acid sequence set forth in any of SEQ ID NOS: 1, 2, 3, 5, 6, 7, and 8, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to any of SEQ ID NOS: 1, 2, 3, 5, 6, 7, and 8, and the immunoglobulin light chain variable domain comprises the amino acid sequence set forth in any of SEQ ID NOS: 9, 10, 11, 13, 14, 15 and 16, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%,
- D84 The anti-NKG2C agent of any of embodiments D1-D83, wherein the immunoglobulin heavy chain variable domain comprises the amino acid sequence set forth in any of SEQ ID NOS: 1, 2, 3, 5, 6, 7, and 8, and the immunoglobulin light chain variable domain comprises the amino acid sequence set forth in any of SEQ ID NOS: 9, 10, 11, 13, 14, 15 and 16. D85.
- the immunoglobulin heavy chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 1, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 1; and the immunoglobulin light chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 9, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO:9.
- D86 The anti-NKG2C agent of any of embodiments D1-D85, wherein the immunoglobulin heavy chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 1, and the immunoglobulin light chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 9. D87.
- the immunoglobulin heavy chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 2, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 2; and the immunoglobulin light chain variable domain comprises the amino acid sequence set forth in SEQ ID NOS: 10, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO:10.
- the immunoglobulin heavy chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 3, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 3; and the immunoglobulin light chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 11, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO:11.
- the immunoglobulin heavy chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 5, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 5; and the immunoglobulin light chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 13, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO:13.
- D91 The anti-NKG2C agent of any of embodiments D1-D90, wherein the immunoglobulin heavy chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 5, and the immunoglobulin light chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 13. D92.
- the immunoglobulin heavy chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 6, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 6; and the immunoglobulin light chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 14, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO:14.
- D93 The anti-NKG2C agent of any of embodiments D1-D92, wherein the immunoglobulin heavy chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 6, and the immunoglobulin light chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 14. D94.
- the immunoglobulin heavy chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 7, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 7; and the immunoglobulin light chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 15, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO:15.
- D95 The anti-NKG2C agent of any of embodiments D1-D94, wherein the immunoglobulin heavy chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 7, and the immunoglobulin light chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 15. D96.
- the immunoglobulin heavy chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 8, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 8; and the immunoglobulin light chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 16, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO:16.
- D97 The anti-NKG2C agent of any of embodiments D1-D96, wherein the immunoglobulin heavy chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 8, and the immunoglobulin light chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 16.
- D98 The anti-NKG2C agent of any of embodiments D1-D97, comprising one immunoglobulin heavy chain variable domain and one immunoglobulin light chain variable domain.
- D99 The anti-NKG2C agent of any of embodiments D1-D98, comprising two immunoglobulin heavy chain variable domains and two immunoglobulin light chain variable domains.
- the anti-NKG2C agent of any of embodiments D1-D99, wherein the immunoglobulin heavy chain variable domain further comprises a signal sequence.
- the anti-NKG2C agent of any of embodiments D1-D101, wherein the immunoglobulin light chain variable domain further comprises a signal sequence.
- the anti-NKG2C agent of embodiment D107 or embodiment D108, wherein the detectable marker or label comprises a detectable moiety.
- the anti-NKG2C agent of any of embodiments D1-D111 that is a single chain fragment.
- the anti-NKG2C agent of any of embodiments D1-D113 for use in the detection of NKG2C in a sample.
- D115. The anti-NKG2C agent of any of embodiments D1-D114, wherein the anti-NKG2C agent binds to an NKG2C expressing cell in a sample.
- D116. The anti-NKG2C agent of embodiment D114 or embodiment D115, wherein the sample comprises immune cells.
- pDCs plasmacytoid dendritic cells
- mDCs myeloid dendritic cells
- innate lymphoid cells mast cells
- eosinophils basophils
- natural killer cells and peripheral blood mononuclear cells (PBMCs).
- PBMCs peripheral blood mononuclear cells
- D126. The anti-NKG2C agent of any of embodiments D1-D125, wherein the anti-NKG2C agent binds to an NKG2C expressing cell.
- D127. The anti-NKG2C agent of any of embodiments D1-D126, wherein the anti-NKG2C agent binds to an NKG2C expressing cell, and increases binding with a target cell.
- the anti-NKG2C agent of any of embodiments D126-D127, wherein the anti-NKG2C agent bound to the NKG2C expressing cell increases the cytotoxic activity of the NKG2C expressing cell.
- D129. The anti-NKG2C agent of any of embodiments D126-D128, wherein the anti-NKG2C agent bound to the NKG2C expressing cell induces lysis of a target cell.
- D130. The anti-NKG2C agent of any of embodiments D127-D129, wherein the target cell is a cell that expresses HLA-E.
- D132 The anti-NKG2C agent of embodiment D131, wherein the disease or disorder is a cancer, a viral infection, an autoimmune disease, an inflammatory disease or a bacterial infection.
- D133 The anti-NKG2C agent of embodiment D131 or embodiment D132, wherein the disease or disorder is a cancer.
- the anti-NKG2C agent of embodiment D133 wherein the cancer is acute myeloid leukemia, acute lymphoblastic leukemia, colorectal, ovarian, gynecologic, liver, glioblastoma, Hodgkin lymphoma, chronic lymphocytic leukemia, esophagus, gastric, pancreas, colon, kidney, head and neck, lung and melanoma.
- the anti-NKG2C agent of embodiment D133 or embodiment D134 wherein the disease or disorder is an autoimmune disease.
- D136 The anti-NKG2C agent of any of embodiments D131-D135, wherein the disease or disorder is a condition characterized by NK cell hyperactivity or NK cell hyperproliferation.
- D137.A diagnostic reanti-NKG2C agent comprising the anti-NKG2C agent of any of embodiments D1- D136.
- D138.A kit comprising the anti-NKG2C agent of any of embodiments D1-D136, or the diagnostic reagent of embodiment D137.
- D139.A composition comprising the anti-NKG2C agent of any of embodiments D1-D136, and a pharmaceutically acceptable excipient.
- D141 An isolated nucleic acid comprising a nucleotide sequence that encodes the immunoglobulin heavy chain variable domain of the agent of any of embodiments D1-D136.
- D142 The isolated nucleic acid of embodiment D141, wherein the immunoglobulin heavy chain variable domain comprises the sequence of nucleotides set forth in any of SEQ ID NOs: 74, 76, 78, 80, 82, 84, 86, 88, 58, 60, 62, 64, 66, 68, 70 and 72.
- D143 The isolated nucleic acid of embodiment D141 or embodiment D142, wherein the immunoglobulin heavy chain variable domain comprises the sequence of nucleotides set forth in SEQ ID NO: 74. D144.
- the isolated nucleic acid of embodiment D141 or embodiment D142, wherein the immunoglobulin heavy chain variable domain comprises the sequence of nucleotides set forth in SEQ ID NO: 76. D145.
- the isolated nucleic acid of embodiment D141 or embodiment D142, wherein the immunoglobulin heavy chain variable domain comprises the sequence of nucleotides set forth in SEQ ID NO: 78. D146.
- the isolated nucleic acid of embodiment D141 or embodiment D142, wherein the immunoglobulin heavy chain variable domain comprises the sequence of nucleotides set forth in SEQ ID NO: 80. D147.
- the isolated nucleic acid of embodiment D141 or embodiment D142, wherein the immunoglobulin heavy chain variable domain comprises the sequence of nucleotides set forth in SEQ ID NO: 82.
- the isolated nucleic acid of embodiment D141 or embodiment D142, wherein the immunoglobulin heavy chain variable domain comprises the sequence of nucleotides set forth in SEQ ID NO: 84. D149.
- the isolated nucleic acid of embodiment D141 or embodiment D142, wherein the immunoglobulin heavy chain variable domain comprises the sequence of nucleotides set forth in SEQ ID NO: 86.
- D150 The isolated nucleic acid of embodiment D141 or embodiment D142, wherein the immunoglobulin heavy chain variable domain comprises the sequence of nucleotides set forth in SEQ ID NO: 88.
- the isolated nucleic acid of embodiment D141 or embodiment D142, wherein the immunoglobulin heavy chain variable domain comprises the sequence of nucleotides set forth in SEQ ID NO: 58.
- D152 The isolated nucleic acid of embodiment D141 or embodiment D142, wherein the immunoglobulin heavy chain variable domain comprises the sequence of nucleotides set forth in SEQ ID NO: 60.
- D153 The isolated nucleic acid of embodiment D141 or embodiment D142, wherein the immunoglobulin heavy chain variable domain comprises the sequence of nucleotides set forth in SEQ ID NO: 62. D154.
- the isolated nucleic acid of embodiment D141 or embodiment D142, wherein the immunoglobulin heavy chain variable domain comprises the sequence of nucleotides set forth in SEQ ID NO: 64. D155.
- the isolated nucleic acid of embodiment D141 or embodiment D142, wherein the immunoglobulin heavy chain variable domain comprises the sequence of nucleotides set forth in SEQ ID NO: 66. D156.
- the isolated nucleic acid of embodiment D141 or embodiment D142, wherein the immunoglobulin heavy chain variable domain comprises the sequence of nucleotides set forth in SEQ ID NO: 68. D157.
- the isolated nucleic acid of embodiment D141 or embodiment D142, wherein the immunoglobulin heavy chain variable domain comprises the sequence of nucleotides set forth in SEQ ID NO: 70.
- D158 The isolated nucleic acid of embodiment D141 or embodiment D142, wherein the immunoglobulin heavy chain variable domain comprises the sequence of nucleotides set forth in SEQ ID NO: 72.
- D159 An isolated nucleic acid comprising a nucleotide sequence that encodes the immunoglobulin light chain variable domain of the agent of any of embodiments D1-D136.
- D160 The isolated nucleic acid molecule of embodiment D159, wherein the immunoglobulin light chain variable domain comprises the sequence of nucleotides set forth in any of SEQ ID NOs: 75, 77, 79, 81, 83, 85, 87, 89, 59, 61, 63, 65, 67, 69, 71, and 73. D161.
- the isolated nucleic acid of embodiment D159 or embodiment D160, wherein the immunoglobulin light chain variable domain comprises the sequence of nucleotides set forth in SEQ ID NO: 75. D162.
- the isolated nucleic acid of embodiment D159 or embodiment D160, wherein the immunoglobulin light chain variable domain comprises the sequence of nucleotides set forth in SEQ ID NO: 77. D163.
- the isolated nucleic acid of embodiment D159 or embodiment D160, wherein the immunoglobulin light chain variable domain comprises the sequence of nucleotides set forth in SEQ ID NO: 79. D164.
- the isolated nucleic acid of embodiment D159 or embodiment D160, wherein the immunoglobulin light chain variable domain comprises the sequence of nucleotides set forth in SEQ ID NO: 81.
- D165 The isolated nucleic acid of embodiment D159 or embodiment D160, wherein the immunoglobulin light chain variable domain comprises the sequence of nucleotides set forth in SEQ ID NO: 83.
- D166 The isolated nucleic acid of embodiment D159 or embodiment D160, wherein the immunoglobulin light chain variable domain comprises the sequence of nucleotides set forth in SEQ ID NO: 85.
- D167 The isolated nucleic acid of embodiment D159 or embodiment D160, wherein the immunoglobulin light chain variable domain comprises the sequence of nucleotides set forth in SEQ ID NO: 87. D168.
- the isolated nucleic acid of embodiment D159 or embodiment D160, wherein the immunoglobulin light chain variable domain comprises the sequence of nucleotides set forth in SEQ ID NO: 89. D169.
- the isolated nucleic acid of embodiment D159 or embodiment D160, wherein the immunoglobulin light chain variable domain comprises the sequence of nucleotides set forth in SEQ ID NO: 59. D170.
- the isolated nucleic acid of embodiment D159 or embodiment D160, wherein the immunoglobulin light chain variable domain comprises the sequence of nucleotides set forth in SEQ ID NO: 61. D171.
- the isolated nucleic acid of embodiment D159 or embodiment D160, wherein the immunoglobulin light chain variable domain comprises the sequence of nucleotides set forth in SEQ ID NO: 63. D172.
- the isolated nucleic acid of embodiment D159 or embodiment D160, wherein the immunoglobulin light chain variable domain comprises the sequence of nucleotides set forth in SEQ ID NO: 65. D173.
- the isolated nucleic acid of embodiment D159 or embodiment D160, wherein the immunoglobulin light chain variable domain comprises the sequence of nucleotides set forth in SEQ ID NO: 67. D174.
- the isolated nucleic acid of embodiment D159 or embodiment D160, wherein the immunoglobulin light chain variable domain comprises the sequence of nucleotides set forth in SEQ ID NO: 69.
- the isolated nucleic acid of embodiment D159 or embodiment D160, wherein the immunoglobulin light chain variable domain comprises the sequence of nucleotides set forth in SEQ ID NO: 71. D176.
- the isolated nucleic acid of embodiment D159 or embodiment D160, wherein the immunoglobulin light chain variable domain comprises the sequence of nucleotides set forth in SEQ ID NO: 73. D177.
- An isolated nucleic acid comprising a nucleotide sequence that encodes the immunoglobulin heavy chain variable domain and the immunoglobulin light chain variable domain of the anti-NKG2C agent of any of embodiments D1-D136.
- D178 The isolated nucleic acid of any of embodiments D141-D177, wherein the nucleotide sequence that encodes the immunoglobulin heavy chain variable domain comprises the sequence set forth in any of SEQ ID NOs: 74, 76, 78, 80, 82, 84, 86, 88, 58, 60, 62, 64, 66, 68, 70 and 72; and the immunoglobulin light chain variable domain comprises the sequence of amino acids set forth in any of SEQ ID NOs: 75, 77, 79, 81, 83, 85, 87, 89, 59, 61, 63, 65, 67, 69, 71, and 73. D179.
- a recombinant expression vector comprising a first expression cassette and a second expression cassette, wherein the first expression cassette comprises a nucleic acid molecule comprising a nucleotide sequence that encodes the immunoglobulin heavy chain variable domain of any one of embodiments D1- D136, and the second expression cassette comprises a nucleic acid molecule comprising a nucleotide sequence that encodes an immunoglobulin light chain variable domain of the anti-NKG2C agent of any one of embodiments D1-D136. D180.
- a recombinant expression vector comprising a first expression cassette and a second expression cassette, wherein the first expression cassette comprises a nucleic acid molecule comprising the isolated nucleic acid of any of embodiments D141-D178, and the second expression cassette comprises a nucleic acid molecule comprising the nucleotide sequence of any of embodiments D141-D178.
- D182. A host cell transfected with the recombinant expression vector of any of embodiments D179-D181. D183.
- a method of detecting NKG2C comprising a) contacting a sample with the anti-NKG2C agent of any of embodiments 1-33, under conditions to bind said anti-NKG2C to an NKG2C receptor on said sample, wherein the binding generates the production of a receptor/anti-NKG2C complex; b) detecting the presence of the receptor/anti-NKG2C complexes; c) wherein the detecting comprises the presence or absence of the NKG2C receptor on said sample.
- a method of treating or preventing a disease or disorder associated with NKG2C in a subject comprising: a) contacting a sample known or suspected to contain NKG2C with the anti-NKG2C agent of any of embodiments D1-D136, b) detecting the presence of complexes comprising NKG2C and the anti-NKG2C agent; wherein the presence of the complexes indicates the presence of a disease or disorder; and c) administering to the subject the anti-NKG2C agent of any of embodiments D1-D136.
- D186 A method of treating or preventing a disease or disorder in a subject, comprising a) detecting the formation of complexes comprising NKG2C and the anti-NKG2C agent of any of embodiments D1-D136 in a sample from the subject; b) administering to a subject in need thereof the anti-NKG2C agent of any of embodiments D1- D136.
- D187 The method of any of embodiments D183-D186, wherein the sample comprises immune cells.
- the immune cell is selected from B cells, plasmacytoid dendritic cells (pDCs), lymphocytes, leukocytes, T cells, monocytes, macrophages, neutrophils, myeloid dendritic cells (mDCs), innate lymphoid cells, mast cells, eosinophils, basophils, natural killer cells, and peripheral blood mononuclear cells (PBMCs).
- pDCs plasmacytoid dendritic cells
- mDCs myeloid dendritic cells
- innate lymphoid cells mast cells
- eosinophils basophils
- natural killer cells and peripheral blood mononuclear cells
- any of the terms “comprising,” “consisting essentially of,” and “consisting of” may be replaced with either of the other two terms.
- the terms and expressions which have been employed are used as terms of description and not of limitation, and use of such terms and expressions do not exclude nay equivalents of the features shown and described or portions thereof, and various modifications are possible within the scope of the technology claimed.
- the term “a” or “an” can refer to one of or a plurality of the elements it modifies (e.g., “a reagent” can mean one or more reagents) unless it is contextually clear either one of the elements or more than one of the elements is described.
- ⁇ refers to a value within 10% of the underlying parameter (i.e., plus or minus 10%), and use of the term “about” at the beginning of a string of values modifies each of the values (i.e., “about 1, 2, and 3” refers to about 1, about 2, and about 3).
- a weight of “about 100 grams” can include weights between 90 grams and 110 grams.
- a listing of values is described herein (e.g., about 50%, 60%, 70%, 80%, 85%, or 86%) the listing included all intermediate and fractional values thereof (e.g., 54%, 85.4%).
Abstract
Compositions and methods for making and using anti-NKG2C agents, for example, monoclonal antibodies, NKG2C-binding antibody fragments, and derivatives are described, as are kits, nucleic acids encoding such molecules, diagnostic reagents and kits that include anti-NKG2C agents, and methods of making and using the same.
Description
ANTI-NKG2C AGENTS AND COMPOSITIONS AND METHODS FOR MAKING AND USING THE SAME Cross Reference to Related Applications This application claims priority from U.S. provisional application No.63/108,174, filed October 30, 2020, entitled "ANTI-NKG2C AGENTS AND COMPOSITIONS AND METHODS FOR MAKING AND USING THE SAME" the contents of each which are incorporated herein by reference in their entirety. Incorporation by Reference of Sequence Listing The present application is being filed along with a Sequence Listing in electronic format. The Sequence Listing is provided as a file entitled BLD014PCTSeqList.TXT, created September 14, 2021, which is 57,348 bytes in size. The information in the electronic format of the Sequence Listing is incorporated herein by reference in its entirety. Field The technology relates in part to agents that bind the NK inhibitory receptor CD94/NK group 2-member C (NKG2C), particularly monoclonal antibodies, antibody fragments, and antibody derivatives specifically reactive to NKG2C under physiological and/or in vitro conditions. Such agents can be useful for laboratory/research purposes (e.g., flow cytometry), and may be used in the treatment and/or prevention of various diseases or disorders through the delivery of pharmaceutical or other compositions that contain such agents. Background The following description includes information that may be useful in understanding the present technology. It is not an admission that any of the information provided herein, or any publication specifically or implicitly referenced herein, is prior art, or even particularly relevant, to the presently claimed technology. Natural Killer (NK) cells play an important role in host immune regulation to a variety of pathological challenges, from viral infections to cancer. Natural Killer cells show a broad array of tissue distribution and phenotypic variability, and therefore express several activating and inhibitory receptors in order to control their function. Natural-killer group 2, member A (NKG2C) is a C-type lectin family activating receptor that forms a heterodimer with CD94, and specifically recognizes the ubiquitously expressed non-
classical MHC molecule HLA-E. Alterations in the expression of NKG2C have been observed in numerous diseases, including human cytomegalovirus (HCMV) and chronic or early HIV-infections. However, there remains a need for reagents, devices and methods of detecting NKG2C for both pre- clinical and clinical application settings. Described herein are particular monoclonal antibodies to NKG2C that provide superior target specificity, signal-to-noise ratios, and the like as compared to other reported anti-NKG2 antibodies, as well as antigen-binding fragments thereof that meet such needs. Summary Provided herein, in some aspects, are anti-NKG2C agents that bind NKG2C, including anti-NKG2C antibodies, NKG2C-binding antibody fragments, derivatives, and variants of such antibodies and antibody fragments or antigen-binding fragments thereof (including immunoconjugates, labeled antibodies and antigen-binding antibody fragments, and the like), diagnostic reagents that comprise such agents, containers and kits that include an anti-NKG2C agent provided herein, and methods of making and using the same. Provided herein, in certain aspects is an anti-NKG2C agent that binds NKG2C under laboratory or physiological conditions, where the agent comprises at least one immunoglobulin heavy chain variable domain and at least one immunoglobulin light chain variable domain, where a) each immunoglobulin heavy chain variable domain of the anti-NKG2C agent comprises first, second, and third heavy chain complementarity determining regions (CDRs), where the first heavy chain CDR (CDRH1) comprises an amino acid sequence that is at least 80% identical to the amino acid sequence X1X2X3X4X5 (SEQ ID NO: 50), where X1 is N, S, or D, X2 is F, T, or Y, X3 is G, Y, or W X4 is M or I, and X5 is H or N; the second heavy chain CDR (CDRH2) comprises an amino acid sequence that is at least 80% identical to the amino acid sequence X1IX3X4X5X6X7X8X9X10X11X12X13X14X15X16X17 (SEQ ID NO: 51), where X1 is Y, R, W, or M, X3 is S, D, or H, X4 is S or P, X5 is G, E, A, or S, X6 is S, N, or D, X7 is S, G, or D, X8 is T, S, N, Y, D, or E, X9 is I or T, X10 is Y, K, E, or R, X11 is Y or L, X12 is A, R, D, or N, X13 is D, P, or Q, X14 is T or K, X15 is V, L, M, or F, X16 is K or Q, and X17 is G or D; the third heavy chain CDR (CDRH3) comprises an amino acid sequence that is at least 80% identical to the amino acid sequence X1X2X3X4X5X6X7X8X9X10X11X12X13X14 (SEQ ID NO: 52), where X1 is S, T, V or H, X2 is V, A, I, or H or Y, X3 is I, T, H, or G, X4 is Y, V, T, or S, X5 is Y, F, H, or N, X6 is A, D, W, or Y, X7 is Y, G, or no amino acid, X8 is D or no amino acid, X9 is R or no amino acid, X10 is Y or no amino acid, X11 is L, Y, N, or W or no amino acid, X12 is M, F, or D, X13 is D, P, or A or no amino acid, and X14 is F, Y, or V; and b) each immunoglobulin light chain variable domain of the anti-NKG2C agent comprises first, second, and third light chain CDRs, where the first light chain CDR (CDRL1) comprises an amino acid sequence that
is at least 80 % identical to the amino acid sequence X
7 8 9 0 3 5 6 7 (SEQ ID NO: 53), where X1 is S or K, X2 is A or S, X4 is Q or S, X7 is D, L, S, or no amino acid, X8 is Y or no amino acid, X9 is D, S, or no amino acid, X10 is G, S, or no amino acid, X11 is D, N, or no amino acid, X12 is Q or no amino acid, X13 is K or no amino acid, X14 is S or N, X15 is Y or D, X16 is M, L, or V; and X17 is Y, N, A or G,; the second light chain CDR (CDRL2) comprises an amino acid sequence that is at least 80% identical to the amino acid sequence X1X2SX4X5X6X7 (SEQ ID NO: 54), where X1 is G, A, R, W, or Y, X2 is A or T, X4 is N or T, X5 is L or R, X6 is E or Y or A, and X7 is S or T; and the third light chain CDR (CDRL3) comprises an amino acid sequence that is at least 80% identical to the amino acid sequence
where X1 is Q or H, X2 is Q or H, X3 is S, Y, D, or no amino acid, X4 is N, H, or Y, X5 is E, S, or L, X6 is D, V, Y, or S, X7 is P or S, and X8 is L, Y, or H. Also provided in certain aspects is a first anti-NKG2C agent that binds NKG2C under laboratory or physiological conditions, where the first agent competitively binds with a second anti-NKG2C agent, which the second agent comprises at least one immunoglobulin heavy chain variable domain and at least one immunoglobulin light chain variable domain, where a) each immunoglobulin heavy chain variable domain of the anti-NKG2C agent comprises first, second, and third heavy chain complementarity determining regions (CDRs), where the first heavy chain CDR (CDRH1) comprises an amino acid sequence that is at least 80% identical to the amino acid sequence X1X2X3X4X5 (SEQ ID NO: 50), where X1 is N, S, or D, X2 is F, T, or Y, X3 is G, Y, or W X4 is M or I, and X5 is H or N; the second heavy chain CDR (CDRH2) comprises an amino acid sequence that is at least 80% identical to the amino acid sequence X
51), where X1 is Y, R, W, or M, X3 is S, D, or H, X4 is S or P, X5 is G, E, A, or S, X6 is S, N, or D, X7 is S, G, or D, X8 is T, S, N, Y, D, or E, X9 is I or T, X10 is Y, K, E, or R, X11 is Y or L, X12 is A, R, D, or N, X13 is D, P, or Q, X14 is T or K, X15 is V, L, M, or F, X16 is K or Q, and X17 is G or D; the third heavy chain CDR (CDRH3) comprises an amino acid sequence that is at least 80% identical to the amino acid sequence X
NO: 52), where X1 is S, T, V or H, X2 is V, A, I, or H or Y, X3 is I, T, H, or G, X4 is Y, V, T, or S, X5 is Y, F, H, or N, X6 is A, D, W, or Y, X7 is Y, G, or no amino acid, X8 is D or no amino acid, X9 is R or no amino acid, X10 is Y or no amino acid, X11 is L, Y, N, or W or no amino acid, X12 is M, F, or D, X13 is D, P, or A or no amino acid, and X14 is F, Y, or V; and b) each immunoglobulin light chain variable domain of the anti-NKG2C agent comprises first, second, and third light chain CDRs, where the first light chain CDR (CDRL1) comprises an amino acid sequence that is at least 80 % identical to the amino acid sequence X
(SEQ ID NO: 53), where X1 is S or K, X2 is A or S, X4 is Q or S, X7 is D, L, S, or no amino acid, X8 is Y or no amino acid, X9 is D, S, or no amino acid, X10 is G, S, or no amino acid, X11 is D, N, or no amino acid, X12 is Q or no amino acid, X13 is K or no amino acid, X14 is S or N, X15 is Y or D, X16 is M, L, or V;
and X17 is Y, N, A or G,; the second light chain CDR (CDRL2) comprises an amino acid sequence that is at least 80% identical to the amino acid sequence X1X2SX4X5X6X7 (SEQ ID NO: 54), where X1 is G, A, R, W, or Y, X2 is A or T, X4 is N or T, X5 is L or R, X6 is E or Y or A, and X7 is S or T; and the third light chain CDR (CDRL3) comprises an amino acid sequence that is at least 80% identical to the amino acid sequence X1X2X3X4X5X6X7X8T (SEQ ID NO: 55), where X1 is Q or H, X2 is Q or H, X3 is S, Y, D, or no amino acid, X4 is N, H, or Y, X5 is E, S, or L, X6 is D, V, Y, or S, X7 is P or S, and X8 is L, Y, or H. Also provided in certain aspects is a first anti-NKG2C agent that binds NKG2C under laboratory or physiological conditions, where the first agent binds to the same epitope as a second anti-NKG2C agent, which the second agent comprises at least one immunoglobulin heavy chain variable domain and at least one immunoglobulin light chain variable domain, where a) each immunoglobulin heavy chain variable domain of the anti-NKG2C agent comprises first, second, and third heavy chain complementarity determining regions (CDRs), where the first heavy chain CDR (CDRH1) comprises an amino acid sequence that is at least 80% identical to the amino acid sequence X1X2X3X4X5 (SEQ ID NO: 50), where X1 is N, S, or D, X2 is F, T, or Y, X3 is G, Y, or M, X4 is M or I, and X5 is H or N; the second heavy chain CDR (CDRH2) comprises an amino acid sequence that is at least 80% identical to the amino acid sequence X1IX3X4X5X6X7X8X9X10X11X12X13X14X15X16X17 (SEQ ID NO: 51), where X1 is N, S, or D, X2s F, T, or Y, X3 is G, Y, or W X4 is M or I, and X5 is H or N; the second heavy chain CDR (CDRH2) comprises an amino acid sequence that is at least 80% identical to the amino acid sequence X1IX3X4X5X6X7X8X9X10X11X12X13X14X15X16X17 (SEQ ID NO: 51), where X1 is Y, R, W, or M, X3 is S, D, or H, X4 is S or P, X5 is G, E, A, or S, X6 is S, N, or D, X7 is S, G, or D, X8 is T, S, N, Y, D, or E, X9 is I or T, X10 is Y, K, E, or R, X11 is Y or L, X12 is A, R, D, or N, X13 is D, P, or Q, X14 is T or K, X15 is V, L, M, or F, X16 is K or Q, and X17 is G or D; the third heavy chain CDR (CDRH3) comprises an amino acid sequence that is at least 80% identical to the amino acid sequence X1X2X3X4X5X6X7X8X9X10X11X12X13X14 (SEQ ID NO: 52), where X1 is S, T, V or H, X2 is V, A, I, or H or Y, X3 is I, T, H, or G, X4 is Y, V, T, or S, X5 is Y, F, H, or N, X6 is A, D, W, or Y, X7 is Y, G, or no amino acid, X8 is D or no amino acid, X9 is R or no amino acid, X10 is Y or no amino acid, X11 is L, Y, N, or W or no amino acid, X12 is M, F, or D, X13 is D, P, or A or no amino acid, and X14 is F, Y, or V; and b) each immunoglobulin light chain variable domain of the anti-NKG2C agent comprises first, second, andhird light chain CDRs, where the first light chain CDR (CDRL1) comprises an amino acid sequence thats at least 80 % identical to the amino acid sequence X1X2SX4SVX7X8X9X10X11X12X13X14X15X16 X17 (SEQ ID NO: 53), where X1 is S or K, X2 is A or S, X4 is Q or S, X7 is D, L, S, or no amino acid, X8 is Y or no amino acid, X9 is D, S, or no amino acid, X10 is G, S, or no amino acid, X11 is D, N, or no amino acid, X12 is Q or no amino acid, X13 is K or no amino acid, X14 is S or N, X15 is Y or D, X16 is M, L, or V; and X17 is Y, N, A or G,; the second light chain CDR (CDRL2) comprises an amino acid sequence that is
at least 80% identical to the amino acid sequence
7 (SEQ ID NO: 54), where X1 is G, A, R, W, or Y, X2 is A or T, X4 is N or T, X5 is L or R, X6 is E or Y or A, and X7 is S or T; and the third light chain CDR (CDRL3) comprises an amino acid sequence that is at least 80% identical to the amino acid sequence
T (SEQ ID NO: 55), where X1 is Q or H, X2 is Q or H, X3 is S, Y, D, or no amino acid, X4 is N, H, or Y, X5 is E, S, or L, X6 is D, V, Y, or S, X7 is P or S, and X8 is L, Y, or H. Also provided in certain aspects are anti-NKG2C agents for detecting NKG2C in a heterogeneous population of immune cells, where NKG2C is detected at a significant level in NK cells and NK T- lymphocytes in the population, and NKG2C is not significantly detected in other immune cells in the population. Also provided in certain aspects are methods of detecting NKG2C is a heterogeneous population of immune cells, comprising contacting the population with an anti-NKG2C agent provided herein, wherein NKG2C is not significantly detected in other immune cells in the population. In one aspect, provided herein are isolated, non-naturally occurring anti-NKG2C agents, particularly antibodies, or antigen-binding fragments or derivatives thereof, that bind NKG2C under physiological conditions. In the context of anti-NKG2C antibodies or antigen-binding fragments, such molecules generally comprise two immunoglobulin heavy chain variable domains and two immunoglobulin light chain variable domains. In such molecules, each of the immunoglobulin heavy and light chain variable domains comprise first, second, and third complementarity determining regions (CDRs) arrayed as follows: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4. In the heavy chain variable domain portions, the first heavy chain CDR (CDRH1) comprises an amino acid sequence that has a sequence identity of at least 65%, optionally a sequence identity of at least 80%, at least 90%, at least 95%, and 100% identity with the amino acid sequence DYYMH, SFGMH, NFGMH, DTYIH, NYWMN, and DTYMH (SEQ ID NOS: 17, 23, 29, 33, 39, 45, respectively), the second heavy chain CDR (CDRH2) comprises an amino acid sequence that has a sequence identity of at least 65%, optionally a sequence of at least 80%, at least 90%, at least 95%, and 100% identity with the amino acid sequence
Y
RIDPANGYTKYDPKFQG (SEQ ID NOS: 18, 24, 30, 34, 40, 46, 49, respectively), and the third heavy chain CDR (CDRH3) comprises an amino acid sequence that has a sequence identity of at least 65%, optionally a sequence identity of at least 80%, at least 90%, at least 95%, and 100% identity with the amino acid sequence HYHYNDPY, SVIYYDYDRYLMDY, SVIYYAYDRYLMDF, TATVFWYFDV, SHGSNYGWFAY, and VITTHWYFDV (SEQ ID NOS: 19, 25, 31, 35, 41, 47, respectively).
In the light chain variable domain portions, the first light chain CDR (CDRL1) comprises an amino acid sequence that has a sequence identity of at least 65%, optionally a sequence identity of at least 80%, at least 90%, at least 95%, and 100% identity with the amino acid sequence SASSSVSYMY, KASQSVDYDGDSYMN, KSSQSVLYSSNQKNYLA, and KASQSVSNDVG (SEQ ID NOS: 20, 26, 36, 42, respectively) the second light chain CDR (CDRL2) comprises an amino acid sequence that has a sequence identity of at least 65%, optionally a sequence of at least 80%, at least 90%, at least 95%, and 100% identity with the amino acid sequence RTSNLAS, AASNLES, GASNLES, WASTRES, and YASNRYT (SEQ ID NOS: 21, 27, 32, 37, 43, respectively), and the third light chain CDR (CDRL3) comprises an amino acid sequence that has a sequence identity of at least 65%, optionally a sequence identity of at least 80%, at least 90%, at least 95%, and 100% identity with the amino acid sequence QHYHSYPYT, QQSNEDPLT, QQSNEVPLT, HQYLSSHT, and QQDYSSPLT (SEQ ID NOS: 22, 28, 38, 44, 48, respectively). In some embodiments, the isolated, non-naturally occurring anti-NKG2C antibodies, or NKG2C-binding fragments thereof, including a first heavy chain CDR having the amino acid sequence NFGMH (SEQ ID NO: 29), the second heavy chain CDR has the amino acid sequence YISSGSSSIYYADTMKG (SEQ ID NO: 34), the third heavy chain CDR has the amino acid sequence SVIYYDYDRYLMDY (SEQ ID NO: 25), the first light chain CDR has the amino acid sequence KASQSVDYDGDSYMN (SEQ ID NO: 26) the second light chain CDR has the amino acid sequence GASNLES (SEQ ID NO: 32), and the third light chain CDR has the amino acid sequence QQSNEVPLT (SEQ ID NO: 38). In some embodiments, the isolated anti-NKG2C agent comprises a non-naturally occurring anti-NKG2C antibody (mAb) comprising two immunoglobulin heavy chain variable domains comprising first, second, and third heavy chain complementarity determining regions (CDRH1-3, respectively) and two immunoglobulin light chain variable domains comprising first, second, and third light chain complementarity determining regions (CDRL1-3, respectively). In some embodiments the antibody comprises immunoglobulin heavy chain variable domains and immunoglobulin light chain variable domains having sets of CDRH1-3 and CDRL1-3 selected from the sequences set forth in Table 1.
In some embodiments, the isolated anti-NKG2C agent comprises a non-naturally occurring anti-NKG2C antibody (mAb) comprising two immunoglobulin heavy chain variable domains and two immunoglobulin light chain variable domains, where the immunoglobulin heavy chain variable domains have an amino acid sequence selected from amongst SEQ ID NOs: 1-3 and 5-8 or an amino acid sequence having at least 65%-95% or more sequence identity with any such heavy chain variable domain sequence and the immunoglobulin light chain variable domains are selected from amongst SEQ ID NOS: 9-11 and 13-16 or
an amino acid sequence having at least 65%-95% or more sequence identity with any such immunoglobulin light chain variable domain sequence. In some embodiments, where the anti-NKG2C agents are antibodies, or antigen-binding antibody fragments thereof, the antibodies (or fragments thereof) are monoclonal antibodies, and may be camel, human, humanized, mouse, rabbit, or other mammalian antibodies or antigen-binding antibody fragments. In some embodiments, the antibody (antigen-binding antibody fragment) is an IgG. In other embodiments, the IgG is an IgG1, IgG2a or IgG2b, or IgG3, or IgG4. In certain embodiments of anti-NKG2C antibodies and antigen-binding antibody fragments that are other than fully human antibodies (i.e., antibodies produced or derived from a mammal capable of producing all or a portion of the human antibody repertoire), the molecules are chimeric or humanized anti-NKG2C antibodies and antigen-binding antibody fragments. In some embodiments, the anti-NKG2C antibody, antigen-binding antibody fragment, or derivative or variant thereof includes a detectable label. In some embodiments, the anti-NKG2C agent, for example, an anti-NKG2C antibody, antigen-binding antibody fragment, or derivative or variant thereof, is part of immunoconjugate that further includes a cytotoxic agent, for example, a nucleic acid, a peptide, a polypeptide, a small molecule, or an aptamer. A related aspect of technology described herein concerns compositions that include an anti-NKG2C agent that is an isolated, non-naturally occurring anti-NKG2C antibody or antigen-binding antibody fragment according to the technology described herein. In addition to containing an anti-NKG2C antibody or an antigen-binding antibody fragment described herein, such compositions typically also include a carrier, for example, a pharmaceutically acceptable carrier. Such compositions may be packaged in containers, which in some embodiments, are further packaged into kits that also include instructions for use. In the context of pharmaceutical compositions, such kit instructions are a package insert containing not only instructions or use but also information about the pharmaceutically active ingredient (e.g., the anti- NKG2C antibody, antigen-binding antibody fragment, or derivative or variant thereof). Another related aspect concerns diagnostics configured to detect NKG2C in a biological sample, often a biological sample taken from a subject. Such kits include a diagnostic reagent that includes an anti- NKG2C agent described herein, for example, an anti-NKG2C antibody, antigen-binding antibody fragment, or derivative or variant thereof conjugated with detectable reagents such as fluorophores or enzyme substrates and/or immobilized on a solid support.
Still other aspects of the technology provided herein concern the manufacture of an anti-NKG2C agent described herein. In the context of anti-NKG2C antibodies (or antigen-binding antibody fragments or derivatives or variants thereof), one such aspect concerns isolated nucleic acid molecules that encode polypeptides provided herein. In some embodiments, such nucleic acid molecules encode an immunoglobulin heavy chain variable domain having a first heavy chain CDR (CDRH1) that includes an amino acid sequence that has a sequence identity of at least 65%, optionally a sequence identity of at least 80%, at least 90%, at least 95%, and 100% identity with the amino acid sequence 65%, optionally a sequence identity of at least 80%, at least 90%, at least 95%, and 100% identity with the amino acid sequence DYYMH, SFGMH, NFGMH, DTYIH, NYWMN, and DTYMH (SEQ ID NOS: 17, 23, 29, 33, 39, 45, respectively), the second heavy chain CDR (CDRH2) comprises an amino acid sequence that has a sequence identity of at least 65%, optionally a sequence of at least 80%, at least 90%, at least 95%, and 100% identity with the amino acid sequence WIDPENDDTEYAPKFQG, YISSGSSTIYYRDTLKG, YISSGSSTIYYADTVKG, YISSGSSSIYYADTMKG, RIDPENGNTKYDPKFQG, MIHPSDSETRLNQKFKD, RIDPANGYTKYDPKFQG (SEQ ID NOS: 18, 24, 30, 34, 40, 46, 49, respectively), and the third heavy chain CDR (CDRH3) comprises an amino acid sequence that has a sequence identity of at least 65%, optionally a sequence identity of at least 80%, at least 90%, at least 95%, and 100% identity with the amino acid sequence HYHYNDPY, SVIYYDYDRYLMDY, SVIYYAYDRYLMDF, TATVFWYFDV, SHGSNYGWFAY, and VITTHWYFDV (SEQ ID NOS: 19, 25, 31, 35, 41, 47, respectively). Such nucleic acids may also encode an immunoglobulin light chain variable domain where a first light chain CDR (CDRL1) that includes an amino acid sequence that has a sequence identity of at last 65%, optionally a sequence identity of at least 80%, at least 90%, at least 95%, and 100% identity with the amino acid sequence SASSSVSYMY, KASQSVDYDGDSYMN, KSSQSVLYSSNQKNYLA, and KASQSVSNDVG (SEQ ID NOS: 20, 26, 36, 42, respectively), a second light chain CDR (CDRL2) that includes an amino acid sequence that has a sequence identity of at least 65%, optionally a sequence of at least 80%, at least 90%, at least 95%, and 100% identity with the amino acid sequence RTSNLAS, AASNLES, GASNLES, WASTRES, and YASNRYT (SEQ ID NOS: 21, 27, 32, 37, 43, respectively), and the third light chain CDR (CDRL3) comprises an amino acid sequence that has a sequence identity of at least 65%, optionally a sequence identity of at least 80%, at least 90%, at least 95%, and 100% identity with the amino acid sequence QHYHSYPYT, QQSNEDPLT, QQSNEVPLT, HQYLSSHT, and QQDYSSPLT (SEQ ID NOS: 22, 28, 38, 44, 48, respectively). In certain embodiments, nucleic acid molecules provided herein encode an immunoglobulin heavy chain variable domain having an amino acid sequence selected from among SEQ ID NOS: 1-3 and 5-8 or an amino acid sequence having at least 65%-95% or more sequence identity with any such heavy chain variable domain sequence and an immunoglobulin light chain variable domain having an amino acid
sequence selected from among SEQ ID NOS: 9-11 and 13-16 or an amino acid sequence having at least 65%-95% or more sequence identity with any such light chain variable domain sequence. Related aspects concern plasmids, and expression cassettes and vectors, that carry nucleic acids provided herein, as well as recombinant host cells transfected with such nucleic acid molecules. Still other aspects of the technology provided herein concern methods of treating or preventing a disease or disorder associated with aberrant levels of NKG2C. Such methods include administering to a subject in need of such treatment an anti-NKG2C agent provided herein (e.g., an anti-NKG2C antibody or antigen-binding fragment, derivative, or variant thereof) in an amount sufficient to effect treatment, thereby treating or preventing the disease or disorder. In certain instances, an anti-NKG2C agent provided herein (e.g., an anti-NKG2C antibody or antigen-binding fragment, derivative, or variant thereof) may be used as an adjuvant or in conjunction with an adjuvant (e.g., for vaccines). Further aspects of the technology provided herein concern diagnostic methods of using an anti-NKG2C agent provided herein, for example, in vitro or in vivo diagnostic assays to detect the presence of NKG2C. Certain embodiments are described further in the following description, examples, claims, and drawings. Brief Description of the Drawings The drawings illustrate certain embodiments of the technology and are not limiting. For clarity and ease of illustration, the drawings are not made to scale and, in some instances, various aspects may be shown exaggerated or enlarged to facilitate an understanding of particular embodiments. Fig.1 shows the amino acid sequence of a representative full-length human NKG2C protein (SEQ ID NO: 56). The amino acid residues 1-70 comprise the cytoplasmic domain, amino acid residues 71-93 comprise the transmembrane domain, and amino acid residues 94-231 comprise the extracellular domain. See, e.g., NCBI Reference Sequence: NP_002251.2. Figs.2A-2B shows the amino acid sequences of the variable domains of the immunoglobulin heavy (SEQ ID NOS: 1-3 and 5-8) and light (SEQ ID NOS: 9-11 and 13-16) chains of the eight different anti-NKG2C antibodies (AB1-8) provided herein. The CDR regions of each of the heavy and light chains are shown in bold and underline. In each of the alignments, three characters (“*”, “:”, and “.”) are used: “*” indicates positions that have a single, fully conserved residue; “:” indicates that one of the following “strong” residue groups is fully conserved: STA; NEQK; NHQK; NDEQ; QHRK; MILV; MILF; HY; and FYW; and “.” indicates that one of the following “weaker” residue groups is fully conserved: CSA; ATV; SAG; STNK; STPA; SGND; SNDEQK; NDEQHK; NEQHRK; FVLIM; and HFY. These are all the positively
scoring residue groups that occur in the Gonnet Pam250 matrix. The “strong” and “weak” residue groups are defined as “strong” score > 0.5 and “weak” score < 0.5, respectively. Fig.3 lists the source, isotype and format for the anti-NKG2C agents described herein. Figs.4A-4D depict the gating strategy used for the detection of cells expressing NKG2C, as assessed by flow cytometry. FIG.4A shows the identification of singlets based on side scatter. FIG.4B shows the forward and side scatter of singlets from FIG.4A. FIG.4C shows lymphocytes co-stained with CD3 and CD19. FIG.4D shows CD3+CD19- lymphocytes co-stained with CD4 and CD8. Figs.5A and 5B, depict results for surface expression of NKG2C on lymphocytes co-stained with CD56 and AB5. FIG.5A depicts a dot plot showing lymphocytes co-stained with AB5 and CD56. FIG.5B shows a histogram of lymphocytes stained with AB5. Figs.6A-6D depict dot plots of total lymphocytes (FIG.6A and FIG.6B) and CD3-CD19- lymphocytes (FIG.6C and FIG.6D) co-stained with CD56 and AB5 (FIG.6A A and FIG.6C) and CD56 and ABI (FIG.6B and FIG.6D). Figs.7A-7F depict histograms showing the staining of subsets of CD3+CD19- lymphocytes with AB5 (FIGs.7A-7C) and Commercial ABI (FIGs.7D-7F). Figs.8A-8P, depict dot plots of total lymphocytes (FIGs.8A-8H) co-stained with CD94 and AB1 (FIG. 8A), AB2 (FIG.8B), AB3 (FIG.8C), AB4 (FIG.8 D), AB5 (FIG.8E), AB6 (FIG.8F), AB7 (FIG.8G), or AB8 (FIG.8H), and CD3-CD19- lymphocytes co-stained with CD56 and AB1 (FIG.8I), AB2 (FIG. 8J), AB3 (FIG.8K), AB4 (FIG.8L), AB5 (FIG.8M), AB6 (FIG.8N), AB7 (FIG.8O), or AB8 (FIG.8P). Figs.9A-9D depict histograms of mouse splenocytes stained with AB3 (FIG.9A), AB4 (Fig.9B), AB5 (Fig.9C), and AB6 (Fig.9D). Figs.10A and 10B, depict results of the ability of the anti-NKG2C antibodies described herein to mediate cell toxicity. Fig.10A depicts the percent of DAPI positive cells in a population of purified primary NK and K562 cells at different effector to target ratios (E:T), with no effector used as control. Fig.10B depicts the percent of DAPI positive cells after treatment with AB1-AB8 antibodies or no-antibody at 10µg/well at an E:T of 2:1, or T only as control. Detailed Description Provided herein are agents that bind NKG2C. In some aspects, the agents that bind NKG2C are antibodies or fragments thereof or antigen binding fragments thereof, that bind to NKG2C. In some embodiments, particular monoclonal antibodies to NKG2C that provide superior target specificity, signal-to-noise ratios,
and the like, as compared to other reported anti-NKG2C antibodies, as well as antigen-binding fragments of such antibodies that bind NKG2C, are provided herein. Also provided herein are methods for producing anti-NKG2C agents, particularly anti-NKG2C antibodies, with desirable properties including affinity and/or specificity for NKG2C and/or its variants. NKG2 (Killer Cell Lectin-Like Receptor), also known as Cluster of Differentiation 159 (CD159), is a family of type II transmembrane protein receptors. The human NKG2 family comprises seven members referred to as NKG2A, NKG2B, NKG2C, NKG2D, NKG2E, NKG2F, and NKG2H. With the exception of NKG2D, all other NKG2 members share substantial sequence homology. NKG2A, NKG2B, NKG2C, NKG2E and NKG2H have been shown to form disulfide-linked heterodimers with the invariant Cluster of Differentiation 94 (CD94) protein, to form functionally distinct heterodimeric receptors. The CD94 associated NKG2 family members (CD94/NKG2) are comprised of C-type lectin receptors that are predominantly expressed on the surface of NK cells, as well as a subset of CD8 + T-lymphocytes. Although the human CD94/NKG2 family has been found to recognize and interact with the same ligand, Human Leukocyte Antigen (HLA)-E, on target cells, different receptor family members can transmit opposing signals via their intracellular domains. While the NKG2A and NKG2B receptors contain immunoreceptor tyrosine-based inhibition motifs (ITAM) and transmit inhibitory signals, in contrast, the NKG2C, NKG2D, NKG2E, and NKG2H receptors are characterized by the presence of a charged amino acid residue in the transmembrane domain mediating interaction with DAP- 12, an adapter molecule containing an immunoreceptor tyrosine-based activation motif (ITAM), that transmit activating signals. The murine CD94-NKG2 receptors recognize the class Ib molecule Qa-1b. The CD94/NKG2C heterodimer is found on the surface of Natural Killer (NK) cells, a subset of T cells, including αβ T cells and memory T cells. Binding to the HLA-E receptor delivers activating signals through immunoreceptor tyrosine-based activation motifs at the cytoplasmic tails of DAP12 transmembrane proteins (Call et al. Nat. Immunol 2010, 11:1023-9). Anti-NKG2C Agents The anti-NKG2C agents (e.g., anti-NKG2C antibodies) provided herein may have a strong binding affinity and/or specificity for NKG2C. In some embodiments, the anti-NKG2C agents provided herein bind all or a portion of the NKG2C receptor, or a fragment thereof. In some embodiments, the antibody or antigen-binding fragment thereof provided herein bind the NKG2C receptor or a fragment thereof. In some embodiments, the anti-NKG2C agents provided herein bind a portion of the NKG2C receptor that is 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:56. In
some embodiments, the antibody or antigen-binding fragment thereof provided herein bind the NKG2C receptor or a fragment thereof that is 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:56. In some embodiments, the anti-NKG2C agents provided herein bind all or a portion of the NKG2C receptor described in SEQ ID NO:56. In some embodiments, the antibody or antigen-binding fragment thereof provided herein bind the NKG2C receptor or a fragment thereof comprising the sequence of amino acids described in SEQ ID NO:56. Precursor human NKG2C protein sequence (UniProtKB - P26717 (NKG2C_HUMAN)/ NCBI Reference Sequence: NP_002251.2) (SEQ ID NO: 56) MDNQGVIYSD LNLPPNPKRQ QRKPKGNKNS ILATEQEITYAELNLQKASQDFQG NDKTYHCKDLPSAPEK LIVGILGIIC LILMASVVTI VVIPSTLIQR HNNSSLNTRT QKARHCGHCPEEWITYSNSC YYIGKERRTW EESLLACTSK NSSLLSIDNE EEMKFLSIIS PSSWIGVFRNSSHHPWVTMN GLAFKHEIKD SDNAELNCAV LQVNRLKSAQ CGSSIIYHCK HKL In some embodiments, the human NKG2C protein sequence comprises a cytoplasmic domain, a transmembrane domain, and an extracellular domain. In some embodiments, the human NKG2C protein sequence comprises a cytoplasmic domain corresponding to amino acid residues 1-70 of SEQ ID NO:56. In some embodiments, the cytoplasmic domain corresponds to the sequence of amino acids of SEQ ID NO:96. In some embodiments, the human NKG2C protein sequence comprises a transmembrane domain corresponding to amino acid residues 71- 93 of SEQ ID NO:56. In some embodiments, the transmembrane domain corresponds to the sequence of amino acids of SEQ ID NO:97. In some embodiments, the human NKG2C protein sequence comprises an extracellular domain corresponding to amino acid residues 94-231 of SEQ ID NO:56. In some embodiments, the extracellular domain corresponds to the sequence of amino acids of SEQ ID NO:98. In some embodiments, the anti-NKG2C agents provided herein bind all or a portion of the NKG2C receptor extracellular domain. In some embodiments, the anti-NKG2C agents provided herein bind all or a portion of the NKG2C receptor extracellular domain corresponding to amino acid residues 94-231 of SEQ ID NO:56. In some embodiments, the anti-NKG2C agents provided herein bind all or a portion of the NKG2C receptor extracellular domain described in SEQ ID NO:98.
In some embodiments, the anti-NKG2C agents provided herein bind all or a portion of the NKG2C receptor extracellular domain that is 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid residues 94-231 of SEQ ID NO:56. In some embodiments, the anti-NKG2C agents provided herein bind all or a portion of the NKG2C receptor extracellular domain that is 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:98. In some embodiments, the agent, antibody or antigen-binding fragment thereof provided herein bind the NKG2C receptor extracellular domain described in SEQ ID NO:98. In some embodiments, anti-NKG2C agents may be chimeric antibodies. In some embodiments, anti- NKG2C agents may be humanized antibodies. In some embodiments, anti-NKG2C agents may be variant antibodies. Antibodies, for example, may have beneficial properties from a therapeutic perspective. Assays for determining the activity of anti-NKG2C antibodies provided herein include, for example, cell-based ELISA (e.g., to measure relative avidity of the antibody for the target on cells), flow cytometry (e.g., to measure cell specificity of the antibody), and cytotoxicity (e.g., to measure potential to mediate direct or indirect killing of NKG2C-expressing target cells). In certain instances, a humanized or variant antibody fails to elicit an immunogenic response upon administration of a therapeutically effective amount of the antibody to a human patient. In certain instances, if an immunogenic response is elicited, the response may be such that the antibody still provides a therapeutic benefit to the patient treated therewith. In some embodiments, the anti-NKG2C agents (e.g., anti-NKG2C antibodies, humanized anti-NKG2C antibodies) provided herein bind the same epitope. To screen for antibodies that bind to an epitope on NKG2C bound by an antibody of interest (e.g., those that block binding of the antibody to NKG2C), a cross-blocking assay such as that described in Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory, Ed Harlow and David Lane (1988), can be performed. In certain instances, epitope mapping, e.g. as described in Champe et al., J. Biol. Chem.270:1388-1394 (1995), in Cunningham and Wells, Science 244:1081 – 1085 (1989) or in Davidson and Doranz, Immunology 143: 13 – 20 (2014), can be performed to determine whether the antibody binds an epitope of interest. In some embodiments, the anti-NKG2C agents provided herein may include anti- NKG2C antibodies, anti-NKG2C antibody fragments (e.g.,anti-NKG2C antigen binding fragments), and anti-NKG2C antibody derivatives. In some embodiments, the agent is isolated (e.g., separated from a component of its natural environment (e.g. an animal, a biological sample)). In some embodiments, the agent is non- naturally occurring (e.g., produced by human intervention). In some embodiments, the agent is a humanized antibody, or an antigen binding fragment thereof. In some embodiments, the agent is a
derivative of a humanized antibody that binds NKG2C. In some embodiments, the agent binds NKG2C under laboratory conditions (e.g., binds NKG2C in vitro, binds NKG2C in a flow cytometry assay, binds NKG2C in an ELISA). In some embodiments, the agent binds NKG2C under physiological conditions (e.g., binds NKG2C in a cell in a subject). Antibodies such as those described herein, may have an immunoglobulin heavy chain variable domain comprising an amino acid sequence represented by the formula: FRH1-CDRH1-FRH2-CDRH2-FRH3- CDRH3-FRH4, where “FRH1-4” represent the four heavy chain framework regions and “CDRH1-3” represent the three hypervariable regions of an anti-NKG2C antibody variable heavy domain. FRH1-4 may be derived from a consensus sequence (for example the most common amino acids of a class, subclass or subgroup of heavy or light chains of human immunoglobulins) or may be derived from an individual human antibody framework region or from a combination of different framework region sequences. Many human antibody framework region sequences are compiled in Kabat et al. (1992) SEQUENCES OF PROTEINS OF IMMUNOLOGICAL INTEREST, National Institutes of Health Publication No.91-3242, for example. In one embodiment, the variable heavy FR is provided by a consensus sequence of a human immunoglobulin subgroup as compiled by Kabat et al., supra. The human variable heavy FR sequence may have substitutions therein, e.g. where the human FR residue is replaced by a corresponding nonhuman residue (by “corresponding nonhuman residue” is meant the nonhuman residue with the same Kabat positional numbering as the human residue of interest when the human and nonhuman sequences are aligned), but replacement with the nonhuman residue is not necessary. For example, a replacement FR residue other than the corresponding nonhuman residue may be selected by phage display. Antibodies such as those described herein, may have an immunoglobulin light chain variable domain comprising an amino acid sequence represented by the formula: FRL1-CDRL1-FRL2-CDRL2-FRL3- CDRL3-FRL4, where “FRL1-4” represents the four framework regions and “CDRL1-3” represents the three hypervariable regions of an anti-NKG2C antibody variable light domain. FRL1-4 may be derived from a consensus sequence (for example the most common amino acids of a class, subclass or subgroup of heavy or light chains of human immunoglobulins) or may be derived from an individual human antibody framework region or from a combination of different framework region sequences. In some embodiments, the immunoglobulin variable light FR is provided by a consensus sequence of a human immunoglobulin subgroup as compiled by Kabat et al., supra.
The human immunoglobulin variable light FR sequence may have substitutions therein, e.g. where the human FR residue is replaced by a corresponding mouse residue, but replacement with the nonhuman residue is not necessary. For example, a replacement residue other than the corresponding nonhuman residue may be selected by phage display. Methods for generating humanized anti-NKG2C antibodies of interest herein are elaborated in more detail below. Generally, the anti-NKG2C agent provided herein comprises at least one immunoglobulin heavy chain variable domain and at least one immunoglobulin light chain variable domain. In some embodiments, an anti-NKG2C agent herein comprises two immunoglobulin heavy chain variable domains and two immunoglobulin light chain variable domains. Typically, each immunoglobulin heavy chain variable domain of the anti-NKG2C agent comprises first, second, and third heavy chain complementarity determining regions (CDRs; CDRH1, CDRH2, CDRH3), and each immunoglobulin light chain variable domain of the anti-NKG2C agent comprises first, second, and third light chain CDRs (DCRL1, CDRL2, CDRL3). CDRH1 In some embodiments, the first heavy chain CDR (CDRH1) of an anti-NKG2C agent provided herein comprises an amino acid sequence that is at least 80% identical to the amino acid sequence X1X2X3X4X5 (SEQ ID NO: 50), X1 is N, S, or D, X2 is F, T, or Y, X3 is G, Y, or W X4 is M or I, and X5 is H or N. In some embodiments, the CDRH1 comprises and amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 50. In some embodiments, the CDRH1 comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 50. In some embodiments, the CDRH1 comprises an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 50. In some embodiments, the CDRH1 comprises the sequence of amino acids set forth in SEQ ID NO:50. The amino acid X1 of SEQ ID NO: 50 may be substituted with any amino acid. In some embodiments, the amino acid X1 of SEQ ID NO: 50 is substituted with a conservative amino acid (e.g., conservative to N, S, and/or D). In some embodiments, the amino acid X1 of SEQ ID NO: 50 is substituted with a neutral amino acid. In some embodiments, the amino acid X1 of SEQ ID NO: 50 is substituted with a hydrophilic amino acid. In some embodiments, the amino acid X1 of SEQ ID NO: 50 is substituted with an acidic amino acid. The amino acid X2 of SEQ ID NO: 50 may be substituted with any amino acid. In some embodiments, the amino acid X2 of SEQ ID NO: 50 is substituted with a conservative amino acid (e.g., conservative to
F, T, and/or Y). In some embodiments, the amino acid X2 of SEQ ID NO: 50 is substituted with an aromatic amino acid. In some embodiments, the amino acid X2 of SEQ ID NO: 50 is substituted with a hydrophilic amino acid. The amino acid X3 of SEQ ID NO: 50 may be substituted with any amino acid. In some embodiments, the amino acid X3 of SEQ ID NO: 50 is substituted with a conservative amino acid (e.g., conservative to G, Y, and/or W). In some embodiments, the amino acid X3 of SEQ ID NO: 50 is substituted with an amino acid that influences chain orientation. In some embodiments, the amino acid X3 of SEQ ID NO: 50 is substituted with an aromatic amino acid. In some embodiments, the amino acid X3 of SEQ ID NO: 50 is substituted with a hydrophobic amino acid. The amino acid X4 of SEQ ID NO: 50 may be substituted with any amino acid. In some embodiments, the amino acid X4 of SEQ ID NO: 50 is substituted with a conservative amino acid (e.g., conservative to M and/or I). In some embodiments, the amino acid X4 of SEQ ID NO: 50 is substituted with a hydrophobic amino acid. The amino acid X5 of SEQ ID NO: 50 may be substituted with any amino acid. In some embodiments, the amino acid X5 of SEQ ID NO: 50 is substituted with a conservative amino acid (e.g., conservative to H and/or N). In some embodiments, the amino acid X5 of SEQ ID NO: 50 is substituted with a basic amino acid. In some embodiments, the amino acid X5 of SEQ ID NO: 50 is substituted with a neutral hydrophilic amino acid. In some embodiments, the CDRH1 of any of the anti-NKG2C agent provided herein comprises an amino acid sequence chosen from DYYMH (SEQ ID NO: 17), SFGMH (SEQ ID NO: 23), NFGMH (SEQ ID NO: 29), DTYIH (SEQ ID NO: 33), NYWMN (SEQ ID NO: 39), and DTYMH (SEQ ID NO: 45). In some embodiments, the CDRH1 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids DYYMH (SEQ ID NO: 17), or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:17. In some embodiments, the CDRH1 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids DYYMH (SEQ ID NO: 17). In some embodiments, the CDRH1 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids SFGMH (SEQ ID NO: 23), or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:23. In some embodiments, the CDRH1 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids SFGMH (SEQ ID NO: 23).
In some embodiments, the CDRH1 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids NFGMH (SEQ ID NO: 29), or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:29. In some embodiments, the CDRH1 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids NFGMH (SEQ ID NO: 29). In some embodiments, the CDRH1 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids DTYIH (SEQ ID NO: 33), or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:33. In some embodiments, the CDRH1 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids DTYIH (SEQ ID NO: 33). In some embodiments, the CDRH1 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids NYWMN (SEQ ID NO: 39), or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:39. In some embodiments, the CDRH1 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids NYWMN (SEQ ID NO: 39). In some embodiments, the CDRH1 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids DTYMH (SEQ ID NO: 45), or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:45. In some embodiments, the CDRH1 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids DTYMH (SEQ ID NO: 45). CDRH2 In some embodiments, the second heavy chain CDR (CDRH2) of an anti-NKG2C agent provided herein comprises an amino acid sequence that is at least 80% identical to the amino acid sequence X1IX3X4X5X6X7X8X9X10X11X12X13X14X15X16X17 (SEQ ID NO: 51), where X1 is Y, R, W, or M; X3 is S, D, or H; X4 is S or P; X5 is G, E, A, or S; X6 is S, N, or D; X7 is S, G, or D; X8 is T, S, N, Y, D, or E; X9 is I or T; X10 is Y, K, E, or R; X11 is Y or L; X12 is A, R, D, or N; X13 is D, P, or Q; X14 is T or K; X15 is V, L, M, or F; X16 is K or Q; and X17 is Y or L. In some embodiments, the CDRH2 comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 51. In some embodiments, the CDRH2 comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 51. In some embodiments, the CDRH2 comprises an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 51. In some embodiments, the CDRH2 comprises the sequence of amino acids set forth in SEQ ID NO: 51.
The amino acid X1 of SEQ ID NO: 51 may be substituted with any amino acid. In some embodiments, the amino acid X1 of SEQ ID NO: 51 is substituted with a conservative amino acid (e.g., Y, R, W, and/or M). In some embodiments, the amino acid X1 of SEQ ID NO: 51 is substituted with an aromatic amino acid. In some embodiments, the amino acid X1 of SEQ ID NO: 51 is substituted with a basic amino acid. In some embodiments, the amino acid X1 of SEQ ID NO: 51 is substituted with a hydrophobic amino acid. The amino acid X3 of SEQ ID NO: 51 may be substituted with any amino acid. In some embodiments, the amino acid X3 of SEQ ID NO: 51 is substituted with a conservative amino acid (e.g., S, D, and/or H). In some embodiments, the amino acid X3 of SEQ ID NO: 51 is substituted with a hydrophilic amino acid. In some embodiments, the amino acid X3 of SEQ ID NO: 51 is substituted with an acidic amino acid. In some embodiments, the amino acid X3 of SEQ ID NO: 51 is substituted with a basic amino acid. The amino acid X4 of SEQ ID NO: 51 may be substituted with any amino acid. In some embodiments, the amino acid X4 of SEQ ID NO: 51 is substituted with a conservative amino acid (e.g., S and/or P). In some embodiments, the amino acid X4 of SEQ ID NO: 51 is a hydrophilic amino acid. In some embodiments, the amino acid X4 of SEQ ID NO: 51 is an amino acid that influences chain orientation. The amino acid X5 of SEQ ID NO: 51 may be substituted with any amino acid. In some embodiments, the amino acid X5 of SEQ ID NO: 51 is substituted with a conservative amino acid (e.g., G, E, A, and/or S). In some embodiments, the amino acid X5 of SEQ ID NO: 51 is an amino acid that influences chain orientation. In some embodiments, the amino acid X5 of SEQ ID NO: 51 is an acidic amino acid. In some embodiments, the amino acid X5 of SEQ ID NO: 51 is a hydrophobic amino acid. In some embodiments, the amino acid X5 of SEQ ID NO: 51 is a hydrophilic amino acid. The amino acid X6 of SEQ ID NO: 51 may be substituted with any amino acid. In some embodiments, the amino acid X6 of SEQ ID NO: 51 is substituted with a conservative amino acid (e.g., S, N, and/or D). In some embodiments, the amino acid X6 of SEQ ID NO: 51 is a hydrophilic amino acid. In some embodiments, the amino acid X6 of SEQ ID NO: 51 is an acidic amino acid. The amino acid X7 of SEQ ID NO: 51 may be substituted with any amino acid. In some embodiments, the amino acid X7 of SEQ ID NO: 51 is substituted with a conservative amino acid (e.g., S, G, and/or D). In some embodiments, the amino acid X7 of SEQ ID NO: 51 is a hydrophilic amino acid. In some embodiments, the amino acid X7 of SEQ ID NO: 51 is an amino acid that influences chain orientation. In some embodiments, the amino acid X7 of SEQ ID NO: 51 is an acidic amino acid.
The amino acid X8 of SEQ ID NO: 51 may be substituted with any amino acid. In some embodiments, the amino acid X8 of SEQ ID NO: 51 is substituted with a conservative amino acid (e.g., T, S, N, Y, D, and/or E). In some embodiments, the amino acid X8 of SEQ ID NO: 51 is a hydrophilic amino acid. In some embodiments, the amino acid X8 of SEQ ID NO: 51 is an aromatic amino acid. In some embodiments, the amino acid X8 of SEQ ID NO: 51 is an acidic amino acid. The amino acid X9 of SEQ ID NO: 51 may be substituted with any amino acid. In some embodiments, the amino acid X9 of SEQ ID NO: 51 is substituted with a conservative amino acid (e.g., I and/or T). In some embodiments, the amino acid X9 of SEQ ID NO: 51 is a hydrophobic amino acid. In some embodiments, the amino acid X9 of SEQ ID NO: 51 is a hydrophilic amino acid. The amino acid X10 of SEQ ID NO: 51 may be substituted with any amino acid. In some embodiments, the amino acid X10 of SEQ ID NO: 51 is substituted with a conservative amino acid (e.g. Y, K, E, and/or R). In some embodiments, the amino acid X10 of SEQ ID NO: 51 is an aromatic amino acid. In some embodiments, the amino acid X10 of SEQ ID NO: 51 is a basic amino acid. In some embodiments, the amino acid X10 of SEQ ID NO: 51 is an acidic amino acid. The amino acid X11 of SEQ ID NO: 51 may be substituted with any amino acid. In some embodiments, the amino acid X11 of SEQ ID NO: 51 is substituted with a conservative amino acid (e.g., Y and/or L). In some embodiments, the amino acid X11 of SEQ ID NO: 51 is substituted with an aromatic amino acid. In some embodiments, the amino acid X11 of SEQ ID NO: 51 is substituted with a hydrophobic amino acid. The amino acid X12 of SEQ ID NO: 51 may be substituted with any amino acid. In some embodiments, the amino acid X12 of SEQ ID NO: 51 is substituted with a conservative amino acid (e.g., A, R, D, and/or N). In some embodiments, the amino acid X12 of SEQ ID NO: 51 is a hydrophobic amino acid. In some embodiments, the amino acid X12 of SEQ ID NO: 51 is a basic amino acid. In some embodiments, the amino acid X12 of SEQ ID NO: 51 is an acid amino acid. In some embodiments, the amino acid X12 of SEQ ID NO: 51 is a hydrophilic amino acid. The amino acid X13 of SEQ ID NO: 51 may be substituted with any amino acid. In some embodiments, the amino acid X13 of SEQ ID NO: 51 is substituted with a conservative amino acid (e.g., D, P, and/or Q). In some embodiments, the amino acid X13 of SEQ ID NO: 51 is an acidic amino acid. In some embodiments, the amino acid X13 of SEQ ID NO: 51 is an amino acid that influences chain orientation. In some embodiments, the amino acid X13 of SEQ ID NO: 51 is a hydrophilic amino acid. The amino acid X14 of SEQ ID NO: 51 may be substituted with any amino acid. In some embodiments, the amino acid X14 of SEQ ID NO: 51 is substituted with a conservative amino acid (e.g., T and/or K). In
some embodiments, the amino acid X14 of SEQ ID NO: 51 is a hydrophilic amino acid. In some embodiments, the amino acid X14 of SEQ ID NO: 51 is a basic amino acid. The amino acid X15 of SEQ ID NO: 51 may be substituted with any amino acid. In some embodiments, the amino acid X15 of SEQ ID NO: 51 is substituted with a conservative amino acid (e.g., V, L, M, and/or F). In some embodiments, the amino acid X15 of SEQ ID NO: 51 is a hydrophobic amino acid. In some embodiments, the amino acid X15 of SEQ ID NO: 51 is an aromatic amino acid. The amino acid X16 of SEQ ID NO: 51 may be substituted with any amino acid. In some embodiments, the amino acid X16 of SEQ ID NO: 51 is substituted with a conservative amino acid (e.g., K and/or Q). In some embodiments, the amino acid X16 of SEQ ID NO: 51 is a basic amino acid. In some embodiments, the amino acid X16 of SEQ ID NO: 51 is a hydrophilic amino acid. The amino acid X17 of SEQ ID NO: 51 may be substituted with any amino acid. In some embodiments, the amino acid X17 of SEQ ID NO: 51 is substituted with a conservative amino acid (e.g., G and/or D). In some embodiments, the amino acid X17 of SEQ ID NO: 51 is an amino acid that influences chain orientation. In some embodiments, the amino acid X17 of SEQ ID NO: 51 is an acidic amino acid. In some embodiments, the CDRH2 of any of the anti-NKG2C agents provided herein comprises an amino acid sequence chosen from WIDPENDDTEYAPKFQG (SEQ ID NO: 18), YISSGSSTIYYRDTLKG (SEQ ID NO: 24), YISSGSSTIYYADTVKG (SEQ ID NO: 30), YISSGSSSIYYADTMKG (SEG ID NO: 34), RIDPENGNTKYDPKFQG (SEQ ID NO: 40), MIHPSDSETRLNQKFKD (SEQ ID NO: 46), and RIDPANGYTKYDPKFQG (SEQ ID NO: 49). In some embodiments, the CDRH2 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids WIDPENDDTEYAPKFQG (SEQ ID NO: 18), or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 18. In some embodiments, the CDRH2 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids WIDPENDDTEYAPKFQG (SEQ ID NO: 18). In some embodiments, the CDRH2 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids YISSGSSTIYYRDTLKG (SEQ ID NO: 24), or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 24. In some embodiments, the CDRH2 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids YISSGSSTIYYRDTLKG (SEQ ID NO: 24).
In some embodiments, the CDRH2 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids YISSGSSTIYYADTVKG (SEQ ID NO: 30), or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 30. In some embodiments, the CDRH2 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids YISSGSSTIYYADTVKG (SEQ ID NO: 30). In some embodiments, the CDRH2 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids YISSGSSSIYYADTMKG (SEG ID NO: 34), or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 34. In some embodiments, the CDRH2 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids YISSGSSSIYYADTMKG (SEG ID NO: 34). In some embodiments, the CDRH2 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids RIDPENGNTKYDPKFQG (SEQ ID NO: 40), or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 40. In some embodiments, the CDRH2 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids RIDPENGNTKYDPKFQG (SEQ ID NO: 40). In some embodiments, the CDRH2 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids MIHPSDSETRLNQKFKD (SEQ ID NO: 46), or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 46. In some embodiments, the CDRH2 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids MIHPSDSETRLNQKFKD (SEQ ID NO: 46). In some embodiments, the CDRH2 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids RIDPANGYTKYDPKFQG (SEQ ID NO: 49), or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 49. In some embodiments, the CDRH2 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids RIDPANGYTKYDPKFQG (SEQ ID NO: 49).
CDRH3 In some embodiments, the third heavy chain CDR (CDRH3) of an anti-NKG2C agent provided herein comprises an amino acid sequence that is at least 80% identical to the amino acid sequence X1X2X3X4X5X6X7X8X9X10X11X12X13X14 (SEQ ID NO: 52), where X1 is S, T, V or H, X2 is V, A, I, or H or Y, X3 is I, T, H, or G, X4 is Y, V, T, or S, X5 is Y, F, H, or N, X6 is A, D, W, or Y, X7 is Y, G, or no amino acid, X8 is D or no amino acid, X9 is R or no amino acid, X10 is Y or no amino acid, X11 is L, Y, N, or W or no amino acid, X12 is M, F, or D, X13 is D, P, or A or no amino acid, and X14 is F, Y, or V. In some embodiments, the third heavy chain CDR (CDRH3) of an anti-NKG2C agent provided herein comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 52. In some embodiments, the CDRH3 comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 52. In some embodiments, the CDRH3 comprises an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 52. In some embodiments, the CDRH3 comprises the sequence of amino acids set forth in SEQ ID NO: 52. The amino acid X1 of SEQ ID NO: 52 may be substituted with any amino acid. In some embodiments, the amino acid X1 of SEQ ID NO: 52 is substituted with a conservative amino acid (e.g., S, T, V and/or H). In some embodiments, the amino acid X1 of SEQ ID NO: 52 is substituted with a hydrophilic amino acid. In some embodiments, the amino acid X1 of SEQ ID NO: 52 is substituted with a hydrophobic amino acid. The amino acid X2 of SEQ ID NO: 52 may be substituted with any amino acid. In some embodiments, the amino acid X2 of SEQ ID NO: 52 is substituted with a conservative amino acid (e.g., V, A, I, H and/or Y). In some embodiments, the amino acid X2 of SEQ ID NO: 52 is substituted with a hydrophobic amino acid. In some embodiments, the amino acid X2 of SEQ ID NO: 52 is a basic amino acid. The amino acid X3 of SEQ ID NO: 52 may be substituted with any amino acid. In some embodiments, the amino acid X3 of SEQ ID NO: 52 is substituted with a conservative amino acid (e.g., I, T, H, and/or G). In some embodiments, the amino acid X3 of SEQ ID NO: 52 is substituted with a hydrophobic amino acid. In some embodiments, the amino acid X3 of SEQ ID NO: 52 is substituted with a basic amino acid. In some embodiments, the amino acid X3 of SEQ ID NO: 52 is substituted with an amino acid that influences chain orientation. The amino acid X4 of SEQ ID NO: 52 may be substituted with any amino acid. In some embodiments, the amino acid X4 of SEQ ID NO: 52 is substituted with a conservative amino acid (e.g., Y, V, T, and/or S). In some embodiments, the amino acid X4 of SEQ ID NO: 52 is substituted with an aromatic amino acid. In some embodiments, the amino acid X4 of SEQ ID NO: 52 is substituted with a hydrophobic
amino acid. In some embodiments, the amino acid X4 of SEQ ID NO: 52 is substituted with a hydrophilic amino acid. The amino acid X5 of SEQ ID NO: 52 may be substituted with any amino acid. In some embodiments, the amino acid X5 of SEQ ID NO: 52 is substituted with a conservative amino acid (e.g., Y, F, H, and/or N). In some embodiments, the amino acid X5 of SEQ ID NO: 52 is substituted with an aromatic amino acid. In some embodiments, the amino acid X5 of SEQ ID NO: 52 is substituted with a basic amino acid. In some embodiments, the amino acid X5 of SEQ ID NO: 52 is substituted with a hydrophilic amino acid. The amino acid X6 of SEQ ID NO: 52 may be substituted with any amino acid. In some embodiments, the amino acid X6 of SEQ ID NO: 52 is substituted with a conservative amino acid (e.g., A, D, W, and/or Y). In some embodiments, the amino acid X6 of SEQ ID NO: 52 is substituted with a hydrophobic amino acid. In some embodiments, the amino acid X6 of SEQ ID NO: 52 is substituted with an acidic amino acid. In some embodiments, the amino acid X6 of SEQ ID NO: 52 is substituted with an aromatic amino acid. The amino acid X7 of SEQ ID NO: 52 may be substituted with any amino acid. In some embodiments, the amino acid X7 of SEQ ID NO: 52 is substituted with a conservative amino acid (e.g., Y, G, and/or no amino acid). In some embodiments, the amino acid X7 of SEQ ID NO: 52 is substituted with an aromatic amino acid. In some embodiments, the amino acid X7 of SEQ ID NO: 52 is substituted with an amino acid that influences chain orientation. In some embodiments, the amino acid X7 of SEQ ID NO: 52 is substituted with no amino acid. The amino acid X8 of SEQ ID NO: 52 may be substituted with any amino acid. In some embodiments, the amino acid X8 of SEQ ID NO: 52 is substituted with a conservative amino acid (e.g., D and/or no amino acid). In some embodiments, the amino acid X8 of SEQ ID NO: 52 is substituted with an acidic amino acid. In some embodiments, the amino acid X8 of SEQ ID NO: 52 is substituted with no amino acid. The amino acid X9 of SEQ ID NO: 52 may be substituted with any amino acid. In some embodiments, the amino acid X9 of SEQ ID NO: 52 is substituted with a conservative amino acid (e.g., R and/or no amino acid). In some embodiments, the amino acid X9 of SEQ ID NO: 52 is substituted with a basic amino acid. In some embodiments, the amino acid X9 of SEQ ID NO: 52 is substituted with no amino acid. The amino acid X10 of SEQ ID NO: 52 may be substituted with any amino acid. In some embodiments, the amino acid X10 of SEQ ID NO: 52 is substituted with a conservative amino acid (e.g. Y and/or no
amino acid). In some embodiments, the amino acid X10 of SEQ ID NO: 52 is substituted with an aromatic amino acid. In some embodiments, the amino acid X10 of SEQ ID NO: 52 is substituted with no amino acid. The amino acid X11 of SEQ ID NO: 52 may be substituted with any amino acid. In some embodiments, the amino acid X11 of SEQ ID NO: 52 is substituted with a conservative amino acid (e.g., L, Y, N, W and/or no amino acid). In some embodiments, the amino acid X11 of SEQ ID NO: 52 is substituted with a hydrophobic amino acid. In some embodiments, the amino acid X11 of SEQ ID NO: 52 is substituted with an aromatic amino acid. In some embodiments, the amino acid X11 of SEQ ID NO: 52 is substituted with a hydrophilic amino acid. The amino acid X12 of SEQ ID NO: 52 may be substituted with any amino acid. In some embodiments, the amino acid X12 of SEQ ID NO: 52 is substituted with a conservative amino acid (e.g., M, F, D and/or no amino acid). In some embodiments, the amino X12 of SEQ ID NO: 52 is substituted with a hydrophobic amino acid. In some embodiments, the amino acid X12 of SEQ ID NO: 52 is substituted with an aromatic amino acid. In some embodiments, the amino acid X12 of SEQ ID NO: 52 is substituted with an acidic amino acid. The amino acid X13 of SEQ ID NO: 52 may be substituted with any amino acid. In some embodiments, the amino acid X13 of SEQ ID NO: 52 is substituted with a conservative amino acid (e.g., D, P, and/or A). In some embodiments, the amino acid X13 of SEQ ID NO: 52 is substituted with an acidic amino acid. In some embodiments, the amino acid X13 of SEQ ID NO: 52 is substituted with an amino acid that influences chain orientation. In some embodiments, the amino acid X13 of SEQ ID NO: 52 is substituted with a hydrophobic amino acid. The amino acid X14 of SEQ ID NO: 52 may be substituted with any amino acid. In some embodiments, the amino acid X14 of SEQ ID NO: 52 is substituted with a conservative amino acid (e.g., F, Y, and/or V). In some embodiments, the amino acid X14 of SEQ ID NO: 52 is substituted with an aromatic amino acid. In some embodiments, the amino acid X14 of SEQ ID NO: 52 is substituted with a hydrophobic amino acid. In some embodiments, the CDRH3 of anti-NKG2C agents provided herein comprises an amino acid sequence chosen from HYHYNDPY (SEQ ID NO: 19), SVIYYDYDRYLMDY (SEQ ID NO: 25), SVIYYAYDRYLMDF (SEQ ID NO: 31), TATVFWYFDV (SEQ ID NO: 35), SHGSNYGWFAY (SEQ ID NO: 41), and VITTHWYFDV (SEQ ID NO: 47).
In some embodiments, the CDRH3 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids HYHYNDPY (SEQ ID NO: 19), or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 19. In some embodiments, the CDRH3 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids HYHYNDPY (SEQ ID NO: 19). In some embodiments, the CDRH3 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids SVIYYDYDRYLMDY (SEQ ID NO: 25), or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 25. In some embodiments, the CDRH3 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids SVIYYDYDRYLMDY (SEQ ID NO: 25). In some embodiments, the CDRH3 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids SVIYYAYDRYLMDF (SEQ ID NO: 31), or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 31. In some embodiments, the CDRH3 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids SVIYYAYDRYLMDF (SEQ ID NO: 31). In some embodiments, the CDRH3 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids TATVFWYFDV (SEQ ID NO: 35), or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 35. In some embodiments, the CDRH3 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids TATVFWYFDV (SEQ ID NO: 35). In some embodiments, the CDRH3 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids SHGSNYGWFAY (SEQ ID NO: 41), or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 41. In some embodiments, the CDRH3 of any
of the anti-NKG2C agents provided herein comprises the sequence of amino acids SHGSNYGWFAY (SEQ ID NO: 41). In some embodiments, the CDRH3 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids VITTHWYFDV (SEQ ID NO: 47), or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 47. In some embodiments, the CDRH3 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids VITTHWYFDV (SEQ ID NO: 47). CDRL1 In some embodiments, the first light chain CDR (CDRL1) of an anti-NKG2C agent provided herein comprises an amino acid sequence that is at least 80% identical to the amino acid sequence KX2SX4SVX7X8X9X10X11X12X13X14X15X16X17 (SEQ ID NO: 53), where X1 is S or K, X2 is A or S, X4 is Q or S, X7 is D, L, S, or no amino acid, X8 is Y or no amino acid, X9 is D, S, or no amino acid, X10 is G, S, or no amino acid, X11 is D, N, or no amino acid, X12 is Q or no amino acid, X13 is K or no amino acid, X14 is S or N, X15 is Y or D, X16 is M, L, or V; and X17 is Y, N, A or G. In some embodiments, the CDRL1 comprises an amino acid sequence that is 90% identical to the amino acid sequence of SEQ ID NO: 53. In some embodiments, the CDRL1 comprises and amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 53. In some embodiments, the CDRL1 comprises an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 53. In some embodiments, the CDRL1 comprises the sequence of amino acids set forth in SEQ ID NO: 53. The amino acid X1 of SEQ ID NO: 53 may be substituted with any amino acid. In some embodiments, the amino acid X1 of SEQ ID NO: 53 is substituted with a conservative amino acid (e.g., S and/or K,). In some embodiments, the amino acid X1 of SEQ ID NO: 53 is substituted with a hydrophobic amino acid. In some embodiments, the amino acid X1 of SEQ ID NO: 53 is substituted with a hydrophilic amino acid. The amino acid X2 of SEQ ID NO: 53 may be substituted with any amino acid. In some embodiments, the amino acid X2 of SEQ ID NO: 53 is substituted with a conservative amino acid (e.g., A and/or S). In some embodiments, the amino acid X2 of SEQ ID NO: 53 is substituted with a hydrophobic amino acid. In some embodiments, the amino acid X2 of SEQ ID NO: 53 is substituted with a hydrophilic amino acid.
The amino acid X4 of SEQ ID NO: 53 may be substituted with any amino acid. In some embodiments, the amino acid X4 of SEQ ID NO: 53 is substituted with a conservative amino acid (e.g., Q and/or S). In some embodiments, the amino acid X4 of SEQ ID NO: 53 is substituted with a hydrophilic amino acid. The amino acid X7 of SEQ ID NO: 53 may be substituted with any amino acid. In some embodiments, the amino acid X7 of SEQ ID NO: 53 is substituted with a conservative amino acid (e.g., D, L, S, and/or no amino acid). In some embodiments, the amino acid X7 of SEQ ID NO: 53 is substituted with an acidic amino acid. In some embodiments, the amino acid X7 of SEQ ID NO: 53 is substituted with a hydrophobic amino acid. In some embodiments, the amino acid X7 of SEQ ID NO: 53 is substituted with a hydrophilic amino acid. In some embodiments, the amino acid X7 of SEQ ID NO: 53 is substituted with no amino acid. The amino acid X8 of SEQ ID NO: 53 may be substituted with any amino acid. In some embodiments, the amino acid X8 of SEQ ID NO: 53 is substituted with a conservative amino acid (e.g., Y and/or no amino acid). In some embodiments, the amino acid X8 of SEQ ID NO: 53 is substituted with an aromatic amino acid. In some embodiments, the amino acid X8 of SEQ ID NO: 53 is substituted with no amino acid. The amino acid X9 of SEQ ID NO: 53 may be substituted with any amino acid. In some embodiments, the amino acid X9 of SEQ ID NO: 53 is substituted with a conservative amino acid (e.g., D, S, and/or no amino acid). In some embodiments, the amino acid X9 of SEQ ID NO: 53 is substituted with an acidic amino acid. In some embodiments, the amino acid X9 of SEQ ID NO: 53 is substituted with a hydrophilic amino acid. In some embodiments, the amino acid X9 of SEQ ID NO: 53 is substituted with no amino acid. The amino acid X10 of SEQ ID NO: 53 may be substituted with any amino acid. In some embodiments, the amino acid X10 of SEQ ID NO: 53 is substituted with a conservative amino acid (e.g., G, S, and/or no amino acid). In some embodiments, the amino acid X10 of SEQ ID NO: 53 is substituted with an amino acid that influences chain orientation. In some embodiments, the amino acid X10 of SEQ ID NO: 53, the amino acid is substituted with a hydrophilic amino acid. In some embodiments, the amino acid X10 of SEQ ID NO: 53 is substituted with no amino acid. The amino acid X11 of SEQ ID NO: 53 may be substituted with any amino acid. In some embodiments, the amino acid X11 of SEQ ID NO: 53 is substituted with a conservative amino acid (e.g., D, N, and/or no amino acid). In some embodiments, the amino acid X11 of SEQ ID NO: 53 is substituted with an acidic amino acid. In some embodiments, the amino acid X11 of SEQ ID NO: 53 is substituted with a
hydrophilic amino acid. In some embodiments, the amino acid X11 of SEQ ID NO: 53 is substituted with no amino acid. The amino acid X12 of SEQ ID NO: 53 may be substituted with any amino acid. In some embodiments, the amino acid X12 of SEQ ID NO: 53 is substituted with a conservative amino acid (e.g., Q and/or no amino acid). In some embodiments, the amino acid X12 of SEQ ID NO: 53 is substituted with a hydrophilic amino acid. In some embodiments, the amino acid X12 of SEQ ID NO: 53 is substituted with no amino acid. The amino acid X13 of SEQ ID NO: 53 may be substituted with any amino acid. In some embodiments, the amino acid X13 is substituted with a conservative amino acid (e.g., K and/or no amino acid). In some embodiments, the amino acid X13 of SEQ ID NO: 53 is substituted with a basic amino acid. In some embodiments, the amino acid X13 of SEQ ID NO: 53 is substituted with no amino acid. The amino acid X14 of SEQ ID NO: 53 may be substituted with any amino acid. In some embodiments, the amino acid X14 of SEQ ID NO: 53 is substituted with a conservative amino acid (e.g., S and/or N). In some embodiments, the amino acid X14 of SEQ ID NO: 53 is substituted with a hydrophilic amino acid. The amino acid X15 of SEQ ID NO: 53 may be substituted with any amino acid. In some embodiments, the amino acid X15 of SEQ ID NO: 53 is substituted with a conservative amino acid (e.g., Y and/or D). In some embodiments, the amino acid X15 of SEQ ID NO: 53 is substituted with an aromatic amino acid. In some embodiments, the amino acid X15 of SEQ ID NO: 53 is substituted with an acidic amino acid. The amino acid X16 of SEQ ID NO: 53 may be substituted with any amino acid. In some embodiments, the amino acid X16 of SEQ ID NO: 53 is substituted with a conservative amino acid (e.g., M, L, and/or V). In some embodiments, the amino acid X16 of SEQ ID NO: 53 is substituted with a hydrophobic amino acid. The amino acid X17 of SEQ ID NO: 53 may be substituted with any amino acid. In some embodiments, the amino acid X17 of SEQ ID NO: 53 is substituted with a conservative amino acid (e.g., Y, N, A and/or G,). In some embodiments, the amino acid X17 of SEQ ID NO: 53 is substituted with a hydrophobic amino acid. In some embodiments, the amino acid X17 of SEQ ID NO: 53 is substituted with a hydrophilic amino acid. In some embodiments, the CDRL1 of any of the anti-NKG2C agents provided herein comprises an amino acid sequence chosen from SASSSVSYMY (SEQ ID NO: 20), KASQSVDYDGDSYMN (SEQ ID NO: 26), KSSQSVLYSSNQKNYLA (SEQ ID NO: 36), and KASQSVSNDVG (SEQ ID NO: 42).
In some embodiments, the CDRL1 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids SASSSVSYMY (SEQ ID NO: 20), or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:20. In some embodiments, the CDRL1 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids SASSSVSYMY (SEQ ID NO: 20). In some embodiments, the CDRL1 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids KASQSVDYDGDSYMN (SEQ ID NO: 26), or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:26. In some embodiments, the CDRL1 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids KASQSVDYDGDSYMN (SEQ ID NO: 26). In some embodiments, the CDRL1 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids KSSQSVLYSSNQKNYLA (SEQ ID NO: 36), or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:36. In some embodiments, the CDRL1 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids KSSQSVLYSSNQKNYLA (SEQ ID NO: 36). In some embodiments, the CDRL1 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids KASQSVSNDVG (SEQ ID NO: 42), or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:42. In some embodiments, the CDRL1 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids KASQSVSNDVG (SEQ ID NO: 42). CDRL2 In some embodiments, the second light chain CDR (CDRL2) of an anti-NKG2C agent provided herein comprises an amino acid sequence that is at least 80% identical to the amino acid sequence X1X2SX4X5X6X7 (SEQ ID NO: 54), where X1 is G, A, R, W, or Y, X2 is A or T, X4 is N or T, X5 is L or R, X6 is E or Y or A, and X7 is S or T. In some embodiments, the CDRL2 comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 54. In some
embodiments, the CDRL2 comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 54. In some embodiments, the CDRL2 comprises an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 54. n some embodiments, the CDRL2 comprises the sequence of amino acids set forth in SEQ ID NO: 54. The amino acid X1 of SEQ ID NO: 54 may be substituted with any amino acid. In some embodiments, the amino acid X1 of SEQ ID NO: 54 is substituted with a conservative amino acid (e.g., G, A, R, W, and/or Y). In some embodiments, the amino acid X1 of SEQ ID NO 54 is substituted with an amino acid that influences chain orientation. In some embodiments, the amino acid X1 of SEQ ID NO: 54 is substituted with a hydrophobic amino acid. In some embodiments, the amino acid X1 of SEQ ID NO: 54 is substituted with a basic amino acid. In some embodiments, the amino acid X1 of SEQ ID NO: 54 is substituted with an aromatic amino acid. The amino acid X2 of SEQ ID NO: 54 may be substituted with any amino acid. In some embodiments, the amino acid X2 of SEQ ID NO: 54 is substituted with a conservative amino acid (e.g., A and/or T). In some embodiments, the amino acid X2 of SEQ ID NO: 54 is substituted with a hydrophobic amino acid. In some embodiments, the amino acid X2 of SEQ ID NO: 54 is substituted with a hydrophilic amino acid. The amino acid X4 of SEQ ID NO: 54 may be substituted with any amino acid. In some embodiments, the amino acid X4 of SEQ ID NO: 54 is substituted with a conservative amino acid (e.g., N and/or T). In some embodiments, the amino acid X4 of SEQ ID NO: 54 is substituted with a hydrophilic amino acid. The amino acid X5 of SEQ ID NO: 54 may be substituted with any amino acid. In some embodiments, the amino acid X5 of SEQ ID NO: 54 is substituted with a conservative amino acid (e.g. L and/or R). In some embodiments, the amino acid X5 of SEQ ID NO: 54 is substituted with a hydrophobic amino acid. In some embodiments, the amino acid X5 of SEQ ID NO: 54 is substituted with a basic amino acid. The amino acid X6 of SEQ ID NO: 54 may be substituted with any amino acid. In some embodiments, the amino acid X6 of SEQ ID NO: 54 is substituted with a conservative amino acid (e.g., E, Y or A). In some embodiments, the amino acid X6 of SEQ ID NO: 54 is substituted with an acidic amino acid. In some embodiments, the amino acid X6 of SEQ ID NO: 54 is substituted with an aromatic amino acid. The amino acid X7 of SEQ ID NO: 54 may be substituted with any amino acid. In some embodiments, the amino acid X7 of SEQ ID NO: 54 is substituted with a conservative amino acid (e.g., S and/or T). In some embodiments, the amino acid X7 of SEQ ID NO: 54 is a hydrophilic amino acid.
In some embodiments, the CDRL2 of any of the anti-NKG2C agents provided herein comprises an amino acid sequence chosen from RTSNLAS (SEQ ID NO: 21), AASNLES (SEQ ID NO: 27), GASNLES (SEQ ID NO: 32), WASTRES (SEQ ID NO: 37), and YASNRYT (SEQ ID NO: 43). In some embodiments, the CDRL2 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids RTSNLAS (SEQ ID NO: 21), or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 21. In some embodiments, the CDRL2 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids RTSNLAS (SEQ ID NO: 21). In some embodiments, the CDRL2 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids AASNLES (SEQ ID NO: 27), or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 27. In some embodiments, the CDRL2 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids AASNLES (SEQ ID NO: 27). In some embodiments, the CDRL2 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids GASNLES (SEQ ID NO: 32), or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 32. In some embodiments, the CDRL2 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids GASNLES (SEQ ID NO: 32). In some embodiments, the CDRL2 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids WASTRES (SEQ ID NO: 37), or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 37. In some embodiments, the CDRL2 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids WASTRES (SEQ ID NO: 37). In some embodiments, the CDRL2 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids YASNRYT (SEQ ID NO: 43), or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,
98%, 99% or more sequence identity to SEQ ID NO: 43. In some embodiments, the CDRL2 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids YASNRYT (SEQ ID NO: 43). CDRL3 In some embodiments, the third light chain CDR (CDRL3) of an anti-NKG2C agent provided herein comprises an amino acid sequence that is at least 80% identical to the amino acid sequence X1X2X3X4X5X6X7X8T (SEQ ID NO: 55), where X1 is Q or H; X2 is Q or H; X3 is S, Y, D, or no amino acid; X4 is N, H, or Y; X5 is E, S, or L; X6 is D, V, Y, or S; X7 is P or S; and X8 is L, Y, or H. In some embodiments, the CDRL3 comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 55. In some embodiments, the CDRL3 comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 55. In some embodiments, the CDRL3 comprises an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 55. In some embodiments, the CDRL3 comprises the sequence of amino acids set forth in SEQ ID NO: 55. The amino acid X1 of SEQ ID NO: 55 may be substituted with any amino acid. In some embodiments, the amino acid X1 of SEQ ID NO: 55 is substituted with a conservative amino acid (e.g., Q and/or H). In some embodiments, the amino acid X1 of SEQ ID NO: 55 is substituted with a hydrophilic amino acid. In some embodiments, the amino acid X1 of SEQ ID NO: 55 is substituted with a basic amino acid. The amino acid X2 of SEQ ID NO: 55 may be substituted with any amino acid. In some embodiments, the amino acid X2 of SEQ ID NO: 55 is substituted with a conservative amino acid (e.g., Q and/or H). In some embodiments, the amino acid X2 of SEQ ID NO: 55 is substituted with a hydrophilic amino acid. In some embodiments, the amino acid X2 of SEQ ID NO: 55 is substituted with a basic amino acid. The amino acid X3 of SEQ ID NO: 55 may be substituted with any amino acid. In some embodiments, the amino acid X3 of SEQ ID NO: 55 is substituted with a conservative amino acid (e.g., S, Y, D, and/or no amino acid). In some embodiments, the amino acid X3 of SEQ ID NO: 55 is substituted with a hydrophilic amino acid. In some embodiments, the amino acid X3 of SEQ ID NO: 55 is substituted with an aromatic amino acid. In some embodiments, the amino acid X3 of SEQ ID NO: 55 is substituted with an acidic amino acid. In some embodiments, the amino acid X3 of SEQ ID NO: 55 is substituted with no amino acid.
The amino acid X4 of SEQ ID NO: 55 may be substituted with any amino acid. In some embodiments, the amino acid X4 of SEQ ID NO: 55 is substituted with a conservative amino acid (e.g., N, H, and/or Y). In some embodiments, the amino acid X4 of SEQ ID NO: 55 is substituted with a hydrophilic amino acid. In some embodiments, the amino acid X4 of SEQ ID NO: 55 is substituted with a basic amino acid. In some embodiments, the amino acid X4 of SEQ ID NO: 55 is substituted with an aromatic amino acid. The amino acid X5 of SEQ ID NO: 55 may be substituted with any amino acid. In some embodiments, the amino acid X5 of SEQ ID NO: 55 is substituted with a conservative amino acid (e.g., E, S, and/or L). In some embodiments, the amino acid X5 of SEQ ID NO: 55 is an acidic amino acid. In some embodiments, the amino acid X5 of SEQ ID NO: 55 is a hydrophilic amino acid. In some embodiments, the amino acid X5 of SEQ ID NO: 55 is a hydrophobic amino acid. The amino acid X6 of SEQ ID NO: 55 may be substituted with any amino acid. In some embodiments, the amino acid X6 of SEQ ID NO: 55 is substituted with a conservative amino acid (e.g., D, V, Y, and/or S). In some embodiments, the amino acid X6 of SEQ ID NO: 55 is substituted with an acidic amino acid. In some embodiments, the amino acid X6 of SEQ ID NO: 55 is substituted with a hydrophobic amino acid. In some embodiments, the amino acid X6 of SEQ ID NO: 55 is substituted with an aromatic amino acid. In some embodiments, the amino acid X6 of SEQ ID NO: 55 is substituted with a hydrophilic amino acid. The amino acid X7 of SEQ ID NO: 55 may be substituted with any amino acid. In some embodiments, the amino acid X7 of SEQ ID NO: 55 is substituted with a conservative amino acid (e.g., P and/or S). In some embodiments, the amino acid X7 of SEQ ID NO: 55 is substituted with an amino acid that influences chain orientation. In some embodiments, the amino acid X7 of SEQ ID NO: 55 is substituted with a hydrophilic amino acid. The amino acid X8 of SEQ ID NO: 55 may be substituted with any amino acid. In some embodiments, the amino acid X8 of SEQ ID NO: 55 is substituted with a conservative amino acid (e.g., L, Y, and/or H). In some embodiments, the amino acid X8 of SEQ ID NO: 55 is substituted with a hydrophobic amino acid. In some embodiments, the amino acid X8 of SEQ ID NO: 55 is substituted with an aromatic amino acid. In some embodiments, the amino acid X8 of SEQ ID NO: 55 is substituted with a basic amino acid. In some embodiments, the CDRL3 of an anti-NKG2C agent provided herein comprises an amino acid sequence chosen from QHYHSYPYT (SEQ ID NO: 22), QQSNEDPLT (SEQ ID NO: 28), QQSNEVPLT (SEQ ID NO: 38), HQYLSSHT (SEQ ID NO: 44), and QQDYSSPLT (SEQ ID NO: 48).
In some embodiments, the CDRL3 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids QHYHSYPYT (SEQ ID NO: 22), or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 22. In some embodiments, the CDRL3 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids QHYHSYPYT (SEQ ID NO: 22). In some embodiments, the CDRL3 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids QQSNEDPLT (SEQ ID NO: 28), or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 28. In some embodiments, the CDRL3 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids QQSNEDPLT (SEQ ID NO: 28), In some embodiments, the CDRL3 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids QQSNEVPLT (SEQ ID NO: 38), or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 38. In some embodiments, the CDRL3 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids QQSNEVPLT (SEQ ID NO: 38). In some embodiments, the CDRL3 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids HQYLSSHT (SEQ ID NO: 44), or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 44. In some embodiments, the CDRL3 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids HQYLSSHT (SEQ ID NO: 44). In some embodiments, the CDRL3 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids QQDYSSPLT (SEQ ID NO: 48), or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 48. In some embodiments, the CDRL3 of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids QQDYSSPLT (SEQ ID NO: 48). CDR sets In some embodiments, any of the anti-NKG2C agents described herein comprises an immunoglobulin heavy chain variable domain comprising a set of CDRs (i.e., CDRH1, CDRH2, CDRH3); and an
immunoglobulin light chain variable domain comprising a set of CDRs (i.e., CDRL1, CDRL2, CDRL3). In some embodiments, any of the antibodies or antigen-binding fragments thereof that bind the NKG2C receptor or fragment thereof described herein comprises an immunoglobulin heavy chain variable domain comprising a set of CDRs (i.e., CDRH1, CDRH2, CDRH3); and an immunoglobulin light chain variable domain comprising a set of CDRs (i.e., CDRL1, CDRL2, CDRL3). In some embodiments, any of the anti-NKG2C agents provided herein comprises two immunoglobulin heavy chain variable domains each comprising a set of CDRs (i.e., CDRH1, CDRH2, CDRH3); and two immunoglobulin light chain variable domains each comprising a set of CDRs (i.e., CDRL1, CDRL2, CDRL3). In some embodiments, any of the antibodies or antigen-binding fragments thereof that bind the NKG2C receptor or fragment thereof described herein comprise one or more immunoglobulin heavy chain variable domains each comprising a set of CDRs (i.e., CDRH1, CDRH2, CDRH3); and one or more immunoglobulin light chain variable domains each comprising a set of CDRs (i.e., CDRL1, CDRL2, CDRL3). In some embodiments, any of the antibodies or antigen-binding fragments thereof that bind the NKG2C receptor or fragment thereof described herein comprise two immunoglobulin heavy chain variable domains each comprising a set of CDRs (i.e., CDRH1, CDRH2, CDRH3); and two immunoglobulin light chain variable domains each comprising a set of CDRs (i.e., CDRL1, CDRL2, CDRL3). Sets of CDRs may comprise any combination of CDR amino acid sequences (i.e., CDRH1, CDRH2, CDRH3; and CDRL1, CDRL2, CDRL3) provided herein. In some embodiments, an immunoglobulin heavy chain variable domain comprises a set of CDRH1, CDRH2 and CDRH3 amino acid sequences, and an immunoglobulin light chain variable domain comprises a set of CDRL1, CDRL2 and CDRL3 amino acid sequences chosen from sets 1-6 provided in the table below. For an anti-NKG2C agent comprising two immunoglobulin heavy chain variable domains and two immunoglobulin light chain variable domains, each immunoglobulin heavy chain variable domain may comprise a set of CDRH1, CDRH2 and CDRH3 amino acid sequences, and each immunoglobulin light chain variable domain may comprise a set of CDRL1, CDRL2 and CDRL3 amino acid sequences chosen from sets 1-6 provided in Table 2.
In some embodiments, the anti-NKG2C agent contains CDRs corresponding to the same set. For example, for an anti-NKG2C agent comprising two immunoglobulin heavy chain variable domains and two immunoglobulin light chain variable domains, each immunoglobulin heavy chain variable domain may comprise a set of CDRH1, CDRH2 and CDRH3 amino acid sequences from set 1, and each immunoglobulin light chain variable domain may comprise a set of CDRL1, CDRL2 and CDRL3 amino acid sequences from set 1. In some embodiments, the anti-NKG2C agent contains CDRs corresponding to the different sets. For example, for an anti-NKG2C agent comprising two immunoglobulin heavy chain variable domains and
two immunoglobulin light chain variable domains, each immunoglobulin heavy chain variable domain may comprise a set of CDRH1, CDRH2 and CDRH3 amino acid sequences from set 1, and each immunoglobulin light chain variable domain may comprise a set of CDRL1, CDRL2 and CDRL3 amino acid sequences from set 2. In another example, for an anti-NKG2C agent comprising two immunoglobulin heavy chain variable domains and two immunoglobulin light chain variable domains, one immunoglobulin heavy chain variable domain may comprise a set of CDRH1, CDRH2 and CDRH3 amino acid sequences from set 1 and the other immunoglobulin heavy chain variable domain may comprise a set of CDRH1, CDRH2 and CDRH3 amino acid sequences from set 2; and one immunoglobulin light chain variable domain may comprise a set of CDRL1, CDRL2 and CDRL3 amino acid sequences from set 1 and the other immunoglobulin light chain variable domain may comprise a set of CDRL1, CDRL2 and CDRL3 amino acid sequences from set 2. In some embodiments, the agent that binds the NKG2C receptor or a fragment thereof, comprises one or more of: a) an immunoglobulin heavy chain variable domain comprising: (i) a heavy chain complementary determining region 1 (CDRH1) comprising the sequence X1X2X3X4X5 (SEQ ID NO: 50), wherein X1 is N, S, or D, X2 is F, T, or Y, X3 is G, Y, or W, X4 is M or I, and X5 is H or N; (ii) a heavy chain complementary determining region 2 (CDRH2) comprising the sequence X1IX3X4X5X6X7X8X9X10X11X12X13X14X15X16X17 (SEQ ID NO: 51), wherein X1 is Y, R, W, or M, X3 is S, D, or H, X4 is S or P, X5 is G, E, A, or S, X6 is S, N, or D, X7 is S, G, or D, X8 is T, S, N, Y, D, or E, X9 is I or T, X10 is Y, K, E, or R, X11 is Y or L, X12 is A, R, D, or N, X13 is D, P, or Q, X14 is T or K, X15 is V, L, M, or F, X16 is K or Q, and X17 is G or D; (iii) a heavy chain complementary determining region 3 (CDRH3) comprising the sequence X1X2X3X4X5X6X7X8X9X10X11X12X13X14 (SEQ ID NO: 52), wherein X1 is S, T, H or V, X2 is V, A, I, Y or H, X3 is I, T, H, or G, X4 is Y, V, T, or S, X5 is Y, F, H, or N, X6 is A, D, W, or Y, X7 is Y, G, or no amino acid, X8 is D or no amino acid, X9 is R or no amino acid, X10 is Y or no amino acid, X11 is L, Y, N, W or no amino acid, X12 is M, F, D, or no amino acid, X13 is D, P, or A, and X14 is F, Y, or V; b) an immunoglobulin light chain variable domain comprising: (i) a light chain complementary determining region 1 (CDRL1) comprising the sequence KX2SX4SVX7X8X9X10X11X12X13X14X15X16 (SEQ ID NO: 53), wherein X1 is S or K, X2 is A or S, X4 is Q or S, X7 is D, L, S, or no amino acid, X8 is Y or no amino acid, X9 is D, S, or no amino acid, X10 is G, S, or no amino acid, X11 is D, N, or no amino acid, X12 is Q or no amino acid, X13 is K or no amino acid, X14 is S or N, X15 is Y or D, X16 is M, L, or V, and X17 is Y, N, A or G;
(ii) a light chain complementary determining region 2 (CDRL2) comprising the sequence X1X2SX4X5X6X7 (SEQ ID NO: 54), wherein X1 is G, A, R, W, or Y, X2 is A or T, X4 is N or T, X5 is L or R, X6 is E, A or Y, and X7 is S or T; and (iii) a light chain complementary determining region 3 (CDRL3) comprising the sequence X1X2X3X4X5X6X7X8T (SEQ ID NO: 55), wherein X1 is Q or H, X2 is Q or H, X3 is S, Y, D, or no amino acid, X4 is N, H, or Y, X5 is E, S, or L, X6 is D, V, Y, or S, X7 is P or S, and X8 is L, Y, or H. In some embodiments, the agent that binds the NKG2C receptor or a fragment thereof, comprises an immunoglobulin heavy chain variable domain comprising: a CDRH1 comprising the sequence of amino acids set forth in SEQ ID NO: 17, SEQ ID NO: 23, SEQ ID NO: 29, SEQ ID NO: 33, SEQ ID NO: 39 or SEQ ID NO:45, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 17, SEQ ID NO: 23, SEQ ID NO: 29, SEQ ID NO: 33, SEQ ID NO: 39 or SEQ ID NO:45; a CDRH2 comprising the sequence of amino acids set forth in SEQ ID NO: 18, SEQ ID NO: 24, SEQ ID NO:30, SEQ ID NO:34, SEQ ID NO:40, SEQ ID NO:46, SEQ ID NO:49, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 18, SEQ ID NO: 24, SEQ ID NO:30, SEQ ID NO:34, SEQ ID NO:40, SEQ ID NO:46, SEQ ID NO:49; and a CDRH3 comprising the sequence of amino acids set forth in SEQ ID NO: 19, SEQ ID NO: 25, SEQ ID NO: 31, SEQ ID NO: 35, SEQ ID NO: 41, SEQ ID NO: 47, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 19, SEQ ID NO: 25, SEQ ID NO: 31, SEQ ID NO: 35, SEQ ID NO: 41, SEQ ID NO: 47. In some embodiments, the agent that binds the NKG2C receptor or a fragment thereof, comprises an immunoglobulin heavy chain variable domain that comprises a CDRH1 comprising the sequence of amino acids set forth in SEQ ID NO: 17, SEQ ID NO: 23, SEQ ID NO: 29, SEQ ID NO: 33, SEQ ID NO: 39 or SEQ ID NO:45; a CDRH2 comprising the sequence of amino acids set forth in SEQ ID NO: 18, SEQ ID NO: 24, SEQ ID NO:30, SEQ ID NO:34, SEQ ID NO:40, SEQ ID NO:46, SEQ ID NO:49; and a CDRH3 comprising the sequence of amino acids set forth in SEQ ID NO: 19, SEQ ID NO: 25, SEQ ID NO: 31, SEQ ID NO: 35, SEQ ID NO: 41, SEQ ID NO: 47. In some embodiments, the agent that binds the NKG2C receptor or a fragment thereof, comprises an immunoglobulin light chain variable domain comprising a CDRL1 comprising the sequence of amino acids set forth in SEQ ID NO: 20; SEQ ID NO: 26, SEQ ID NO: 36 or SEQ ID NO: 42 or a sequence of
amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 20; SEQ ID NO: 26, SEQ ID NO: 36 or SEQ ID NO: 42; a CDRL2 comprising the sequence of amino acids set forth in SEQ ID NO: 21, SEQ ID NO: 27, SEQ ID NO: 32, SEQ ID NO: 37, SEQ ID NO: 43, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 21, SEQ ID NO: 27, SEQ ID NO: 32, SEQ ID NO: 37, SEQ ID NO: 43; and a CDRL3 comprising the sequence of amino acids set forth in SEQ ID NO: 22, SEQ ID NO: 28, SEQ ID NO: 38, SEQ ID NO: 44, SEQ ID NO: 48, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 22, SEQ ID NO: 28, SEQ ID NO: 38, SEQ ID NO: 44, SEQ ID NO: 48, In some embodiments, the agent that binds the NKG2C receptor or a fragment thereof, comprises an immunoglobulin light chain variable domain comprising a CDRL1 comprising a sequence of amino acids set forth in SEQ ID NO: 20; SEQ ID NO: 26, SEQ ID NO: 36 or SEQ ID NO: 42; a CDRL2 comprising a sequence of amino acids set forth in SEQ ID NO: 21, SEQ ID NO: 27, SEQ ID NO: 32, SEQ ID NO: 37, SEQ ID NO: 43; and a CDRL3 comprising a sequence of amino acids set forth in SEQ ID NO: 22, SEQ ID NO: 28, SEQ ID NO: 38, SEQ ID NO: 44, SEQ ID NO: 48. In some embodiments, the agent that binds the NKG2C receptor or a fragment thereof, comprises a CDRH1 comprising the sequence set forth in SEQ ID NO: 17, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 17, a CDRH2 comprising the sequence set forth in SEQ ID NO: 18, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 18; and a CDRH3 comprising the sequence set forth in SEQ ID NO: 19, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 19. In some embodiments, the agent that binds the NKG2C receptor or a fragment thereof, comprises a CDRH1 comprising the sequence set forth in SEQ ID NO: 17, the CDRH2 comprises the sequence set forth in SEQ ID NO: 18; and the CDRH3 comprises the sequence set forth in SEQ ID NO: 19.
In some embodiments, the agent that binds the NKG2C receptor or a fragment thereof, comprises a CDRH1 comprising the sequence set forth in SEQ ID NO: 23, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 23, a CDRH2 comprising the sequence set forth in SEQ ID NO: 24,or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 24; and a CDRH3 comprising the sequence set forth in SEQ ID NO: 25, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 25. In some embodiments, the agent that binds the NKG2C receptor or a fragment thereof, comprises a CDRH1 comprising the sequence set forth in SEQ ID NO: 23, the CDRH2 comprises the sequence set forth in SEQ ID NO: 24; and the CDRH3 comprises the sequence set forth in SEQ ID NO: 25. In some embodiments, the agent that binds the NKG2C receptor or a fragment thereof, comprises a CDRH1 comprising the sequence set forth in SEQ ID NO: 29, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:29, a CDRH2 comprising the sequence set forth in SEQ ID NO: 30,or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 30; and a CDRH3 comprising the sequence set forth in SEQ ID NO: 31, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 31. In some embodiments, the agent that binds the NKG2C receptor or a fragment thereof, comprises a CDRH1 comprising the sequence set forth in SEQ ID NO: 29, the CDRH2 comprises the sequence set forth in SEQ ID NO: 30; and the CDRH3 comprises the sequence set forth in SEQ ID NO: 31. In some embodiments, the agent that binds the NKG2C receptor or a fragment thereof, comprises a CDRH1 comprising the sequence set forth in SEQ ID NO: 29, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:29, a CDRH2 comprising the
sequence set forth in SEQ ID NO: 34, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:34; and a CDRH3 comprising the sequence set forth in SEQ ID NO: 25, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 25. In some embodiments, the agent that binds the NKG2C receptor or a fragment thereof, comprises a CDRH1 comprising the sequence set forth in SEQ ID NO: 29, the CDRH2 comprises the sequence set forth in SEQ ID NO: 34; and the CDRH3 comprises the sequence set forth in SEQ ID NO: 25. In some embodiments, the agent that binds the NKG2C receptor or a fragment thereof, comprises a CDRH1 comprising the sequence set forth in SEQ ID NO: 33, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 33, a CDRH2 comprising the sequence set forth in SEQ ID NO: 40, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:40; and a CDRH3 comprising the sequence set forth in SEQ ID NO: 35, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 35. In some embodiments, the agent that binds the NKG2C receptor or a fragment thereof, comprises a CDRH1 comprising the sequence set forth in SEQ ID NO:33 , the CDRH2 comprises the sequence set forth in SEQ ID NO: 40; and the CDRH3 comprises the sequence set forth in SEQ ID NO: 35. In some embodiments, the agent that binds the NKG2C receptor or a fragment thereof, comprises a CDRH1 comprising the sequence set forth in SEQ ID NO: 39, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 39, a CDRH2 comprising the sequence set forth in SEQ ID NO: 46, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 46; and a CDRH3 comprising the sequence set forth in SEQ ID NO: 41, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%,
88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 41. In some embodiments, the agent that binds the NKG2C receptor or a fragment thereof, comprises a CDRH1 comprising the sequence set forth in SEQ ID NO: 39, the CDRH2 comprises the sequence set forth in SEQ ID NO: 46; and the CDRH3 comprises the sequence set forth in SEQ ID NO: 41. In some embodiments, the agent that binds the NKG2C receptor or a fragment thereof, comprises a CDRH1 comprising the sequence set forth in SEQ ID NO: 45, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 45, a CDRH2 comprising the sequence set forth in SEQ ID NO: 49, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 49; and a CDRH3 comprising the sequence set forth in SEQ ID NO: 47, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 47. In some embodiments, the agent that binds the NKG2C receptor or a fragment thereof, comprises a CDRH1 comprising the sequence set forth in SEQ ID NO: 45, the CDRH2 comprises the sequence set forth in SEQ ID NO: 49; and the CDRH3 comprises the sequence set forth in SEQ ID NO: 47. In some embodiments, the agent that binds the NKG2C receptor or a fragment thereof, comprises a CDRL1 comprising the sequence set forth in SEQ ID NO: 20, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 20; a CDRL2 comprising the sequence set forth in SEQ ID NO: 21, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:21; and a CDRL3 comprising the sequence set forth in SEQ ID NO: 22, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:22.
In some embodiments, the agent that binds the NKG2C receptor or a fragment thereof, comprises a CDRL1 comprising the sequence set forth in SEQ ID NO: 20, a CDRL2 comprising the sequence set forth in SEQ ID NO: 21; and a CDRL3 comprising the sequence set forth in SEQ ID NO: 22. In some embodiments, the agent that binds the NKG2C receptor or a fragment thereof, comprises a CDRL1 comprising the sequence set forth in SEQ ID NO: 26, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:26; a CDRL2 comprising the sequence set forth in SEQ ID NO: 27 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:27; and a CDRL3 comprising the sequence set forth in SEQ ID NO:28 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:28. In some embodiments, the agent that binds the NKG2C receptor or a fragment thereof, comprises a CDRL1 comprising the sequence set forth in SEQ ID NO: 26, a CDRL2 comprising the sequence set forth in SEQ ID NO: 27; and a CDRL3 comprising the sequence set forth in SEQ ID NO: 28. In some embodiments, the agent that binds the NKG2C receptor or a fragment thereof, comprises a CDRL1 comprising the sequence set forth in SEQ ID NO: 26, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:26; a CDRL2 comprising the sequence set forth in SEQ ID NO: 32 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:32; and a CDRL3 comprising the sequence set forth in SEQ ID NO: 28 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:28. In some embodiments, the agent that binds the NKG2C receptor or a fragment thereof, comprises a CDRL1 comprising the sequence set forth in SEQ ID NO: 26, a CDRL2 comprising the sequence set forth in SEQ ID NO: 32; and a CDRL3 comprising the sequence set forth in SEQ ID NO: 28. In some embodiments, the agent that binds the NKG2C receptor or a fragment thereof, comprises a CDRL1 comprising the sequence set forth in SEQ ID NO: 26, or a sequence of amino acids that exhibits
at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:26; a CDRL2 comprising the sequence set forth in SEQ ID NO: 32 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:32; and a CDRL3 comprising the sequence set forth in SEQ ID NO: 38 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:38. In some embodiments, the agent that binds the NKG2C receptor or a fragment thereof, comprises a CDRL1 comprising the sequence set forth in SEQ ID NO: 26, a CDRL2 comprising the sequence set forth in SEQ ID NO: 32; and a CDRL3 comprising the sequence set forth in SEQ ID NO: 38. In some embodiments, the agent that binds the NKG2C receptor or a fragment thereof, comprises a CDRL1 comprising the sequence set forth in SEQ ID NO: 36, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:36; a CDRL2 comprising the sequence set forth in SEQ ID NO:37 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:37; and a CDRL3 comprising the sequence set forth in SEQ ID NO:44 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:44. In some embodiments, the agent that binds the NKG2C receptor or a fragment thereof, comprises a CDRL1 comprising the sequence set forth in SEQ ID NO: 36, a CDRL2 comprising the sequence set forth in SEQ ID NO: 37; and a CDRL3 comprising the sequence set forth in SEQ ID NO: 44. In some embodiments, the agent that binds the NKG2C receptor or a fragment thereof, comprises a CDRL1 comprising the sequence set forth in SEQ ID NO: 42, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:42; a CDRL2 comprising the sequence set forth in SEQ ID NO: 43 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:43; and a CDRL3 comprising the sequence set forth in SEQ ID NO:48 or a
sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:48. In some embodiments, the agent that binds the NKG2C receptor or a fragment thereof, comprises a CDRL1 comprising the sequence set forth in SEQ ID NO:42 , a CDRL2 comprising the sequence set forth in SEQ ID NO: 43; and a CDRL3 comprising the sequence set forth in SEQ ID NO: 48. In some embodiments, the agent that binds the NKG2C receptor or a fragment thereof, comprises a CDRL1 comprising the sequence set forth in SEQ ID NO: 48, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:48; a CDRL2 comprising the sequence set forth in SEQ ID NO: 37 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:37; and a CDRL3 comprising the sequence set forth in SEQ ID NO: 44 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:44. In some embodiments, the agent that binds the NKG2C receptor or a fragment thereof, comprises a CDRL1 comprising the sequence set forth in SEQ ID NO: 48, a CDRL2 comprising the sequence set forth in SEQ ID NO: 37; and a CDRL3 comprising the sequence set forth in SEQ ID NO: 44. In some embodiments, the agent binds the NKG2C receptor or a fragment thereof, comprises a CDRH1 comprising the sequence of amino acids set forth in SEQ ID NO: 17, 23, 29, 33, 39 or 45, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 17, 23, 29, 33, 39 or 45, a CDRH2 comprising a sequence of amino acids set forth in SEQ ID NO: 18, 24, 30, 34, 40, 46 or 49, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 18, 24, 30, 34, 40, 46 or 49; a CDRH3 comprising a sequence of amino acids set forth in SEQ ID NO: 19, 25, 31, 35, 41 or 47, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 19, 25, 31, 35, 41 or 47; a CDRL1 comprising a sequence of amino acids set forth in SEQ ID NO: 20, 26, 36 or 42, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%,
95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 20, 26, 36 or 42; a CDRL2 comprising a sequence of amino acids set forth in SEQ ID NO: 21, 27, 32, 37 or 43, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 21, 27, 32, 37 or 43; and a CDRL3 comprising a sequence of amino acids set forth in SEQ ID NO: 22, 28, 38, 44 or 48, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 22, 28, 38, 44 or 48. In some embodiments, the agent binds the NKG2C receptor or a fragment thereof, comprises a CDRH1 comprising the sequence of amino acids set forth in SEQ ID NO: 17, 23, 29, 33, 39 or 45; a CDRH2 comprising a sequence of amino acids set forth in SEQ ID NO: 18, 24, 30, 34, 40, 46 or 49; a CDRH3 comprising a sequence of amino acids set forth in SEQ ID NO: 19, 25, 31, 35, 41 or 47; a CDRL1 comprising a sequence of amino acids set forth in SEQ ID NO: 20, 26, 36 or 42; a CDRL2 comprising a sequence of amino acids set forth in SEQ ID NO: 21, 27, 32, 37 or 43; and a CDRL3 comprising a sequence of amino acids set forth in SEQ ID NO: 22, 28, 38, 44 or 48. In some embodiments, the agent that binds the NKG2C receptor or a fragment thereof, comprises a CDRH1 comprising the sequence set forth in SEQ ID NO: 17 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:17, a CDRH2 comprising the sequence set forth in SEQ ID NO:18 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:18; a CDRH3 comprising the sequence set forth in SEQ ID NO:19 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:19; a CDRL1 comprising the sequence set forth in SEQ ID NO:20, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:20, a CDRL2 comprising the sequence set forth in SEQ ID NO:21 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:21; and a CDRL3 comprising the sequence set forth in SEQ ID NO:22 or a
sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:22. In some embodiments, the agent that binds the NKG2C receptor or a fragment thereof, comprises a CDRH1 comprising the sequence set forth in SEQ ID NO: 17, a CDRH2 comprising the sequence set forth in SEQ ID NO: 18; a CDRH3 comprising the sequence set forth in SEQ ID NO: 19; a CDRL1 comprising the sequence set forth in SEQ ID NO: 20, a CDRL2 comprising the sequence set forth in SEQ ID NO: 21; and a CDRL3 comprising the sequence set forth in SEQ ID NO: 22. In some embodiments, the agent that binds the NKG2C receptor or a fragment thereof, comprises a CDRH1 comprising the sequence set forth in SEQ ID NO:23 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:23, a CDRH2 comprising the sequence set forth in SEQ ID NO:24 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:24; a CDRH3 comprising the sequence set forth in SEQ ID NO:25 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:25; a CDRL1 comprising the sequence set forth in SEQ ID NO:26 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:26, a CDRL2 comprising the sequence set forth in SEQ ID NO:27 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:27; and a CDRL3 comprising the sequence set forth in SEQ ID NO:28 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:28. In some embodiments, the agent that binds the NKG2C receptor or a fragment thereof, comprises a CDRH1 comprising the sequence set forth in SEQ ID NO:23, a CDRH2 comprising the sequence set forth in SEQ ID NO: 24; a CDRH3 comprising the sequence set forth in SEQ ID NO: 25; a CDRL1 comprising the sequence set forth in SEQ ID NO: 26, a CDRL2 comprising the sequence set forth in SEQ ID NO: 27; and a CDRL3 comprising the sequence set forth in SEQ ID NO: 28.
In some embodiments, the agent that binds the NKG2C receptor or a fragment thereof, comprises a CDRH1 comprising the sequence set forth in SEQ ID NO:29 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:29, a CDRH2 comprising the sequence set forth in SEQ ID NO:30 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:30; a CDRH3 comprising the sequence set forth in SEQ ID NO:31, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:31; a CDRL1 comprising the sequence set forth in SEQ ID NO:26 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:26, a CDRL2 comprising the sequence set forth in SEQ ID NO:32, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:32; and a CDRL3 comprising the sequence set forth in SEQ ID NO:28 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:28. In some embodiments, the agent that binds the NKG2C receptor or a fragment thereof, comprises a CDRH1 comprising the sequence set forth in SEQ ID NO: 29, a CDRH2 comprising the sequence set forth in SEQ ID NO: 30; a CDRH3 comprising the sequence set forth in SEQ ID NO: 31; a CDRL1 comprising the sequence set forth in SEQ ID NO: 26, a CDRL2 comprising the sequence set forth in SEQ ID NO: 32; and a CDRL3 comprising the sequence set forth in SEQ ID NO: 28. In some embodiments, the agent that binds the NKG2C receptor or a fragment thereof, comprises a CDRH1 comprising the sequence set forth in SEQ ID NO:29 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:29, a CDRH2 comprising the sequence set forth in SEQ ID NO:34 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:34; a CDRH3 comprising the sequence set forth in SEQ ID NO:25, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:25; a CDRL1 comprising the sequence set forth in SEQ ID NO:26 or a sequence of amino acids that exhibits at least
80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:26, a CDRL2 comprising the sequence set forth in SEQ ID NO:32, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:32; and a CDRL3 comprising the sequence set forth in SEQ ID NO:38 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:38. In some embodiments, the agent that binds the NKG2C receptor or a fragment thereof, comprises a CDRH1 comprising the sequence set forth in SEQ ID NO: 29, a CDRH2 comprising the sequence set forth in SEQ ID NO: 34; a CDRH3 comprising the sequence set forth in SEQ ID NO: 25; a CDRL1 comprising the sequence set forth in SEQ ID NO: 26, a CDRL2 comprising the sequence set forth in SEQ ID NO: 32; and a CDRL3 comprising the sequence set forth in SEQ ID NO: 38. In some embodiments, the agent that binds the NKG2C receptor or a fragment thereof, comprises a CDRH1 comprising the sequence set forth in SEQ ID NO:33, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:33, a CDRH2 comprising the sequence set forth in SEQ ID NO:40, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:40; a CDRH3 comprising the sequence set forth in SEQ ID NO:35, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:35; a CDRL1 comprising the sequence set forth in SEQ ID NO:36, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:36, a CDRL2 comprising the sequence set forth in SEQ ID NO:37, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:37; and a CDRL3 comprising the sequence set forth in SEQ ID NO:44, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:44.
In some embodiments, the agent that binds the NKG2C receptor or a fragment thereof, comprises a CDRH1 comprising the sequence set forth in SEQ ID NO:33, a CDRH2 comprising the sequence set forth in SEQ ID NO:40; a CDRH3 comprising the sequence set forth in SEQ ID NO: 35; a CDRL1 comprising the sequence set forth in SEQ ID NO: 36, a CDRL2 comprising the sequence set forth in SEQ ID NO: 37; and a CDRL3 comprising the sequence set forth in SEQ ID NO: 44. In some embodiments, the agent that binds the NKG2C receptor or a fragment thereof, comprises a CDRH1 comprising the sequence set forth in SEQ ID NO:39, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:39, a CDRH2 comprising the sequence set forth in SEQ ID NO:46, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:46; a CDRH3 comprising the sequence set forth in SEQ ID NO:41, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:41; a CDRL1 comprising the sequence set forth in SEQ ID NO:42, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:42, a CDRL2 comprising the sequence set forth in SEQ ID NO:43, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:43; and a CDRL3 comprising the sequence set forth in SEQ ID NO:48, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:48. In some embodiments, the agent that binds the NKG2C receptor or a fragment thereof, comprises a CDRH1 comprising the sequence set forth in SEQ ID NO:39, a CDRH2 comprising the sequence set forth in SEQ ID NO: 46; a CDRH3 comprising the sequence set forth in SEQ ID NO: 41; a CDRL1 comprising the sequence set forth in SEQ ID NO: 42, a CDRL2 comprising the sequence set forth in SEQ ID NO: 43; and a CDRL3 comprising the sequence set forth in SEQ ID NO: 48. In some embodiments, the agent that binds the NKG2C receptor or a fragment thereof, comprises a CDRH1 comprising the sequence set forth in SEQ ID NO:45, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:45, a CDRH2 comprising the sequence set
forth in SEQ ID NO:49, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:49; a CDRH3 comprising the sequence set forth in SEQ ID NO:47 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:47; a CDRL1 comprising the sequence set forth in SEQ ID NO:48, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:48, a CDRL2 comprising the sequence set forth in SEQ ID NO:37, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:37; and a CDRL3 comprising the sequence set forth in SEQ ID NO:44, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:44. In some embodiments, the agent that binds the NKG2C receptor or a fragment thereof, comprises a CDRH1 comprising the sequence set forth in SEQ ID NO:45, a CDRH2 comprising the sequence set forth in SEQ ID NO:49; a CDRH3 comprising the sequence set forth in SEQ ID NO:47; a CDRL1 comprising the sequence set forth in SEQ ID NO:48, a CDRL2 comprising the sequence set forth in SEQ ID NO:37; and a CDRL3 comprising the sequence set forth in SEQ ID NO:44. VH In some embodiments, the anti-NKG2C agent provided herein may comprise an immunoglobulin heavy chain variable domain (VH). In some embodiments, an immunoglobulin heavy chain variable domain (VH) of an anti-NKG2C agent provided herein comprises a polypeptide that is at least 80% identical to the amino acid sequence
NO: 1), e.g., 80% or more, 81% or more, 82% or more, 83% or more, 84% or more, 85% or more, 86% or more, 87% or more, 88% or more, 89% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more, identical to the amino acid sequence of SEQ ID NO: 1. In some embodiments, the VH comprises a polypeptide that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1. In some embodiments, the VH comprises a polypeptide that is at least 95% identical to the amino acid sequence of SEQ ID NO: 1. In
some embodiments, the VH comprises a polypeptide that is 100% identical to the amino acid sequence of SEQ ID NO: 1. In some embodiments, the VH comprises the sequence of amino acids set forth in SEQ ID NO: 1. In some embodiments, the anti-NKG2C agent provided herein may comprise a heavy chain variable domain (VH). In some embodiments, a heavy chain variable domain (VH) of an anti-NKG2C agent provided herein comprises a polypeptide that is at least 80% identical to the amino acid sequence
(SEQ ID NO: 2), e.g., 80% or more, 81% or more, 82% or more, 83% or more, 84% or more, 85% or more, 86% or more, 87% or more, 88% or more, 89% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more, identical to the amino acid sequence of SEQ ID NO: 2. In some embodiments, the VH comprises a polypeptide that is at least 90 % identical to the amino acid sequence of SEQ ID NO: 2. In some embodiments, the VH comprises a polypeptide that is at least 95 % identical to the amino acid sequence of SEQ ID NO: 2. In some embodiments, the VH comprises a polypeptide that is 100 % identical to the amino acid sequence of SEQ ID NO: 2. In some embodiments, the VH comprises the sequence of amino acids set forth in SEQ ID NO:2 In some embodiments, the anti-NKG2C agent provided herein may comprise a heavy chain variable domain (VH). In some embodiments, a heavy chain variable domain (VH) of an anti-NKG2C agent provided herein comprises a polypeptide that is at least 80% identical to the amino acid sequence D A
(SEQ ID NO: 3), e.g., 80% or more, 81% or more, 82% or more, 83% or more, 84% or more, 85% or more, 86% or more, 87% or more, 88% or more, 89% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more, identical to the amino acid sequence of SEQ ID NO: 3. In some embodiments, a VH comprises a polypeptide that is at least 90 % identical to the amino acid sequence of SEQ ID NO: 3. In some embodiments, a VH comprises a polypeptide that is at least 95 % identical to the amino acid sequence of SEQ ID NO: 3. In some embodiments, a VH comprises a polypeptide that is 100 % identical to the amino acid sequence of SEQ ID NO: 3. In some embodiments, the VH comprises the sequence of amino acids set forth in SEQ ID NO:3. In some embodiments, the anti-NKG2C agent provided herein may comprise a heavy chain variable domain (VH). In some embodiments, a heavy chain variable domain (VH) of an anti-NKG2C agent
provided herein comprises a polypeptide that is at least 80% identical to the amino acid sequence
Q Q (SEQ ID NO: 5), e.g., 80% or more, 81% or more, 82% or more, 83% or more, 84% or more, 85% or more, 86% or more, 87% or more, 88% or more, 89% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more, identical to the amino acid sequence of SEQ ID NO: 5. In some embodiments, a VH comprises a polypeptide that is at least 90% identical to the amino acid sequence of SEQ ID NO: 5. In some embodiments, a VH comprises a polypeptide that is at least 95% identical to the amino acid sequence of SEQ ID NO: 5. In some embodiments, a VH comprises a polypeptide that is 100% identical to the amino acid sequence of SEQ ID NO: 5. In some embodiments, the VH comprises the sequence of amino acids set forth in SEQ ID NO:5. In some embodiments, the anti-NKG2C agent provided herein may comprise a heavy chain variable domain (VH). In some embodiments, a heavy chain variable domain (VH) of an anti-NKG2C agent provided herein comprises a polypeptide that is at least 80% identical to the amino acid sequence E
Q QQ Q Q D
ID NO: 6), e.g., 80% or more, 81% or more, 82% or more, 83% or more, 84% or more, 85% or more, 86% or more, 87% or more, 88% or more, 89% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more, identical to the amino acid sequence of SEQ ID NO: 6. In some embodiments, a VH comprises a polypeptide that is at least 90% identical to the amino acid sequence of SEQ ID NO: 6. In some embodiments, a VH comprises a polypeptide that is at least 95 % identical to the amino acid sequence of SEQ ID NO: 6. In some embodiments, a VH comprises a polypeptide that is 100% identical to the amino acid sequence of SEQ ID NO: 6. In some embodiments, the VH comprises the sequence of amino acids set forth in SEQ ID NO:6. In some embodiments, the anti-NKG2C agent provided herein may comprise a heavy chain variable domain (VH). In some embodiments, a heavy chain variable domain (VH) of an anti-NKG2C agent provided herein comprises a polypeptide that is at least 80% identical to the amino acid sequence Q N
(SEQ ID NO: 7), e.g., 80% or more, 81% or more, 82% or more, 83% or more, 84% or more, 85% or more, 86% or more, 87% or more, 88% or more, 89% or more, 90% or more, 91% or more, 92% or more,
93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more, identical to the amino acid sequence of SEQ ID NO: 7. In some embodiments, a VH comprises a polypeptide that is at least 90% identical to the amino acid sequence of SEQ ID NO: 7. In some embodiments, a VH comprises a polypeptide that is at least 95% identical to the amino acid sequence of SEQ ID NO: 7. In some embodiments, a VH comprises a polypeptide that is 100% identical to the amino acid sequence of SEQ ID NO: 7. In some embodiments, the VH comprises the sequence of amino acids set forth in SEQ ID NO:7. In some embodiments, the anti-NKG2C agent provided herein may comprise a heavy chain variable domain (VH). In some embodiments, a heavy chain variable domain (VH) of an anti-NKG2C agent provided herein comprises a polypeptide that is at least 80% identical to the amino acid sequence
NO: 8), e.g., 80% or more, 81% or more, 82% or more, 83% or more, 84% or more, 85% or more, 86% or more, 87% or more, 88% or more, 89% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more, identical to the amino acid sequence of SEQ ID NO: 8. In some embodiments, a VH comprises a polypeptide that is at least 90% identical to the amino acid sequence of SEQ ID NO: 8. In some embodiments, a VH comprises a polypeptide that is at least 95% identical to the amino acid sequence of SEQ ID NO: 8. In some embodiments, a VH comprises a polypeptide that is 100 % identical to the amino acid sequence of SEQ ID NO: 8. In some embodiments, the VH comprises the sequence of amino acids set forth in SEQ ID NO:8. In some embodiments, a VH of an anti-NKG2C agent provided herein comprises a polypeptide chosen from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO: 8. In some embodiments, the VH of any of the anti-NKG2C agents provided herein further comprises a signal sequence. In some embodiments, VH signal sequence of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids set forth in SEQ ID NO: 90, 92 or 94. In some embodiments, VH signal sequence of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids set forth in SEQ ID NO:90. In some embodiments, VH signal sequence of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids set forth in SEQ ID NO:92. In some embodiments, VH signal sequence of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids set forth in SEQ ID NO:94.
VL In some embodiments, the anti-NKG2C agent provided herein may comprise an immunoglobulin light chain variable domain (VL). In some embodiments, a immunoglobulin light chain variable domain (VL) of an anti-NKG2C agent provided herein comprises a polypeptide that is at least 80% identical to the amino acid sequence Q
Q QQ A
Q ( Q NO: 9), e.g., 80% or more, 81% or more, 82% or more, 83% or more, 84% or more, 85% or more, 86% or more, 87% or more, 88% or more, 89% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more, identical to the amino acid sequence of SEQ ID NO: 9. In some embodiments, a VL comprises a polypeptide that is at least 90% identical to the amino acid sequence of SEQ ID NO: 9. In some embodiments, a VL comprises a polypeptide that is at least 95% identical to the amino acid sequence of SEQ ID NO: 9. In some embodiments, a VL comprises a polypeptide that is 100% identical to the amino acid sequence of SEQ ID NO: 9. In some embodiments, the VL comprises the sequence of amino acids set forth in SEQ ID NO: 9. In some embodiments, the anti-NKG2C agent provided herein may comprise an immunoglobulin light chain variable domain (VL). In some embodiments, an immunoglobulin light chain variable domain (VL) of an anti-NKG2C agent provided herein comprises a polypeptide that is at least 80% identical to the amino acid sequence D E
: 10), e.g., 80% or more, 81% or more, 82% or more, 83% or more, 84% or more, 85% or more, 86% or more, 87% or more, 88% or more, 89% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more, identical to the amino acid sequence of SEQ ID NO: 10. In some embodiments, a VL comprises a polypeptide that is at least 90% identical to the amino acid sequence of SEQ ID NO: 10. In some embodiments, a VL comprises a polypeptide that is at least 95% identical to the amino acid sequence of SEQ ID NO: 10. In some embodiments, a VL comprises a polypeptide that is 100% identical to the amino acid sequence of SEQ ID NO: 10. In some embodiments, the VL comprises the sequence of amino acids set forth in SEQ ID NO: 10. In some embodiments, any of the anti-NKG2C agents provided herein may comprise an immunoglobulin light chain variable domain (VL). In some embodiments, a light chain variable domain (VL) of an anti- NKG2C agent provided herein comprises a polypeptide that is at least 80% identical to the amino acid sequence D
ESGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPLTFGAGTKLELK (SEQ ID NO: 11), e.g., 80% or more, 81% or more, 82% or more, 83% or more, 84% or more, 85% or more, 86% or more, 87% or more, 88% or more, 89% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more, identical to the amino acid sequence of SEQ ID NO: 11. In some embodiments, a VL comprises a polypeptide that is at least 90 % identical to the amino acid sequence of SEQ ID NO: 11. In some embodiments, a VL comprises a polypeptide that is at least 95% identical to the amino acid sequence of SEQ ID NO: 11. In some embodiments, a VL comprises a polypeptide that is 100% identical to the amino acid sequence of SEQ ID NO: 11. In some embodiments, the VL comprises the sequence of amino acids set forth in SEQ ID NO: 11. In some embodiments, the anti-NKG2C agent provided herein may comprise an immunoglobulin light chain variable domain (VL). In some embodiments, an immunoglobulin light chain variable domain (VL) of an anti-NKG2C agent provided herein comprises a polypeptide that is at least 80% identical to the amino acid sequence D E
e.g., 80% or more, 81% or more, 82% or more, 83% or more, 84% or more, 85% or more, 86% or more, 87% or more, 88% or more, 89% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more, identical to the amino acid sequence of SEQ ID NO: 13. In some embodiments, a VL comprises a polypeptide that is at least 90 % identical to the amino acid sequence of SEQ ID NO: 13. In some embodiments, a VL comprises a polypeptide that is at least 95% identical to the amino acid sequence of SEQ ID NO: 13. In some embodiments, a VL comprises a polypeptide that is 100% identical to the amino acid sequence of SEQ ID NO: 13. In some embodiments, the VL comprises the sequence of amino acids set forth in SEQ ID NO: 13. In some embodiments, the anti-NKG2C agent provided herein may comprise an immunoglobulin light chain variable domain (VL). In some embodiments, an immunoglobulin light chain variable domain (VL) of an anti-NKG2C agent provided herein comprises a polypeptide that is at least 80% identical to the amino acid sequence
e.g., 80% or more, 81% or more, 82% or more, 83% or more, 84% or more, 85% or more, 86% or more, 87% or more, 88% or more, 89% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94%
or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more, identical to the amino acid sequence of SEQ ID NO: 14. In some embodiments, a VL comprises a polypeptide that is at least 90% identical to the amino acid sequence of SEQ ID NO: 14. In some embodiments, a VL comprises a polypeptide that is at least 95% identical to the amino acid sequence of SEQ ID NO: 14. In some embodiments, a VL comprises a polypeptide that is 100% identical to the amino acid sequence of SEQ ID NO: 14. In some embodiments, the VL comprises the sequence of amino acids set forth in SEQ ID NO: 14. In some embodiments, the anti-NKG2C agent provided herein may comprise an immunoglobulin light chain variable domain (VL). In some embodiments, an immunoglobulin light chain variable domain (VL) of an anti-NKG2C agent provided herein comprises a polypeptide that is at least 80% identical to the amino acid sequence S
(SEQ ID NO: 15), e.g., 80% or more, 81% or more, 82% or more, 83% or more, 84% or more, 85% or more, 86% or more, 87% or more, 88% or more, 89% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more, identical to the amino acid sequence of SEQ ID NO: 15. In some embodiments, a VL comprises a polypeptide that is at least 90 % identical to the amino acid sequence of SEQ ID NO: 15. In some embodiments, a VL comprises a polypeptide that is at least 95% identical to the amino acid sequence of SEQ ID NO: 15. In some embodiments, a VL comprises a polypeptide that is 100% identical to the amino acid sequence of SEQ ID NO: 15. In some embodiments, the VL comprises the sequence of amino acids set forth in SEQ ID NO: 15. In some embodiments, the anti-NKG2C agent provided herein may comprise an immunoglobulin light chain variable domain (VL). In some embodiments, an immunoglobulin light chain variable domain (VL) of an anti-NKG2C agent provided herein comprises a polypeptide that is at least 80% identical to the amino acid sequence N E
e.g., 80% or more, 81% or more, 82% or more, 83% or more, 84% or more, 85% or more, 86% or more, 87% or more, 88% or more, 89% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more, identical to the amino acid sequence of SEQ ID NO: 16. In some embodiments, a VL comprises a polypeptide that is at least 90% identical to the amino acid sequence of SEQ ID NO: 16. In some embodiments, a VL comprises a
polypeptide that is at least 95% identical to the amino acid sequence of SEQ ID NO: 16. In some embodiments, a VL comprises a polypeptide that is 100% identical to the amino acid sequence of SEQ ID NO: 16. In some embodiments, the VL comprises the sequence of amino acids set forth in SEQ ID NO: 16. In some embodiments, a VL of an anti-NKG2C agent provided herein comprises a polypeptide chosen from SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, and SEQ ID NO: 16. In some embodiments, the VL of any of the anti-NKG2C agents provided herein further comprises a signal sequence. In some embodiments, VL signal sequence of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids set forth in SEQ ID NO: 91, 93 or 95. In some embodiments, VL signal sequence of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids set forth in SEQ ID NO:91. In some embodiments, VL signal sequence of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids set forth in SEQ ID NO:93. In some embodiments, VL signal sequence of any of the anti-NKG2C agents provided herein comprises the sequence of amino acids set forth in SEQ ID NO:95. Fc In some embodiments, any of the anti-NKG2C agents provided herein may comprise a fragment crystallizable region (Fc region). An Fc region typically forms the tail of an antibody and can interact with certain cell surface receptors and certain components of the complement system. An Fc region may include, for example, two polypeptides, each derived from the second (CH2) and third (CH3) constant domains of an antibody heavy chain. The amino acid sequence of a wild-type CH2-CH3 portion of an Fc region is provided below (positioning is as in the EU index as in Kabat et al. (1992) SEQUENCES OF PROTEINS OF IMMUNOLOGICAL INTEREST, National Institutes of Health Publication No.91-3242) (SEQ ID NO:57).
In some embodiments, an Fc region includes one or more modifications (e.g., one or more amino acid substitutions, insertions, or deletions relative to a comparable wild-type Fc region). Agents comprising modified Fc regions (variant agents) typically have altered phenotypes relative to agents comprising wild- type Fc regions. A variant agent phenotype may be expressed as altered serum half-life, altered stability, altered susceptibility to cellular enzymes, or altered effector function (e.g., as assayed in an NK dependent or macrophage dependent assay). Fc region modifications that alter effector function may include modifications that increase binding to activating receptors (e.g., FcγRIIA (CD16A) and reduce binding to inhibitory receptors (e.g., FcγRIIB (CD32B) (see, e.g., Stavenhagen, J.B. et al. (2007) Cancer Res.57(18):8882-8890)). Examples of variants of human IgG1 Fc regions with reduced binding to CD32B and/or increased binding to CD16A contain F243L, R292P, Y300L, V305I and/or P396L substitutions. Amino acid positions correspond to the amino acid numbering of the CH2-CH3 domain provided above. In some embodiments, an Fc region includes one or more modifications that reduce or abrogate binding of the Fc to Fc receptors. Such modifications may include amino acid substitutions at positions 234, 235, 265 and 297 (see e.g., U.S. Patent No 5,624,821, which is incorporated by reference herein). Example substitutions include one or more of L234A, L235A, D265A and N297Q. Amino acid positions correspond to the amino acid numbering of the CH2-CH3 domain provided above. In some embodiments, an Fc region includes one or more modifications that alter (relative to a wild-type Fc region) the Ratio of Affinities of the modified Fc region to an activating FcγR (such as FcγRIIA or FcγRIIIA) relative to an inhibiting FcγR (such as FcγRIIB):
Where a modified Fc region has a Ratio of Affinities greater than 1, an anti-NKG2C agent herein may have particular use in providing a therapeutic or prophylactic treatment of a disease, disorder, or infection, or the amelioration of a symptom thereof, where an enhanced efficacy of effector cell function (e.g., ADCC) mediated by FcγR is desired, e.g., cancer or infectious disease. Where a modified Fc region has a Ratio of Affinities less than 1, an anti-NKG2C agent herein may have particular use in providing a therapeutic or prophylactic treatment of a disease or disorder, or the amelioration of a symptom thereof, where a decreased efficacy of effector cell function mediated by FcγR is desired, e.g., autoimmune or inflammatory disorders. Table 3 lists example single, double, triple, quadruple and quintuple amino acid substitutions having a Ratio of Affinities greater than 1 or less than 1 (see e.g., PCT Publication Nos. WO 04/063351; WO 06/088494; WO 07/024249; WO 06/113665; WO 07/021841; WO 07/106707; WO 2008/140603, each of which is incorporated by reference herein). Amino acid positions correspond to the amino acid numbering of the CH2-CH3 domain provided above.
Agents that competitively bind with an anti-NKG2C agent Provided herein are anti-NKG2C agents that competitively bind, or are capable of competitively binding, with one or more anti-NKG2C agents described herein. In particular, provided herein are anti-NKG2C agents that compete, or are capable of competing, with one or more anti-NKG2C agents described herein for binding to NKG2C. Such agents that compete, or are capable of competing, with anti-NKG2C agents described herein may be referred to as competitor agents. In certain instances, an agent (i.e., competitor agent) may be considered to compete for binding to NKG2C when the competitor binds to the same general region of NKG2C as an anti-NKG2C agent described herein (i.e., extracellular region or leucine- rich binding domain). In certain instances, an agent (i.e., competitor agent) may be considered to compete
for binding to NKG2C when the competitor binds to the exact same region of NKG2C as an anti-NKG2C agent described herein (e.g., exact same peptide (linear epitope) or exact same surface amino acids (conformational epitope)). In certain instances, an agent (i.e., competitor agent) may be considered capable of competing for binding to NKG2C when the competitor binds to the same general region of NKG2C as an anti-NKG2C agent described herein (i.e., extracellular region or leucine-rich binding domain) under suitable assay conditions. In certain instances, an agent (i.e., competitor agent) may be considered capable of competing for binding to NKG2C when the competitor binds to the exact same region of NKG2C as an anti-NKG2C agent described herein (e.g., exact same peptide (linear epitope) or exact same surface amino acids (conformational epitope)) under suitable assay conditions. In certain instances, an agent (i.e., competitor agent) may be considered to compete for binding to NKG2C when the competitor blocks the binding of one or more anti-NKG2C agents described herein to NKG2C. In certain instances, an agent (i.e., competitor agent) may be considered capable of competing for binding to NKG2C when the competitor blocks the binding of one or more anti-NKG2C agents described herein to NKG2C under suitable assay conditions. Whether a competitor blocks the binding of one or more anti-NKG2C agents described herein to NKG2C may be determined using a suitable competition assay or blocking assay, such as, for example, a blocking assay as described in Example x herein. A competitor agent may block binding of one or more anti-NKG2C agents described herein to NKG2C in a competition or blocking assay by 50% or more, and conversely, one or more anti-NKG2C agents described herein may block binding of the competitor agent to NKG2C in a competition or blocking assay by about 50% or more. For example, an agent (i.e., competitor agent) may block binding of one or more anti-NKG2C agents described herein to NKG2C in a competition or blocking assay by about 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%, and conversely, one or more anti- NKG2C agents described herein may block binding of the competitor agent to NKG2C in a competition or blocking assay by about 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%. In certain instances, an agent (i.e., competitor agent) may be considered to compete for binding to NKG2C when the competitor binds to NKG2C with a similar affinity as one or more anti-NKG2C agents described herein. In certain instances, an agent (i.e., competitor agent) may be considered capable of competing for binding to NKG2C when the competitor binds to NKG2C with a similar affinity as one or more anti-NKG2C agents described herein under suitable assay conditions. In some embodiments, an agent (i.e., competitor agent) is considered to compete for binding to NKG2C when the competitor binds to NKG2C with an affinity that is at least about 50% of the affinity of one or more anti-NKG2C agents described herein. For example, an agent (i.e., competitor agent) may be considered to compete for
binding to NKG2C when the competitor binds to NKG2C with an affinity that is at least about 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% of the affinity of one or more anti-NKG2C agents described herein. A competitor agent may comprise any feature described herein for anti-NKG2C agents. Also provided herein are anti-NKG2C agents that bind to, or are capable of binding to, the same epitope as one or more anti-NKG2C agents described herein. In particular, provided herein are anti-NKG2C agents that compete with one or more anti-NKG2C agents described herein for binding to the same epitope on NKG2C. Such agents that bind the same epitope may be referred to as epitope competitors. In certain instances, an epitope competitor may bind to the exact same region of NKG2C as an anti-NKG2C agent described herein (e.g., exact same peptide (linear epitope) or exact same surface amino acids (conformational epitope)). In certain instances, epitope competitor blocks the binding of one or more anti-NKG2C agents described herein to NKG2C. An epitope competitor may block binding of one or more anti-NKG2C agents described herein to NKG2C in a competition assay by about 50% or more, and conversely, one or more anti-NKG2C agents described herein may block binding of the epitope competitor to NKG2C in a competition assay by 50% or more. In certain instances, an epitope competitor binds to NKG2C with a similar affinity as one or more anti-NKG2C agents described herein. In some embodiments, an epitope competitor binds to NKG2C with an affinity that is at least about 50% of the affinity of one or more anti-NKG2C agents described herein. For example, an epitope competitor may bind to NKG2C with an affinity that is at least about 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% of the affinity of one or more anti-NKG2C agents described herein. An epitope competitor may comprise any feature described herein for anti-NKG2C agents. Antibody Preparation In some embodiments, an anti-NKG2C agent is an antibody. In some embodiments, any of the anti- NKG2C agents provided herein is an antibody or antigen-binding fragment thereof. Methods for generating anti-NKG2C antibodies, antigen-binding fragments thereof and variants of anti-NKG2C antibodies are described in the Examples below. In some embodiments, an anti-NKG2C agent is a humanized antibody, or an antigen binding fragment thereof. In some embodiments, an anti-NKG2C agent is a humanized antibody, or a derivative thereof that binds NKG2C. Humanized anti-NKG2C antibodies may be prepared based on a nonhuman anti-NKG2C antibody. Fully human antibodies may also be prepared, e.g., in a genetically engineered (i.e., transgenic) mouse (e.g., from Medarex) that, when presented with an immunogen, can produce a human antibody that does not necessarily require CDR grafting. These antibodies are fully human (100% human protein sequences) from animals such as mice in which the non-human antibody genes are suppressed and replaced with human antibody gene expression.
Antibodies may be generated against NKG2C when presented to these genetically engineered mice or other animals that can to produce human frameworks for the relevant CDRs. Where a variant is generated, the parent antibody is prepared. Example techniques for generating such nonhuman antibody and parent antibodies are described in the following sections. Antigen Preparation The antigen for production of antibodies may be, e.g., intact NKG2C, particularly expressed in cells, or a portion of NKG2C (e.g. N-terminal domain, C-terminal domain, a cytoplasmic domain, an intra-organelle domain, a transmembrane domain, an extracellular domain, an ectodomain, a TIR domain, a leucine-rich domain, or a NKG2C fragment comprising a desired epitope). Other forms of antigens useful for generating antibodies will be apparent to those skilled in the art. Polyclonal Antibodies Polyclonal antibodies may be raised in animals (vertebrate or invertebrates, including mammals, birds and fish, including cartilaginous fish) by multiple subcutaneous (sc) or intraperitoneal (ip) injections of a relevant antigen and an adjuvant. It may be useful to conjugate the relevant antigen to a protein or other carrier that is immunogenic in the species to be immunized, e.g., keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, or soybean trypsin inhibitor using a bifunctional or derivatizing agent, for example, maleimidobenzoyl sulfosuccinimide ester (conjugation through cysteine residues), N- hydroxysuccinimide (through lysine residues), glutaraldehyde, succinic anhydride, SOCl2, or R1N=C=NR, where R and R1 are different alkyl groups. Non-protein carriers (e.g., colloidal gold) also may be used for antibody production. In some embodiments, animals are immunized against the antigen, immunogenic conjugates, or derivatives by combining, e.g., 100 µg or 5 µg of the protein or conjugate (for rabbits or mice, respectively) with three volumes of Freund's complete adjuvant and injecting the solution intradermally at multiple sites. One month later the animals are boosted with one-fifth to one-tenth of the original amount of peptide or conjugate in Freund's complete adjuvant by subcutaneous injection at multiple sites. Seven to 14 days later the animals are bled and the serum is assayed for antibody titer. Animals are boosted until the titer plateaus. Often, the animal is boosted with the conjugate of the same antigen, but conjugated to a different protein and/or through a different cross-linking reagent. Conjugates also can be made in
recombinant cell culture as protein fusions. Also, aggregating agents such as alum are suitably used to enhance the immune response. Monoclonal Antibodies Monoclonal antibodies may be made using the hybridoma method first described by Kohler et al., Nature, 256:495 (1975), or may be made by other methods such as recombinant DNA methods (U.S. Pat. No. 4,816,567). In the hybridoma method, a mouse or other appropriate host animal, such as a hamster or macaque monkey, is immunized as hereinabove described to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the protein used for immunization. Alternatively, lymphocytes may be immunized in vitro. Lymphocytes then are fused with myeloma cells using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding, Monoclonal Antibodies: Principles and Practice, pp.59-103 (Academic Press, 1986)). In some embodiments, hybridoma cells are seeded and grown in a suitable culture medium that may contain one or more substances that inhibit the growth or survival of the unfused, parental myeloma cells. For example, if the parental myeloma cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine (HAT medium), which substances prevent the growth of HGPRT-deficient cells. Preferred myeloma cells are those that fuse efficiently, support stable high-level production of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. Among these, preferred myeloma cell lines are murine myeloma lines, such as SP-2 or X63-Ag8-653 cells available from the American Type Culture Collection, Rockville, Md. USA. Human myeloma and mouse- human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies (Kozbor, J. Immunol., 133:3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications, pp.51-63 (Marcel Dekker, Inc., New York, 1987)). Culture medium in which hybridoma cells are growing is assayed for production of monoclonal antibodies directed against the antigen. The binding specificity of monoclonal antibodies produced by hybridoma cells may be determined by immunoprecipitation, by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbant assay (ELISA), or by flow cytometric analysis of cells expressing the membrane antigen. The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson et al., Anal. Biochem., 107:220 (1980). 66
After hybridoma cells are identified that produce antibodies of the desired specificity, affinity, and/or activity, the clones may be subcloned by limiting dilution procedures and grown by standard methods (Goding, Monoclonal Antibodies: Principles and Practice, pp.59-103 (Academic Press, 1986)). Suitable culture media for this purpose include, for example, D-MEM or RPMI-1640 medium. In addition, the hybridoma cells may be grown in vivo as ascites tumors in an animal. The monoclonal antibodies secreted by the subclones are suitably separated from the culture medium, ascites fluid, or serum by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography. DNA encoding the monoclonal antibodies is readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the monoclonal antibodies). Alternatively, cDNA may be prepared from mRNA and the cDNA then subjected to DNA sequencing. The hybridoma cells serve as a preferred source of such genomic DNA or RNA for cDNA preparation. Once isolated, the DNA may be placed into expression vectors, which are well known in the art, and which are then transfected into host cells such as E coli cells, simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. Recombinant production of antibodies will be described in more detail below. Humanization and Amino Acid Sequence Variants General methods for humanization of antibodies are described, for example, in U.S. Patent Nos.5861155, 6479284, 6407213, 6639055, 6500931, 5530101, 5585089, 5693761, 5693762, 6180370, 5714350, 6350861, 5777085, 5834597, 5882644, 5932448, 6013256, 6129914, 6210671, 6329511, 5225539, 6548640, and 5624821, each of which is incorporated by reference herein. In certain embodiments, it may be desirable to generate amino acid sequence variants of these humanized antibodies, particularly where these improve the binding affinity or other biological properties of the antibody. Amino acid sequence variants of the anti-NKG2C antibody are prepared by introducing appropriate nucleotide changes into the anti-NKG2C antibody DNA, or by peptide synthesis. Such variants include, for example, deletions from, and/or insertions into and/or substitutions of, residues within the amino acid sequences of the anti-NKG2C antibodies of the examples herein. Any combination of deletion, insertion, and substitution is made to arrive at the final construct, provided that the final construct possesses the desired characteristics. The amino acid changes also may alter post-translational processes of the
humanized or variant anti-NKG2C antibody, such as changing the number or position of glycosylation sites. One method for identification of certain residues or regions of the anti-NKG2C antibody that are preferred locations for mutagenesis is called “alanine scanning mutagenesis,” as described by Cunningham and Wells Science, 244:1081-1085 (1989). Here, a residue or group of target residues are identified (e.g., charged residues such as arg, asp, his, lys, and glu) and replaced by a neutral or negatively charged amino acid (most preferably alanine or polyalanine) to affect the interaction of the amino acids with NKG2C antigen. Those amino acid locations demonstrating functional sensitivity to the substitutions then are refined by introducing further or other variants at, or for, the sites of substitution. Thus, while the site for introducing an amino acid sequence variation is predetermined, the nature of the mutation per se need not be predetermined. For example, to analyze the performance of a mutation at a given site, alanine scanning or random mutagenesis is conducted at the target codon or region and the expressed anti- NKG2C antibody variants are screened for the desired activity. Amino acid sequence insertions include amino- and/or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as intra-sequence insertions of single or multiple amino acid residues. Examples of terminal insertions include an N-terminal methionyl residue or the antibody fused to an epitope tag. Other insertional variants include the fusion of an enzyme or a polypeptide that increases the serum half-life of the antibody to the N- or C-terminus of the antibody. Another type of variant is an amino acid substitution variant. These variants have at least one amino acid residue removed from the antibody molecule and a different residue inserted in its place. The sites of greatest interest for substitutional mutagenesis include the hypervariable regions, but FR alterations are also contemplated. Conservative substitutions are preferred, but more substantial changes may be introduced and the products may be screened. Examples of substitutions are listed below: Example Amino Acid Residue Substitutions
Substantial modifications in the biological properties of an antibody are accomplished by selecting substitutions that differ significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain. Naturally occurring residues are divided into groups based on common side-chain properties: (1) hydrophobic: norleucine, met, ala, val, leu, ile; (2) neutral hydrophilic: cys, ser, thr; (3) acidic: asp, glu; (4) basic: asn, gln, his, lys, arg; (5) residues that influence chain orientation: gly, pro; and (6) aromatic: trp, tyr, phe. Non-conservative substitutions will entail exchanging a member of one of these classes for another class. Any cysteine residue not involved in maintaining the proper conformation of the antibody also may be substituted, to improve the oxidative stability of the molecule and prevent aberrant crosslinking. Conversely, cysteine bond(s) may be added to the antibody to improve its stability (particularly where the antibody is an antibody fragment such as an Fv fragment). One type of substitutional variant involves substituting one or more hypervariable region residues of a parent antibody (e.g. a humanized or human antibody). Generally, the resulting variant(s) selected for
further development will have improved biological properties relative to the parent antibody from which they are generated. A convenient way for generating such substitutional variants is affinity maturation using phage display. Briefly, several hypervariable region sites (e.g.6-7 sites) are mutated to generate all possible amino substitutions at each site. The antibody variants thus generated are displayed in a monovalent fashion from filamentous phage particles as fusions to the gene III product of M13 packaged within each particle. The phage-displayed variants are then screened for their biological activity (e.g. binding affinity) as herein disclosed. In order to identify candidate hypervariable region sites for modification, alanine-scanning mutagenesis can be performed to identify hypervariable region residues contributing significantly to antigen binding. Alternatively, or in addition, it may be beneficial to analyze a crystal structure of the antigen-antibody complex to identify contact points between the antibody and antigen. Such contact residues and neighboring residues are candidates for substitution according to the techniques elaborated herein. Once such variants are generated, the panel of variants is subjected to screening as described herein and antibodies with superior properties in one or more relevant assays may be selected for further development. Another type of amino acid variant of the antibody alters the original glycosylation pattern of the antibody. By altering is meant deleting one or more carbohydrate moieties found in the antibody, and/or adding one or more glycosylation sites that are not present in the antibody. Glycosylation of antibodies is typically either N-linked and/or or O-linked. N-linked refers to the attachment of the carbohydrate moiety to the side chain of an asparagine residue. The tripeptide sequences asparagine-X-serine and asparagine- X-threonine, where X is any amino acid except proline, are the most common recognition sequences for enzymatic attachment of the carbohydrate moiety to the asparagine side chain. Thus, the presence of either of these tripeptide sequences in a polypeptide creates a potential glycosylation site. O-linked glycosylation refers to the attachment of one of the sugars N-acetylgalactosamine, galactose, or xylose to a hydroxyamino acid, most commonly serine or threonine, although 5-hydroxyproline or 5-hydroxylysine may also be used. Addition of glycosylation sites to the antibody is conveniently accomplished by altering the amino acid sequence such that it contains one or more of the above-described tripeptide sequences (for N-linked glycosylation sites). The alteration may also be made by the addition of, or substitution by, one or more serine or threonine residues to the sequence of the original antibody (for O-linked glycosylation sites). Nucleic acid molecules encoding amino acid sequence variants of anti-NKG2C antibodies herein are prepared by a variety of methods known in the art. These methods include, but are not limited to,
isolation from a natural source (in the case of naturally occurring amino acid sequence variants) or preparation by oligonucleotide-mediated (or site-directed) mutagenesis, PCR mutagenesis, and cassette mutagenesis of an earlier prepared variant or a non-variant version of an anti-NKG2C antibody. Human Antibodies As an alternative to humanization, human antibodies can be generated. For example, transgenic animals (e.g., mice) may be generated that are capable, upon immunization, of producing a full repertoire of human antibodies in the absence of endogenous immunoglobulin production. For example, a homozygous deletion of the antibody heavy-chain joining region (JH) gene in chimeric and germ-line mutant mice results in complete inhibition of endogenous antibody production. Transfer of the human germ-line immunoglobulin gene array into such germ-line mutant mice can result in the production of human antibodies upon antigen challenge (see, e.g., Jakobovits et al., Proc. Natl. Acad. Sci. USA, 90:2551 (1993); Jakobovits et al., Nature, 362:255-258(1993); Bruggermann et al., Year in Immuno., 7:33 (1993); and U.S. Pat. Nos.5,591,669, 5,589,369 and 5,545,807). Human antibodies also can be derived from phage-display libraries (Hoogenboom et al., J. Mol. Biol., 227:381 (1991); Marks et al., J. Mol. Biol., 222:581-597 (1991); and U.S. Pat. Nos.5,565,332 and 5,573,905). Human antibodies also may be generated by in vitro activated B cells (see U.S. Pat. Nos.5,567,610 and 5,229,275). Antigen-Binding Antibody Fragments In certain embodiments, an anti-NKG2C agent is an antibody fragment that retains at least one desired activity, including antigen binding. Various techniques have been developed for the production of antibody fragments. In some instances, these fragments are derived via proteolytic digestion of intact antibodies (see, e.g., Morimoto et al., Journal of Biochemical and Biophysical Methods 24:107-117(1992) and Brennan et al., Science 229:81 (1985)). In some instances, these fragments are produced directly by recombinant host cells. For example, Fab'-SH fragments can be directly recovered from E. coli and chemically coupled to form F(ab')2 fragments (Carter et al., Bio/Technology 10:163-167 (1992)). In some instances, the F(ab')2 is formed using the leucine zipper GCN4 to promote assembly of the F(ab')2 molecule. According to another approach, Fv, Fab or F(ab')2 fragments can be isolated directly from recombinant host cell culture. Other techniques for the production of antibody fragments will be apparent to the skilled practitioner.
Multispecific Antibodies and other Agents In some embodiments, an anti-NKG2C agent comprises a first binding moiety and a second binding moiety, where the first binding moiety is specifically reactive with a first molecule that is NKG2C and the second binding moiety is specifically reactive with a second molecule that is a molecular species different from the first molecule. Such agents may comprise a plurality of first binding moieties, a plurality of second binding moieties, or a plurality of first binding moieties and a plurality of second binding moieties. Preferably, the ratio of first binding moieties to second binding moieties is about 1:1, although it may range from about 1000:1 to about 1:1000, where the ratio may be measured in terms of valency. In those embodiments where the first moiety is an antibody, the second binding moiety may also be an antibody. In some embodiments, the first and second moieties are linked via a linker moiety, which may have two to many 100’s or even thousands of valencies for attachment of first and second binding moieties by one or different chemistries. Examples of bispecific antibodies include those that are reactive against two different epitopes; in some instances, one epitope is a NKG2C epitope and the second epitope is on an unrelated soluble molecule. In some embodiments, the bispecific antibody is reactive against an epitope on NKG2C and against an epitope on a different molecule found on the surface of the same cell. In some embodiments, the bispecific antibody is reactive against an epitope on NKG2C and against an epitope on a different molecule found on the surface of a different cell. Compositions herein may also comprise a first agent and a second agent, where the first agent comprises a first binding moiety specifically reactive with a first molecule (e.g., NKG2C) and the second agent comprises a second binding moiety specifically reactive with a second molecule that is a molecular species different than the first molecule. The first and/or second agent may be an antibody. The ratio of first agent to second agent may range from about 1,000:1 to 1: 1,000, although the preferred ratio is about 1:1. In some embodiments, it may be desirable to generate multispecific (e.g. bispecific) anti-NKG2C antibodies having binding specificities for at least two different epitopes. Certain bispecific antibodies may bind to two different epitopes of NKG2C. Bispecific antibodies can be prepared as full-length antibodies or antibody fragments (e.g., F(ab')2 bispecific antibodies). According to one for making bispecific antibodies, the interface between a pair of antibody molecules can be engineered to maximize the percentage of heterodimers that are recovered from recombinant cell culture. The preferred interface comprises at least a part of the CH3 domain of an antibody constant domain. In this method, one or more small amino acid side chains from the interface of the first antibody molecule are replaced with larger side chains (e.g., tyrosine or tryptophan). Compensatory “cavities” of
identical or similar size to the large side chain(s) are created on the interface of the second antibody molecule by replacing large amino acid side chains with smaller ones (e.g., alanine or threonine). This provides a mechanism for increasing the yield of the heterodimer over other unwanted end-products such as homodimers (see e.g., WO96/27011 published Sep.6, 1996). Bispecific antibodies include cross-linked or “heteroconjugate” antibodies. For example, one of the antibodies in the heteroconjugate can be coupled to avidin, the other to biotin. Heteroconjugate antibodies may be made using any convenient cross-linking methods. Suitable cross-linking agents are well known in the art, and are disclosed in U.S. Pat. No.4,676,980, along with a number of cross-linking techniques. Any suitable technique may be used for generating bispecific antibodies from antibody fragments. For example, bispecific antibodies can be prepared using chemical linkage. In certain methods, intact antibodies are proteolytically cleaved to generate F(ab')2 fragments (see e.g., Brennan et al., Science 229:81 (1985), which is incorporated by reference herein). These fragments are reduced in the presence of the dithiol complexing agent sodium arsenite to stabilize vicinal dithiols and prevent intermolecular disulfide formation. The Fab' fragments generated are then converted to thionitrobenzoate (TNB) derivatives. One of the Fab'-TNB derivatives is then reconverted to the Fab'-thiol by reduction with mercaptoethylamine and is mixed with an equimolar amount of the other Fab'-TNB derivative to form the bispecific antibody. In yet a further embodiment, Fab'-SH fragments directly recovered from E. coli can be chemically coupled in vitro to form bispecific antibodies (see e.g., Shalaby et al., J. Exp. Med. 175:217-225 (1992), which is incorporated by reference herein). Any suitable technique for making and isolating bispecific antibody fragments directly from recombinant cell culture may be used. For example, bispecific antibodies have been produced using leucine zippers (see e.g., Kostelny et al., J. Immunol.148(5):1547-1553 (1992), which is incorporated by reference herein). The leucine zipper peptides from the Fos and Jun proteins were linked to the Fab' portions of two different antibodies by gene fusion. The antibody homodimers were reduced at the hinge region to form monomers and then re-oxidized to form the antibody heterodimers. This method can also be utilized for the production of antibody homodimers. The “diabody” technology described by Hollinger et al., Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993) has provided an alternative mechanism for making bispecific antibody fragments. The fragments comprise a heavy-chain variable domain (VH) connected to a light- chain variable domain (VL) by a linker that is too short to allow pairing between the two domains on the same chain. Accordingly, the VH and VL domains of one fragment are forced to pair with the complementary VL and VH domains of another fragment, thereby forming two antigen-binding sites.
Another strategy for making bispecific antibody fragments by the use of single-chain Fv (scFv) dimers (see e.g., Gruber et al., J. Immunol.152:5368 (1994), which is incorporated by reference herein). In certain instances, a bispecific antibody may be a “linear antibody” produced as described in Zapata et al. Protein Eng.8(10):1057-1062 (1995), which is incorporated by reference herein. Antibodies with two valencies or more are contemplated herein. An antibody (or polymer or polypeptide) herein comprising one or more binding sites per arm or fragment thereof will be referred to herein as “multivalent” antibody. For example, a “bivalent” antibody herein comprises two binding sites per Fab or fragment thereof whereas a “trivalent” polypeptide herein comprises three binding sites per Fab or fragment thereof. In a multivalent polymer herein, the two or more binding sites per Fab may be binding to the same or different antigens. For example, the two or more binding sites in a multivalent polypeptide herein may be directed against the same antigen, for example against the same parts or epitopes of said antigen or against two or more same or different parts or epitopes of said antigen; and/or may be directed against different antigens; or a combination thereof. Thus, a bivalent polypeptide herein, for example, may comprise two identical binding sites, may comprise a first binding sites directed against a first part or epitope of an antigen and a second binding site directed against the same part or epitope of said antigen or against another part or epitope of said antigen; or may comprise a first binding sites directed against a first part or epitope of an antigen and a second binding site directed against a different antigen. However, as will be clear from the description hereinabove, the technology herein is not limited thereto, in the sense that a multivalent polypeptide herein may comprise any number of binding sites directed against the same or different antigens. In one embodiment the multivalent polypeptide comprises at least two ligand binding elements, one of which contains one or more CDR peptide sequences shown herein. In another embodiment the multivalent polypeptide comprises three ligand binding sites, each independently selected from the CDR sequences disclosed herein. In certain embodiments, at least one of the ligand binding elements binds NKG2C. In one embodiment, at least one of the ligand binding elements binds another target. In one embodiment, there are up to 10,000 binding elements in a multivalent binding molecule, and the ligand binding elements may be linked to a scaffold. An antibody (or polymer or polypeptide) herein that contains at least two binding sites per Fab or fragment thereof, in which at least one binding site is directed against a first antigen and a second binding site directed against a second antigen different from the first antigen, may also be referred to as “multispecific.” Thus, a “bispecific” polymer comprises at least one site directed against a first antigen
and at least one second site directed against a second antigen, whereas a “trispecific” is a polymer that comprises at least one binding site directed against a first antigen, at least one further binding site directed against a second antigen, and at least one further binding site directed against a third antigen; and the like. Accordingly, in their simplest form, a bispecific polypeptide herein is a bivalent polypeptide (per Fab) of the technology provided herein. However, as will be clear from the description hereinabove, the technology herein is not limited thereto, in the sense that a multispecific polypeptide herein may comprise any number of binding sites directed against two or more different antigens. Other Modifications Other modifications of an anti-NKG2C agent are contemplated. For example, technology herein also pertains to immunoconjugates comprising an antibody described herein (e.g., an anti-NKG2C antibody) conjugated to a cytotoxic agent such as a toxin (e.g., an enzymatically active toxin of bacterial, fungal, plant or animal origin, or fragments thereof), or a radioactive isotope (for example, a radioconjugate), or a cytotoxic drug. Such conjugates are sometimes referred to as “agent-drug conjugates” or “ADC”. Conjugates are made using a variety of bifunctional protein coupling agents such as N-succinimidyl-3-(2- pyridyldithiol) propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis (p-azidobenzoyl)hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as tolyene 2,6- diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). Anti-NKG2C agents (e.g., anti-NKG2C antibodies) disclosed herein may be formulated as immunoliposomes. Liposomes containing an antibody are prepared by methods known in the art, such as described in Epstein et al., Proc. Natl. Acad. Sci. USA 82:3688 (1985); Hwang et al., Proc. Natl Acad. Sci. USA 77:4030 (1980); and U.S. Pat. Nos.4,485,045 and 4,544,545. Liposomes with enhanced circulation time are disclosed in U.S. Pat. No.5,013,556. For example, liposomes can be generated by the reverse phase evaporation method with a lipid composition comprising phosphatidyl choline, cholesterol and PEG-derivatized phosphatidylethanolamine (PEG-PE). Liposomes are extruded through filters of defined pore size to yield liposomes with the desired diameter. Fab' fragments of an antibody provided herein can be conjugated to the liposomes as described in Martin et al., J. Biol. Chem.257:286-288 (1982) via a disulfide interchange reaction. Another active ingredient is optionally contained within the liposome.
Enzymes or other polypeptides can be covalently bound to an anti-NKG2C agent (e.g., anti-NKG2C antibody) by techniques well known in the art such as the use of the heterobifunctional cross-linking reagents discussed above. In some embodiments, fusion proteins comprising at least the antigen binding region of an antibody provided herein linked to at least a functionally active portion of an enzyme can be constructed using recombinant DNA techniques well known in the art (see, e.g., Neuberger et al., Nature 312:604-608 (1984)). In certain embodiments, it may be desirable to use an antibody fragment, rather than an intact antibody, to increase penetration of target tissues and cells, for example. In such instances, it may be desirable to modify the antibody fragment in order to increase its serum half-life. This may be achieved, for example, by incorporation of a salvage receptor binding epitope into the antibody fragment (e.g., by mutation of the appropriate region in the antibody fragment or by incorporating the epitope into a peptide tag that is then fused to the antibody fragment at either end or in the middle, e.g., by DNA or peptide synthesis; see, e.g., WO96/32478 published Oct.17, 1996). Covalent modifications of an anti-NKG2C agent (e.g., anti-NKG2C antibody) are also included within the scope of this technology. For example, modifications may be made by chemical synthesis or by enzymatic or chemical cleavage of an anti-NKG2C antibody. Other types of covalent modifications of an antibody are introduced into the molecule by reacting targeted amino acid residues of the antibody with an organic derivatizing agent that is capable of reacting with selected side chains or the N- or C-terminal residues. Example covalent modifications of polypeptides are described in U.S. Pat. No.5,534,615, specifically incorporated herein by reference. A preferred type of covalent modification of the antibody comprises linking the antibody to one of a variety of non-proteinaceous polymers, e.g., polyethylene glycol, polypropylene glycol, or polyoxyalkylenes, in the manner set forth in U.S. Pat. Nos.4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192 or 4,179,337. Nucleic acids, vectors, host cells, and recombinant methods Provided herein are isolated nucleic acids encoding any of the anti-NKG2C agents (e.g., anti-NKG2C antibody) described herein, and vectors and host cells comprising any of the nucleic acids provided herein, and recombinant techniques for the production of the agent or antibody. A nucleic acid herein may include one or more subsequences, each referred to as a polynucleotide. Provided herein are nucleic acids (e.g., isolated nucleic acids) comprising a nucleotide sequence that encodes an anti-NKG2C agent or antibody, or fragment thereof. In some embodiments, a nucleic acid
encodes an immunoglobulin heavy chain variable domain of an anti-NKG2C agent provided herein. In some embodiments, the immunoglobulin heavy chain variable domain is encoded by the sequence of nucleotides set forth in any of SEQ ID NOs: 74, 76, 78, 80, 82, 84, 86 and 88, or sequence of nucleotides having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to any of SEQ ID NOs: 74, 76, 78, 80, 82, 84, 86 and 88. In some embodiments, the immunoglobulin heavy chain variable domain is encoded by the sequence of nucleotides set forth in any of SEQ ID NOs: 74, 76, 78, 80, 82, 84, 86 and 88. In some embodiments, the immunoglobulin heavy chain variable domain is encoded by the sequence of nucleotides set forth in any of SEQ ID NOs: 58, 60, 62, 64, 66, 68, 70 and 72, or sequence of nucleotides having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to any of SEQ ID NOs: 58, 60, 62, 64, 66, 68, 70 and 72. In some embodiments, the immunoglobulin heavy chain variable domain contains a signal sequence and is encoded by the sequence of nucleotides set forth in any of SEQ ID NOs:58, 60, 62, 64, 66, 68, 70 and 72. In some embodiments, a nucleic acid encodes an immunoglobulin light chain variable domain of an anti- NKG2C agent provided herein. In some embodiments, the immunoglobulin light chain variable domain does not contain a signal sequence, and is encoded by the sequence of nucleotides set forth in any of SEQ ID NOs:75, 77, 79, 81, 83, 85, 87, and 89 or sequence of nucleotides having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to any of SEQ ID NOs: 75, 77, 79, 81, 83, 85, 87, and 89. In some embodiments, the immunoglobulin light chain variable domain does not contain a signal sequence, and is encoded by the sequence of nucleotides set forth in any of SEQ ID NOs: 59, 61, 63, 65, 67, 69, 71, and 73. or sequence of nucleotides having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to any of SEQ ID NOs: 59, 61, 63, 65, 67, 69, 71, and 73. In some embodiments, the immunoglobulin light chain variable domain does contain a signal sequence, and is encoded by the sequence of nucleotides set forth in any of SEQ ID NOs:59, 61, 63, 65, 67, 69, 71, and 73. In some embodiments, a nucleic acid encodes an immunoglobulin heavy chain variable domain and an immunoglobulin light chain variable domain of an anti-NKG2C agent provided herein. In some embodiments, a nucleic acid comprises a nucleotide sequence that encodes an amino acid sequence of any one of SEQ ID NOS:1-8 and 9-16. For example, a nucleic acid may comprise a nucleotide sequence that encodes a CDR amino acid sequence of any one of SEQ ID NOS: 17-49. A nucleic acid may comprise a
nucleotide sequence that encodes an immunoglobulin heavy chain variable domain amino acid sequence of any one of SEQ ID NOS: 1-3 and 5-8. A nucleic acid may comprise a nucleotide sequence that encodes an immunoglobulin light chain variable domain amino acid sequence of any one of SEQ ID NOS: 9-11 and 13-16. For recombinant production of an anti-NKG2C agent or antibody, a nucleic acid encoding the anti- NKG2C agent or antibody may be isolated and inserted into a replicable vector for further cloning (amplification of the DNA) or for expression. In certain instances, an anti-NKG2C agent or antibody may be produced by homologous recombination, e.g. as described in U.S. Pat. No.5,204,244, specifically incorporated herein by reference. DNA encoding an anti-NKG2C agent or antibody can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the antibody). Many vectors are available. The vector components generally include, but are not limited to, one or more of the following: a signal sequence, an origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence, e.g., as described in U.S. Pat. No.5,534,615 issued Jul.9, 1996 and specifically incorporated herein by reference. Suitable host cells for cloning or expressing DNA in vectors herein are prokaryote, yeast, or higher eukaryote cells. Suitable prokaryotes for this purpose include eubacteria, such as Gram-negative or Gram-positive organisms, for example, Enterobacteriaceae such as Escherichia, e.g., E. coli, Enterobacter, Erwinia, Klebsiella, Proteus, Salmonella, e.g., Salmonella typhimurium, Serratia, e.g., Serratia marcescans, and Shigella, as well as Bacilli such as B. subtilis and B. licheniformis (e.g., B. licheniformis 41P disclosed in DD 266,710 published 12 Apr.1989), Pseudomonas such as P. aeruginosa, and Streptomyces. One preferred E. coli cloning host is E. coli 294 (ATCC 31,446), although other strains such as E. coli B, E. coli X1776 (ATCC 31,537), and E. coli W3110 (ATCC 27,325) are suitable. These examples are illustrative rather than limiting. In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for anti-NKG2C agent/antibody-encoding vectors. Saccharomyces cerevisiae, or common baker's yeast, is the most commonly used among lower eukaryotic host microorganisms. A number of other genera, species, and strains are commonly available and useful herein, such as Schizosaccharomyces pombe; Kluyveromyces hosts such as, e.g., K. lactis, K. fragilis (ATCC 12,424), K. bulgaricus (ATCC 16,045), K. wickeramii (ATCC 24,178), K. waltii (ATCC 56,500), K. drosophilarum (ATCC 36,906), K. thermotolerans, and K. marxianus; yarrowia (EP 402,226); Pichia pastoris (EP
183,070); Candida; Trichoderma reesia (EP 244,234); Neurospora crassa; Schwanniomyces such as Schwanniomyces occidentalis; and filamentous fungi such as, e.g., Neurospora, Penicillium, Tolypocladium, and Aspergillus hosts such as A. nidulans and A. niger. Suitable host cells for the expression of anti-NKG2C agents/antibodies (e.g., glycosylated anti-NKG2C agents/antibodies) are derived from multicellular organisms. Examples of invertebrate cells include plant and insect cells. Numerous baculoviral strains and variants and corresponding permissive insect host cells from hosts such as Spodoptera frugiperda (caterpillar), Aedes aegypti (mosquito), Aedes albopictus (mosquito), Drosophila melanogaster (fruitfly), and Bombyx mori (silk moth) have been identified. A variety of viral strains for transfection are publicly available, e.g., the L-1 variant of Autographa californica NPV and the Bm-5 strain of Bombyx mori NPV, and such viruses may be used as the virus herein according to the present technology, particularly for transfection of Spodoptera frugiperda cells. Plant cell cultures of cotton, corn, potato, soybean, petunia, tomato, and tobacco can also be utilized as hosts. Suitable host cells for the expression of anti-NKG2C agents/antibodies also may include vertebrate cells (e.g., mammalian cells). Vertebrate cells may be propagated in culture (tissue culture). Examples of useful mammalian host cell lines include monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture, Graham et al., J. Gen Virol.36:59 (1977)); baby hamster kidney cells (BHK, ATCC CCL 10); Chinese hamster ovary cells/-DHFR (CHO, Urlaub et al., Proc. Natl. Acad. Sci. USA 77:4216 (1980)); mouse Sertoli cells (TM4, Mather, Biol. Reprod.23:243-251 (1980)); monkey kidney cells (CV1 ATCC CCL 70); African green monkey kidney cells (VERO-76, ATCC CRL-1587); human cervical carcinoma cells (HELA, ATCC CCL 2); canine kidney cells (MDCK, ATCC CCL 34); buffalo rat liver cells (BRL 3A, ATCC CRL 1442); human lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065); mouse mammary tumor (MMT 060562, ATCC CCL51); TRI cells (Mather et al., Annals N.Y. Acad. Sci. 383:44-68 (1982)); MRC 5 cells; FS4 cells; and a human hepatoma line (Hep G2). Host cells may be transformed with the above-described expression or cloning vectors for antibody production and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences. Host cells used to produce an agent/antibody herein may be cultured in a variety of media. Commercially available media such as Ham's F10 (Sigma), Minimal Essential Medium ((MEM), (Sigma), RPMI-1640
(Sigma), and Dulbecco's Modified Eagle's Medium ((DMEM), Sigma) are suitable for culturing the host cells. In addition, any of the media described in Ham et al., Meth. Enz.58:44 (1979), Barnes et al., Anal. Biochem.102:255 (1980), U.S. Pat. Nos.4,767,704; 4,657,866; 4,927,762; 4,560,655; or 5,122,469; WO 90/03430; WO 87/00195; or U.S. Pat. Re.30,985 may be used as culture media for the host cells. Any of these media may be supplemented as necessary with hormones and/or other growth factors (such as insulin, transferrin, or epidermal growth factor), salts (such as sodium chloride, calcium, magnesium, and phosphate), buffers (such as HEPES), nucleotides (such as adenosine and thymidine), antibiotics (such as GENTAMYCIN™), trace elements (defined as inorganic compounds usually present at final concentrations in the micromolar range), and glucose or an equivalent energy source. Any other necessary supplements may also be included at appropriate concentrations that would be known to those skilled in the art. The culture conditions, such as temperature, pH, and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan. When using recombinant techniques, an agent/antibody can be produced intracellularly, in the periplasmic space, or directly secreted into the medium. If the antibody is produced intracellularly, as a first step, the particulate debris, either host cells or lysed fragments, is removed, for example, by centrifugation or ultrafiltration. Carter et al., Bio/Technology 10:163-167 (1992) describe a procedure for isolating antibodies that are secreted to the periplasmic space of E. coli. Briefly, cell paste is thawed in the presence of sodium acetate (pH 3.5), EDTA, and phenylmethylsulfonylfluoride (PMSF) over about 30 minutes. Cell debris can be removed by centrifugation. Where the antibody is secreted into the medium, supernatants from such expression systems are generally first concentrated using a commercially available protein concentration filter, for example, an Amicon or Millipore Pellicon ultrafiltration unit. A protease inhibitor such as PMSF may be included in any of the foregoing steps to inhibit proteolysis and antibiotics may be included to prevent the growth of adventitious contaminants. The agent/antibody composition prepared from the cells can be purified using, for example, hydroxylapatite chromatography, gel electrophoresis, dialysis, and affinity chromatography, with affinity chromatography being the preferred purification technique. The suitability of protein A as an affinity ligand depends on the species and isotype of any immunoglobulin Fc domain that is present in the antibody. Protein A can be used to purify antibodies that are based on human heavy chains (Lindmark et al., J. Immunol. Meth.62:1-13 (1983)). Protein G is recommended for all mouse isotypes and for human γ3 (Guss et al., EMBO J.5:15671575 (1986)). The matrix to which the affinity ligand is attached is most often agarose, but other matrices are available. Mechanically stable matrices such as controlled pore glass or poly(styrenedivinyl)benzene allow for faster flow rates and shorter processing times than can be
achieved with agarose. Where the antibody comprises a CH3 domain, Bakerbond ABX.TM. resin (J. T. Baker, Phillipsburg, N.J.) is useful for purification. Other techniques for protein purification, such as fractionation on an ion-exchange column, ethanol precipitation, Reverse Phase HPLC, chromatography on silica, chromatography on heparin SEPHAROSE™, chromatography on an anion or cation exchange resin (such as a polyaspartic acid column), chromatofocusing, SDS-PAGE, and ammonium sulfate precipitation are also available depending on the antibody to be recovered. Following any preliminary purification step(s), the mixture comprising the agent or antibody of interest and contaminants may be subjected to low pH hydrophobic interaction chromatography using an elution buffer at a pH between about 2.5-4.5, and may be performed at low salt concentrations (e.g., from about 0-0.25M salt). Pharmaceutical formulations, dosing, and routes of administration The present technology provides anti-NKG2C agents and antibodies, fragments or antigen-binding fragments thereof and related compositions, which may be useful for elimination of NKG2C expressing cells from the body, for example, and for identification and quantification of the number of NKG2C expressing cells in tissue samples, for example. Therapeutic methods and compositions of the present technology may be referred to as “NKG2C-based” in order to indicate that these therapies can change the relative or absolute numbers of undesirable or toxic NKG2C expressing cells such as lymphomas or autoimmune B lymphocytes. In some embodiments, one way to control the amount of undesirable NKG2C expressing cells in a patient is by providing a composition that comprises one or more anti-NKG2C antibodies fragments or antigen- binding fragments thereof to cause cytotoxic activity towards the NKG2C-expressing cells, for example. In some embodiments, any of the anti-NKG2C agents or anti-NKG2C antibodies described herein are capable of binding a cell. In some embodiments, the cell is a natural killer (NK) cell. In some embodiments, the cell is a lymphocyte. In some embodiments, the lymphocyte is a CD8+ lymphocyte. In some embodiments, the cell selected from B cells, plasmacytoid dendritic cells (pDCs), lymphocytes, leukocytes, T cells, monocytes, macrophages, neutrophils, myeloid dendritic cells (mDCs), innate lymphoid cells, mast cells, eosinophils, basophils, natural killer cells, and the like. In some embodiments, the cell is selected from a heterogeneous population of immune cells including peripheral blood 81
mononuclear cells (PBMCs) which may include, for example, T cells, B cells, natural killer cells, and monocytes. In some embodiments, the cell bound by any of the anti-NKG2C agents or anti-NKG2C antibodies interacts with a target cell that expresses HLA-E. In some embodiments, the target cell is a cancer cell. In some embodiments, the target cell is a cancer cell that expresses HLA-E. In some embodiments, the target cell is a cancer cell that over-expresses HLA-E. In some of any embodiments, the HLA-E is expressed on the surface of the target or cancer cell. In some embodiments, any of the anti-NKG2C agents or anti-NKG2C antibodies described herein specifically bind NKG2C on a cell. In some embodiments, any of the anti-NKG2C agents or anti-NKG2C antibodies described herein specifically bind NKG2C and do not specifically bind NKG2C or NKG2E. In some embodiments, any of the anti-NKG2C agents or anti-NKG2C antibodies described herein block the binding of HLA-E to NKG2C. In some embodiments, the cell is a cell with a disease or disorder. In some embodiments, the disease or disorder is a cancer, a viral infection, an autoimmune disease, an inflammatory disease or a bacterial infection. In some embodiments, the disease or disorder is a cancer including but not limited to acute myeloid leukemia, acute lymphoblastic leukemia, colorectal, ovarian, gynecologic, liver, glioblastoma, Hodgkin lymphoma, chronic lymphocytic leukemia, esophagus, gastric, pancreas, colon, kidney, head and neck, lung and melanoma. In some embodiments, any of the ani-NKG2C agents provided herein can be used to treat a disease or disorder by blocking the NKG2C receptor on NKG2C expressing cells in a subject. In some embodiments, any of the anti-NKG2C agents provided herein are provided as a composition. In some embodiments, the composition increases the cytotoxic activity of NKG2C-expressing cells. In some embodiments, the composition restores the cytotoxic activity of NKG2C-expressing cells. In some embodiments, the composition causes cytotoxic activity towards cells targeted by NKG2C-expressing cells. In some embodiments, one way to control the amount of undesirable NKG2C expressing cells in a patient is by providing a composition that comprises one or more anti-NKG2C agents, antibodies, fragments or antigen-binding fragments thereof to cause cytotoxic activity towards cells targeted by NKG2C-expressing cells. In some embodiments, the disease or disorder is associates with aberrant levels of HLA-E. In some embodiments, the disease or disorder is a cancer. In some embodiments, the disease or disorder is a cancer that expresses HLA-E. In some embodiments, the disease or disorder is a cancer, a viral infection, an autoimmune disease, an inflammatory disease or a bacterial infection. In some embodiments, the
disease or disorder is a cancer including but not limited to acute myeloid leukemia, acute lymphoblastic leukemia, colorectal, ovarian, gynecologic, liver, glioblastoma, Hodgkin lymphoma, chronic lymphocytic leukemia, esophagus, gastric, pancreas, colon, kidney, head and neck, lung and melanoma. In some embodiments, the disease or disorder is a condition characterized by NK cell hyperactivity or NK cell hyperproliferation. In some embodiments, when any of the anti-NKG2C agents or anti-NKG2C antibodies described herein bind NKG2C on a cell, the binding of NKG2C to HLA-E to on a target cell is blocked. In some embodiments, the binding of any of the anti-NKG2C agents or anti-NKG2C antibodies described herein to NKG2C on a cell, blocks to ability of the NKG2C on the cell from interacting with HLA-E to on a target cell. In some embodiments, when any of the anti-NKG2C agents or anti-NKG2C antibodies described herein bind NKG2C on a cell, the cell causes the target cell to lyse. Anti-NKG2C agents/antibodies may be formulated in a pharmaceutical composition that is useful for a variety of purposes, including the treatment of diseases, disorders or physical trauma. Pharmaceutical compositions comprising one or more anti-NKG2C agents/antibodies herein may be incorporated into kits and medical devices for such treatment. Medical devices may be used to administer pharmaceutical compositions herein to a patient in need thereof, and according to one embodiment of the technology, kits are provided that include such devices. Such devices and kits may be designed for routine administration, including self-administration, of the pharmaceutical compositions herein. Therapeutic formulations of an agent or antibody may be prepared for storage by mixing the agent/antibody having the desired degree of purity with optional physiologically acceptable carriers, excipients or stabilizers (Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980)), in the form of lyophilized formulations or aqueous solutions. Acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-
forming counter-ions such as sodium; metal complexes (e.g., Zn-protein complexes); and/or non-ionic surfactants such as TWEENTM, PLURONICSTM or polyethylene glycol (PEG). Formulations herein may also contain more than one active compound as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. Such molecules are suitably present in combination in amounts that are effective for the purpose intended. Active ingredients may also be entrapped in microcapsule prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsule and poly-(methylmethacylate) microcapsule, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules) or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980). Formulations for in vivo administration generally are sterile. This may be accomplished for instance by filtration through sterile filtration membranes, for example. Sustained-release preparations may be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the agent/antibody, which matrices are in the form of shaped articles, e.g., films, or microcapsule. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly(vinyl alcohol)), polylactides (U.S. Pat. No.3,773,919), copolymers of L-glutamic acid and .gamma. ethyl-L- glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the Lupron Depot.TM. (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid. While polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods. When encapsulated agents/antibodies remain in the body for a long time, they may denature or aggregate as a result of exposure to moisture at 37° C, resulting in a loss of biological activity and possible changes in immunogenicity. Rational strategies can be devised for stabilization depending on the mechanism involved. For example, if the aggregation mechanism is discovered to be intermolecular S-- bond formation through thio-disulfide interchange, stabilization may be achieved by modifying sulfhydryl residues, lyophilizing from acidic solutions, controlling moisture
content, using appropriate additives, and developing specific polymer matrix compositions. For therapeutic applications, anti-NKG2C agents, e.g., antibodies, provided herein are administered to a mammal, e.g., a human, in a pharmaceutically acceptable dosage form such as those discussed above, including those that may be administered to a human intravenously as a bolus or by continuous infusion over a period of time, or by intramuscular, intraperitoneal, intra-cerebrospinal, subcutaneous, intra- articular, intrasynovial, intrathecal, oral, topical, or inhalation routes. For the prevention or treatment of disease, the appropriate dosage of agent/antibody will depend on the type of disease to be treated, as defined above, the severity and course of the disease, whether the antibody is administered for preventive or therapeutic purposes, previous therapy, the patient's clinical history and response to the antibody, and the discretion of the attending physician. The antibody is suitably administered to the patient at one time or over a series of treatments. Depending on the type and severity of the disease, about 1 μg/kg to about 50 mg/kg (e.g., 0.1-20 mg/kg) of antibody may be an initial candidate dosage for administration to the patient, whether, for example, by one or more separate administrations, or by continuous infusion. A typical daily or weekly dosage might range from about 1 µg/kg to about 20 mg/kg or more, depending on the factors mentioned above. For repeated administrations over several days or longer, depending on the condition, the treatment is repeated until a desired suppression of disease symptoms occurs. However, other dosage regimens may be useful. The progress of this therapy is easily monitored by conventional techniques and assays, including, for example, radiographic imaging. Detection methods using the antibody to determine NKG2C levels in bodily fluids or tissues may be used in order to optimize patient exposure to the therapeutic antibody. In some embodiments, a composition comprising an anti-NKG2C agent herein (e.g., an mAb that interferes with NKG2C activity) is administered as a monotherapy, and in some embodiments, the composition comprising the anti-NKG2C agent is administered as part of a combination therapy. In some cases, the effectiveness of the agent/antibody in preventing or treating disease may be improved by administering the agent/antibody serially or in combination with another agent that is effective for those purposes, such as a chemotherapeutic drug for treatment of cancer or a microbial infection. In other cases, the anti-NKG2C agent may serve to enhance or sensitize cells to chemotherapeutic treatment, thus permitting efficacy at lower doses and with lower toxicity. Certain combination therapies include, in addition to administration of the composition comprising an agent that reduces the number of NKG2C expressing cells, delivering a second therapeutic regimen selected from the group consisting of
administration of a chemotherapeutic agent, radiation therapy, surgery, and a combination of any of the foregoing. Such other agents may be present in the composition being administered or may be administered separately. Also, the anti-NKG2C agent may be suitably administered serially or in combination with the other agent or modality, e.g., chemotherapeutic drug or radiation for treatment of cancer, infection, and the like, or an immunosuppressive drug. Provided herein are compositions comprising any of the anti-NKG2C agents described herein. In some embodiments, the composition comprising any of the anti-NKG2C agents described herein includes a pharmaceutically acceptable excipient. Research and diagnostic, including clinical diagnostic, uses for anti-NKG2C agents herein Provided herein are diagnostic reagents comprising an anti-NKG2C agent described herein. For example, anti-NKG2C agents, e.g., antibodies, provided herein may be used to detect and/or purify NKG2C, e.g., from bodily fluid(s) or expressed on cells in bodily fluids or tissues. Also provided herein are methods for detecting NKG2C. For example, a method may comprise contacting a sample (e.g., a biological sample known or suspected of to contain NKG2C) with an anti-NKG2C agent provided herein, and, if the sample contains NKG2C, detecting NKG2C:anti-NKG2C complexes. Also provided herein are reagents comprising an anti-NKG2C agent described herein and methods for detecting NKG2C for research purposes. Anti-NKG2C antibodies, for example, may be useful in diagnostic assays for NKG2C, e.g., detecting its presence in specific cells, tissues, or bodily fluids. Such diagnostic methods may be useful in diagnosis, e.g., of a hyperproliferative disease or disorder. In some embodiments, the disease or disorder is a cancer, a viral infection, an autoimmune disease, an inflammatory disease or a bacterial infection. In some embodiments, the disease or disorder is a cancer including but not limited to acute myeloid leukemia, acute lymphoblastic leukemia, colorectal, ovarian, gynecologic, liver, glioblastoma, Hodgkin lymphoma, chronic lymphocytic leukemia, esophagus, gastric, pancreas, colon, kidney, head and neck, lung and melanoma. In some embodiments, any of the anti-NKG2C agents or anti-NKG2C antibodies described herein are capable of binding a cell. In some embodiments, the cell is a natural killer (NK) cell. In some embodiments, the cell is a lymphocyte. In some embodiments, the lymphocyte is a CD8+ lymphocyte.
In some embodiments, any of the anti-NKG2C agents or anti-NKG2C antibodies described herein specifically bind NKG2C on a cell. In some embodiments, any of the anti-NKG2C agents or anti-NKG2C antibodies described herein specifically bind NKG2C and do not specifically bind NKG2A or NKG2E. Thus, clinical diagnostic uses as well as research uses are comprehended herein. In some embodiments, an anti-NKG2C agent/antibody comprises a detectable marker or label. In some embodiments, an anti-NKG2C agent/antibody is conjugated to a detectable marker or label. For example, for research and diagnostic applications, an anti-NKG2C agent/antibody may be labeled with a detectable moiety. Numerous labels are available which are generally grouped into the following categories: (a) Radioisotopes, such as 35S, 14C, 125I, 3H, and 131I. The antibody can be labeled with the radioisotope using the techniques described in Current Protocols in Immunology, Volumes 1 and 2, Coligen et al., Ed. Wiley-Interscience, New York, N.Y., Pubs. (1991), for example, and radioactivity can be measured using scintillation counting. (b) Fluorescent labels such as rare earth chelates (europium chelates) or fluorescein and its derivatives, rhodamine and its derivatives, dansyl, Lissamine, phycoerythrin, Texas Red and Brilliant VioletTM are available. The fluorescent labels can be conjugated to the antibody using the techniques disclosed in Current Protocols in Immunology, supra, for example. Fluorescence can be quantified using a flow cytometer, imaging microscope or fluorimeter. (c) Various enzyme-substrate labels are available and U.S. Pat. No.4,275,149 provides a review of some of these. The enzyme generally catalyzes a chemical alteration of the chromogenic substrate that can be measured using various techniques. For example, the enzyme may catalyze a color change in a substrate, which can be measured spectrophotometrically. Alternatively, the enzyme may alter the fluorescence or chemiluminescence of the substrate. Techniques for quantifying a change in fluorescence are described above. The chemiluminescent substrate becomes electronically excited by a chemical reaction and may then emit light that can be measured (using a chemilluminometer, for example) or donates energy to a fluorescent acceptor. Examples of enzymatic labels include luciferases (e.g., firefly luciferase and bacterial luciferase; U.S. Pat. No.4,737,456), luciferin, 2,3-dihydrophthalazinediones, malate dehydrogenase, urease, peroxidase such as horseradish peroxidase (HRPO), alkaline phosphatase, beta-galactosidase, glucoamylase, lysozyme, saccharide oxidases (e.g., glucose oxidase, galactose oxidase, and glucose-6-phosphate dehydrogenase), heterocyclicoxidases (such as uricase and xanthine oxidase), lactoperoxidase, microperoxidase, and the like. Techniques for conjugating enzymes to antibodies are described in O'Sullivan et al., Methods for the Preparation of Enzyme-Antibody Conjugates for use in Enzyme Immunoassay, in Methods in Enzym. (ed J. Langone & H. Van Vunakis), Academic press, New York, 73:147-166 (1981).
Examples of enzyme-substrate combinations include, for example: (i) Horseradish peroxidase (HRP) with hydrogen peroxidase as a substrate, where the hydrogen peroxidase oxidizes a dye precursor (e.g., orthophenylene diamine (OPD) or 3,3',5,5'-tetramethyl benzidine hydrochloride (TMB)); (ii) alkaline phosphatase (AP) with para-Nitrophenyl phosphate as chromogenic substrate; and (iii) .beta.-D-galactosidase (.beta.-D-Gal) with a chromogenic substrate (e.g., p-nitrophenyl-β-D- galactosidase) or fluorogenic substrate 4-methylumbelliferyl-.beta.-D-galactosidase. Numerous other enzyme-substrate combinations may be used (e.g., U.S. Pat. Nos.4,275,149 and 4,318,980, each of which is incorporated by reference herein). In certain instances, the label is indirectly conjugated with the agent/antibody. The skilled artisan will be aware of various techniques for achieving this. For example, an antibody can be conjugated with biotin and any of the three broad categories of labels mentioned above can be conjugated with avidin, or vice versa. Biotin binds selectively to avidin and thus, the label can be conjugated with the antibody in this indirect manner. Alternatively, to achieve indirect conjugation of the label with the antibody, the antibody is conjugated with a small hapten (e.g., digoxin) and one of the different types of labels mentioned above is conjugated with an anti-hapten antibody (e.g., anti-digoxin antibody). Thus, indirect conjugation of the label with the antibody can be achieved. In some embodiments, an anti-NKG2C agent/antibody need not be labeled, and the presence thereof can be detected, e.g., using a labeled antibody which binds to an anti-NKG2C antibody. In some embodiments, an anti-NKG2C agent/antibody herein is immobilized on a solid support or substrate. In some embodiments, an anti-NKG2C agent/antibody herein is non-diffusively immobilized on a solid support (e.g., the anti-NKG2C agent/antibody does not detach from the solid support). A solid support or substrate can be any physically separable solid to which an anti-NKG2C agent/antibody can be directly or indirectly attached including, but not limited to, surfaces provided by microarrays and wells, and particles such as beads (e.g., paramagnetic beads, magnetic beads, microbeads, nanobeads), microparticles, and nanoparticles. Solid supports also can include, for example, chips, columns, optical fibers, wipes, filters (e.g., flat surface filters), one or more capillaries, glass and modified or functionalized glass (e.g., controlled-pore glass (CPG)), quartz, mica, diazotized membranes (paper or nylon), polyformaldehyde, cellulose, cellulose acetate, paper, ceramics, metals, metalloids,
semiconductive materials, quantum dots, coated beads or particles, other chromatographic materials, magnetic particles; plastics (including acrylics, polystyrene, copolymers of styrene or other materials, polybutylene, polyurethanes, TEFLON™, polyethylene, polypropylene, polyamide, polyester, polyvinylidenedifluoride (PVDF), and the like), polysaccharides, nylon or nitrocellulose, resins, silica or silica-based materials including silicon, silica gel, and modified silicon, Sephadex®, Sepharose®, carbon, metals (e.g., steel, gold, silver, aluminum, silicon and copper), inorganic glasses, conducting polymers (including polymers such as polypyrole and polyindole); micro or nanostructured surfaces such as nucleic acid tiling arrays, nanotube, nanowire, or nanoparticulate decorated surfaces; or porous surfaces or gels such as methacrylates, acrylamides, sugar polymers, cellulose, silicates, or other fibrous or stranded polymers. In some embodiments, the solid support or substrate may be coated using passive or chemically-derivatized coatings with any number of materials, including polymers, such as dextrans, acrylamides, gelatins or agarose. Beads and/or particles may be free or in connection with one another (e.g., sintered). In some embodiments, a solid support or substrate can be a collection of particles. In some embodiments, the particles can comprise silica, and the silica may comprise silica dioxide. In some embodiments the silica can be porous, and in certain embodiments the silica can be non-porous. In some embodiments, the particles further comprise an agent that confers a paramagnetic property to the particles. In certain embodiments, the agent comprises a metal, and in certain embodiments the agent is a metal oxide, (e.g., iron or iron oxides, where the iron oxide contains a mixture of Fe2+ and Fe3+). An anti- NKG2C agent/antibody may be linked to a solid support by covalent bonds or by non-covalent interactions and may be linked to a solid support directly or indirectly (e.g., via an intermediary agent such as a spacer molecule or biotin). Agents and antibodies provided herein may be employed in any known assay method, such as flow cytometry, immunohistochemistry, immunofluorescence, mass cytometry (e.g., Cytof instrument), competitive binding assays, direct and indirect sandwich assays, and immunoprecipitation assays. Zola, Monoclonal Antibodies: A Manual of Techniques, pp.147-158 (CRC Press, Inc.1987). In some embodiments, the method comprises the use of a single primary antibody to specifically identify the presence of the target molecule expressed on the surface of a dispersed suspension of individual cells. Flow cytometry and mass cytometry assays generally involve the use of a single primary antibody to specifically identify the presence of the target molecule expressed on the surface of a dispersed suspension of individual cells. The dispersed cells are typically obtained from a biological fluid sample, e.g., blood, but may also be obtained from a dispersion of single cells prepared from a solid tissue sample such as spleen or tumor biopsy. The primary antibody may be directly conjugated with a detectable
moiety, e.g., a fluorophore such as phycoerythrin for flow cytometry or a heavy metal chelate for mass cytometry. Alternatively, the primary antibody may be unlabeled or labeled with an undetectable tag such as biotin, and the primary antibody is then detected by a detectably labeled secondary antibody that specifically recognizes the primary antibody itself or the tag on the primary antibody. The labeled cells are then analyzed in an instrument capable of single cell detection, e.g., flow cytometer, mass cytometer, fluorescence microscope or brightfield light microscope, to identify those individual cells in the dispersed population or tissue sample that express the target recognized by the primary antibody. Detailed description of the technological basis and practical application of flow cytometry principles may be found in, e.g., Shapiro, Practical Flow Cytometry, 4th Edition, Wiley, 2003. In some embodiments, the method comprises the use of two antibodies, each capable of binding to a different immunogenic portion, or epitope. Sandwich assays involve the use of two antibodies, each capable of binding to a different immunogenic portion, or epitope, of the protein that is detected. In a sandwich assay, the test sample analyte is bound by a first antibody that is immobilized on a solid support, and thereafter a second antibody binds to the analyte, thus forming an insoluble three-part complex. See, e.g., U.S. Pat. No.4,376,110. The second antibody may itself be labeled with a detectable moiety (direct sandwich assays) or may be measured using an anti-immunoglobulin antibody that is labeled with a detectable moiety (indirect sandwich assay). For example, one type of sandwich assay is an ELISA assay, in which case the detectable moiety is an enzyme. In a cell ELISA, the target cell population may be attached to the solid support using antibodies first attached to the support and that recognize different cell surface proteins. These first antibodies capture the cells to the support. NKG2C on the surface of the cells can then be detected by adding anti-NKG2C antibody to the captured cells and detecting the amount of NKG2C antibody attached to the cells. In certain instances, fixed and permeabilized cells may be used, and in such instances, surface NKG2C and intracellular NKG2C may be detected. For immunohistochemistry, the blood or tissue sample may be fresh or frozen or may be embedded in paraffin and fixed with a preservative such as formalin, for example. The agents/antibodies herein also may be used for in vivo diagnostic assays. Generally, the antibody is labeled with a radionuclide (such as 111In, 99Tc, 14C, 131I, 125I, 3H, 32P, or 35S) so that the bound target molecule can be localized using immunoscintillography. Detection of NKG2C in immune cells
Provided herein are agents and methods for detecting NKG2C in immune cells. Detection of NKG2C in immune cells may refer to detection on the surface of immune cells (e.g., by surface staining) and/or inside immune cells (e.g., by intracellular staining). In some embodiments, any of the agents provided herein may be used for detection of NKG2C on the surface of immune cells. In some embodiments, any of the agents provided herein may be used for detection of intracellular NKG2C in immune cells. In some embodiments, the immune cell is selected from B cells, plasmacytoid dendritic cells (pDCs), lymphocytes, leukocytes, T cells, monocytes, macrophages, neutrophils, myeloid dendritic cells (mDCs), innate lymphoid cells, mast cells, eosinophils, basophils, natural killer cells, and the like. In some embodiments, a heterogeneous population of immune cells comprises peripheral blood mononuclear cells (PBMCs) which may include, for example, T cells, B cells, natural killer cells, and monocytes. In some embodiments, agents and methods are provided for detecting NKG2C in a heterogeneous population of immune cells. A heterogeneous population of immune cells may comprise two or more types of immune cells. For example, a heterogeneous population of immune cells may comprise two or more of lymphocytes, T cells, natural killer cells, and the like. In some embodiments, a heterogeneous population of immune cells comprises peripheral blood mononuclear cells (PBMCs) which may include, for example, T cells, B cells, natural killer cells, and monocytes. Generally, cells are contacted with an anti-NKG2C agent described herein (e.g., in a flow cytometry assay as described in Example x; or any suitable protein or cell detection assay). In some embodiments, NKG2C is detected at a significant level in certain immune cells by an anti-NKG2C agent described herein. NKG2C may be detected at a significant level by an anti-NKG2C agent described herein in certain immune cells and not significantly detected in other immune cells. The level of NKG2C detection in certain immune cells may vary according to certain factors such as, for example, type of detection assay, type of detection reagent (e.g., type of dye), antibody concentration, donor cell variability, and the like. Detection of NKG2C at a significant level may refer to a particular signal to noise (S:N) ratio (e.g., threshold or range) measured in a flow cytometry assay. In some embodiments, NKG2C is detected at a significant level in NK cells, as well as a subset of CD8+ T-lymphocytes. Accordingly, in some embodiments, NKG2C is detected at a significant level in CD56+ NK cells. CD56, also referred to as neural cell adhesion molecule (NCAM), NCAM1, MSK39, neural cell adhesion molecule 1, is a hemophilic binding glycoprotein expressed on the surface of neurons, glia, skeletal muscle, and also in the hematopoietic system. CD56 is most associated with natural killer cells, but is also detected on γδ T cells, activated CD8+ T cells, and dendritic cells.
NCAM is a glycoprotein of the Immunoglobulin (Ig) superfamily, with 27 isoforms produced by alternative mRNA splicing. The three main isoforms of NCAM vary only in their cytoplasmic domain: NCAM-120 kDa (GPI anchored), NCAM-140 kDa (short cytoplasmic domain), and NCAM-180 kDa (long cytoplasmic domain). The extracellular domain of NCAM consists of five immunoglobulin-like (Ig) domains followed by two fibronectin type III (FNIII) domains. The Ig domains of NCAM are involved in hemophilic binding to NCAM, while the FNIII domains are involved in signaling that leads to neurite outgrowth. In addition to NK cells and activated T cells, CD56 is detected on tumors such as myeloma, myeloid leukemia, neuroendocrine tumors, Wilm’s tumor, neuroblastoma, extranodal NK/T cell lymphoma, nasal type, pancreatic acinar cell carcinoma, pheochromocytoma, paraganglioma, small cell lung carcinoma, and Ewing’s sarcoma family of tumors. In some embodiments, NKG2C is not significantly detected in certain immune cells by an anti-NKG2C agent described herein. For example, NKG2C may not be significantly detected in certain lymphocytes (e.g., plasmacytoid dendritic cells (pDCs) and/or B cells). No significant detection of NKG2C in certain lymphocytes (e.g., CD304+ plasmacytoid dendritic cells and/or CD19+CD3- B cells). No significant detection of NKG2C in certain lymphocytes (e.g., CD304+ plasmacytoid dendritic cells and/or CD19+CD3- B cells) may refer to a particular signal to noise (S:N) ratio (e.g., threshold or range) measured in a flow cytometry assay. In some embodiments, no significant detection of noise (N) in certain lymphocytes (e.g., CD304+ plasmacytoid dendritic cells and/or CD19+CD3- B cells) refers to a signal to noise (S:N) ratio of about 1.5 or less. In some embodiments, no significant detection of NKG2C in certain lymphocytes (e.g., CD304+ plasmacytoid dendritic cells and/or CD19+CD3- B cells) refers to a signal to noise (S:N) ratio of about 1 or less. Kits incorporating anti-NKG2C agents herein An anti-NKG2C agent (e.g., an anti-NKG2C antibody) herein may be provided in a kit, for example, a packaged combination of reagents in predetermined amounts with instructions for use (e.g., instructions for performing a diagnostic assay; instructions for performing a laboratory assay). In some embodiments, the kit is a diagnostic kit configured to detect NKG2C in a sample (e.g., a biological sample). Where the anti-NKG2C agent is labeled with a fluorophore, the kit may include an identical isotype negative control irrelevant antibody to control for non-specific binding of the anti-NKG2C agent. Where the anti-NKG2C agent is labeled with an enzyme, the kit may include substrates and cofactors required by the enzyme (e.g., a substrate precursor which provides the detectable chromophore or fluorophore). Additional additives may be included such as stabilizers, buffers (e.g., a block buffer or lysis buffer), and the like.
The relative amounts of the various reagents may be varied widely to provide for concentrations in solution of the reagents that substantially optimize the sensitivity of the assay. In certain instances, reagents may be provided as dry powders (e.g., lyophilized powder), including excipients that on dissolution will provide a reagent solution having the appropriate concentration. Articles of Manufacture In another aspect of the present technology, an article of manufacture containing materials useful for the treatment, or diagnosis, of the disorders described above is provided. An article of manufacture may comprise a container and a label. Suitable containers include, for example, bottles, vials, syringes, and test tubes. Containers may be formed from a variety of materials such as glass or plastic. A container may hold a composition that is effective for treating a condition and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). An active anti-NKG2C agent in the composition may be an anti-NKG2C antibody. A label on, or associated with, the container indicates that the composition is used for treating, or diagnosing, a condition of choice. The article of manufacture may further comprise a second container comprising a pharmaceutically acceptable buffer, such as phosphate-buffered saline, Ringer’s solution and dextrose solution; and may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, syringes, and package inserts with instructions for use. Certain terms used herein An “agent” generally refers to an antibody, antibody fragment, antigen binding fragment thereof, derivative, variants of such antibodies and antibody fragments or antigen-binding fragments thereof (including immunoconjugates, labeled antibodies and antigen-binding antibody fragments, and the like). An “acceptor human framework” generally refers to a framework comprising the amino acid sequence of an immunoglobulin heavy chain variable domain (VH) framework or an immunoglobulin light chain variable domain (VL) framework derived from a human immunoglobulin framework or a human consensus framework, as defined herein. An acceptor human framework “derived from” a human immunoglobulin framework or a human consensus framework may comprise the same amino acid sequence thereof, or it may contain amino acid sequence changes. In some embodiments, the number of framework amino acid changes are 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, or 2 or less. In some embodiments, the VH and/or VL acceptor human framework(s) is(are)
identical in sequence to the VH and/or VL human immunoglobulin framework amino acid sequence or human consensus framework amino acid sequence. “Framework” or “FR” generally refers to variable domain residues other than hypervariable region (HVR) residues. The FR of a variable domain generally consists of four FR domains: FR1; FR2; FR3; and FR4. Accordingly, the HVR and FR sequences generally appear in the following sequence in VH (or VL): FR1-H1(L1)-FR2-H2(L2)-FR3-H3(L3)-FR4. A “human consensus framework” generally refers to a framework that represents the most commonly occurring amino acid residues in a selection of human immunoglobulin VL or VH framework sequences. Generally, the selection of human immunoglobulin VL or VH sequences is from a subgroup of variable domain sequences. Generally, the subgroup of sequences is a subgroup as in Kabat et al., Sequences of Proteins of Immunological Interest, Fifth Edition, NIH Publication 91-3242, Bethesda Md. (1991), vols. 1-3. In some embodiments, for the VL, the subgroup is subgroup kappa I as in Kabat et al., supra. In some embodiments, for the VH, the subgroup is subgroup III as in Kabat et al., supra. The term “hypervariable region” or “HVR” generally refers to each of the regions of an antibody variable domain that are hypervariable in sequence and/or form structurally defined loops (“hypervariable loops”). Generally, native four-chain antibodies comprise six HVRs; three in the VH (H1, H2, H3), and three in the VL (L1, L2, L3). HVRs generally comprise amino acid residues from the hypervariable loops and/or from the “complementarity determining regions” (CDRs), the latter being of highest sequence variability and/or involved in antigen recognition. The precise amino acid sequence boundaries of a given CDR or FR can be readily determined using any number of well-known schemes, including those described in Kabat et al. (1991), “Sequences of Proteins of Immunological Interest,” 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD (“Kabat” numbering scheme), Al-Lazikani et al., (1997) JMB 273,927-948 (“Chothia” numbering scheme), MacCallum et al., J. Mol. Biol.262:732-745 (1996), “Antibody-antigen interactions: Contact analysis and binding site topography,” J. Mol. Biol.262, 732-745,” (“Contact” numbering scheme), Martin et al., Proc. Natl. Acad. Sci., 86:9268-9272 (1989) (“AbM” numbering scheme), Lefranc MP et al., “IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains,” Dev Comp Immunol, 2003 Jan;27(1):55-77 (“IMGT” numbering scheme), and Honegger A and Plückthun A, “Yet another numbering scheme for immunoglobulin variable
domains: an automatic modeling and analysis tool,” J Mol Biol, 2001 Jun 8;309(3):657-70, (“Aho” numbering scheme). The boundaries of a given CDR or FR may vary depending on the scheme used for identification. For example, the Kabat scheme is based on structural alignments, while the Chothia scheme is based on structural information. Numbering for both the Kabat and Chothia schemes is based upon the most common antibody region sequence lengths, with insertions accommodated by insertion letters for example, “30aa” and deletions appearing in some antibodies. The two schemes place certain insertions and deletions (“indels”) at different positions, resulting in differential numbering. The Contact scheme is based on analysis of complex crystal structures and is similar in many respects to the Chothia numbering scheme. Table 1, below, lists exemplary position boundaries of CDRH1, CDRH2, CDRH3, and CDRL1, CDRL2, and CDRL3 as identified by Kabat, Chothia, and Contact schemes, respectively. For CDRH1, residue numbering is listed using both the Kabat and Chothia numbering schemes. FRs are located between CDRs, for example, with FRH1 located between CDRH1 and CDRH2, and so forth. It is noted that because the shown Kabat numbering scheme places insertions at H35A and H35B, the end of the Chothia CDRH1 loop when numbered using the shown Kabat numbering convention varies between H32 and H34, depending on the length of the loop.
1 - Kabat et al. (1991), “Sequences of Proteins of Immunological Interest,” 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD 2 - Al-Lazikani et al., (1997) JMB 273,927-948
CDRs also comprise “specificity determining residues,” or “SDRs,” which are residues that contact a particular antigen. Unless otherwise indicated, HVR residues and other residues in the variable domain (e.g., FR residues) are numbered herein according to Kabat et al., supra. The term “variable region” or “variable domain” generally refers to the domain of an antibody heavy or light chain that is involved in binding the antibody to antigen. The variable domains of the heavy chain and light chain (VH and VL, respectively) of a native antibody generally have similar structures, with each domain comprising four conserved framework regions (FRs) and three hypervariable regions (HVRs). See, e.g., Kindt et al. Kuby Immunology, 6th ed., W.H. Freeman and Co., page 91 (2007). A single VH or VL domain may be sufficient to confer antigen-binding specificity. Furthermore, antibodies that bind a particular antigen may be isolated using a VH or VL domain from an antibody that binds the antigen to screen a library of complementary VL or VH domains, respectively. See, e.g., Portolano et al., J. Immunol.150:880-887 (1993); Clarkson et al., Nature 352:624-628 (1991). “Affinity” generally refers to the strength of the sum total of non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless indicated otherwise, “binding affinity” refers to intrinsic binding affinity, which reflects a 1:1 interaction between members of a binding pair (e.g., antibody and antigen). The affinity of a molecule X for its partner Y can generally be represented by a dissociation constant (Kd). Affinity can be measured by common methods known in the art, including those described herein. Specific illustrative and example embodiments for measuring binding affinity are described elsewhere herein. In some instances, antibodies herein bind to a target (e.g., NKG2C) with a high affinity, e.g., a Kd value of no more than about 1 x 10-7 M; preferably no more than about 1 x 10-8 M; and preferably no more than about 5 x 10-9 M. An “affinity matured” antibody generally refers to an antibody with one or more alterations in one or more hypervariable regions (HVRs), compared to a parent antibody that does not possess such alterations. Preferably, such alterations result in improved affinity of the antibody for its target antigen. The term “anti-NKG2C agent” generally refers to a molecule that is, or comprises, one or more anti- NKG2C antibodies, NKG2C-binding antibody fragments, or NKG2C-binding antibody derivatives. The terms “anti-NKG2C antibody” and “an antibody that binds to NKG2C” generally refer to an antibody that is capable of binding NKG2C with sufficient affinity and/or specificity such that the antibody is useful as a research tool, diagnostic agent and/or therapeutic agent in targeting NKG2C. In some
embodiments, the extent of binding of an anti-NKG2C antibody (or antigen-binding fragment thereof) to an unrelated, non-NKG2C protein is less than about 10% of the binding of the antibody to NKG2C as measured, e.g., by a radioimmunoassay (RIA) or by Scatchard analysis or by surface plasmon resonance, such as, for example, Biacore. In certain embodiments, an antibody that binds to NKG2C has a dissociation constant (Kd) of 0.1 µM, 100 nM, 10 nM, 1 nM, 0.1 nM, 0.01 nM, or 0.001 nM (e.g., 10-7 M or less, e.g., from 10-7 M to 10-13 M). In certain embodiments, an anti-NKG2C antibody binds to an epitope of NKG2C that is conserved among NKG2C from different species. The term “antibody” herein is used in the broadest sense and includes polyclonal and monoclonal antibodies, including intact antibodies and functional (antigen-binding) antibody fragments, including fragment antigen binding (Fab) fragments, F(ab')2 fragments, Fab’ fragments, Fv fragments, recombinant IgG (rIgG) fragments, variable heavy chain (VH) regions capable of specifically binding the antigen, single chain antibody fragments, including single chain variable fragments (scFv), and single domain antibodies (e.g., sdAb, sdFv, nanobody) fragments. The term encompasses genetically engineered and/or otherwise modified forms of immunoglobulins, such as intrabodies, peptibodies, chimeric antibodies, fully human antibodies, humanized antibodies, and heteroconjugate antibodies, multispecific, e.g., bispecific, antibodies, diabodies, triabodies, and tetrabodies, tandem di-scFv, tandem tri-scFv. Unless otherwise stated, the term “antibody” should be understood to encompass functional antibody fragments thereof. The term also encompasses intact or full-length antibodies, including antibodies of any class or sub-class, including IgG and sub-classes thereof, IgM, IgE, IgA, and IgD. An “antibody derivative” generally refers to a molecule other than an intact antibody that comprises a portion derived from an intact antibody (or antigen-binding fragment thereof) and that binds the antigen to which the intact antibody (or antigen-binding fragment thereof) binds. Examples of antibody derivatives include but are not limited to single chain variable fragments (scFv), diabodies, triabodies, and the like, aptamers comprising multiple antigen-binding antibody fragments, single chain variable fragments, diabodies, triabodies, and the like. An “antibody fragment” or “antigen-binding antibody fragment” generally refers to a molecule other than an intact antibody that comprises a portion of an intact antibody that binds the antigen to which the intact antibody binds. Examples of antibody fragments include but are not limited to Fv, Fab, Fab', Fab'-SH, F(ab')2 and multispecific antibodies formed from antibody fragments.
The terms “full length antibody,” “intact antibody,” and “whole antibody” are used herein interchangeably to refer to an antibody having a structure substantially similar to a native antibody structure or having heavy chains that contain an Fc region as defined herein. The term “Fc region” generally refers to a C-terminal region of an immunoglobulin heavy chain that contains at least a portion of the constant region. The term includes native sequence Fc regions and variant Fc regions. In one embodiment, a human IgG heavy chain Fc region extends from Cys226, or from Pro230, to the carboxyl-terminus of the heavy chain. However, the C-terminal lysine (Lys447) of the Fc region may or may not be present. Unless otherwise specified herein, numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system, also called the EU index, as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md., 1991. An “antibody that binds to the same epitope” as a reference antibody (e.g., an antibody that binds NKG2C) generally refers to an antibody that blocks binding of the reference antibody to its antigen in a competition assay by 50% or more, and conversely, the reference antibody blocks binding of the antibody to its antigen in a competition assay by 50% or more. The term “chimeric” antibody generally refers to an antibody in which a portion of the heavy and/or light chain is derived from a particular source or species, while the remainder of the heavy and/or light chain is derived from a different source or species. A “human antibody” generally refers to an antibody that possesses an amino acid sequence corresponding to that of an antibody produced by a human or a human cell or derived from a non-human source that utilizes human antibody repertoires or other human antibody-encoding sequences. This definition of a human antibody specifically excludes a “humanized” antibody comprising non-human antigen-binding residues. A “humanized” antibody generally refers to a chimeric antibody comprising amino acid residues from non-human HVRs and amino acid residues from human FRs. In certain embodiments, a humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the HVRs (e.g., CDRs) correspond to those of a non-human antibody, and all or substantially all of the FRs correspond to those of a human antibody. A humanized antibody optionally may comprise at least a portion of an antibody constant region derived from a human antibody. In some
embodiments, a humanized antibody (or antigen-binding fragment or derivative thereof), when aligned with the antibody from which the acceptor framework regions were derived, includes one or more amino acid substitutions (or deletions or insertions) at desired locations. In some such embodiments, the amino acid residue(s) substituted (or inserted or deleted) at a particular position in the human (or other) or other FR corresponds to the amino acid residue(s) at the corresponding location(s) in the parent antibody (i.e., the non-human antibody from which the CDRs or HVRs were derived). A “humanized form” of an antibody, e.g., a non-human antibody, refers to an antibody that has undergone humanization. The term “antibody drug conjugate” (ADC) or “immunoconjugate” generally refers to a particular class of agent-drug conjugates. Here, “agent-drug conjugate” is an anti-NKG2C agent (e.g., an anti-NKG2C antibody or NKG2C-binding fragment or derivative thereof) conjugated to one or more heterologous molecule(s), including, but not limited to, a cytotoxic agent. The term “cytotoxic agent” generally refers to a substance that inhibits or prevents a cellular function and/or causes cell death or destruction. Cytotoxic agents include, but are not limited to, radioactive isotopes (e.g., At211, I131, I125, Y90, Re186, Re188, Sm153, Bi212, P32, Pb212, and radioactive isotopes of Lu); chemotherapeutic agents or drugs (e.g., methotrexate, adriamycin, vinca alkaloids (vincristine, vinblastine, etoposide), doxorubicin, melphalan, mitomycin C, chlorambucil, daunorubicin or other intercalating agents); growth inhibitory agents; enzymes and fragments thereof such as nucleolytic enzymes; antibiotics; toxins such as small molecule toxins or enzymatically active toxins of bacterial, fungal, plant or animal origin, including fragments and/or variants thereof; and the various antitumor or anticancer agents disclosed below. A “diagnostic reagent” generally refers to a compound, e.g., a target-specific antibody (or antigen- binding thereof) used to perform a diagnostic assay. “Effector functions” generally refer to those biological activities attributable to the Fc region of an antibody, which vary with the antibody isotype. Examples of antibody effector functions include: C1q binding and complement dependent cytotoxicity (CDC); Fc receptor binding; antibody-dependent cell- mediated cytotoxicity (ADCC); phagocytosis; down regulation of cell surface receptors (e.g. B cell receptor); and B cell activation.
An “effective amount” of an agent, e.g., a pharmaceutical formulation, generally refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic or prophylactic result. The term “epitope” generally refers to the particular site on an antigen molecule to which an antibody binds. The terms “host cell”, “host cell line”, and “host cell culture” are used interchangeably and generally refer to cells into which exogenous nucleic acid has been introduced, including the progeny of such cells. Host cells include “transformants” and “transformed cells,” which include the primary transformed cell and progeny derived therefrom without regard to the number of passages. Progeny may not be completely identical in nucleic acid content to a parent cell, but may contain mutations. Mutant progeny that have the same function or biological activity as screened or selected for in the originally transformed cell are included herein. A “rabbit antibody” generally refers to an antibody that possesses an amino acid sequence that corresponds to that of an antibody produced by a rabbit or a rabbit cell or derived from a non-rabbit source that utilizes rabbit antibody repertoires or other rabbit antibody-encoding sequences. An “immunoconjugate” generally refers to an antibody (or antigen-binding fragment or derivative thereof) conjugated to one or more heterologous molecule(s), including, but not limited to, a cytotoxic agent. An immunoconjugate is equivalent to the term “antibody drug conjugate” (ADC). An “individual” or “patient” or “subject” generally is a mammal. Mammals include, but are not limited to, domesticated animals (e.g., cows, sheep, cats, dogs, and horses), primates (e.g., humans and non- human primates such as monkeys), rabbits, and rodents (e.g., mice and rats). In certain embodiments, the individual or subject is a human. An “isolated” molecule (e.g., nucleic acid, antibody) generally refers to a molecule that has been separated from a component of its original environment (e.g., the natural environment if it is naturally occurring, or a host cell if expressed exogenously), and thus is altered by human intervention (e.g., "by the hand of man") from its original environment. In some embodiments, for example, an antibody is purified to greater than 95% or 99% purity as determined by, for example, electrophoretic (e.g., SDS- PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatographic (e.g., ion exchange or reverse phase HPLC). An isolated nucleic acid may refer to a nucleic acid molecule contained in cells
that ordinarily contain the nucleic acid molecule, but the nucleic acid molecule is present extra- chromosomally or at a chromosomal location that is different from its natural chromosomal location. In some embodiments, an isolated nucleic acid can be provided with fewer non-nucleic acid components (e.g., protein, lipid) than the amount of components present in a source sample. A composition comprising isolated nucleic acid can be about 50% to greater than 99% free of non-nucleic acid components. A composition comprising isolated nucleic acid can be about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or greater than 99% free of non-nucleic acid components. “Isolated nucleic acid encoding an anti-NKG2C antibody” or “isolated polynucleotide encoding an anti- NKG2C antibody” generally refers one or more nucleic acid molecules encoding antibody heavy and light chains (or fragments thereof), including such nucleic acid molecule(s) in a single vector or separate vectors, and such nucleic acid molecule(s) present at one or more locations in a recombinant host cell. The term “NKG2C” generally refers to any native, mature NKG2C that results from processing of a NKG2C precursor protein in a cell. The term includes NKG2C from any vertebrate source, including mammals such as primates (e.g. humans and cynomolgus or rhesus monkeys) and rodents (e.g., mice and rats), unless otherwise indicated. The term also includes naturally occurring variants of NKG2C, e.g., splice variants or allelic variants. The amino acid sequence of an example full-length human NKG2C protein is shown in Fig.1 (SEQ ID NO: 56). The term “NKG2C-positive cell” generally refers to any cell that expresses NKG2C on its surface or on an intracellular membrane or organelle (e.g., endosome, ER, Golgi apparatus, lysosome, and the like). Some cells, including those infected by a microbe or associated with some cancer types and tumors, exhibit up-regulation of NKG2C expression. The term “monoclonal antibody” generally refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical (as assessed at the level of Ig heavy and/or light chain amino acid sequence) and/or bind the same epitope, except for possible variant antibodies, e.g., containing naturally occurring mutations or arising during production of a monoclonal antibody preparation, such variants generally being present in minor amounts. In contrast to polyclonal antibody preparations, which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody of a monoclonal antibody preparation is directed against a single determinant on an antigen. Thus, the modifier “monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous
population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies to be used in accordance with the present technology may be made by a variety of techniques, including, but not limited to, the hybridoma method, recombinant DNA methods, phage-display methods, and methods utilizing transgenic animals containing all or part of the human immunoglobulin loci, such methods and other example methods for making monoclonal antibodies being described herein. The term “package insert” generally refers to instructions customarily included in commercial packages of therapeutic products, that contain information about the indications, usage, dosage, administration, combination therapy, contraindications and/or warnings concerning the use of such therapeutic products. “Percent (%) amino acid sequence identity” with respect to a reference polypeptide sequence generally refers to the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the reference polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining % amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. The term “pharmaceutical composition” generally refers to a preparation that is in such form as to permit the biological activity of an active ingredient contained therein to be effective, and which contains no additional components which are unacceptably toxic to a subject to which the formulation would be administered. A “pharmaceutically acceptable carrier” generally refers to an ingredient in a pharmaceutical formulation, other than an active ingredient, which is nontoxic to a subject. A pharmaceutically acceptable carrier includes, but is not limited to, a buffer, excipient, stabilizer, or preservative. As used herein, “treatment” (and grammatical variations thereof such as “treat” or “treating”) generally refers to clinical intervention in an attempt to alter the natural course of the individual being treated, and can be performed either for prophylaxis or during the course of clinical pathology. Desirable effects of 102
treatment include, but are not limited to, preventing occurrence or recurrence of disease, alleviation of symptoms, diminishment of any direct or indirect pathological consequences of the disease, preventing metastasis, decreasing the rate of disease progression, amelioration or palliation of the disease state, and remission or improved prognosis. In some embodiments, antibodies herein are used to delay development of a disease or to slow the progression of a disease. The term “vector” generally refers to a nucleic acid molecule capable of propagating another nucleic acid to which it is linked. The term includes the vector as a self-replicating nucleic acid structure as well as the vector incorporated into the genome of a host cell into which it has been introduced. Certain vectors are capable of directing the expression of nucleic acids to which they are operatively linked. Such vectors are referred to herein as “expression vectors.” Examples The examples set forth below illustrate certain embodiments and do not limit the technology. Example 1: Creation and Characterization of anti-NKG2C Hybridomas This Example describes the preparation of hybridomas that secrete monoclonal antibodies that react with NKG2C, as expressed in vivo. The resulting anti-NKG2C antibodies are suitable for a variety of purposes, including in diagnostic assays, examples of which are provided in the examples below. Common strains of laboratory mice, e.g., BALB/c or C57/BL6, or rats, e.g., Sprague Dawley, were immunized with an NKG2C immunogen. Following immunization of mice, hybridomas were formed using standard protocols to fuse myeloma cells with spleen, and draining lymph node cells harvested from the animals. Following selection, fusions were cloned in HAT medium and plated to approximately one cell/well in microtiter plates. Culture supernatants were subsequently tested against NKG2C-expressing cell transfectants, e.g., HEK 293 or RBL, by flow cytometry. Wells with successful staining profiles were then sub-cultured into larger vessels until sufficient cells were present to allow subcloning. Further characterization of the hybridoma subclone candidates was performed by flow cytometry using NKG2C- transfected cells. Selected candidate clones were further screened by flow cytometry against human blood cells divided into distinct subsets (e.g., lymphocytes), as well as against one or more cell lines generated from diseased and/or infected human cells. As compared to an isotype control, the percentage of positive cells in each blood cell subset was quantified. Basis for clone selection included strong reactivity against immune cells that express NKG2C (e.g., natural killer cells, natural killer T cells, and activated CD8+ T cells) but no appreciable reactivity against
other blood cell populations (e.g., certain lymphocytes, B cells); ability to detect NKG2C on the cell surface; ability to detect NKG2C on the cell surface of natural killer (NK) cells and natural killer T cells (NK T cells; ability to detect NKG2C on the cell surface of CD8+ T cells; ability to detect intracellular NKG2C in NK cells; ability to detect intracellular NKG2C in NK T cells; and/or ability to detect intracellular NKG2C in CD8+ T cells. Example 2: Sequencing of the Anti- NKG2C Antibody Variable Regions Cells from the anti-NKG2C hybridoma cell lines described in Example 1, above were grown in standard mammalian tissue culture media. Total RNA was isolated from hybridoma cells from various clones expressing anti-NKG2C monoclonal antibodies using a procedure based on the RNeasy Mini kit (Qiagen). Briefly, the RNA was used to generate first strand cDNA, both light chain and heavy chain variable domain cDNAs were amplified by a 5’-RACE technique, and positive clones were prepared by PCR and then subjected to DNA sequencing of multiple clones. Amino acid sequences of the individual variable domains (CDRs and Framework regions), including the CDR1, CDR2, and CDR3 regions, for both the heavy and light chains for four different antibodies (clones), designated AB 1-8 (also referred to herein as antibodies 1-8, and clones 1-8), are shown in Fig. 2. The various heavy and light chain CDR sequences are shown in Table 1, below.
Example 3: Detection of Cells Expressing NKG2C This example describes flow cytometry-based detection of human peripheral blood mononuclear cells (PBMCs) using certain anti-NKG2C monoclonal antibodies provided herein. PBMC Isolation Human peripheral blood mononuclear cells (PBMCs) were isolated under aseptic conditions through a gradient of Ficoll-Paque PLUS (GE Healthcare) according manufacturer instructions. Surface Staining PBMCs were counted and adjusted in Cell Staining Buffer (BioLegend, cat. #420201) to a cell density of 0.7-1x107 cells/mL. A 100 µL cell suspension (0.7-1x106 total cells) was stained with various cell surface markers (e.g., CD3, CD4, CD8, CD19, NCAM-1/CD56, and CD94, and/or NKG2C/CD159c for 15 minutes in the dark. All reagents used are from BioLegend unless otherwise indicated. Flow Cytometry/Gating Hierarchy Single cells (singlets) were identified through flow cytometry by SSC-H and SSC-A (Fig.4A), and lymphocytes, monocytes, and granulocytes were identified based on their forward (FSC-A) and side scatter (SSC-A) profiles (Fig.4B). Subsets of lymphocytes (including CD3-CD19+ B lymphocytes, CD3+CD19- T lymphocytes, CD3-CD19- lymphocytes, were identified as shown in Fig.4C. Of the CD3+CD19- lymphocytes, additional subsets of CD4-CD8+ lymphocytes, CD4-CD8- lymphocytes, CD4+CD8- lymphocytes) were identified as represented in the dot plots of Fig.4D. Results
For surface expression of NKG2C, total lymphocytes (Fig.5A and Fig.5B) and CD3-CD19- lymphocytes (Fig.5C and Fig.5D) were co-stained with either CD56 and AB5 (Fig.5A and Fig.5C) or CD56 and ABI (Fig.5B and Fig.5D), which were used to identify both NK cells and total lymphocytes positive for CD56. AB5 showed a similar staining pattern as commercially available anti-NKG2C antibody, ABI, in both total lymphocytes (Fig.6A and Fig.6B) as well as CD3-CD19- lymphocytes (Fig.6C and Fig.6D). Additionally, AB5 (Figs.7A-7C) specifically stained CD3+CD19- lymphocyte subsets (CD4+CD8-, CD4-CD8-, and CD4-CD8+) at a similar level of that of the commercially available anti-NKG2C antibody, ABI (Figs.7D-7F). The specificity of AB1, AB2, AB3, AB4, AB5, AB6, AB7, and AB8 for NKG2C was supported by co-staining total lymphocytes with CD94/KLRD1, which is reported to form a heterodimer with NKG2 (Figs.8A-8H). Similarly, NK cells were specifically identified within CD3- CD19- lymphocytes by co-staining with CD56 and each of AB1, AB2, AB3, AB4, AB5, AB6, AB7, and AB8 (Figs.8I-8P, panels I-P). Finally, the anti-NKG2C antibodies AB3, AB4, AB5, and AB6, did not cross react with NKG2C expressed on mouse splenocytes (Fig.9). Example 4: Functional Assay This example describes a functional assay based on NKG2C detection in cells that highly express the target. K562 cells (target) were labeled with CFSE (BioLegend Cat. #423801). PBMCs were isolated and purified primary NK (effector) cells were purified by MojoSort Isolation kit (BioLegend Cat. #480054). A standard was set up with the effector:target ration (E:T) of 4:1, 2:1, 1:1, and 1:2 (Fig.10A). To identify the function of anti-NKG2C antibodies in NK cell-mediated cytotoxicity, E:T ratio was set to 2:1. Antibodies were mixed with target cells and effector cells at 440 nM (10µg/well). Cells were then incubated at 370C for 4 hours. After 4-hour incubation, cells were washed once and DAPI (BioLegend Cat. #422801) was added to the cells to label dead cells and samples were collected for flow cytometry analysis. As shown in Fig.10B, all exemplary anti-NKG2C antibodies were capable of inhibiting the cytotoxicity of NK cells, as compared to no antibody control. Example 6: Blocking assay This example describes the ability of the exemplary anti-NKG2C antibodies described herein to block the
binding of a ligand to the cell surface receptor. PBMC isolation Human peripheral blood mononuclear cells (PBMCs) were isolated through a gradient of Ficoll-Paque PLUS (GE Healthcare) according to manufacturer instructions, and as described above. Blocking Assay PBMCs were incubated with 5 µg purified AB1, AB2, AB3, AB4, AB5, AB6, AB7, AB8, ABII antibodies, or 1.5 µg of NKG2E recombinant protein, for 15 minutes in the dark. AB1, AB2, AB3, AB4, AB5, AB6, AB7, AB8, ABII antibodies, and NKG2E recombinant protein were used as blocking agents. In certain instances, no blocking agents were used. Cells were then incubated with PE conjugated antibody or isotype control for 15 minutes. Cells were washed, acquired on a BD Canto II and analyzed using FlowJo software. Calculations for % Blocking Percentage original MFI was calculated by dividing the MFI of samples blocked with AB1, AB2, AB3, AB4, AB5, AB6, AB7, AB8 ABII antibodies, and NKG2E recombinant protein by the MFI of samples blocked with isotype MOPC-21. This value was subtracted from 100 to get a blocking percentage. The formula is shown below:
The results for calculated MFI and % blocking are described in Table 2.
As shown in Table 2, all exemplary anti-NKG2C antibodies were capable of blocking AB5, with minimal to no activity on blocking of MOPC-21, ABII and NKG2E. Example 7: Examples of sequences Provided below are examples of amino acid sequences related to the technology described herein. Table 3 lists CDR sequences and SEQ ID NOs for exemplaryanti-NKG2C antibodies provided herein.
CDRH1
CDRH2
X14 = F, Y, or V CDRL1
CDRL2
X X X X X
CDRL3
Precursor human NKG2C protein sequence (UniProtKB - P26717 (NKG2C_HUMAN)/ NCBI Reference Sequence: NP_002251.2) (SEQ ID NO: 56) 1 mnkqrgtfse vslaqdpkrq qrkpkgnkss isgteqeifq velnlqnpsl nhqgidkiyd 61 cqgllpppek ltaevlgiic ivlmatvlkt ivlipfleqn nfspntrtqk arhcghcpee 121 witysnscyy igkerrtwee sllactskns sllsidneee mkflasilps swigvfrnss 181 hhpwvtingl afkhkikdsd naelncavlq vnrlksaqcg ssmiyhckhk l Example 8: Examples of embodiments The examples set forth below illustrate certain embodiments and do not limit the technology. A1. An anti-NKG2C agent that binds NK inhibitory receptor CD94/NK group 2 member C (NKG2C) under laboratory or physiological conditions, wherein the agent comprises at least one immunoglobulin heavy chain variable domain and/or at least one immunoglobulin light chain variable domain, wherein: 113
a) each immunoglobulin heavy chain variable domain of the anti-NKG2C agent comprises first, second, and third heavy chain complementarity determining regions (CDRs), wherein the first heavy chain CDR (CDRH1) comprises an amino acid sequence that is at least 80 percent identical to the amino acid sequence X1X2X3X4X5 (SEQ ID NO: 50), wherein
the second heavy chain CDR (CDRH2) comprises an amino acid sequence that is at least 80 percent identical to the amino acid sequence X
NO: 51), wherein E,
the third heavy chain CDR (CDRH3) comprises an amino acid sequence that is at least 80 percent identical to the amino acid sequence X
4 (SEQ ID NO: 52), wherein
b) each immunoglobulin light chain variable domain of the anti-NKG2C agent comprises first, second, and third light chain CDRs, wherein the first light chain CDR (CDRL1) comprises an amino acid sequence that is at least 80 percent identical to the amino acid sequence KX2SX4SVX7X8X9X10X11X12X13X14X15X16 (SEQ ID NO: 53), wherein
the second light chain (CDRL2) comprises an amino acid sequence that is at least 80 percent identical to the amino acid sequence X1X2SX4X5X6X7 (SEQ ID NO: 54), wherein
the third light chain CDR (CDRL3) comprises an amino acid sequence that is at least 80 percent identical to the amino acid sequence X1X2X3X4X5X6X7X8T (SEQ ID NO: 55), wherein
A2. The anti-NKG2C agent of embodiment A1, wherein the CDRH1 comprises and amino acid sequence that is at least 85 percent identical to the amino acid sequence of SEQ ID NO: 50. A3. The anti-NKG2C agent of embodiment A1, wherein the CDRH1 comprises an amino acid sequence that is at least 90 percent identical to the amino acid sequence of SEQ ID NO: 50. A4. The anti-NKG2C agent of embodiment A1, wherein the CDRH1 comprises an amino acid sequence that is at least 95 percent identical to the amino acid sequence of SEQ ID NO: 50. A5. The anti-NKG2C agent of embodiment A1, wherein the CDRH1 comprises an amino acid sequence that is 100 percent identical to the amino acid sequence of SEQ ID NO: 50. A6. The anti-NKG2C agent of any one of embodiments A1 to A5, wherein the CDRH2 comprises an amino acid sequence that is at least 85 percent identical to the amino acid sequence of SEQ ID NO: 51. A7. The anti-NKG2C agent of any one of embodiments A1 to A5, wherein the CDRH2 comprises an amino acid sequence that is at least 90 percent identical to the amino acid sequence of SEQ ID NO: 51. A8. The anti-NKG2C agent of any one of embodiments A1 to A5, wherein the CDRH2 comprises an amino acid sequence that is at least 95 percent identical to the amino acid sequence of SEQ ID NO: 51. A9. The anti-NKG2C agent of any one of embodiments A1 to A5, wherein the CDRH2 comprises an amino acid sequence that is 100 percent identical to the amino acid sequence of SEQ ID NO: 51. A10. The anti-NKG2C agent of any one of embodiments A1 to A9, wherein the CDRH3 comprises an amino acid sequence that is at least 85 percent identical to the amino acid sequence of SEQ ID NO: 52. A11. The anti-NKG2C agent of any one of embodiments A1 to A9, wherein the CDRH3 comprises an amino acid sequence that is at least 90 percent identical to the amino acid sequence of SEQ ID NO: 52.
A12. The anti-NKG2C agent of any one of embodiments A1 to A9, wherein the CDRH3 comprises an amino acid sequence that is at least 95 percent identical to the amino acid sequence of SEQ ID NO: 52. A13. The anti-NKG2C agent of any one of embodiments A1 to A9, wherein the CDRH3 comprises an amino acid sequence that is 100 percent identical to the amino acid sequence of SEQ ID NO: 52. A14. The anti-NKG2C agent of any one of embodiments A1 to A13, wherein the CDRL1 comprises an amino acid sequence that is at least 85 percent identical to the amino acid sequence of SEQ ID NO: 53. A15. The anti-NKG2C agent of any one of embodiments A1 to A13, wherein the CDRL1 comprises an amino acid sequence that is at least 90 percent identical to the amino acid sequence of SEQ ID NO: 53. A16. The anti-NKG2C agent of any one of embodiments A1 to A13, wherein the CDRL1 comprises an amino acid sequence that is at least 95 percent identical to the amino acid sequence of SEQ ID NO: 53. A17. The anti-NKG2C agent of any one of embodiments A1 to A13, wherein the CDRL1 comprises an amino acid sequence that is 100 percent identical to the amino acid sequence of SEQ ID NO: 53. A18. The anti-NKG2C agent of any one of embodiments A1 to A17, wherein the CDRL2 comprises an amino acid sequence that is at least 85 percent identical to the amino acid sequence of SEQ ID NO: 54. A19. The anti-NKG2C agent of any one of embodiments A1 to A17, wherein the CDRL2 comprises an amino acid sequence that is at least 90 percent identical to the amino acid sequence of SEQ ID NO: 54. A20. The anti-NKG2C agent of any one of embodiments A1 to A17, wherein the CDRL2 comprises an amino acid sequence that is at least 95 percent identical to the amino acid sequence of SEQ ID NO: 54. A21. The anti-NKG2C agent of any one of embodiments A1 to A17, wherein the CDRL2 comprises an amino acid sequence that is 100 percent identical to the amino acid sequence of SEQ ID NO: 54. A22. The anti-NKG2C agent of any one of embodiments A1 to A21, wherein the CDRL3 comprises an amino acid sequence that is at least 85 percent identical to the amino acid sequence of SEQ ID NO: 55. A23. The anti-NKG2C agent of any one of embodiments A1 to A21, wherein the CDRL3 comprises an amino acid sequence that is at least 90 percent identical to the amino acid sequence of SEQ ID NO: 55. A24. The anti-NKG2C agent of any one of embodiments A1 to A21, wherein the CDRL3 comprises an amino acid sequence that is at least 95 percent identical to the amino acid sequence of SEQ ID NO: 55. A25. The anti-NKG2C agent of any one of embodiments A1 to A21, wherein the CDRL3 comprises an amino acid sequence that is 100 percent identical to the amino acid sequence of SEQ ID NO: 55. A26. The anti-NKG2C agent of any one of embodiments A1 to A25, wherein the CDRH1 comprises an amino acid sequence chosen from DYYMH (SEQ ID NO: 17), SFGMH (SEQ ID NO: 23), NFGMH (SEQ ID NO: 29), DTYIH (SEQ ID NO: 33), NYWMN (SEQ ID NO: 39), and DTYMH (SEQ ID NO: 45).
A27. The anti-NKG2C agent of any one of embodiments A1 to A26, wherein the CDRH2 comprises an amino acid sequence chosen from WIDPENDDTEYAPKFQG (SEQ ID NO: 18), YISSGSSTIYYRDTLKG (SEQ ID NO: 24), YISSGSSTIYYADTVKG (SEQ ID NO: 30), YISSGSSSIYYADTMKG (SEQ ID NO: 34), RIDPENGNTKYDPKFQG (SEQ ID NO: 40), MIHPSDSETRLNQKFKD (SEQ ID NO: 46), and RIDPANGYTKYDPKFQG (SEQ ID NO: 49). A28. The anti-NKG2C agent of any one of embodiments A1 to A27, wherein the CDRH3 comprises an amino acid sequence chosen from HYHYNDPY (SEQ ID NO: 19), SVIYYDYDRYLMDY (SEQ ID NO: 25), SVIYYAYDRYLMDF (SEQ ID NO: 31), TATVFWYFDV (SEQ ID NO: 35), SHGSNYGWFAY (SEQ ID NO: 41), and VITTHWYFDV (SEQ ID NO: 47). A29. The anti-NKG2C agent of any one of embodiments A1 to A28, wherein CDRL1 comprises an amino acid sequence chosen from SASSSVSYMY (SEQ ID NO: 20), KASQSVDYDGDSYMN (SEQ ID NO: 26), KSSQSVLYSSNQKNYLA (SEQ ID NO: 36), KASQSVSNDVG (SEQ ID NO: 42), and KSSQSVLYSSNQKNYLA (SEQ ID NO: 48). A30. The anti-NKG2C agent of any one embodiments A1 to A29, wherein CDRL2 comprises an amino acid sequence chosen from RTSNLAS (SEQ ID NO: 21), AASNLES (SEQ ID NO: 27), GASNLES (SEQ ID NO: 32), WASTRES (SEQ ID NO: 37), and YASNRYT (SEQ ID NO: 43). A31. The anti-NKG2C agent of any one of embodiments A1 to A30, wherein CDRL3 comprises an amino acid sequence chosen from QHYHSYPYT (SEQ ID NO: 22), QQSNEDPLT (SEQ ID NO: 28), QQSNEVPLT (SEQ ID NO: 38), HQ-YLSSHT (SEQ ID NO: 44), and QQDYSSPLT (SEQ ID NO: 48). A32. The anti-NKG2C agent of any one of embodiments A1 to A31, which comprises two immunoglobulin heavy chain variable domains and two immunoglobulin light chain variable domains. A33. The anti-NKG2C agent of embodiment A32, wherein the two immunoglobulin heavy chain variable domains each comprise a set of CDRH1, CDRH2, and CDRH3 amino acid sequences. A34. The anti-NKG2C agent of embodiment A32 and A33, wherein the two immunoglobulin light chain variable domains each comprise a set of CDRL1, CDRL2, and CDRL3 amino acid sequences. A35. The anti-NKG2C agent of any one of embodiments A1 to A34, wherein each immunoglobulin heavy chain variable domain comprises a set of CDRH1, CDRH2, CDRH3 amino acid sequences and each immunoglobulin light chain variable domain comprises a set of CDRL1, CDRL2, and CDRL3 amino acid sequences chosen from sets 1-8:
A36. The anti-NKG2C agent of embodiment A35, wherein all CDR sequences are from the same set. A37. The anti-NKG2C agent of any one of embodiments A1 to A36, wherein the agent is isolated. A38. The anti-NKG2C agent of any one of embodiments A1 to A37 wherein the agent is non-naturally occurring. A39. The anti-NKG2C agent of any one of embodiments A1 to A38, wherein the agent is an antibody, or antigen-binding fragment thereof.
A40. The anti-NKG2C agent of any one of embodiments A1 to A38, wherein the agent is an antibody, or derivative thereof. A41. The anti-NKG2C agent of any one of embodiments A1 to A40, wherein the agent is a humanized antibody, or an antigen binding fragment thereof. A42. The anti-NKG2C agent of any one of embodiments A1 to A40, wherein the agent is a derivative of a humanized antibody that binds NKG2C. A43. The anti-NKG2C agent of any one of embodiments A1 to A42, wherein the agent comprises a detectable marker or label. A44. The anti-NKG2C agent of any one of embodiments A1 to A43, wherein the agent is conjugated to a detectable marker or label. A45. The anti-NKG2C agent of any one of embodiments A1 to A44, wherein the agent is non-diffusively immobilized on a solid support. A46. A diagnostic reagent comprising the anti-NKG2C agent of any one of embodiments A1 to A45. A47. A kit comprising the anti-NKG2C agent of any one of embodiments A1 to A45 or the diagnostic reagent of embodiment A46. A48. A diagnostic kit configured to detect NK inhibitory receptor CD94/NK group 2 member C (NKG2C) in a biological sample, wherein the kit comprises the anti-NKG2C agent of any one of embodiments A1 to A45 or the diagnostic reagent of embodiment A46. A49. An isolated nucleic acid molecule comprising a nucleotide sequence that encodes an immunoglobulin heavy chain variable domain of the anti-NKG2C agent of any one of embodiments A1 to A45. A50. An isolated nucleic acid molecule comprising a nucleotide sequence that encodes an immunoglobulin light chain variable domain of the anti-NKG2C agent of any one of embodiments A1 to A45. A51. A recombinant expression vector comprising a first expression cassette and a second expression cassette, wherein the first expression cassette comprises a promoter and a nucleic acid molecule comprising a nucleotide sequence that encodes an immunoglobulin heavy chain variable domain of the anti-NKG2C agent of any one of embodiments A1 to A45, and the second expression cassette comprises a promoter and a nucleic acid molecule comprising a nucleotide sequence that encodes an immunoglobulin light chain variable domain of the anti-NKG2C agent of any one of embodiments A1 to A45. A52. A recombinant host cell transfected with the recombinant expression vector of embodiment A51.
A53. A method of detecting NKG2C, comprising contacting a sample known or suspected to contain NKG2C with the anti-NKG2C agent of any one of embodiments A1 to A45, and, if the sample contains NKG2C, detecting NKG2C:anti-NKG2C complexes. B1. A first anti-NKG2C agent that binds NKG2C under laboratory or physiological conditions, wherein the first agent competitively binds, or is capable of competitively binding, with a second anti-NKG2C agent, which second agent is the anti-NKG2C agent of any one of embodiments A1 to A36. B2. A first anti-NKG2C agent that binds NKG2C under laboratory or physiological conditions, wherein the first agent binds to, or is capable of binding to, the same epitope as a second anti-NKG2C agent, which second agent is the anti-NKG2C agent of any one of embodiments A1 to A36. B3. The first anti-NKG2C agent of embodiment B1 or B2, wherein the first agent and/or second agent is isolated. B4. The first anti-NKG2C agent of any one of embodiments B1 to B3, wherein the first agent and/or second agent is non-naturally occurring. B5. The first anti-NKG2C agent of any one of embodiments B1 to B4, wherein the first agent and/or second agent is an antibody, or derivative. B6. The first anti-NKG2C agent of any one of embodiments B1 to B4, wherein the first agent and/or second agent is an antibody, or derivative thereof. B7. The first anti-NKG2C agent of any one of embodiments B1 to B6, wherein the first agent and/or second agent is a humanized antibody, or an antigen binding fragment thereof. B8. The first anti-NKG2C agent of any one of embodiments B1 to B6, wherein the first agent and/or second agent is a derivative of a humanized antibody that binds NKG2C. B9. The first anti-NKG2C agent of any one of embodiments B1 to B8, comprising a detectable marker or label. B10. The first anti-NKG2C agent of any one of embodiments B1 to B9, wherein the first agent is conjugated to a detectable marker or label. B11. The first anti-NKG2C agent of any one of embodiments B1 to B10, wherein the first agent is non- diffusively immobilized on a solid support. B12. A diagnostic reagent comprising the first anti-NKG2C agent of any one of embodiments B1 to B11. B13. A kit comprising the first anti-NKG2C agent of any one of embodiments B1 to B11 or the diagnostic reagent of embodiment B12. B14. A diagnostic kit configured to detect NK inhibitory receptor CD94/NK group 2 member A (NKG2C) in a biological sample, wherein the kit comprises the first anti-NKG2C agent of any one of embodiments B1 to B11 or the diagnostic reagent of embodiment B12.
B15. An isolated nucleic acid molecule comprising a nucleotide sequence that encodes an immunoglobulin heavy chain variable domain of the first anti-NKG2C agent of any one of embodiments B1 to B11. B16. An isolated nucleic acid molecule comprising a nucleotide sequence that encodes an immunoglobulin light chain variable domain of the first anti-NKG2C agent of any one of embodiments B1 to B11. B17. A recombinant expression vector comprising a first expression cassette and a second expression cassette, wherein the first expression cassette comprises a promoter and a nucleic acid molecule comprising a nucleotide sequence that encodes an immunoglobulin heavy chain variable domain of the first anti-NKG2C agent of any one of embodiments B1 to B11, and the second expression cassette comprises a promoter and a nucleic acid molecule comprising a nucleotide sequence that encodes an immunoglobulin light chain variable domain of the first anti-NKG2C agent of any one of embodiments B1 to B11. B18. A recombinant host cell transfected with the recombinant expression vector of embodiment B17. B19. A method of detecting NKG2C, comprising contacting a sample known or suspected to contain NKG2C with the first anti-NKG2C agent of any one of embodiments B1 to B11, and, if the sample contains NKG2C, detecting NKG2C:anti-NKG2C complexes. C1. An anti-NKG2C agent for detecting NKG2C in a heterogeneous population of immune cells, wherein NKG2C is detected at a significant level in natural killer (NK) cells and/or CD8+ T lymphocytes in the population, and NKG2C is not significantly detected in other immune cells in the population. C2. The anti-NKG2C agent of embodiment C1, wherein the anti-NKG2C agent comprises at least one immunoglobulin heavy chain variable domain and at least one immunoglobulin light chain variable domain, wherein: i) each immunoglobulin heavy chain variable domain of the anti-NKG2C agent comprises first, second, and third heavy chain complementarity determining regions (CDRs); and ii) each immunoglobulin light chain variable domain of the anti-NKG2C agent comprises first, second, and third light chain CDRs. C3. The anti-NKG2C agent of embodiment C2, wherein the first heavy chain CDR (CDRH1) comprises an amino acid sequence that is at least 80 percent identical to the amino acid sequence X1X2X3X4X5 (SEQ ID NO: 50), wherein
X5 is H or N. C4. The anti-NKG2C agent of embodiment C2 or C3, wherein the second heavy chain CDR (CDRH2) comprises an amino acid sequence that is at least 80 percent identical to the amino acid sequence
1 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 (SEQ ID NO: 51), wherein
C5. The anti-NKG2C agent of embodiment C2, C3, or C4, wherein the third heavy chain CDR (CDRH3) comprises an amino acid sequence that is at least 80 percent identical to the amino acid sequence
14 (SEQ ID NO: 52), wherein
C6. The anti-NKG2C agent of any one of embodiments C2 to C5, wherein the first light chain CDR (CDRL1) comprises an amino acid sequence that is at least 80 percent identical to the amino acid sequence X1X2SX4SVX7X8X9X10X11X12X13X14X15X16 X17 (SEQ ID NO: 53), wherein
C7. The anti-NKG2C agent of any one of embodiments C2 to C6, wherein the second light chain CDR (CDRL2) comprises an amino acid sequence that is at least 80 percent identical to the amino acid sequence X1X2SX4X5X6X7 (SEQ ID NO: 54), wherein
C8. The anti-NKG2C agent of any one of embodiments C2 to C7, wherein the third light chain CDR (CDRL3) comprises an amino acid sequence that is at least 80 percent identical to the amino acid sequence X1X2X3X4X5X6X7X8T (SEQ ID NO: 55), wherein X1 is Q or H,
C9. The anti-NKG2C agent of any one of embodiments C2 to C8, wherein the CDRH1 comprises an amino acid sequence that is at least 85 percent identical to the amino acid sequence of SEQ ID NO: 50. C10. The anti-NKG2C agent of any one of embodiments C2 to C8, wherein the CDRH1 comprises an amino acid sequence that is at least 90 percent identical to the amino acid sequence of SEQ ID NO: 50. C11. The anti-NKG2C agent of any one of embodiments C2 to C8, wherein the CDRH1 comprises an amino acid sequence that is at least 95 percent identical to the amino acid sequence of SEQ ID NO: 50. C12. The anti-NKG2C agent of any one of embodiments C2 to C8, wherein the CDRH1 comprises an amino acid sequence that is 100 percent identical to the amino acid sequence of SEQ ID NO: 50. C13. The anti-NKG2C agent of any one of embodiments C2 to C12, wherein the CDRH2 comprises an amino acid sequence that is at least 85 percent identical to the amino acid sequence of SEQ ID NO: 51. C14. The anti-NKG2C agent of any one of embodiments C2 to C12, wherein the CDRH2 comprises an amino acid sequence that is at least 90 percent identical to the amino acid sequence of SEQ ID NO: 51. C15. The anti-NKG2C agent of any one of embodiments C2 to C12, wherein the CDRH2 comprises an amino acid sequence that is at least 95 percent identical to the amino acid sequence of SEQ ID NO: 51. C16. The anti-NKG2C agent of any one of embodiments C2 to C12, wherein the CDRH2 comprises an amino acid sequence that is 100 percent identical to the amino acid sequence of SEQ ID NO: 51. C17. The anti-NKG2C agent of any one of embodiments C2 to C16, wherein the CDRH3 comprises an amino acid sequence that is at least 85 percent identical to the amino acid sequence SEQ ID NO: 52. C18. The anti-NKG2C agent of any one of embodiments C2 to C16, wherein the CDRH3 comprises an amino acid sequence that is at least 90 percent identical to the amino acid sequence of SEQ ID NO: 52. C19. The anti-NKG2C agent of any one of embodiments C2 to C16, wherein the CDRH3 comprises an amino acid sequence that is at least 95 percent identical to the amino acid sequence of SEQ ID NO: 52. C20. The anti-NKG2C agent of any one of embodiments C2 to C16, wherein the CDRH3 comprises an amino acid sequence that is 100 percent identical to the amino acid sequence of SEQ ID NO: 52. C21. The anti-NKG2C agent of any one of embodiments C2 to C20, wherein the CDRL1 comprises an amino acid sequence that is at least 85 percent identical to the amino acid sequence of SEQ ID NO: 53.
C22. The anti-NKG2C agent of any one of embodiments C2 to C20, wherein the CDRL1 comprises an amino acid sequence that is at least 90 percent identical to the amino acid sequence of SEQ ID NO: 53. C23. The anti-NKG2C agent of any one of embodiments C2 to C20, wherein the CDRL1 comprises an amino acid sequence that is at least 95 percent identical to the amino acid sequence of SEQ ID NO: 53. C24. The anti-NKG2C agent of any one of embodiments C2 to C20, wherein the CDRL1 comprises an amino acid sequence that is 100 percent identical to the amino acid sequence of SEQ ID NO: 53. C25. The anti-NKG2C agent of any one of embodiments C2 to C24, wherein the CDRL2 comprises an amino acid sequence that is at least 85 percent identical to the amino acid sequence of SEQ ID NO: 54. C26. The anti-NKG2C agent of any one of embodiments C2 to C24, wherein the CDRL2 comprises an amino acid sequence that is at least 90 percent identical to the amino acid sequence of SEQ ID NO: 54. C27. The anti-NKG2C agent of any one of embodiments C2 to C24, wherein the CDRL2 comprises an amino acid sequence that is at least 95 percent identical to the amino acid sequence of SEQ ID NO: 54. C28. The anti-NKG2C agent of any one of embodiments C2 to C24, wherein the CDRL2 comprises an amino acid sequence that is 100 percent identical to the amino acid sequence of SEQ ID NO: 54. C29. The anti-NKG2C agent of any one of embodiments C2 to C28, wherein the CDRL3 comprises an amino acid sequence that is at least 85 percent identical to the amino acid sequence of SEQ ID NO: 55. C30. The anti-NKG2C agent of any one of embodiments C2 to C28, wherein the CDRL3 comprises an amino acid sequence that is at least 90 percent identical to the amino acid sequence of SEQ ID NO: 55. C31. The anti-NKG2C agent of any one of embodiments C2 to C28, wherein the CDRL3 comprises an amino acid sequence that is at least 95 percent identical to the amino acid sequence of SEQ ID NO: 55. C32. The anti-NKG2C agent of any one of embodiments C2 to C28, wherein the CDRL3 comprises an amino acid sequence that is 100 percent identical to the amino acid sequence of SEQ ID NO: 55. C33. The anti-NKG2C agent of any one of embodiments C2 to C32, wherein the CDRH1 comprises an amino acid sequence chosen from DYYMH (SEQ ID NO: 17), SFGMH (SEQ ID NO: 23), NFGMH (SEQ ID NO: 29), DTYIH (SEQ ID NO: 33), NYWMN (SEQ ID NO: 39), and DTYMH (SEQ ID NO: 45). C34. The anti-NKG2C agent of any one of embodiments C2 to C33, wherein the CDRH2 comprises an amino acid sequence chosen from WIDPENDDTEYAPKFQG (SEQ ID NO: 18), Y
(SEQ ID NO: 24), Y
(SEQ ID NO: 30), Y
34), RIDPENGNTKYDPKFQG (SEQ ID NO: 40), MIHPSDSETRLNQKFKD (SEQ ID NO: 46), and RIDPANGYTKYDPKFQG (SEQ ID NO: 49). C35. The anti-NKG2C agent of any one of embodiments C2 to C34, wherein the CDRH3 comprises an amino acid sequence chosen from HYHYNDPY (SEQ ID NO: 19), SVIYYDYDRYLMDY (SEQ ID
NO: 25), SVIYYAYDRYLMDF (SEQ ID NO: 31), TATVFWYFDV (SEQ ID NO: 35), SHGSNYGWFAY (SEQ ID NO: 41), and VITTHWYFDV (SEQ ID NO: 47). C36. The anti-NKG2C agent of any one of embodiments C2 to C35, wherein the CDRL1 comprises an amino acid sequence chosen from SASSSVSYMY (SEQ ID NO: 20), KASQSVDYDGDSYMN (SEQ ID NO: 26), KSSQSVLYSSNQKNYLA (SEQ ID NO: 36), KASQSVSNDVG (SEQ ID NO: 42), and KSSQSVLYSSNQKNYLA (SEQ ID NO: 48). C37. The anti-NKG2C agent of any one of embodiments C2 to C36, wherein the CDRL2 comprises an amino acid sequence chosen from RTSNLAS (SEQ ID NO: 21), AASNLES (SEQ ID NO: 27), GASNLES (SEQ ID NO: 32), WASTRES (SEQ ID NO: 37), and YASNRYT (SEQ ID NO: 43). C38. The anti-NKG2C agent of any one of embodiments C2 to C37, wherein the CDRL3 comprises an amino acid sequence chosen from QHYHSYPYT (SEQ ID NO: 22), QQSNEDPLT (SEQ ID NO: 28), QQSNEVPLT (SEQ ID NO: 38), HQ-YLSSHT (SEQ ID NO: 44), and QQDYSSPLT (SEQ ID NO: 48). C39. The anti-NKG2C agent of any one of embodiments C1 to C38, which comprises two immunoglobulin heavy chain variable domains and two immunoglobulin light chain variable domains. C40. The anti-NKG2C agent of embodiment C39, wherein the two immunoglobulin heavy chain variable domains each comprise a set of CDRH1, CDRH2, and CDRH3 amino acid sequences. C41. The anti-NKG2C agent of embodiment C39 or C40, wherein the two immunoglobulin light chain variable domains each comprise a set of CDRL1, CDRL2, and CDRL3 amino acid sequences. C42. The anti-NKG2C agent of any one of embodiments C2 to C41, wherein each immunoglobulin heavy chain variable domain comprises a set of CDRH1, CDRH2, and CDRH3 amino acid sequences and each immunoglobulin light chain variable domain comprises a set of CDRL1, CDRL2, and CDRL3 amino acid sequences chosen from sets 1-8:
C43. The anti-NKG2C agent of embodiment C42, wherein all CDR sequences are from the same set. C44. The anti-NKG2C agent of any one of embodiments C1 to C43, wherein NKG2C is detected at a significant level in NK cells. C45. The anti-NKG2C agent of embodiment C44, wherein NKG2C is detected in NK cells using a flow cytometry assay. C46. The anti-NKG2C agent of embodiment C1 to C43, wherein NKG2C is detected at a significant level in CD8+ T cells. C47. The anti-NKG2C agent of embodiment C46, wherein NKG2C is detected in CD8+ T cells using a flow cytometry assay. C48. The anti-NKG2C agent o any one of embodiments C1 to C47, wherein NKG2C is not significantly detected in other immune cells in the population, wherein the other immune cells comprise one or more of plasmacytoid dendritic cells, B cells, and monocytes. C49. The anti-NKG2C agent of any one of embodiments C1 to C48, wherein the agent is isolated. C50. The anti-NKG2C agent of any one of embodiments C1 to C49, wherein the agent is non-naturally occurring.
C51. The anti-NKG2C agent of any one of embodiments C1 to C50, wherein the agent is an antibody, or antigen-binding fragment thereof. C52. The anti-NKG2C agent of any one of embodiments C1 to C50, wherein the agent is an antibody, or derivative thereof. C53. The anti-NKG2C agent of any one of embodiments C1 to C52, wherein the agent is a humanized antibody, or an antigen binding fragment thereof. C54. The anti-NKG2C agent of any one of embodiments C1 to C52, wherein the agent is a derivative of a humanized antibody that bind NKG2C. C55. The anti-NKG2C agent of any one of embodiments C1 to C54, wherein the agent comprises a detectable marker or label. C56. The anti-NKG2C agent of any one of embodiments C1 to C55, wherein the agent is conjugated to a detectable marker or label. C57. The anti-NKG2C agent of any one of embodiments C1 to C56, wherein the agent is non-diffusively immobilized on a solid support. C58. A diagnostic reagent comprising the anti-NKG2C agent of any one of embodiments C1 to C57. C59. A kit comprising the anti-NKG2C agent of any one of embodiments C1 to C57 or the diagnostic reagent of embodiment C58. C60. A diagnostic kit configured to detect NKG2C in a biological sample, wherein the kit comprises the anti-NKG2C agent of any one of embodiments C1 to C57 or the diagnostic reagent of embodiment C58. C61. An isolated nucleic acid molecule comprising a nucleotide sequence that encodes an immunoglobulin heavy chain variable domain of the anti-NKG2C agent of any one of embodiments C1 to C57. C62. An isolated nucleic acid molecule comprising a nucleotide sequence that encodes an immunoglobulin light chain variable domain of the anti-NKG2C agent of any one of embodiments C1 to C57. C63. A recombinant expression vector comprising a first expression cassette and a second expression cassette, wherein the first expression cassette comprises a promoter and a nucleic acid molecule comprising a nucleotide sequence that encodes an immunoglobulin heavy chain variable domain of the anti-NKG2C agent of any one of embodiments C1 to C57, and the second expression cassette comprises a promoter and a nucleic acid molecule comprising a nucleotide sequence that encodes an immunoglobulin light chain variable domain of the anti-NKG2C agent of any one of embodiments C1 to C57. C64. A recombinant host cell transfected with the recombinant expression vector of embodiment C63.
C65. A method of detecting NKG2C, comprising contacting a sample known or suspected to contain NKG2C with the anti-NKG2C agent of any one of embodiments C1 to C57, and, if the sample contains NKG2C, detecting NKG2C:anti-NKG2C complexes. C66. A method of detecting NKG2C in a heterogeneous population of immune cells, comprising contacting the population with an anti-NKG2C agent of any one of embodiments C1 to C57, and, if the population contains cells expressing NKG2C, detecting NKG2C:anti-NKG2C complexes. D1. An anti-NKG2C agent that binds the NKG2C receptor or a fragment thereof, comprising one or more of: a) an immunoglobulin heavy chain variable domain comprising: (i) a heavy chain complementary determining region 1 (CDRH1) comprising the sequence X1X2X3X4X5 (SEQ ID NO: 50), wherein X1 is N, S, or D, X2 is F, T, or Y, X3 is G, Y, or W, X4 is M or I, and X5 is H or N; (ii) a heavy chain complementary determining region 2 (CDRH2) comprising the sequence X1IX3X4X5X6X7X8X9X10X11X12X13X14X15X16X17 (SEQ ID NO: 51), wherein X1 is Y, R, W, or M, X3 is S, D, or H, X4 is S or P, X5 is G, E, A, or S, X6 is S, N, or D, X7 is S, G, or D, X8 is T, S, N, Y, D, or E, X9 is I or T, X10 is Y, K, E, or R, X11 is Y or L, X12 is A, R, D, or N, X13 is D, P, or Q, X14 is T or K, X15 is V, L, M, or F, X16 is K or Q, and X17 is G or D; (iii) a heavy chain complementary determining region 3 (CDRH3) comprising the sequence X1X2X3X4X5X6X7X8X9X10X11X12X13X14 (SEQ ID NO: 52), wherein X1 is S, T, H or V, X2 is V, A, I, Y or H, X3 is I, T, H, or G, X4 is Y, V, T, or S, X5 is Y, F, H, or N, X6 is A, D, W, or Y, X7 is Y, G, or no amino acid, X8 is D or no amino acid, X9 is R or no amino acid, X10 is Y or no amino acid, X11 is L, Y, N, W or no amino acid, X12 is M, F, D, or no amino acid, X13 is D, P, or A, and X14 is F, Y, or V; b) an immunoglobulin light chain variable domain comprising: (i) a light chain complementary determining region 1 (CDRL1) comprising the sequence KX2SX4SVX7X8X9X10X11X12X13X14X15X16 (SEQ ID NO: 53), wherein X1 is S or K, X2 is A or S, X4 is Q or S, X7 is D, L, S, or no amino acid, X8 is Y or no amino acid, X9 is D, S, or no amino acid, X10 is G, S, or no amino acid, X11 is D, N, or no amino acid, X12 is Q or no amino acid, X13 is K or no amino acid, X14 is S or N, X15 is Y or D, X16 is M, L, or V, and X17 is Y, N, A or G; (ii) a light chain complementary determining region 2 (CDRL2) comprising the sequence X1X2SX4X5X6X7 (SEQ ID NO: 54), wherein X1 is G, A, R, W, or Y, X2 is A or T, X4 is N or T, X5 is L or R, X6 is E, A or Y, and X7 is S or T; and (iii) a light chain complementary determining region 3 (CDRL3) comprising the sequence X1X2X3X4X5X6X7X8T (SEQ ID NO: 55), wherein X1 is Q or H, X2 is Q or H, X3 is S, Y, D, or no amino acid, X4 is N, H, or Y, X5 is E, S, or L, X6 is D, V, Y, or S, X7 is P or S, and X8 is L, Y, or H.
D2. The anti-NKG2C agent of embodiment D1, wherein the immunoglobulin heavy chain variable domain comprises a CDRH1 comprising the sequence of amino acids set forth in SEQ ID NO: 17, SEQ ID NO: 23, SEQ ID NO: 29, SEQ ID NO: 33, SEQ ID NO: 39 or SEQ ID NO:45, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 17, SEQ ID NO: 23, SEQ ID NO: 29, SEQ ID NO: 33, SEQ ID NO: 39 or SEQ ID NO:45; a CDRH2 comprising the sequence of amino acids set forth in SEQ ID NO: 18, SEQ ID NO: 24, SEQ ID NO:30, SEQ ID NO:34, SEQ ID NO:40, SEQ ID NO:46, SEQ ID NO:49, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 18, SEQ ID NO: 24, SEQ ID NO:30, SEQ ID NO:34, SEQ ID NO:40, SEQ ID NO:46, SEQ ID NO:49; and a CDRH3 comprising the sequence of amino acids set forth in SEQ ID NO: 19, SEQ ID NO: 25, SEQ ID NO: 31, SEQ ID NO: 35, SEQ ID NO: 41, SEQ ID NO: 47, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 19, SEQ ID NO: 25, SEQ ID NO: 31, SEQ ID NO: 35, SEQ ID NO: 41, SEQ ID NO: 47. D3. The anti-NKG2C agent of embodiment D1 or embodiment D2, wherein the immunoglobulin heavy chain variable domain comprises a CDRH1 comprising the sequence of amino acids set forth in SEQ ID NO: 17, SEQ ID NO: 23, SEQ ID NO: 29, SEQ ID NO: 33, SEQ ID NO: 39 or SEQ ID NO:45; a CDRH2 comprising the sequence of amino acids set forth in SEQ ID NO: 18, SEQ ID NO: 24, SEQ ID NO:30, SEQ ID NO:34, SEQ ID NO:40, SEQ ID NO:46, SEQ ID NO:49; and a CDRH3 comprising the sequence of amino acids set forth in SEQ ID NO: 19, SEQ ID NO: 25, SEQ ID NO: 31, SEQ ID NO: 35, SEQ ID NO: 41, SEQ ID NO: 47. D4. The anti-NKG2C agent of any of embodiments D1-D3, wherein the immunoglobulin light chain variable domain comprises a CDRL1 comprising the sequence of amino acids set forth in SEQ ID NO: 20; SEQ ID NO: 26, SEQ ID NO: 36 or SEQ ID NO: 42 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 20; SEQ ID NO: 26, SEQ ID NO: 36 or SEQ ID NO: 42; a CDRL2 comprising the sequence of amino acids set forth in SEQ ID NO: 21, SEQ ID NO: 27, SEQ ID NO: 32, SEQ ID NO: 37, SEQ ID NO: 43, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 21, SEQ ID NO: 27, SEQ ID NO: 32, SEQ ID NO: 37, SEQ ID NO: 43; and a CDRL3 comprising the sequence of amino acids set forth in SEQ ID NO: 22, SEQ ID NO: 28, SEQ ID NO: 38, SEQ ID NO: 44, SEQ ID NO: 48, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%,
95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 22, SEQ ID NO: 28, SEQ ID NO: 38, SEQ ID NO: 44, SEQ ID NO: 48. D5. The anti-NKG2C agent of any of embodiments D1-D4, wherein the immunoglobulin light chain variable domain comprises a CDRL1 comprising a sequence of amino acids set forth in SEQ ID NO: 20; SEQ ID NO: 26, SEQ ID NO: 36 or SEQ ID NO: 42; a CDRL2 comprising a sequence of amino acids set forth in SEQ ID NO: 21, SEQ ID NO: 27, SEQ ID NO: 32, SEQ ID NO: 37, SEQ ID NO: 43; and a CDRL3 comprising a sequence of amino acids set forth in SEQ ID NO: 22, SEQ ID NO: 28, SEQ ID NO: 38, SEQ ID NO: 44, SEQ ID NO: 48. D6. The anti-NKG2C agent of any of embodiments D1-D5, wherein the CDRH1 comprises the sequence set forth in SEQ ID NO: 17, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 17, the CDRH2 comprises the sequence set forth in SEQ ID NO: 18, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 18; and the CDRH3 comprises the sequence set forth in SEQ ID NO: 19, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 19. D7. The anti-NKG2C agent of any of embodiments D1-D6, wherein the CDRH1 comprises the sequence set forth in SEQ ID NO: 17, the CDRH2 comprises the sequence set forth in SEQ ID NO: 18; and the CDRH3 comprises the sequence set forth in SEQ ID NO: 19. D8. The anti-NKG2C agent of any of embodiments D1-D5, wherein the CDRH1 comprises the sequence set forth in SEQ ID NO: 23, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 23, the CDRH2 comprises the sequence set forth in SEQ ID NO: 24,or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 24; and the CDRH3 comprises the sequence set forth in SEQ ID NO: 25, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 25. D9. The anti-NKG2C agent of any of embodiments D1-D5 and D8, wherein the CDRH1 comprises the sequence set forth in SEQ ID NO: 23, the CDRH2 comprises the sequence set forth in SEQ ID NO: 24; and the CDRH3 comprises the sequence set forth in SEQ ID NO: 25. D10. The anti-NKG2C agent of any of embodiments D1-D5, wherein the CDRH1 comprises the sequence set forth in SEQ ID NO: 16, or a sequence of amino acids that exhibits at least 80%, 81%, 82%,
83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:16; the CDRH2 comprises the sequence set forth in SEQ ID NO: 17 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:17; and the CDRH3 comprises the sequence set forth in SEQ ID NO: 18 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:18. D11. The anti-NKG2C agent of any of embodiments D1-D5 and D10, wherein the CDRH1 comprises the sequence set forth in SEQ ID NO: 16, the CDRH2 comprises the sequence set forth in SEQ ID NO: 17; and the CDRH3 comprises the sequence set forth in SEQ ID NO: 18. D12. The anti-NKG2C agent of any of embodiments D1-D5, wherein the CDRH1 comprises the sequence set forth in SEQ ID NO: 23, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 23, the CDRH2 comprises the sequence set forth in SEQ ID NO: 24,or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 24; and the CDRH3 comprises the sequence set forth in SEQ ID NO: 25, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 25. D13. The anti-NKG2C agent of any of embodiments D1-D5 and D12, wherein the CDRH1 comprises the sequence set forth in SEQ ID NO: 23, the CDRH2 comprises the sequence set forth in SEQ ID NO: 24; and the CDRH3 comprises the sequence set forth in SEQ ID NO: 25. D14. The anti-NKG2C agent of any of embodiments D1-D5, wherein the CDRH1 comprises the sequence set forth in SEQ ID NO: 29, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:29, the CDRH2 comprises the sequence set forth in SEQ ID NO: 30,or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 30; and the CDRH3 comprises the sequence set forth in SEQ ID NO: 31, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 31. D15. The anti-NKG2C agent of any of embodiments D1-D5 and D14, wherein the CDRH1 comprises the sequence set forth in SEQ ID NO: 29, the CDRH2 comprises the sequence set forth in SEQ ID NO: 30; and the CDRH3 comprises the sequence set forth in SEQ ID NO: 31.
D16. The anti-NKG2C agent of any of embodiments D1-D5, wherein the CDRH1 comprises the sequence set forth in SEQ ID NO: 29, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:29, the CDRH2 comprises the sequence set forth in SEQ ID NO: 34, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:34; and the CDRH3 comprises the sequence set forth in SEQ ID NO: 25, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 25. D17. The anti-NKG2C agent of any of embodiments D1-D5 and D16, wherein the CDRH1 comprises the sequence set forth in SEQ ID NO: 29, the CDRH2 comprises the sequence set forth in SEQ ID NO: 34; and the CDRH3 comprises the sequence set forth in SEQ ID NO: 25. D18. The anti-NKG2C agent of any of embodiments D1-D5, wherein the CDRH1 comprises the sequence set forth in SEQ ID NO: 33, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 33, the CDRH2 comprises the sequence set forth in SEQ ID NO: 40, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:40; and the CDRH3 comprises the sequence set forth in SEQ ID NO: 35, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 35. D19. The anti-NKG2C agent of any of embodiments D1-D5 and D18, wherein the CDRH1 comprises the sequence set forth in SEQ ID NO:33, the CDRH2 comprises the sequence set forth in SEQ ID NO: 40; and the CDRH3 comprises the sequence set forth in SEQ ID NO: 35. D20. The anti-NKG2C agent of any of embodiments D1-D5, wherein the CDRH1 comprises the sequence set forth in SEQ ID NO: 39, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 39, the CDRH2 comprises the sequence set forth in SEQ ID NO: 46, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 46; and the CDRH3 comprises the sequence set forth in SEQ ID NO: 41, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 41. 134
D21. The anti-NKG2C agent of any of embodiments D1-D5 and D20, wherein the CDRH1 comprises the sequence set forth in SEQ ID NO: 39, the CDRH2 comprises the sequence set forth in SEQ ID NO: 46; and the CDRH3 comprises the sequence set forth in SEQ ID NO: 41. D22. The anti-NKG2C agent of any of embodiments D1-D5, wherein the CDRH1 comprises the sequence set forth in SEQ ID NO: 45, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 45, the CDRH2 comprises the sequence set forth in SEQ ID NO: 49, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 49; and the CDRH3 comprises the sequence set forth in SEQ ID NO: 47, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 47. D23. The anti-NKG2C agent of any of embodiments D1-D5 and D22, wherein the CDRH1 comprises the sequence set forth in SEQ ID NO: 45, the CDRH2 comprises the sequence set forth in SEQ ID NO: 49; and the CDRH3 comprises the sequence set forth in SEQ ID NO: 47. D24. The anti-NKG2C agent of any of embodiments D1-D23, wherein the CDRL1 comprises the sequence set forth in SEQ ID NO: 20, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 20; the CDRL2 comprises the sequence set forth in SEQ ID NO: 21, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:21; and the CDRL3 comprises the sequence set forth in SEQ ID NO: 22, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:22. D25. The anti-NKG2C agent of any of embodiments D1-D24, wherein the CDRL1 comprises the sequence set forth in SEQ ID NO: 20, the CDRL2 comprises the sequence set forth in SEQ ID NO: 21; and the CDRL3 comprises the sequence set forth in SEQ ID NO: 22. D26. The anti-NKG2C agent of any of embodiments D1-D23, wherein the CDRL1 comprises the sequence set forth in SEQ ID NO: 26, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:26; the CDRL2 comprises the sequence set forth in SEQ ID NO: 27 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:27; and the CDRL3 comprises the sequence set forth in SEQ ID NO:28 or a sequence of amino acids
that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:28. D27. The anti-NKG2C agent of any of embodiments D1-D23 and D26, wherein the CDRL1 comprises the sequence set forth in SEQ ID NO: 26, the CDRL2 comprises the sequence set forth in SEQ ID NO: 27; and the CDRL3 comprises the sequence set forth in SEQ ID NO: 28. D28. The anti-NKG2C agent of any of embodiments D1-D23, wherein the CDRL1 comprises the sequence set forth in SEQ ID NO: 26, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:26; the CDRL2 comprises the sequence set forth in SEQ ID NO: 32 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:32; and the CDRL3 comprises the sequence set forth in SEQ ID NO: 28 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:28. D29. The anti-NKG2C agent of any of embodiments D1-D23 and D28, wherein the CDRL1 comprises the sequence set forth in SEQ ID NO: 26, the CDRL2 comprises the sequence set forth in SEQ ID NO: 32; and a CDRL3 comprising the sequence set forth in SEQ ID NO: 28. D30. The anti-NKG2C agent of any of embodiments D1-D23, wherein the CDRL1 comprises the sequence set forth in SEQ ID NO: 26, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:26; the CDRL2 comprises the sequence set forth in SEQ ID NO: 32 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:32; and the CDRL3 comprises the sequence set forth in SEQ ID NO: 38 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:38. D31. The anti-NKG2C agent of any of embodiments D1-D23 and D30, wherein the CDRL1 comprises the sequence set forth in SEQ ID NO: 26, the CDRL2 comprises the sequence set forth in SEQ ID NO: 32; and the CDRL3 comprises the sequence set forth in SEQ ID NO: 38. D32. The anti-NKG2C agent of any of embodiments D1-D23, wherein the CDRL1 comprises the sequence set forth in SEQ ID NO: 36, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:36; the CDRL2 comprises the sequence set forth in SEQ ID NO:37 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%,
88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:37; and the CDRL3 comprises the sequence set forth in SEQ ID NO:44 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:44. D33. The anti-NKG2C agent of any of embodiments D1-D23 and D32, wherein the CDRL1 comprises the sequence set forth in SEQ ID NO: 36, the CDRL2 comprises the sequence set forth in SEQ ID NO: 37; and the CDRL3 comprises the sequence set forth in SEQ ID NO: 44. D34. The anti-NKG2C agent of any of embodiments D1-D23, wherein the CDRL1 comprises the sequence set forth in SEQ ID NO: 42, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:42; the CDRL2 comprises the sequence set forth in SEQ ID NO: 43 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:43; and the CDRL3 comprises the sequence set forth in SEQ ID NO:48 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:48. D35. The anti-NKG2C agent of any of embodiments D1-D23 and D34, wherein the CDRL1 comprises the sequence set forth in SEQ ID NO:42, the CDRL2 comprises the sequence set forth in SEQ ID NO: 43; and the CDRL3 comprises the sequence set forth in SEQ ID NO: 48. D36. The anti-NKG2C agent of any of embodiments D1-D23, wherein the CDRL1 comprises the sequence set forth in SEQ ID NO: 48, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:48; the CDRL2 comprises the sequence set forth in SEQ ID NO: 37 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:37; and the CDRL3 comprises the sequence set forth in SEQ ID NO: 44 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:44. D37. The anti-NKG2C agent of any of embodiments D1-D23 and D36, wherein the CDRL1 comprises the sequence set forth in SEQ ID NO: 48, the CDRL2 comprises the sequence set forth in SEQ ID NO: 37; and the CDRL3 comprises the sequence set forth in SEQ ID NO: 44. D38. The anti-NKG2C agent of any of embodiments D1-D37, wherein the CDRH1 comprises the sequence of amino acids set forth in SEQ ID NO: 17, 23, 29, 33, 39 or 45, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%,
94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 17, 23, 29, 33, 39 or 45, the CDRH2 comprises a sequence of amino acids set forth in SEQ ID NO: 18, 24, 30, 34, 40, 46 or 49, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 18, 24, 30, 34, 40, 46 or 49; the CDRH3 comprises a sequence of amino acids set forth in SEQ ID NO: 19, 25, 31, 35, 41 or 47, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 19, 25, 31, 35, 41 or 47; the CDRL1 comprises a sequence of amino acids set forth in SEQ ID NO: 20, 26, 36 or 42, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 20, 26, 36 or 42; the CDRL2 comprises a sequence of amino acids set forth in SEQ ID NO: 21, 27, 32, 37 or 43, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 21, 27, 32, 37 or 43; and the CDRL3 comprises a sequence of amino acids set forth in SEQ ID NO: 22, 28, 38, 44 or 48, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 22, 28, 38, 44 or 48. D39. The anti-NKG2C agent of any of embodiments D1-D38, wherein the CDRH1 comprises the sequence of amino acids set forth in SEQ ID NO: 17, 23, 29, 33, 39 or 45; the CDRH2 comprises a sequence of amino acids set forth in SEQ ID NO: 18, 24, 30, 34, 40, 46 or 49; the CDRH3 comprises a sequence of amino acids set forth in SEQ ID NO: 19, 25, 31, 35, 41 or 47; the CDRL1 comprises a sequence of amino acids set forth in SEQ ID NO: 20, 26, 36 or 42; the CDRL2 comprises a sequence of amino acids set forth in SEQ ID NO: 21, 27, 32, 37 or 43; and the CDRL3 comprises a sequence of amino acids set forth in SEQ ID NO: 22, 28, 38, 44 or 48. D40. The anti-NKG2C agent of any of embodiments D1-D39, wherein the CDRH1 comprises the sequence set forth in SEQ ID NO: 17 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:17, the CDRH2 comprises the sequence set forth in SEQ ID NO:18 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:18; the CDRH3 comprises the sequence set forth in SEQ ID NO:19 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%,
94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:19; the CDRL1 comprises the sequence set forth in SEQ ID NO:20, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:20, the CDRL2 comprises the sequence set forth in SEQ ID NO:21 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:21; and the CDRL3 comprises the sequence set forth in SEQ ID NO:22 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:22. D41. The anti-NKG2C agent of any of embodiments D1-D40, wherein the CDRH1 comprises the sequence set forth in SEQ ID NO: 17, a CDRH2 comprising the sequence set forth in SEQ ID NO: 18; a CDRH3 comprising the sequence set forth in SEQ ID NO: 19; a CDRL1 comprising the sequence set forth in SEQ ID NO: 20, a CDRL2 comprising the sequence set forth in SEQ ID NO: 21; and a CDRL3 comprising the sequence set forth in SEQ ID NO: 22. D42. The anti-NKG2C agent of any of embodiments D1-D41, wherein the CDRH1 comprises the sequence set forth in SEQ ID NO:23, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:23, the CDRH2 comprises the sequence set forth in SEQ ID NO:24 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:24; the CDRH3 comprises the sequence set forth in SEQ ID NO:25 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:25; the CDRL1 comprises the sequence set forth in SEQ ID NO:26 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:26, the CDRL2 comprises the sequence set forth in SEQ ID NO:27 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:27; and the CDRL3 comprises the sequence set forth in SEQ ID NO:28 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:28. D43. The anti-NKG2C agent of any of embodiments D1-D44, wherein the CDRH1 comprises the sequence set forth in SEQ ID NO:23, the CDRH2 comprises the sequence set forth in SEQ ID NO: 24; the CDRH3 comprises the sequence set forth in SEQ ID NO: 25; the CDRL1 comprises the sequence set
forth in SEQ ID NO: 26, the CDRL2 comprises the sequence set forth in SEQ ID NO: 27; and the CDRL3 comprises the sequence set forth in SEQ ID NO: 28. D44. The anti-NKG2C agent of any of embodiments D1-D43, wherein the CDRH1 comprises the sequence set forth in SEQ ID NO:29 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:29, the CDRH2 comprises the sequence set forth in SEQ ID NO:30 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:30; the CDRH3 comprises the sequence set forth in SEQ ID NO:31, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:31; the CDRL1 comprises the sequence set forth in SEQ ID NO:26 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:26, the CDRL2 comprises the sequence set forth in SEQ ID NO:32, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:32; and the CDRL3 comprises the sequence set forth in SEQ ID NO:28, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:28. D45. The anti-NKG2C agent of any of embodiments D1-D44, wherein the CDRH1 comprises the sequence set forth in SEQ ID NO: 29, the CDRH2 comprises the sequence set forth in SEQ ID NO: 30; the CDRH3 comprises the sequence set forth in SEQ ID NO: 31; the CDRL1 comprises the sequence set forth in SEQ ID NO: 26, the CDRL2 comprises the sequence set forth in SEQ ID NO: 32; and the CDRL3 comprises the sequence set forth in SEQ ID NO: 28. D46. The anti-NKG2C agent of any of embodiments D1-D45, wherein the CDRH1 comprises the sequence set forth in SEQ ID NO:29, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:29, the CDRH2 comprises the sequence set forth in SEQ ID NO:34 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:34; the CDRH3 comprises the sequence set forth in SEQ ID NO:25, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:25; the CDRL1 comprises the sequence set forth in SEQ ID NO:26 or a sequence of amino acids that exhibits at least 80%, 81%, 82%,
83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:26, the CDRL2 comprises the sequence set forth in SEQ ID NO:32, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:32; and the CDRL3 comprises the sequence set forth in SEQ ID NO:38 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:38. D47. The anti-NKG2C agent of any of embodiments D1-D46, wherein the CDRH1 comprises the sequence set forth in SEQ ID NO: 29, the CDRH2 comprises the sequence set forth in SEQ ID NO: 34; the CDRH3 comprises the sequence set forth in SEQ ID NO: 25; a CDRL1 comprising the sequence set forth in SEQ ID NO: 26, the CDRL2 comprises the sequence set forth in SEQ ID NO: 32; and the CDRL3 comprises the sequence set forth in SEQ ID NO: 38. D48. The anti-NKG2C agent of any of embodiments D1-D47, wherein the CDRH1 comprises the sequence set forth in SEQ ID NO:33, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:33, the CDRH2 comprises the sequence set forth in SEQ ID NO:40, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:40; the CDRH3 comprises the sequence set forth in SEQ ID NO:35, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:35; the CDRL1 comprises the sequence set forth in SEQ ID NO:36, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:36, the CDRL2 comprises the sequence set forth in SEQ ID NO:37, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:37; and the CDRL3 comprises the sequence set forth in SEQ ID NO:44, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:44. D49. The anti-NKG2C agent of any of embodiments D1-D48, wherein the CDRH1 comprises the sequence set forth in SEQ ID NO:33, the CDRH2 comprises the sequence set forth in SEQ ID NO:40; the CDRH3 comprises the sequence set forth in SEQ ID NO: 35; the CDRL1 comprises the sequence set forth in SEQ ID NO: 36, the CDRL2 comprises the sequence set forth in SEQ ID NO: 37; and the CDRL3 comprises the sequence set forth in SEQ ID NO: 44. 141
D50. The anti-NKG2C agent of any of embodiments D1-D49, wherein the CDRH1 comprises the sequence set forth in SEQ ID NO:39, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:39, the CDRH2 comprises the sequence set forth in SEQ ID NO:46, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:46; the CDRH3 comprises the sequence set forth in SEQ ID NO:41, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:41; the CDRL1 comprises the sequence set forth in SEQ ID NO:42, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:42, the CDRL2 comprises the sequence set forth in SEQ ID NO:43, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:43; and the CDRL3 comprises the sequence set forth in SEQ ID NO:48, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:48. D51. The anti-NKG2C agent of any of embodiments D1-D50, wherein the CDRH1 comprises the sequence set forth in SEQ ID NO:39, the CDRH2 comprises the sequence set forth in SEQ ID NO: 46; the CDRH3 comprises the sequence set forth in SEQ ID NO: 41; the CDRL1 comprises the sequence set forth in SEQ ID NO: 42, the CDRL2 comprises the sequence set forth in SEQ ID NO: 43; and the CDRL3 comprises the sequence set forth in SEQ ID NO: 48. D52. The anti-NKG2C agent of any of embodiments D1-D51, wherein the CDRH1 comprises the sequence set forth in SEQ ID NO:45, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:45, the CDRH2 comprises the sequence set forth in SEQ ID NO:49, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:49; the CDRH3 comprises the sequence set forth in SEQ ID NO:47 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:47; the CDRL1 comprises the sequence set forth in SEQ ID NO:48, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:48, the CDRL2 comprises the sequence set forth in SEQ ID
NO:37, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:37; and the CDRL3 comprises the sequence set forth in SEQ ID NO:44, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:44. D53. The anti-NKG2C agent of any of embodiments D1-D52, wherein the CDRH1 comprises the sequence set forth in SEQ ID NO:45, the CDRH2 comprises the sequence set forth in SEQ ID NO:49; the CDRH3 comprises the sequence set forth in SEQ ID NO:47; the CDRL1 comprises the sequence set forth in SEQ ID NO:48, the CDRL2 comprises the sequence set forth in SEQ ID NO:37; and the CDRL3 comprises the sequence set forth in SEQ ID NO:44. D54. The anti-NKG2C agent of any of embodiments D1-D53, wherein the immunoglobulin heavy chain variable domain comprises the amino acid sequence set forth in any of SEQ ID NOS: 1, 2, 3, 5, 6, 7, and 8, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to any of SEQ ID NOS: 1, 2, 3, 5, 6, 7, and 8. D55. The anti-NKG2C agent of any of embodiments D1-D54, wherein the immunoglobulin heavy chain variable domain comprises the amino acid sequence set forth in any of SEQ ID NOS: 1, 2, 3, 5, 6, 7, and 8. D55. The anti-NKG2C agent of any of embodiments D1-D54, wherein the immunoglobulin heavy chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 1 or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO:1. D56. The anti-NKG2C agent of any of embodiments D1-D55, wherein the immunoglobulin heavy chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 1. D57. The anti-NKG2C agent of any of embodiments D1-D56, wherein the immunoglobulin heavy chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 2 or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO:2. D58. The anti-NKG2C agent of any of embodiments D1-D57, wherein the immunoglobulin heavy chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 2. D59. The anti-NKG2C agent of any of embodiments D1-D58, wherein the immunoglobulin heavy chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 3, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO:3. 143
D60. The anti-NKG2C agent of any of embodiments D1-D59, wherein the immunoglobulin heavy chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 3. D61. The anti-NKG2C agent of any of embodiments D1-D60, wherein the immunoglobulin heavy chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 5, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO:5. D62. The anti-NKG2C agent of any of embodiments D1-D61, wherein the immunoglobulin heavy chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 5. D63. The anti-NKG2C agent of any of embodiments D1-D62, wherein the immunoglobulin heavy chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 6, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO:6. D64. The anti-NKG2C agent of any of embodiments D1-D63, wherein the immunoglobulin heavy chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 6. D65. The anti-NKG2C agent of any of embodiments D1-D64, wherein the immunoglobulin heavy chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 7, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO:7. D66. The anti-NKG2C agent of any of embodiments D1-D65, wherein the immunoglobulin heavy chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 7. D67. The anti-NKG2C agent of any of embodiments D1-D66, wherein the immunoglobulin light chain variable domain comprises the amino acid sequence set forth in any of SEQ ID NOS: 9, 10, 11, 13, 14, 15 and 16, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to any of SEQ ID NOS: 9, 10, 11, 13, 14, 15 and 16. D68. The anti-NKG2C agent of any of embodiments D1-D67, wherein the immunoglobulin light chain variable domain comprises the amino acid sequence set forth in any of SEQ ID NOS: 9, 10, 11, 13, 14, 15 and 16. D69. The anti-NKG2C agent of any of embodiments D1-D68, wherein the immunoglobulin light chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 9, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO:9. D70. The anti-NKG2C agent of any of embodiments D1-D69, wherein the immunoglobulin light chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 9.
D71. The anti-NKG2C agent of any of embodiments D1-D70, wherein the immunoglobulin light chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 10, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 10. D72. The anti-NKG2C agent of any of embodiments D1-D71, wherein the immunoglobulin light chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 10. D73. The anti-NKG2C agent of any of embodiments D1-D72, wherein the immunoglobulin light chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 11, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 11. D74. The anti-NKG2C agent of any of embodiments D1-D73, wherein the immunoglobulin light chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 11. D75. The anti-NKG2C agent of any of embodiments D1-D74, wherein the immunoglobulin light chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 13, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 13. D76. The anti-NKG2C agent of any of embodiments D1-D75, wherein the immunoglobulin light chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 13. D77. The anti-NKG2C agent of any of embodiments D1-D76, wherein the immunoglobulin light chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 14, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 14. D78. The anti-NKG2C agent of any of embodiments D1-D77, wherein the immunoglobulin light chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 14. D79. The anti-NKG2C agent of any of embodiments D1-D78, wherein the immunoglobulin light chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 15, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 15. D80. The anti-NKG2C agent of any of embodiments D1-D79, wherein the immunoglobulin light chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 15. D81. The anti-NKG2C agent of any of embodiments D1-D80, wherein the immunoglobulin light chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 16, or a sequence having at
least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 16. D82. The anti-NKG2C agent of any of embodiments D1-D81, wherein the immunoglobulin light chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 16. D83. The anti-NKG2C agent of any of embodiments D1-D82, wherein the immunoglobulin heavy chain variable domain comprises the amino acid sequence set forth in any of SEQ ID NOS: 1, 2, 3, 5, 6, 7, and 8, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to any of SEQ ID NOS: 1, 2, 3, 5, 6, 7, and 8, and the immunoglobulin light chain variable domain comprises the amino acid sequence set forth in any of SEQ ID NOS: 9, 10, 11, 13, 14, 15 and 16, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to any of SEQ ID NOS: 9, 10, 11, 13, 14, 15 and 16. D84. The anti-NKG2C agent of any of embodiments D1-D83, wherein the immunoglobulin heavy chain variable domain comprises the amino acid sequence set forth in any of SEQ ID NOS: 1, 2, 3, 5, 6, 7, and 8, and the immunoglobulin light chain variable domain comprises the amino acid sequence set forth in any of SEQ ID NOS: 9, 10, 11, 13, 14, 15 and 16. D85. The anti-NKG2C agent of any of embodiments D1-D84, wherein the immunoglobulin heavy chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 1, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 1; and the immunoglobulin light chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 9, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO:9. D86. The anti-NKG2C agent of any of embodiments D1-D85, wherein the immunoglobulin heavy chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 1, and the immunoglobulin light chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 9. D87. The anti-NKG2C agent of any of embodiments D1-D86, wherein the immunoglobulin heavy chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 2, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 2; and the immunoglobulin light chain variable domain comprises the amino acid sequence set forth in SEQ ID NOS: 10, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO:10.
D43. The anti-NKG2C agent of any of embodiments D1-D39 and D42, wherein the immunoglobulin heavy chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 2, and the immunoglobulin light chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 10. D88. The anti-NKG2C agent of any of embodiments D1-D87, wherein the immunoglobulin heavy chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 3, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 3; and the immunoglobulin light chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 11, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO:11. D89. The anti-NKG2C agent of any of embodiments D1-D88, wherein the immunoglobulin heavy chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 3, and the immunoglobulin light chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 11. D90. The anti-NKG2C agent of any of embodiments D1-D89, wherein the immunoglobulin heavy chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 5, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 5; and the immunoglobulin light chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 13, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO:13. D91. The anti-NKG2C agent of any of embodiments D1-D90, wherein the immunoglobulin heavy chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 5, and the immunoglobulin light chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 13. D92. The anti-NKG2C agent of any of embodiments D1-D91, wherein the immunoglobulin heavy chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 6, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 6; and the immunoglobulin light chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 14, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO:14. D93. The anti-NKG2C agent of any of embodiments D1-D92, wherein the immunoglobulin heavy chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 6, and the immunoglobulin light chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 14.
D94. The anti-NKG2C agent of any of embodiments D1-D93, wherein the immunoglobulin heavy chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 7, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 7; and the immunoglobulin light chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 15, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO:15. D95. The anti-NKG2C agent of any of embodiments D1-D94, wherein the immunoglobulin heavy chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 7, and the immunoglobulin light chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 15. D96. The anti-NKG2C agent of any of embodiments D1-D95, wherein the immunoglobulin heavy chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 8, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO: 8; and the immunoglobulin light chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 16, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to SEQ ID NO:16. D97. The anti-NKG2C agent of any of embodiments D1-D96, wherein the immunoglobulin heavy chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 8, and the immunoglobulin light chain variable domain comprises the amino acid sequence set forth in SEQ ID NO: 16. D98. The anti-NKG2C agent of any of embodiments D1-D97, comprising one immunoglobulin heavy chain variable domain and one immunoglobulin light chain variable domain. D99. The anti-NKG2C agent of any of embodiments D1-D98, comprising two immunoglobulin heavy chain variable domains and two immunoglobulin light chain variable domains. D100. The anti-NKG2C agent of any of embodiments D1-D99, wherein the immunoglobulin heavy chain variable domain further comprises a signal sequence. D101. The anti-NKG2C agent of embodiment D100, wherein the signal sequence comprises the sequence set forth in SEQ ID NO: 90, 92 and 94. D102. The anti-NKG2C agent of any of embodiments D1-D101, wherein the immunoglobulin light chain variable domain further comprises a signal sequence. D103. The anti-NKG2C agent of embodiment D102, wherein the signal sequence comprises the sequence set forth in SEQ ID NO: 91, 93 and 95. D104. The anti-NKG2C agent of any of any of embodiments D1-D103, wherein the anti-NKG2C agent is an antibody or antigen-binding fragment thereof.
D105. The anti-NKG2C agent of any of embodiments D1-D104, wherein the anti-NKG2C agent is isolated. D106. The anti-NKG2C agent of any of embodiments D1-D105, wherein the anti-NKG2C agent is humanized. D107. The anti-NKG2C agent of any of embodiments D1-D106, wherein the anti-NKG2C agent is conjugated. D108.The anti-NKG2C agent of embodiment D107, wherein the anti-NKG2C agent is conjugated to a detectable marker or label. D109. The anti-NKG2C agent of embodiment D107 or embodiment D108, wherein the detectable marker or label comprises a detectable moiety. D110.The anti-NKG2C agent of embodiment D109, wherein the detectable moiety is a radioisotope, fluorescent label or enzyme-substrate label. D111. The anti-NKG2C agent of any of embodiments D1-D110, wherein the anti-NKG2C agent is non- diffusively immobilized on a solid support. D112. The anti-NKG2C agent of any of embodiments D1-D111, that is a single chain fragment. D113.The anti-NKG2C agent of embodiment D112, wherein the single chain fragment is a single chain variable fragment (scFv). D114.The anti-NKG2C agent of any of embodiments D1-D113, for use in the detection of NKG2C in a sample. D115.The anti-NKG2C agent of any of embodiments D1-D114, wherein the anti-NKG2C agent binds to an NKG2C expressing cell in a sample. D116.The anti-NKG2C agent of embodiment D114 or embodiment D115, wherein the sample comprises immune cells. D117.The anti-NKG2C of any of embodiments D114-D116, wherein the sample comprises a heterogenous population of immune cells. D118.The anti-NKG2C of embodiment D116 or embodiment D117, wherein the immune cell is selected from B cells, plasmacytoid dendritic cells (pDCs), lymphocytes, leukocytes, T cells, monocytes, macrophages, neutrophils, myeloid dendritic cells (mDCs), innate lymphoid cells, mast cells, eosinophils, basophils, natural killer cells, and peripheral blood mononuclear cells (PBMCs). D119.The anti-NKG2C of any of embodiments D114-D118, wherein the detection comprises the use of a single anti-NKG2C agent to identify the presence of a complex comprising NKG2C and the anti-NKG2C agent. D120.The anti-NKG2C of any of embodiments D114-D119, wherein the detection comprises the use of two anti-NKG2C agents, each capable of binding to a different portion of NKG2C.
D121.The anti-NKG2C of any of embodiments D114-D120, wherein the detection of NKG2C is on the surface of immune cells. D122. The anti-NKG2C of any of embodiments D114-D121, wherein NKG2C is detected intracellularly. D123.The anti-NKG2C of any of embodiments D114-D122, wherein the detection of NKG2C indicates the presence or absence of a disease or disorder. D124. The anti-NKG2C of any of embodiments D114-D123, wherein the detection is performed in vitro. D125. The anti-NKG2C of any of embodiments D114-D124, wherein the detection is performed in vivo. D126.The anti-NKG2C agent of any of embodiments D1-D125, wherein the anti-NKG2C agent binds to an NKG2C expressing cell. D127.The anti-NKG2C agent of any of embodiments D1-D126, wherein the anti-NKG2C agent binds to an NKG2C expressing cell, and increases binding with a target cell. D128.The anti-NKG2C agent of any of embodiments D126-D127, wherein the anti-NKG2C agent bound to the NKG2C expressing cell increases the cytotoxic activity of the NKG2C expressing cell. D129.The anti-NKG2C agent of any of embodiments D126-D128, wherein the anti-NKG2C agent bound to the NKG2C expressing cell induces lysis of a target cell. D130.The anti-NKG2C agent of any of embodiments D127-D129, wherein the target cell is a cell that expresses HLA-E. D131.The anti-NKG2C agent of any of embodiments D127-D130, wherein the target cell is a cell associated with a disease or disorder. D132.The anti-NKG2C agent of embodiment D131, wherein the disease or disorder is a cancer, a viral infection, an autoimmune disease, an inflammatory disease or a bacterial infection. D133. The anti-NKG2C agent of embodiment D131 or embodiment D132, wherein the disease or disorder is a cancer. D134.The anti-NKG2C agent of embodiment D133, wherein the cancer is acute myeloid leukemia, acute lymphoblastic leukemia, colorectal, ovarian, gynecologic, liver, glioblastoma, Hodgkin lymphoma, chronic lymphocytic leukemia, esophagus, gastric, pancreas, colon, kidney, head and neck, lung and melanoma. D135. The anti-NKG2C agent of embodiment D133 or embodiment D134, wherein the disease or disorder is an autoimmune disease. D136.The anti-NKG2C agent of any of embodiments D131-D135, wherein the disease or disorder is a condition characterized by NK cell hyperactivity or NK cell hyperproliferation. D137.A diagnostic reanti-NKG2C agent comprising the anti-NKG2C agent of any of embodiments D1- D136.
D138.A kit comprising the anti-NKG2C agent of any of embodiments D1-D136, or the diagnostic reagent of embodiment D137. D139.A composition comprising the anti-NKG2C agent of any of embodiments D1-D136, and a pharmaceutically acceptable excipient. D140.The composition of embodiment D139, wherein the anti-NKG2C is used as an adjuvant or in conjunction with an adjuvant. D141.An isolated nucleic acid comprising a nucleotide sequence that encodes the immunoglobulin heavy chain variable domain of the agent of any of embodiments D1-D136. D142.The isolated nucleic acid of embodiment D141, wherein the immunoglobulin heavy chain variable domain comprises the sequence of nucleotides set forth in any of SEQ ID NOs: 74, 76, 78, 80, 82, 84, 86, 88, 58, 60, 62, 64, 66, 68, 70 and 72. D143.The isolated nucleic acid of embodiment D141 or embodiment D142, wherein the immunoglobulin heavy chain variable domain comprises the sequence of nucleotides set forth in SEQ ID NO: 74. D144. The isolated nucleic acid of embodiment D141 or embodiment D142, wherein the immunoglobulin heavy chain variable domain comprises the sequence of nucleotides set forth in SEQ ID NO: 76. D145. The isolated nucleic acid of embodiment D141 or embodiment D142, wherein the immunoglobulin heavy chain variable domain comprises the sequence of nucleotides set forth in SEQ ID NO: 78. D146. The isolated nucleic acid of embodiment D141 or embodiment D142, wherein the immunoglobulin heavy chain variable domain comprises the sequence of nucleotides set forth in SEQ ID NO: 80. D147. The isolated nucleic acid of embodiment D141 or embodiment D142, wherein the immunoglobulin heavy chain variable domain comprises the sequence of nucleotides set forth in SEQ ID NO: 82. D148. The isolated nucleic acid of embodiment D141 or embodiment D142, wherein the immunoglobulin heavy chain variable domain comprises the sequence of nucleotides set forth in SEQ ID NO: 84. D149. The isolated nucleic acid of embodiment D141 or embodiment D142, wherein the immunoglobulin heavy chain variable domain comprises the sequence of nucleotides set forth in SEQ ID NO: 86. D150. The isolated nucleic acid of embodiment D141 or embodiment D142, wherein the immunoglobulin heavy chain variable domain comprises the sequence of nucleotides set forth in SEQ ID NO: 88. D151.The isolated nucleic acid of embodiment D141 or embodiment D142, wherein the immunoglobulin heavy chain variable domain comprises the sequence of nucleotides set forth in SEQ ID NO: 58. D152. The isolated nucleic acid of embodiment D141 or embodiment D142, wherein the immunoglobulin heavy chain variable domain comprises the sequence of nucleotides set forth in SEQ ID NO: 60. D153. The isolated nucleic acid of embodiment D141 or embodiment D142, wherein the immunoglobulin heavy chain variable domain comprises the sequence of nucleotides set forth in SEQ ID NO: 62.
D154. The isolated nucleic acid of embodiment D141 or embodiment D142, wherein the immunoglobulin heavy chain variable domain comprises the sequence of nucleotides set forth in SEQ ID NO: 64. D155. The isolated nucleic acid of embodiment D141 or embodiment D142, wherein the immunoglobulin heavy chain variable domain comprises the sequence of nucleotides set forth in SEQ ID NO: 66. D156. The isolated nucleic acid of embodiment D141 or embodiment D142, wherein the immunoglobulin heavy chain variable domain comprises the sequence of nucleotides set forth in SEQ ID NO: 68. D157. The isolated nucleic acid of embodiment D141 or embodiment D142, wherein the immunoglobulin heavy chain variable domain comprises the sequence of nucleotides set forth in SEQ ID NO: 70. D158. The isolated nucleic acid of embodiment D141 or embodiment D142, wherein the immunoglobulin heavy chain variable domain comprises the sequence of nucleotides set forth in SEQ ID NO: 72. D159. An isolated nucleic acid comprising a nucleotide sequence that encodes the immunoglobulin light chain variable domain of the agent of any of embodiments D1-D136. D160. The isolated nucleic acid molecule of embodiment D159, wherein the immunoglobulin light chain variable domain comprises the sequence of nucleotides set forth in any of SEQ ID NOs: 75, 77, 79, 81, 83, 85, 87, 89, 59, 61, 63, 65, 67, 69, 71, and 73. D161. The isolated nucleic acid of embodiment D159 or embodiment D160, wherein the immunoglobulin light chain variable domain comprises the sequence of nucleotides set forth in SEQ ID NO: 75. D162. The isolated nucleic acid of embodiment D159 or embodiment D160, wherein the immunoglobulin light chain variable domain comprises the sequence of nucleotides set forth in SEQ ID NO: 77. D163. The isolated nucleic acid of embodiment D159 or embodiment D160, wherein the immunoglobulin light chain variable domain comprises the sequence of nucleotides set forth in SEQ ID NO: 79. D164. The isolated nucleic acid of embodiment D159 or embodiment D160, wherein the immunoglobulin light chain variable domain comprises the sequence of nucleotides set forth in SEQ ID NO: 81. D165. The isolated nucleic acid of embodiment D159 or embodiment D160, wherein the immunoglobulin light chain variable domain comprises the sequence of nucleotides set forth in SEQ ID NO: 83. D166. The isolated nucleic acid of embodiment D159 or embodiment D160, wherein the immunoglobulin light chain variable domain comprises the sequence of nucleotides set forth in SEQ ID NO: 85. D167. The isolated nucleic acid of embodiment D159 or embodiment D160, wherein the immunoglobulin light chain variable domain comprises the sequence of nucleotides set forth in SEQ ID NO: 87. D168. The isolated nucleic acid of embodiment D159 or embodiment D160, wherein the immunoglobulin light chain variable domain comprises the sequence of nucleotides set forth in SEQ ID NO: 89. D169. The isolated nucleic acid of embodiment D159 or embodiment D160, wherein the immunoglobulin light chain variable domain comprises the sequence of nucleotides set forth in SEQ ID NO: 59.
D170. The isolated nucleic acid of embodiment D159 or embodiment D160, wherein the immunoglobulin light chain variable domain comprises the sequence of nucleotides set forth in SEQ ID NO: 61. D171. The isolated nucleic acid of embodiment D159 or embodiment D160, wherein the immunoglobulin light chain variable domain comprises the sequence of nucleotides set forth in SEQ ID NO: 63. D172. The isolated nucleic acid of embodiment D159 or embodiment D160, wherein the immunoglobulin light chain variable domain comprises the sequence of nucleotides set forth in SEQ ID NO: 65. D173. The isolated nucleic acid of embodiment D159 or embodiment D160, wherein the immunoglobulin light chain variable domain comprises the sequence of nucleotides set forth in SEQ ID NO: 67. D174. The isolated nucleic acid of embodiment D159 or embodiment D160, wherein the immunoglobulin light chain variable domain comprises the sequence of nucleotides set forth in SEQ ID NO: 69. D175. The isolated nucleic acid of embodiment D159 or embodiment D160, wherein the immunoglobulin light chain variable domain comprises the sequence of nucleotides set forth in SEQ ID NO: 71. D176. The isolated nucleic acid of embodiment D159 or embodiment D160, wherein the immunoglobulin light chain variable domain comprises the sequence of nucleotides set forth in SEQ ID NO: 73. D177. An isolated nucleic acid comprising a nucleotide sequence that encodes the immunoglobulin heavy chain variable domain and the immunoglobulin light chain variable domain of the anti-NKG2C agent of any of embodiments D1-D136. D178.The isolated nucleic acid of any of embodiments D141-D177, wherein the nucleotide sequence that encodes the immunoglobulin heavy chain variable domain comprises the sequence set forth in any of SEQ ID NOs: 74, 76, 78, 80, 82, 84, 86, 88, 58, 60, 62, 64, 66, 68, 70 and 72; and the immunoglobulin light chain variable domain comprises the sequence of amino acids set forth in any of SEQ ID NOs: 75, 77, 79, 81, 83, 85, 87, 89, 59, 61, 63, 65, 67, 69, 71, and 73. D179. A recombinant expression vector comprising a first expression cassette and a second expression cassette, wherein the first expression cassette comprises a nucleic acid molecule comprising a nucleotide sequence that encodes the immunoglobulin heavy chain variable domain of any one of embodiments D1- D136, and the second expression cassette comprises a nucleic acid molecule comprising a nucleotide sequence that encodes an immunoglobulin light chain variable domain of the anti-NKG2C agent of any one of embodiments D1-D136. D180. A recombinant expression vector comprising a first expression cassette and a second expression cassette, wherein the first expression cassette comprises a nucleic acid molecule comprising the isolated nucleic acid of any of embodiments D141-D178, and the second expression cassette comprises a nucleic acid molecule comprising the nucleotide sequence of any of embodiments D141-D178. D181. The recombinant expression vector of embodiment D179 or embodiment D180, wherein the first and second expression cassettes comprise a promoter.
D182. A host cell transfected with the recombinant expression vector of any of embodiments D179-D181. D183. A method of detecting NKG2C, comprising a) contacting a sample with the anti-NKG2C agent of any of embodiments 1-33, under conditions to bind said anti-NKG2C to an NKG2C receptor on said sample, wherein the binding generates the production of a receptor/anti-NKG2C complex; b) detecting the presence of the receptor/anti-NKG2C complexes; c) wherein the detecting comprises the presence or absence of the NKG2C receptor on said sample. D184.The method of embodiment D183, wherein the method is performed in vitro. D185. A method of treating or preventing a disease or disorder associated with NKG2C in a subject, comprising: a) contacting a sample known or suspected to contain NKG2C with the anti-NKG2C agent of any of embodiments D1-D136, b) detecting the presence of complexes comprising NKG2C and the anti-NKG2C agent; wherein the presence of the complexes indicates the presence of a disease or disorder; and c) administering to the subject the anti-NKG2C agent of any of embodiments D1-D136. D186.A method of treating or preventing a disease or disorder in a subject, comprising a) detecting the formation of complexes comprising NKG2C and the anti-NKG2C agent of any of embodiments D1-D136 in a sample from the subject; b) administering to a subject in need thereof the anti-NKG2C agent of any of embodiments D1- D136. D187. The method of any of embodiments D183-D186, wherein the sample comprises immune cells. D188. The method of embodiment D187, wherein the immune cell is selected from B cells, plasmacytoid dendritic cells (pDCs), lymphocytes, leukocytes, T cells, monocytes, macrophages, neutrophils, myeloid dendritic cells (mDCs), innate lymphoid cells, mast cells, eosinophils, basophils, natural killer cells, and peripheral blood mononuclear cells (PBMCs). * * * The entirety of each patent, patent application, publication and document referenced herein hereby is incorporated by reference. Citation of the above patents, patent applications, publications and documents is not an admission that any of the foregoing is pertinent prior art, nor does it constitute any admission as to the contents or date of these publications or documents. Their citation is not an indication of a search for relevant disclosures. All statements regarding the date(s) or contents of the documents is based on available information and is not an admission as to their accuracy or correctness.
Modifications may be made to the foregoing without departing from the basic aspects of the technology. Although the technology has been described in substantial detail with reference to one or more specific embodiments, those of ordinary skill in the art will recognize that changes may be made to embodiments specifically disclosed in this application, yet these modifications and improvements are within the scope and spirit of the technology. The technology illustratively described herein suitably may be practiced in the absence of any element(s) not specifically disclosed herein. Thus, for example, in each instance herein any of the terms “comprising,” “consisting essentially of,” and “consisting of” may be replaced with either of the other two terms. The terms and expressions which have been employed are used as terms of description and not of limitation, and use of such terms and expressions do not exclude nay equivalents of the features shown and described or portions thereof, and various modifications are possible within the scope of the technology claimed. The term “a” or “an” can refer to one of or a plurality of the elements it modifies (e.g., “a reagent” can mean one or more reagents) unless it is contextually clear either one of the elements or more than one of the elements is described. The term “about” as used herein refers to a value within 10% of the underlying parameter (i.e., plus or minus 10%), and use of the term “about” at the beginning of a string of values modifies each of the values (i.e., “about 1, 2, and 3” refers to about 1, about 2, and about 3). For example, a weight of “about 100 grams” can include weights between 90 grams and 110 grams. Further, when a listing of values is described herein (e.g., about 50%, 60%, 70%, 80%, 85%, or 86%) the listing included all intermediate and fractional values thereof (e.g., 54%, 85.4%). Thus, it should be understood that although the present technology has been specifically disclosed by representative embodiments and optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and such modifications and variations are considered within the scope of this technology. Certain embodiments of the technology are set forth in the claim(s) that follow(s).
Claims
What is claimed is: 1. An anti-NKG2C agent that binds the NKG2C receptor or a fragment thereof, comprising one or more of: a) an immunoglobulin heavy chain variable domain comprising: (i) a heavy chain complementary determining region 1 (CDRH1) comprising the sequence
(SEQ ID NO: 50), wherein X1 is N, S, or D, X2 is F, T, or Y, X3 is G, Y, or W, X4 is M or I, and X5 is H or N; (ii) a heavy chain complementary determining region 2 (CDRH2) comprising the sequence X
(SEQ ID NO: 51), wherein X1 is Y, R, W, or M, X3 is S, D, or H, X4 is S or P, X5 is G, E, A, or S, X6 is S, N, or D, X7 is S, G, or D, X8 is T, S, N, Y, D, or E, X9 is I or T, X10 is Y, K, E, or R, X11 is Y or L, X12 is A, R, D, or N, X13 is D, P, or Q, X14 is T or K, X15 is V, L, M, or F, X16 is K or Q, and X17 is G or D; (iii) a heavy chain complementary determining region 3 (CDRH3) comprising the sequence X
(SEQ ID NO: 52), wherein X1 is S, T, H or V, X2 is V, A, I, Y or H, X3 is I, T, H, or G, X4 is Y, V, T, or S, X5 is Y, F, H, or N, X6 is A, D, W, or Y, X7 is Y, G, or no amino acid, X8 is D or no amino acid, X9 is R or no amino acid, X10 is Y or no amino acid, X11 is L, Y, N, W or no amino acid, X12 is M, F, D, or no amino acid, X13 is D, P, or A, and X14 is F, Y, or V; b) an immunoglobulin light chain variable domain comprising: (i) a light chain complementary determining region 1 (CDRL1) comprising the sequence K
(SEQ ID NO: 53), wherein X1 is S or K, X2 is A or S, X4 is Q or S, X7 is D, L, S, or no amino acid, X8 is Y or no amino acid, X9 is D, S, or no amino acid, X10 is G, S, or no amino acid, X11 is D, N, or no amino acid, X12 is Q or no amino acid, X13 is K or no amino acid, X14 is S or N, X15 is Y or D, X16 is M, L, or V, and X17 is Y, N, A or G; (ii) a light chain complementary determining region 2 (CDRL2) comprising the sequence X1X2SX4X5X6X7 (SEQ ID NO: 54), wherein X1 is G, A, R, W, or Y, X2 is A or T, X4 is N or T, X5 is L or R, X6 is E, A or Y, and X7 is S or T; and (iii) a light chain complementary determining region 3 (CDRL3) comprising the sequence
T (SEQ ID NO: 55), wherein X1 is Q or H, X2 is Q or H, X3 is S, Y, D, or no amino acid, X4 is N, H, or Y, X5 is E, S, or L, X6 is D, V, Y, or S, X7 is P or S, and X8 is L, Y, or H.
2. The anti-NKG2C agent of claim 1, wherein the immunoglobulin heavy chain variable domain comprises a CDRH1 comprising the sequence of amino acids set forth in SEQ ID NO: 17, SEQ ID NO: 23, SEQ ID NO: 29, SEQ ID NO: 33, SEQ ID NO: 39 or SEQ ID NO:45, or a sequence of amino acids
that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 17, SEQ ID NO: 23, SEQ ID NO: 29, SEQ ID NO: 33, SEQ ID NO: 39 or SEQ ID NO:45; a CDRH2 comprising the sequence of amino acids set forth in SEQ ID NO: 18, SEQ ID NO: 24, SEQ ID NO:30, SEQ ID NO:34, SEQ ID NO:40, SEQ ID NO:46, SEQ ID NO:49, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 18, SEQ ID NO: 24, SEQ ID NO:30, SEQ ID NO:34, SEQ ID NO:40, SEQ ID NO:46, SEQ ID NO:49; and a CDRH3 comprising the sequence of amino acids set forth in SEQ ID NO: 19, SEQ ID NO: 25, SEQ ID NO: 31, SEQ ID NO: 35, SEQ ID NO: 41, SEQ ID NO: 47, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 19, SEQ ID NO: 25, SEQ ID NO: 31, SEQ ID NO: 35, SEQ ID NO: 41, SEQ ID NO: 47.
3.The anti-NKG2C agent of claim 1 or claim 2, wherein the immunoglobulin light chain variable domain comprises a CDRL1 comprising the sequence of amino acids set forth in SEQ ID NO: 20; SEQ ID NO: 26, SEQ ID NO: 36 or SEQ ID NO: 42 or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 20; SEQ ID NO: 26, SEQ ID NO: 36 or SEQ ID NO: 42; a CDRL2 comprising the sequence of amino acids set forth in SEQ ID NO: 21, SEQ ID NO: 27, SEQ ID NO: 32, SEQ ID NO: 37, SEQ ID NO: 43, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 21, SEQ ID NO: 27, SEQ ID NO: 32, SEQ ID NO: 37, SEQ ID NO: 43; and a CDRL3 comprising the sequence of amino acids set forth in SEQ ID NO: 22, SEQ ID NO: 28, SEQ ID NO: 38, SEQ ID NO: 44, SEQ ID NO: 48, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 22, SEQ ID NO: 28, SEQ ID NO: 38, SEQ ID NO: 44, SEQ ID NO: 48.
4. The anti-NKG2C agent of any one of claims 1-3, wherein the CDRH1 comprises the sequence of amino acids set forth in SEQ ID NO: 17, 23, 29, 33, 39 or 45, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 17, 23, 29, 33, 39 or 45, the CDRH2 comprises a sequence of amino acids set forth in SEQ ID NO: 18, 24, 30, 34, 40, 46 or 49, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%,
90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 18, 24, 30, 34, 40, 46 or 49; the CDRH3 comprises a sequence of amino acids set forth in SEQ ID NO: 19, 25, 31, 35, 41 or 47, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 19, 25, 31, 35, 41 or 47; the CDRL1 comprises a sequence of amino acids set forth in SEQ ID NO: 20, 26, 36 or 42, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 20, 26, 36 or 42; the CDRL2 comprises a sequence of amino acids set forth in SEQ ID NO: 21, 27, 32, 37 or 43, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 21, 27, 32, 37 or 43; and the CDRL3 comprises a sequence of amino acids set forth in SEQ ID NO: 22, 28, 38, 44 or 48, or a sequence of amino acids that exhibits at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 22, 28, 38, 44 or 48. 5. The anti-NKG2C agent of any one of claims 1-4, wherein the immunoglobulin heavy chain variable domain comprises the amino acid sequence set forth in any of SEQ ID NOS: 1, 2, 3, 5, 6, 7, and 8, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to any of SEQ ID NOS: 1, 2, 3, 5, 6, 7, and 8. 6. The anti-NKG2C agent of any one of claims 1-5, wherein the immunoglobulin light chain variable domain comprises the amino acid sequence set forth in any of SEQ ID NOS: 9, 10, 11, 13, 14, 15 and 16, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to any of SEQ ID NOS: 9, 10, 11, 13, 14, 15 and 16. 7. The anti-NKG2C agent of any one of claims 1-6, wherein the immunoglobulin heavy chain variable domain comprises the amino acid sequence set forth in any of SEQ ID NOS: 1, 2, 3, 5, 6, 7, and 8, or a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to any of SEQ ID NOS: 1, 2, 3,
5,
6,
7, and 8, and the immunoglobulin light chain variable domain comprises the amino acid sequence set forth in any of SEQ ID NOS: 9, 10, 11, 13, 14, 15 and 16, or a sequence having at least 80%, 81%, 82%,
83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to any of SEQ ID NOS: 9, 10, 11, 13, 14, 15 and 16.
8. The anti-NKG2C agent of any one of claims 1-7, comprising one immunoglobulin heavy chain variable domain and one immunoglobulin light chain variable domain.
9. The anti-NKG2C agent of any one of claims 1-8, comprising two immunoglobulin heavy chain variable domains and two immunoglobulin light chain variable domains.
10. The anti-NKG2C agent of any of any one of claims 1-9, wherein the anti-NKG2C agent is an antibody or antigen-binding fragment thereof.
11. The anti-NKG2C agent of any one of claims 1-10, wherein the anti-NKG2C agent is isolated.
12. The anti-NKG2C agent of any one of claims 1-11, wherein the anti-NKG2C agent is humanized.
13. The anti-NKG2C agent of any one of claims 1-12, wherein the anti-NKG2C agent is conjugated to a detectable marker or label.
14. The anti-NKG2C agent of claim 13, wherein the detectable marker or label comprises a detectable moiety.
15. The anti-NKG2C agent of any one of claims 1-14, wherein the anti-NKG2C agent is non-diffusively immobilized on a solid support.
16. The anti-NKG2C agent of any one of claims 1-15, that is a single chain fragment.
17.The anti-NKG2C agent of claim 16, wherein the single chain fragment is a single chain variable fragment (scFv).
18.The anti-NKG2C agent of any one of claims 1-17, for use in the detection of NKG2C in a sample.
19.The anti-NKG2C agent of any one of claims 1-18, wherein the anti-NKG2C agent binds to an NKG2C expressing cell in a sample.
20.The anti-NKG2C agent of claim 18 or claim 19, wherein the sample comprises immune cells.
21.The anti-NKG2C of claim 20, wherein the immune cell is selected from B cells, plasmacytoid dendritic cells (pDCs), lymphocytes, leukocytes, T cells, monocytes, macrophages, neutrophils, myeloid dendritic cells (mDCs), innate lymphoid cells, mast cells, eosinophils, basophils, natural killer cells, and peripheral blood mononuclear cells (PBMCs).
22.The anti-NKG2C of any one of claims 18-21, wherein the detection of NKG2C is on the surface of immune cells.
23. The anti-NKG2C of any one of claims 18-21, wherein NKG2C is detected intracellularly.
24. The anti-NKG2C of any one of claims 18-23, wherein the detection is performed in vitro.
25. The anti-NKG2C of any one of claims 18-23, wherein the detection is performed in vivo.
26.The anti-NKG2C agent of any one of claims 1-25, wherein the anti-NKG2C agent binds to an NKG2C expressing cell.
27.The anti-NKG2C agent of any one of claims 1-26, wherein the anti-NKG2C agent binds to an NKG2C expressing cell, and increases binding with a target cell.
28.The anti-NKG2C agent of claim 26 or claim 27, wherein the anti-NKG2C agent bound to the NKG2C expressing cell increases the cytotoxic activity of the NKG2C expressing cell.
29.The anti-NKG2C agent of any one of claims 26-28, wherein the anti-NKG2C agent bound to the NKG2C expressing cell induces lysis of a target cell.
30.The anti-NKG2C agent of any one of claims 27-29, wherein the target cell is a cell that expresses HLA-E.
31.The anti-NKG2C agent of any one of claims 27-30, wherein the target cell is a cell associated with a disease or disorder.
32.The anti-NKG2C agent of claim 31, wherein the disease or disorder is a cancer, a viral infection, an autoimmune disease, an inflammatory disease or a bacterial infection.
33.The anti-NKG2C agent of claim 32, wherein the cancer is acute myeloid leukemia, acute lymphoblastic leukemia, colorectal, ovarian, gynecologic, liver, glioblastoma, Hodgkin lymphoma, chronic lymphocytic leukemia, esophagus, gastric, pancreas, colon, kidney, head and neck, lung and melanoma.
34.A diagnostic reanti-NKG2C agent comprising the anti-NKG2C agent of any one of claims 1-33.
35.A kit comprising the anti-NKG2C agent of any one of claims 1-33, or the diagnostic reagent of claim 34.
36.A composition comprising the anti-NKG2C agent of any one of claims 1-33, and a pharmaceutically acceptable excipient.
37.An isolated nucleic acid comprising a nucleotide sequence that encodes the immunoglobulin heavy chain variable domain of the anti-NKG2C agent of any one of claims 1-33.
38.The isolated nucleic acid of claim 37, wherein the immunoglobulin heavy chain variable domain comprises the sequence of nucleotides set forth in any of SEQ ID NOs: 74, 76, 78, 80, 82, 84, 86, 88, 58, 60, 62, 64, 66, 68, 70 and 72.
39. An isolated nucleic acid comprising a nucleotide sequence that encodes the immunoglobulin light chain variable domain of the agent of any one of claims 1-33.
40. The isolated nucleic acid molecule of claim 39, wherein the immunoglobulin light chain variable domain comprises the sequence of nucleotides set forth in any of SEQ ID NOs: 75, 77, 79, 81, 83, 85, 87, 89, 59, 61, 63, 65, 67, 69, 71, and 73.
41. An isolated nucleic acid comprising a nucleotide sequence that encodes the immunoglobulin heavy chain variable domain and the immunoglobulin light chain variable domain of the anti-NKG2C agent of any one of claims 1-33.
42.The isolated nucleic acid of claim 41, wherein the nucleotide sequence that encodes the immunoglobulin heavy chain variable domain comprises the sequence set forth in any of SEQ ID NOs: 74, 76, 78, 80, 82, 84, 86, 88, 58, 60, 62, 64, 66, 68, 70 and 72; and the immunoglobulin light chain variable domain comprises the sequence of amino acids set forth in any of SEQ ID NOs: 75, 77, 79, 81, 83, 85, 87, 89, 59, 61, 63, 65, 67, 69, 71, and 73.
43. A recombinant expression vector comprising a first expression cassette and a second expression cassette, wherein the first expression cassette comprises a nucleic acid molecule comprising a nucleotide sequence that encodes the immunoglobulin heavy chain variable domain of any one of claims 1-33, and the second expression cassette comprises a nucleic acid molecule comprising a nucleotide sequence that encodes an immunoglobulin light chain variable domain of the anti-NKG2C agent of any one of claims 1-33.
44. The recombinant expression vector of claim 43, wherein the first and second expression cassettes comprise a promoter.
45. A host cell transfected with the recombinant expression vector of any of claim 43 or claim 44.
46. A method of detecting NKG2C in a sample, comprising, a) contacting a sample with the anti-NKG2C agent of any one of claims 1-33, under conditions to bind said anti-NKG2C to an NKG2C receptor on said sample, wherein the binding generates the production of a receptor/anti-NKG2C complex; b) detecting the presence of the receptor/anti-NKG2C complexes; c) wherein the detecting comprises the presence or absence of the NKG2C receptor on said sample.
47. A method of treating or preventing a disease or disorder associated with NKG2C in a subject, comprising: a) contacting a sample known or suspected to contain NKG2C with the anti-NKG2C agent of any one of claims 1-33, b) detecting the presence of complexes comprising NKG2C and the anti-NKG2C agent; wherein the presence of the complexes indicates the presence of a disease or disorder; and c) administering to the subject the anti-NKG2C agent of any one of claims 1-33.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063108174P | 2020-10-30 | 2020-10-30 | |
US63/108,174 | 2020-10-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022093640A1 true WO2022093640A1 (en) | 2022-05-05 |
Family
ID=78650082
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2021/056211 WO2022093640A1 (en) | 2020-10-30 | 2021-10-22 | Anti-nkg2c agents and compositions and methods for making and using the same |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2022093640A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115957319A (en) * | 2022-10-14 | 2023-04-14 | 北京东方百泰生物科技股份有限公司 | Injection preparation of anti-NKG 2A monoclonal antibody |
Citations (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4301144A (en) | 1979-07-11 | 1981-11-17 | Ajinomoto Company, Incorporated | Blood substitute containing modified hemoglobin |
US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
EP0183070A2 (en) | 1984-10-30 | 1986-06-04 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
WO1987000195A1 (en) | 1985-06-28 | 1987-01-15 | Celltech Limited | Animal cell culture |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4670417A (en) | 1985-06-19 | 1987-06-02 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
EP0244234A2 (en) | 1986-04-30 | 1987-11-04 | Alko Group Ltd. | Transformation of trichoderma |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DD266710A3 (en) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Process for the biotechnical production of alkaline phosphatase |
WO1990003430A1 (en) | 1988-09-23 | 1990-04-05 | Cetus Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5534615A (en) | 1994-04-25 | 1996-07-09 | Genentech, Inc. | Cardiac hypertrophy factor and uses therefor |
US5545807A (en) | 1988-10-12 | 1996-08-13 | The Babraham Institute | Production of antibodies from transgenic animals |
WO1996027011A1 (en) | 1995-03-01 | 1996-09-06 | Genentech, Inc. | A method for making heteromultimeric polypeptides |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
WO1996032478A1 (en) | 1995-04-14 | 1996-10-17 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
US5589369A (en) | 1992-02-11 | 1996-12-31 | Cell Genesys Inc. | Cells homozygous for disrupted target loci |
US5591669A (en) | 1988-12-05 | 1997-01-07 | Genpharm International, Inc. | Transgenic mice depleted in a mature lymphocytic cell-type |
US5624821A (en) | 1987-03-18 | 1997-04-29 | Scotgen Biopharmaceuticals Incorporated | Antibodies with altered effector functions |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US5777085A (en) | 1991-12-20 | 1998-07-07 | Protein Design Labs, Inc. | Humanized antibodies reactive with GPIIB/IIIA |
US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
US5861155A (en) | 1993-12-08 | 1999-01-19 | Astra Ab | Humanized antibodies and uses thereof |
US5882644A (en) | 1996-03-22 | 1999-03-16 | Protein Design Labs, Inc. | Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof |
US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
US6013256A (en) | 1996-09-24 | 2000-01-11 | Protein Design Labs, Inc. | Method of preventing acute rejection following solid organ transplantation |
US6129914A (en) | 1992-03-27 | 2000-10-10 | Protein Design Labs, Inc. | Bispecific antibody effective to treat B-cell lymphoma and cell line |
US6210671B1 (en) | 1992-12-01 | 2001-04-03 | Protein Design Labs, Inc. | Humanized antibodies reactive with L-selectin |
US6329511B1 (en) | 1998-12-01 | 2001-12-11 | Protein Design Labs, Inc. | Humanized antibodies to γ-interferon |
US6407213B1 (en) | 1991-06-14 | 2002-06-18 | Genentech, Inc. | Method for making humanized antibodies |
US6479284B1 (en) | 1998-03-13 | 2002-11-12 | Dana-Farber Cancer Institute, Inc. | Humanized antibody and uses thereof |
US6500931B1 (en) | 1992-11-04 | 2002-12-31 | Medarex, Inc. | Humanized antibodies to Fc receptors for immunoglobulin G on human mononuclear phagocytes |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
WO2004063351A2 (en) | 2003-01-09 | 2004-07-29 | Macrogenics, Inc. | IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME |
WO2006088494A2 (en) | 2004-07-12 | 2006-08-24 | Macrogenics, Inc. | Identification and engineering of antibodies with variant fc regions and methods of using the same |
WO2006113665A2 (en) | 2005-04-15 | 2006-10-26 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
WO2007021841A2 (en) | 2005-08-10 | 2007-02-22 | Macrogenics, Inc. | Identification and engineering of antibodies with variant fc regions and methods of using same |
WO2007024249A2 (en) | 2004-11-10 | 2007-03-01 | Macrogenics, Inc. | Engineering fc antibody regions to confer effector function |
WO2007106707A2 (en) | 2006-03-10 | 2007-09-20 | Macrogenics, Inc. | Identification and engineering of antibodies with variant heavy chains and methods of using same |
WO2008140603A2 (en) | 2006-12-08 | 2008-11-20 | Macrogenics, Inc. | METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING |
EP2952899A1 (en) * | 2014-06-06 | 2015-12-09 | Fundacio Institut mar d'Investigacions Médiques (IMIM) | NKG2C as prognostic marker in multiple sclerosis |
-
2021
- 2021-10-22 WO PCT/US2021/056211 patent/WO2022093640A1/en active Application Filing
Patent Citations (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4301144A (en) | 1979-07-11 | 1981-11-17 | Ajinomoto Company, Incorporated | Blood substitute containing modified hemoglobin |
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DD266710A3 (en) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Process for the biotechnical production of alkaline phosphatase |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
EP0183070A2 (en) | 1984-10-30 | 1986-06-04 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
US4670417A (en) | 1985-06-19 | 1987-06-02 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
WO1987000195A1 (en) | 1985-06-28 | 1987-01-15 | Celltech Limited | Animal cell culture |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
EP0244234A2 (en) | 1986-04-30 | 1987-11-04 | Alko Group Ltd. | Transformation of trichoderma |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
US5624821A (en) | 1987-03-18 | 1997-04-29 | Scotgen Biopharmaceuticals Incorporated | Antibodies with altered effector functions |
US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
WO1990003430A1 (en) | 1988-09-23 | 1990-04-05 | Cetus Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
US5545807A (en) | 1988-10-12 | 1996-08-13 | The Babraham Institute | Production of antibodies from transgenic animals |
US5591669A (en) | 1988-12-05 | 1997-01-07 | Genpharm International, Inc. | Transgenic mice depleted in a mature lymphocytic cell-type |
US6180370B1 (en) | 1988-12-28 | 2001-01-30 | Protein Design Labs, Inc. | Humanized immunoglobulins and methods of making the same |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5693761A (en) | 1988-12-28 | 1997-12-02 | Protein Design Labs, Inc. | Polynucleotides encoding improved humanized immunoglobulins |
US5585089A (en) | 1988-12-28 | 1996-12-17 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5693762A (en) | 1988-12-28 | 1997-12-02 | Protein Design Labs, Inc. | Humanized immunoglobulins |
EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
US6639055B1 (en) | 1991-06-14 | 2003-10-28 | Genentech, Inc. | Method for making humanized antibodies |
US6407213B1 (en) | 1991-06-14 | 2002-06-18 | Genentech, Inc. | Method for making humanized antibodies |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
US5777085A (en) | 1991-12-20 | 1998-07-07 | Protein Design Labs, Inc. | Humanized antibodies reactive with GPIIB/IIIA |
US5589369A (en) | 1992-02-11 | 1996-12-31 | Cell Genesys Inc. | Cells homozygous for disrupted target loci |
US6350861B1 (en) | 1992-03-09 | 2002-02-26 | Protein Design Labs, Inc. | Antibodies with increased binding affinity |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US6129914A (en) | 1992-03-27 | 2000-10-10 | Protein Design Labs, Inc. | Bispecific antibody effective to treat B-cell lymphoma and cell line |
US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
US6500931B1 (en) | 1992-11-04 | 2002-12-31 | Medarex, Inc. | Humanized antibodies to Fc receptors for immunoglobulin G on human mononuclear phagocytes |
US6210671B1 (en) | 1992-12-01 | 2001-04-03 | Protein Design Labs, Inc. | Humanized antibodies reactive with L-selectin |
US5861155A (en) | 1993-12-08 | 1999-01-19 | Astra Ab | Humanized antibodies and uses thereof |
US5534615A (en) | 1994-04-25 | 1996-07-09 | Genentech, Inc. | Cardiac hypertrophy factor and uses therefor |
WO1996027011A1 (en) | 1995-03-01 | 1996-09-06 | Genentech, Inc. | A method for making heteromultimeric polypeptides |
WO1996032478A1 (en) | 1995-04-14 | 1996-10-17 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5882644A (en) | 1996-03-22 | 1999-03-16 | Protein Design Labs, Inc. | Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof |
US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
US6013256A (en) | 1996-09-24 | 2000-01-11 | Protein Design Labs, Inc. | Method of preventing acute rejection following solid organ transplantation |
US6479284B1 (en) | 1998-03-13 | 2002-11-12 | Dana-Farber Cancer Institute, Inc. | Humanized antibody and uses thereof |
US6329511B1 (en) | 1998-12-01 | 2001-12-11 | Protein Design Labs, Inc. | Humanized antibodies to γ-interferon |
WO2004063351A2 (en) | 2003-01-09 | 2004-07-29 | Macrogenics, Inc. | IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME |
WO2006088494A2 (en) | 2004-07-12 | 2006-08-24 | Macrogenics, Inc. | Identification and engineering of antibodies with variant fc regions and methods of using the same |
WO2007024249A2 (en) | 2004-11-10 | 2007-03-01 | Macrogenics, Inc. | Engineering fc antibody regions to confer effector function |
WO2006113665A2 (en) | 2005-04-15 | 2006-10-26 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
WO2007021841A2 (en) | 2005-08-10 | 2007-02-22 | Macrogenics, Inc. | Identification and engineering of antibodies with variant fc regions and methods of using same |
WO2007106707A2 (en) | 2006-03-10 | 2007-09-20 | Macrogenics, Inc. | Identification and engineering of antibodies with variant heavy chains and methods of using same |
WO2008140603A2 (en) | 2006-12-08 | 2008-11-20 | Macrogenics, Inc. | METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING |
EP2952899A1 (en) * | 2014-06-06 | 2015-12-09 | Fundacio Institut mar d'Investigacions Médiques (IMIM) | NKG2C as prognostic marker in multiple sclerosis |
Non-Patent Citations (46)
Title |
---|
"Antibodies, A Laboratory Manual", 1988, COLD SPRING HARBOR LABORATORY |
"Antibody-antigen interactions: Contact analysis and binding site topography", J. MOL. BIOL., vol. 262, pages 732 - 745 |
"NCBI", Database accession no. NP_002251.2 |
"Remington's Pharmaceutical Sciences", 1980 |
AL-LAZIKANI ET AL., JMB, vol. 273, 1997, pages 927 - 948 |
BARNES ET AL., ANAL. BIOCHEM, vol. l02, 1980, pages 255 |
BRENNAN ET AL., SCIENCE, vol. 229, 1985, pages 81 |
BRODEUR ET AL.: "Monoclonal Antibody Production Techniques and Applications", 1987, MARCEL DEKKER, INC., pages: 147 - 158 |
BRUGGERMANN ET AL., YEAR IN IMMUNO., vol. 7, 1993, pages 33 |
CALL ET AL., NAT. IMMUNOL, vol. 11, 2010, pages 1023 - 9 |
CARTER ET AL., BIO/TECHNOLOGY, vol. 10, 1992, pages 163 - 167 |
CHAMPE ET AL., J. BIOL. CHEM., vol. 270, 1995, pages 1388 - 1394 |
CLARKSON ET AL., NATURE, vol. 1, 2, 1991, pages 624 - 628 |
CUNNINGHAMWELLS, SCIENCE, vol. 244, 1989, pages 1081 - 1085 |
DAVIDSONDORANZ, IMMUNOLOGY, vol. 143, 2014, pages 13 - 20 |
EPSTEIN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 82, 1985, pages 3688 |
GRAHAM ET AL., J. GEN VIROL., vol. 36, 1977, pages 59 |
GRUBER ET AL., J. IMMUNOL., vol. 152, 1994, pages 5368 |
GUSS ET AL., EMBO J., vol. 5, 1986, pages 15671575 - 103 |
HAM ET AL., METH. ENZ., vol. 58, 1979, pages 44 |
HONEGGER APLIICKTHUN A: "Yet another numbering scheme for immunoglobulin variable domains: an automatic modeling and analysis tool", J MOL BIOL, vol. 309, no. 3, 8 June 2001 (2001-06-08), pages 657 - 70, XP004626893, DOI: 10.1006/jmbi.2001.4662 |
HOOGENBOOM ET AL., J. MOL. BIOL., vol. 222, 1991, pages 581 - 597 |
HWANG ET AL., PROC. NATL ACAD. SCI. USA, vol. 77, 1980, pages 4030 |
JAKOBOVITS ET AL., NATURE, vol. 362, 1993, pages 255 - 258 |
JAKOBOVITS ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448 |
KINDT ET AL.: "Kuby Immunology", 2007, W.H. FREEMAN AND CO., pages: 91 |
KOHLER ET AL., NATURE, vol. 256, 1975, pages 495 |
KOSTELNY ET AL., J. IMMUNOL., vol. 148, no. 5, 1992, pages 1547 - 1553 |
KOZBOR, J. IMMUNOL., vol. 133, 1984, pages 3001 |
LEFRANC MP ET AL.: "IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains", DEV COMP IMMUNOL, vol. 27, no. l, January 2003 (2003-01-01), pages 55 - 77, XP055585227, DOI: 10.1016/S0145-305X(02)00039-3 |
LINDMARK ET AL., J. IMMUNOL. METH., vol. 62, 1983, pages 1 - 13 |
MACCALLUM ET AL., J. MOL. BIOL., vol. 262, 1996, pages 732 - 745 |
MARTIN ET AL., J. BIOL. CHEM., vol. 257, 1982, pages 286 - 288 |
MARTIN ET AL., PROC. NATL. ACAD. SCI., vol. 86, 1989, pages 9268 - 9272 |
MATHER ET AL., ANNALS N.Y. ACAD. SCI., vol. 383, 1982, pages 44 - 68 |
MATHER, BIOL. REPROD., vol. 23, 1980, pages 243 - 251 |
MORIMOTO ET AL., JOURNAL OF BIOCHEMICAL AND BIOPHYSICAL METHODS, vol. 24, 1992, pages 107 - 117 |
MUNSON ET AL., ANAL. BIOCHEM., vol. 107, 1980, pages 220 |
NEUBERGER ET AL., NATURE, vol. 312, 1984, pages 604 - 608 |
O'SULLIVAN ET AL.: "Methods for the Preparation of Enzyme-Antibody Conjugates for use in Enzyme Immunoassay, in Methods in Enzym", vol. 73, 1981, ACADEMIC PRESS, pages: 147 - 166 |
PORTOLANO ET AL., J. IMMUNOL., vol. 150, 1993, pages 880 - 887 |
SHALABY ET AL., J. EXP. MED., vol. 175, 1992, pages 217 - 225 |
SHAPIRO: "Practical Flow Cytometry", 2003, WILEY |
STAVENHAGEN, J.B. ET AL., CANCER RES., vol. 57, no. 18, 2007, pages 8882 - 8890 |
URLAUB ET AL., PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4216 |
ZAPATA ET AL., PROTEIN ENG, vol. 8, no. 10, 1995, pages 1057 - 1062 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115957319A (en) * | 2022-10-14 | 2023-04-14 | 北京东方百泰生物科技股份有限公司 | Injection preparation of anti-NKG 2A monoclonal antibody |
CN115957319B (en) * | 2022-10-14 | 2023-06-30 | 北京东方百泰生物科技股份有限公司 | Injection preparation of anti-NKG 2A monoclonal antibody |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7155126B2 (en) | Antibody that specifically binds to human IL-15 and use thereof | |
TWI574976B (en) | Humanized anti-cxcr5 antibodies, derivatives thereof and their use | |
JP2022023058A (en) | HUMANIZED ANTI-COMPLEMENT FACTOR C1q ANTIBODIES AND USES THEREOF | |
CN107849136B (en) | anti-TfR antibodies and their use in the treatment of proliferative and inflammatory diseases | |
JP2023538782A (en) | CCR8 antibody and its uses | |
JP2006516408A (en) | Method for generating high affinity antibodies | |
WO2007044756A2 (en) | Monoclonal antibodies recognizing human ccr8 | |
US20210047432A1 (en) | Therapeutic anti-spla2-gib antibodies and the uses thereof | |
TW201938584A (en) | Anti-PLA2-GIB antibodies and the uses thereof | |
US20210206873A1 (en) | Anti-tlr9 agents and compositions and methods for making and using the same | |
WO2022093640A1 (en) | Anti-nkg2c agents and compositions and methods for making and using the same | |
WO2022093641A1 (en) | Anti-nkg2a agents and compositions and methods for making and using the same | |
WO2022241034A1 (en) | Anti-ccr8 antibodies, antigen-binding fragments thereof, and agents and compositions and methods for making and using the same | |
WO2022187050A1 (en) | Anti-cd117 agents and compositions and methods for making and using the same | |
WO2009132251A2 (en) | Methods and compositions comprising anti-idiotypic antibodies to anti-mmp-14 antibodies | |
WO2023114701A2 (en) | Cd28 binding antibodies and antigen binding fragments thereof | |
US20210095018A1 (en) | Anti-tetraspanin 33 agents and compositions and methods for making and using the same | |
JP2024505674A (en) | Anti-IL1RAP antibody | |
US20230054169A1 (en) | Anti-tlr7 agents and compositions and methods for making and using the same | |
US10227419B2 (en) | Antibodies targeting B-cell receptor complex membrane bound IgM and uses thereof | |
WO2024020051A1 (en) | Anti-cd157 antibodies, antigen-binding fragments thereof and compositions and methods for making and using the same | |
WO2024040114A2 (en) | Anti-axl antibodies, antigen-binding fragments thereof and methods for making and using the same | |
WO2022182562A1 (en) | ANTI-SARS-CoV-2 SPIKE GLYCOPROTEIN S1 AGENTS AND COMPOSITIONS | |
WO2023133470A2 (en) | Tmprss2 binding antibodies and antigen binding fragments thereof | |
WO2023086989A1 (en) | Transthyretin (ttr) monomer binding antibodies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21810204 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21810204 Country of ref document: EP Kind code of ref document: A1 |